a:280:{i:216490;a:29:{s:5:"title";s:17:"ACTH_Acne Therapy";s:3:"nid";s:6:"216490";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"ACTH";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:12:"Acne Therapy";s:22:"field_monograph_name_f";s:23:"Acné, Traitement de l'";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"C;P";s:21:"field_monograph_url_e";s:92:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_acne-eng.php";s:21:"field_monograph_url_f";s:92:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_acne-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:0:"";s:16:"field_legacy_nid";s:6:"100795";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216491;a:35:{s:5:"title";s:21:"AGI_Ginseng, American";s:3:"nid";s:6:"216491";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"AGI";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:17:"Ginseng, American";s:22:"field_monograph_name_f";s:24:"Ginseng à cinq folioles";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:616:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.  Note: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicants’ discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:749:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.  Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:880:"Proof of sale or permit must be available for possession of the cultivated Panax quinquefolius because the wildlife species is endangered: (i) Panax quinquefolius is protected under the federal Species at Risk Act (SARA). Under section 32(2) of this Act, no person shall possess, collect, buy, sell or trade an individual of a wildlife species that is listed as an extirpated species, an endangered species or a threatened species, or any part or derivative of such an individual (JC 2002), (ii) Panax quinquefolius is protected by the Quebec Act Respecting Threatened or Vulnerable Species. Under this Act, it is prohibited to possess, trade, or harm this species, or to disturb its habitat (EC 2009).; The medicinal ingredient may comply with the specifications outlined in the American Ginseng, Powdered American Ginseng monographs published in the U.S. Pharmacopoeia (USP 32).";s:21:"field_specification_f";s:1031:"Une preuve d’achat ou un permis pour posséder la plante cultivée Panax quinquefolius doit être disponible puisque la plante est une espèce en péril à l’état sauvage :  (i) Panax quinquefolius est protégée au Canada par la Loi sur les espèces en péril (LEP). Selon la section 32(2) de cette loi, il est interdit de posséder, de collectionner, d’acheter, de vendre ou d’échanger un individu – notamment partie d’un individu ou produit qui en provient – d’une espèce sauvage inscrite comme espèce disparue du pays, en voie de disparition ou menacée (JC 2002), (ii) Panax quinquefolius est protégée au Québec par la Loi sur les espèces menacées ou vulnérables (LEMV). Cette loi interdit de nuire aux individus de cette espèce, d’en posséder, d’en faire le commerce et de perturber leur habitat (EC 2009).;  L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies American Ginseng, Powdered American Ginseng de la pharmacopée américaine (USP 32).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-11-10";s:16:"field_legacy_nid";s:6:"100796";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:9:"AGIN;APP1";s:15:"field_mono_risk";s:15:"AGI_CW1;AGI_CW2";s:21:"field_mono_citation_e";s:167:"PVIPQ;BEHM;CHMMM;UPHCDI;FIVEBAT;SERDIGO;SARAPR;THEPHA2;MEDICAR;KAD;BKGINS;AMODHER;MEDHER;SARA;EDEAG;HERBBK74;HERCOM;CCMM2;XOVER;POSTPR;IMPGLYC;GRIN;TNF27;PCBDP2;AGWARF";s:21:"field_mono_citation_f";s:167:"PVIPQ;BEHM;CHMMM;UPHCDI;FIVEBAT;SERDIGO;SARAPR;THEPHA2;MEDICAR;KAD;BKGINS;AMODHER;MEDHER;SARA;EDEAG;HERBBK74;HERCOM;CCMM2;XOVER;POSTPR;IMPGLYC;GRIN;TNF27;PCBDP2;AGWARF";s:26:"field_reference_reviewed_e";s:1231:"CAMAI;PBTHMSD;PEAK;DIPSEPG;HMPC;GPMCMA;AEPGBE;MUGNA;EEPG;MENESG;HERMED2;CRFAT;CVTE002;SEDMEN;ISEEGA;EXPCEM;CGCEM;BHP2;BHP;BPH;BHCOM;BHCOM2;HPDT;SHHEP;PRGHDI;ALCOHO;PSYWB;MVCGE;GINRB1;ANTITUM;AMYLOID;EDS;EPGQL;AGUSQL;UCAMCW;CPCAWM;MCF7;PS2EXP;CITES;MIIGIF;PGQUAL;INTEXE;SUPRA;RISKBEN;HUUCT;ESCOP;ABPP;HDINT;HDIRARR;ESPG;ESTREC;INTWAR;GVB;COPD;P450HDI;BOTSUP;PLC;ESHSSSD;WHITECT;25PREP;GINCOS;POTIN;KRGEDPR;ICTG;GPGCM;FRSC;ITIS;IBHMPD;WARGIN;NMCDAG;PC12;SJWGIN;MOUSE;NAGE;MENOMET;ROUJIN;IFRSAAG;MMND;NUTBOTIN;DDDCCP;DDCCP;DDECP;GPECPM;ICPHV;EEESD;MODCOG;PANAXG;MATING;SUNGIN;APNAGE;LACTATE;PROTOP;8OHDG;PEGRG2;EGRCCPME;ESTROG;ABETA;ASTROCY;MRBDS;BDSUPPW;TAMP;MPETD;ECPRS;PCTPE;HMPL;HERSAF;PPP;DHINT;KANJANG;NPSPG;NAE;NEEGEI;NEEGI;MALECOP;GSBNO;HAGAG;APHROD;SADEMGS;12CUMH;FISTULA;CAMAD;PPRC97;EENAG;IMEDSC;PGGLUC;GLYCAE;NNAGRR;POTVAC;CHRBRON;GBPG;RGEESTE;NAAGP;8POPGIN;DOSEESC;PPGLYC;VEAG;INFERT;GTNIDDP;EXERTS;LTINAG;PURIF;GENRG3;ERGUVEF;400MGPG;OPIOIDS;DGHAOA;HEART;CLIMSYN;AXONAL;NEUNET;AB2535;SKNSH;TNF24;IWGGGG;AIM;EFFGIN;GLINREG;AGAPG;CHEMOPR;AOBOT;IMMUNO;MURINE;COLONCAN;POLYACE;HERMEDI;SPECIES;WHOMON3;WHOMON;HDPP2;DBCEQL;ESGEQL;PHC;PNCBDP;SRISEWOA;PCBDP;AGLEAF;PERPIA;EGIGH;CNAIVE;ESCPG;PEGIVHC;GRADED;PCWFSCS;SYNAPTO;LESION";s:26:"field_reference_reviewed_f";s:1231:"CAMAI;PBTHMSD;PEAK;DIPSEPG;HMPC;GPMCMA;AEPGBE;MUGNA;EEPG;MENESG;HERMED2;CRFAT;CVTE002;SEDMEN;ISEEGA;EXPCEM;CGCEM;BHP2;BHP;BPH;BHCOM;BHCOM2;HPDT;SHHEP;PRGHDI;ALCOHO;PSYWB;MVCGE;GINRB1;ANTITUM;AMYLOID;EDS;EPGQL;AGUSQL;UCAMCW;CPCAWM;MCF7;PS2EXP;CITES;MIIGIF;PGQUAL;INTEXE;SUPRA;RISKBEN;HUUCT;ESCOP;ABPP;HDINT;HDIRARR;ESPG;ESTREC;INTWAR;GVB;COPD;P450HDI;BOTSUP;PLC;ESHSSSD;WHITECT;25PREP;GINCOS;POTIN;KRGEDPR;ICTG;GPGCM;FRSC;ITIS;IBHMPD;WARGIN;NMCDAG;PC12;SJWGIN;MOUSE;NAGE;MENOMET;ROUJIN;IFRSAAG;MMND;NUTBOTIN;DDDCCP;DDCCP;DDECP;GPECPM;ICPHV;EEESD;MODCOG;PANAXG;MATING;SUNGIN;APNAGE;LACTATE;PROTOP;8OHDG;PEGRG2;EGRCCPME;ESTROG;ABETA;ASTROCY;MRBDS;BDSUPPW;TAMP;MPETD;ECPRS;PCTPE;HMPL;HERSAF;PPP;DHINT;KANJANG;NPSPG;NAE;NEEGEI;NEEGI;MALECOP;GSBNO;HAGAG;APHROD;SADEMGS;12CUMH;FISTULA;CAMAD;PPRC97;EENAG;IMEDSC;PGGLUC;GLYCAE;NNAGRR;POTVAC;CHRBRON;GBPG;RGEESTE;NAAGP;8POPGIN;DOSEESC;PPGLYC;VEAG;INFERT;GTNIDDP;EXERTS;LTINAG;PURIF;GENRG3;ERGUVEF;400MGPG;OPIOIDS;DGHAOA;HEART;CLIMSYN;AXONAL;NEUNET;AB2535;SKNSH;TNF24;IWGGGG;AIM;EFFGIN;GLINREG;AGAPG;CHEMOPR;AOBOT;IMMUNO;MURINE;COLONCAN;POLYACE;HERMEDI;SPECIES;WHOMON3;WHOMON;HDPP2;DBCEQL;ESGEQL;PHC;PNCBDP;SRISEWOA;PCBDP;AGLEAF;PERPIA;EGIGH;CNAIVE;ESCPG;PEGIVHC;GRADED;PCWFSCS;SYNAPTO;LESION";}i:216492;a:35:{s:5:"title";s:11:"ALF_Alfalfa";s:3:"nid";s:6:"216492";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"ALF";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:7:"Alfalfa";s:22:"field_monograph_name_f";s:7:"Luzerne";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-01-22";s:16:"field_legacy_nid";s:6:"100797";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:31:"ALF_CW1;ALF_CW2;ALF_CI1;ALF_CI2";s:21:"field_mono_citation_e";s:45:"HERMED2;BHP2;BHP;50COM;HERCDI;THEHER;DMH;GRIN";s:21:"field_mono_citation_f";s:52:"HERMED2;BHP2;BHP;50COM;HERCDI;PHAPHY;THEHER;DMH;GRIN";s:26:"field_reference_reviewed_e";s:36:"BEHM;THEPHA;BOTSAF;HMPL;HEART;PNCBDP";s:26:"field_reference_reviewed_f";s:36:"BEHM;THEPHA;BOTSAF;HMPL;HEART;PNCBDP";}i:216493;a:36:{s:5:"title";s:17:"ALO_O_Aloe - Oral";s:3:"nid";s:6:"216493";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"ALO_O";s:18:"field_group_name_e";s:4:"Aloe";s:18:"field_group_name_f";s:6:"Aloès";s:22:"field_monograph_name_e";s:11:"Aloe - Oral";s:22:"field_monograph_name_f";s:23:"Aloès vulgaire - Orale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:92:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_aloe-eng.php";s:21:"field_monograph_url_f";s:92:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_aloe-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:684:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.  Notes: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant. Claims for traditional use must include the term "Herbal Medicine"";s:12:"field_note_f";s:846:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.  Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.Les allégations concernant l’usage traditionnel doivent inclure le terme « phytothérapie ».";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:343:"The medicinal ingredient may comply with the specifications outlined in one of the following pharmacopoeial monographs:  'Barbados Aloes' or 'Standardised Aloes Dry Extract' monograph in British Pharmacopoeia, 'Aloes, Barbados' or 'Aloes Dry Extract, Standardised' monograph in European Pharmacopoeia, and 'Aloe' monograph in US Pharamcopoeia.";s:21:"field_specification_f";s:356:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes:  'Barbados Aloes' ou 'Standardised Aloes Dry Extract' de la Pharmacopée britannique (BP), 'Aloes, Barbados' ou 'Aloes Dry Extract, Standardised' de la Pharmacopée européenne (Ph. Eur.) et 'Aloe' de la Pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-10-31";s:16:"field_legacy_nid";s:6:"100798";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:5:"ADU12";s:15:"field_dose_note";s:9:"ALOE;APP1";s:19:"field_mono_duration";s:7:"ALOODUR";s:15:"field_mono_risk";s:70:"PERS;WORS;ALOO_CW1;ALOO_CW2;ALOO_CW3;ALOO_CW4;ALOO_CI1;ALOO_CI2;ALO_AR";s:21:"field_mono_citation_e";s:120:"HERMED2;HBNPD;CGCEM;50COM;ENHCI2;BHCOM;UPHCDI8;HERCDI;CHMAB;KAD;POSTDA;AMODHER;BOTSAF;HERCOM;HTCH;MART35;GRIN;WHOMON;PHC";s:21:"field_mono_citation_f";s:141:"HERMED2;HBNPD;CGCEM;50COM;PMM;ENHCI2;BHCOM;UPHCDI8;HERCDI;PHAPHY;CHMAB;KAD;POSTDA;AMODHER;NOMEN;BOTSAF;HTCH;MART35;GRIN;WHOMON;PLATHE;WEP;PHC";s:26:"field_reference_reviewed_e";s:79:"ECMM;AVHCW;HGHP;STIMLAX;MEDHER;WNDHEA;BURNWH;DMH;HERSAF;PPP;PPHPP;AVSYSR;PNCBDP";s:26:"field_reference_reviewed_f";s:79:"ECMM;AVHCW;HGHP;STIMLAX;MEDHER;WNDHEA;BURNWH;DMH;HERSAF;PPP;PPHPP;AVSYSR;PNCBDP";}i:216494;a:35:{s:5:"title";s:20:"ALO_T_Aloe - Topical";s:3:"nid";s:6:"216494";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"ALO_T";s:18:"field_group_name_e";s:4:"Aloe";s:18:"field_group_name_f";s:6:"Aloès";s:22:"field_monograph_name_e";s:14:"Aloe - Topical";s:22:"field_monograph_name_f";s:25:"Aloès vulgaire - Topique";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:92:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_aloe-eng.php";s:21:"field_monograph_url_f";s:92:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_aloe-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:684:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.  Notes: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant. Claims for traditional use must include the term "Herbal Medicine"";s:12:"field_note_f";s:846:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.  Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.Les allégations concernant l’usage traditionnel doivent inclure le terme « phytothérapie ».";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:343:"The medicinal ingredient may comply with the specifications outlined in one of the following pharmacopoeial monographs:  'Barbados Aloes' or 'Standardised Aloes Dry Extract' monograph in British Pharmacopoeia, 'Aloes, Barbados' or 'Aloes Dry Extract, Standardised' monograph in European Pharmacopoeia, and 'Aloe' monograph in US Pharamcopoeia.";s:21:"field_specification_f";s:356:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes:  'Barbados Aloes' ou 'Standardised Aloes Dry Extract' de la Pharmacopée britannique (BP), 'Aloes, Barbados' ou 'Aloes Dry Extract, Standardised' de la Pharmacopée européenne (Ph. Eur.) et 'Aloe' de la Pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-10-31";s:16:"field_legacy_nid";s:6:"100799";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:4:"ADU2";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:16:"PERS;WORS;ALO_AR";s:21:"field_mono_citation_e";s:120:"HERMED2;HBNPD;CGCEM;50COM;ENHCI2;BHCOM;UPHCDI8;HERCDI;CHMAB;KAD;POSTDA;AMODHER;BOTSAF;HERCOM;HTCH;MART35;GRIN;WHOMON;PHC";s:21:"field_mono_citation_f";s:141:"HERMED2;HBNPD;CGCEM;50COM;PMM;ENHCI2;BHCOM;UPHCDI8;HERCDI;PHAPHY;CHMAB;KAD;POSTDA;AMODHER;NOMEN;BOTSAF;HTCH;MART35;GRIN;WHOMON;PLATHE;WEP;PHC";s:26:"field_reference_reviewed_e";s:79:"ECMM;AVHCW;HGHP;STIMLAX;MEDHER;WNDHEA;BURNWH;DMH;HERSAF;PPP;PPHPP;AVSYSR;PNCBDP";s:26:"field_reference_reviewed_f";s:79:"ECMM;AVHCW;HGHP;STIMLAX;MEDHER;WNDHEA;BURNWH;DMH;HERSAF;PPP;PPHPP;AVSYSR;PNCBDP";}i:216495;a:36:{s:5:"title";s:12:"ANG_Angelica";s:3:"nid";s:6:"216495";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"ANG";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:8:"Angelica";s:22:"field_monograph_name_f";s:25:"Angélique archangélique";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:106:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_angelica-angelique-eng.php";s:21:"field_monograph_url_f";s:106:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_angelica-angelique-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-01-15";s:16:"field_legacy_nid";s:6:"100800";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:6:"ANGOCC";s:15:"field_mono_risk";s:40:"PERS;WORS;ANG_CW1;ANG_CW2;ANG_CW3;ANG_CI";s:21:"field_mono_citation_e";s:91:"HERMED2;HBNPD;BHP;CGCEM;EXPCEM;BHCOM2;HERCDI;PATSC;KAD;AMODHER;MEDHER;HERCOM;DMH;GRIN;HDPP2";s:21:"field_mono_citation_f";s:86:"HERMED2;HBNPD;BHP;CGCEM;EXPCEM;PMM;BHCOM2;HERCDI;PATSC;KAD;AMODHER;MEDHER;DMH;PPS;GRIN";s:26:"field_reference_reviewed_e";s:28:"HERMED;BOTSAF;PPP;NAE;PNCBDP";s:26:"field_reference_reviewed_f";s:41:"HERMED;BOTSAF;HERCOM;PPP;NAE;PNCBDP;HDPP2";}i:216496;a:29:{s:5:"title";s:27:"ANDA_Anti-Dandruff Products";s:3:"nid";s:6:"216496";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"ANDA";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:22:"Anti-Dandruff Products";s:22:"field_monograph_name_f";s:27:"Antipelliculaires, produits";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"C;P";s:21:"field_monograph_url_e";s:52:"atReq.do?atid=antidandruff_anitpelliculaire&lang=eng";s:21:"field_monograph_url_f";s:52:"atReq.do?atid=antidandruff_anitpelliculaire&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:0:"";s:16:"field_legacy_nid";s:6:"100801";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216497;a:36:{s:5:"title";s:10:"ARN_Arnica";s:3:"nid";s:6:"216497";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"ARN";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:6:"Arnica";s:22:"field_monograph_name_f";s:6:"Arnica";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:29:"atReq.do?atid=arnica&lang=eng";s:21:"field_monograph_url_f";s:29:"atReq.do?atid=arnica&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:726:"For arnica products in semi-solid dosage forms, refer to the Arnica semi-solid dosage forms monograph.The arnica monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.  Notes: Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion.The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.Claims for traditional use must include the term "Herbal Medicine"";s:12:"field_note_f";s:832:"Pour les produits d’arnica utilisant des formes posologiques semi-solides, se référer à la monographie  Arnica – Formes posologiques semi-solides .La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal.
Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont. Les allégations relatives à l’utilisation traditionnelle doivent inclure les termes « en phytohérapie/herboristerie »";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:219:"The medicinal ingredient may comply with the specifications outlined in the Arnica Flower Monographs published in the European or British Pharmacopoeias and Arnica Tincture Monographs published in European Pharmacopoeia";s:21:"field_specification_f";s:270:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies Arnica Flower publiées dans les Pharmacopées britannique (BP) ou européenne (Ph. Eur.) et Arnica Tincture monograph publiées dans les Pharmacopé eeuropéenne(Ph. Eur.)";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2011-06-24";s:16:"field_legacy_nid";s:6:"100803";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:14:"ARN1;ARN2;ARN3";s:15:"field_mono_risk";s:24:"PERS;WORS;ARN_CI4;ARN_AR";s:21:"field_mono_citation_e";s:144:"EXPCEM;BHCOM2;UPHCDI8;HERCDI;ESCOP;AMODHER;MEDHER;HERCOM;HERSAF;ARNR1;ARNR2;ARNR3;ARNR4;ARNR5;ARNR6;ARNR7;ARNR8;ARNR9;ARNR10;TURM9;ARNR11;ARNR12";s:21:"field_mono_citation_f";s:151:"EXPCEM;BHCOM2;UPHCDI8;HERCDI;PHAPHY;ESCOP;AMODHER;MEDHER;HERSAF;PLATHE;ARNR1;ARNR2;ARNR3;ARNR4;ARNR5;ARNR6;ARNR7;ARNR8;ARNR9;ARNR10;TURM9;ARNR11;ARNR12";s:26:"field_reference_reviewed_e";s:55:"ARNRR1;ARNRR2;ARNRR3;ARNRR4;ARNRR5;ARNRR6;ARNRR7;ARNRR8";s:26:"field_reference_reviewed_f";s:55:"ARNRR1;ARNRR2;ARNRR3;ARNRR4;ARNRR5;ARNRR6;ARNRR7;ARNRR8";}i:216498;a:32:{s:5:"title";s:15:"ASH_Ashwagandha";s:3:"nid";s:6:"216498";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"ASH";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:11:"Ashwagandha";s:22:"field_monograph_name_f";s:11:"Ashwagandha";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:99:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_ashwagandha-eng.php";s:21:"field_monograph_url_f";s:99:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_ashwagandha-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2007-04-18";s:16:"field_legacy_nid";s:6:"100804";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_mono_risk";s:15:"ASH_CW1;ASH_CW2";s:21:"field_mono_citation_e";s:72:"APIP1V1;HBNPD;REMI;HAMP;IHR;MMIT;BOTSAF;HERCOM;IMM;PAPD;AHPTCA;GRIN;MHAY";s:21:"field_mono_citation_f";s:72:"APIP1V1;HBNPD;REMI;HAMP;IHR;MMIT;BOTSAF;HERCOM;IMM;PAPD;AHPTCA;GRIN;MHAY";}i:216499;a:35:{s:5:"title";s:14:"AST_Astragalus";s:3:"nid";s:6:"216499";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"AST";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:10:"Astragalus";s:22:"field_monograph_name_f";s:9:"Astragale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:108:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_astragalus-astragale-eng.php";s:21:"field_monograph_url_f";s:108:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_astragalus-astragale-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:619:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.     Note: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:752:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.     Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:191:"The medicinal ingredient may comply with the specifications outlined in the British Pharmacopoeia (BP) monographs Astragalus root for use in THM and Processed Astragalus Root for use in THMP.";s:21:"field_specification_f";s:223:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie officinale "Astragalus root for use in THM et Processed Astragalus Root for use in THMP" de la pharmacopée britannique (BP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2010-07-07";s:16:"field_legacy_nid";s:6:"100805";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:19:"AST_CW;AST_CI;PREGC";s:21:"field_mono_citation_e";s:76:"CHMMM;HERCDI;CDP;HERCOM;PPRC2;CCMM;ASTRHP;GRIN;ASTR1;ASTR2;ASTR3;ASTR4;ASTR5";s:21:"field_mono_citation_f";s:80:"CHMMM;HERCDI;PHAPHY;CDP;PPS;PPRC2;CCMM;ASTRHP;GRIN;ASTR1;ASTR2;ASTR3;ASTR4;ASTR5";s:26:"field_reference_reviewed_e";s:4:"PGNM";s:26:"field_reference_reviewed_f";s:11:"HERCOM;PGNM";}i:216500;a:35:{s:5:"title";s:9:"AVE_Avens";s:3:"nid";s:6:"216500";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"AVE";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:5:"Avens";s:22:"field_monograph_name_f";s:8:"Benoîte";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:101:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_avens-benoite-eng.php";s:21:"field_monograph_url_f";s:101:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_avens-benoite-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-01-15";s:16:"field_legacy_nid";s:6:"100806";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:15:"PERS;WORS;PREGC";s:21:"field_mono_citation_e";s:36:"BHP;AMODHER;HERCOM;GRIN;HDPP2;PNCBDP";s:21:"field_mono_citation_f";s:36:"BHP;AMODHER;HERCOM;GRIN;HDPP2;PNCBDP";s:26:"field_reference_reviewed_e";s:17:"HERMED2;KAD;PDRHM";s:26:"field_reference_reviewed_f";s:17:"HERMED2;KAD;PDRHM";}i:216501;a:35:{s:5:"title";s:17:"BET_Beta-Carotene";s:3:"nid";s:6:"216501";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"BET";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:13:"Beta-Carotene";s:22:"field_monograph_name_f";s:15:"Bêta-carotène";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:787:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.      Notes:   (i)  Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.  (ii)  Consult Appendix 1 for definitions of the following terms: Adequate Intake (AI), Recommended Dietary Allowance (RDA), Tolerable Upper Intake Level (UL).";s:12:"field_note_f";s:924:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.       Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués. (ii) Consulter l’annexe 1 pour les définitions des termes suivants : apport suffisant (AS), apport nutritionnel recommandé (ANR), apport maximal tolérable (AMT)";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:301:"The medicinal ingredient may comply with the specifications outlined in the Beta Carotene and Beta Carotene Capsules monographs published in the U.S. Pharmacopeia (USP 32), and the Betacarotene monographs published in the European Pharmacopoeia (Ph. Eur. 2008) and the British Pharmacopoeia (BP 2008).";s:21:"field_specification_f";s:323:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales Beta Carotene et Beta Carotene Capsules publiées dans la pharmacopée américaine (USP 32), et les monographies officinales publiées dans les pharmacopées européenne (Ph. Eur. 2007) et britannique (BP 2008).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2010-06-11";s:16:"field_legacy_nid";s:6:"100807";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:26:"CH03;ADU;AD1418;AD913;CH48";s:15:"field_dose_note";s:33:"MIN_VIA;MAXBET;ADUL;CONBET;BETDOS";s:15:"field_mono_risk";s:6:"BET_CW";s:21:"field_mono_citation_e";s:82:"LUNGC;EPH4;FAO67;ANHM;NUTREC;IOMDRI;FCC;COMBBCVA;VITAR3;EP8;MNHD;MART35;DUAL;TNF27";s:21:"field_mono_citation_f";s:82:"LUNGC;EPH4;FAO67;ANHM;NUTREC;IOMDRI;FCC;COMBBCVA;VITAR3;EP8;MNHD;MART35;DUAL;TNF27";s:26:"field_reference_reviewed_e";s:178:"ISOSTUD;KINETIC;VITRR1;SIDT;REPLYVAN;HCMM;DDLS;VITSUP;VARIAB;DUALISO;DRIVAVK;NHPREG;FDREG;ABSRET;DBLTRC;FILIPINO;RETEQ;VAEQ;INTPINT;INDONE;VAEE;VAEHA;CHINAD;CARBIO;REPLYRUS;VMRHN";s:26:"field_reference_reviewed_f";s:178:"ISOSTUD;KINETIC;VITRR1;SIDT;REPLYVAN;HCMM;DDLS;VITSUP;VARIAB;DUALISO;DRIVAVK;NHPREG;FDREG;ABSRET;DBLTRC;FILIPINO;RETEQ;VAEQ;INTPINT;INDONE;VAEE;VAEHA;CHINAD;CARBIO;REPLYRUS;VMRHN";}i:216502;a:35:{s:5:"title";s:21:"BIL_O_Bilberry - Oral";s:3:"nid";s:6:"216502";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"BIL_O";s:18:"field_group_name_e";s:8:"Bilberry";s:18:"field_group_name_f";s:8:"Myrtille";s:22:"field_monograph_name_e";s:15:"Bilberry - Oral";s:22:"field_monograph_name_f";s:16:"Myrtille - Orale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:619:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.     Note: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:752:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.     Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:273:"The medicinal ingredient may comply with the specifications outlined in the following pharmacopoeial monographs: 'Dried Bilberry' in BP, 'Bilberry Fruit, Dried' and 'Fresh Bilberry Fruit Dry Extract, Refined and Standardised' in Ph. Eur., 'Powdered Bilberry Extract' in USP";s:21:"field_specification_f";s:297:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes: 'Dried Bilberry' dans la BP, 'Bilberry Fruit, Dried' et 'Fresh Bilberry Fruit Dry Extract, Refined and Standardised' dans la Ph. Eur., 'Powdered Bilberry Extract' dans la USP";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2010-06-08";s:16:"field_legacy_nid";s:6:"100808";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:17:"BILO_CW1;BILO_CW2";s:21:"field_mono_citation_e";s:89:"HERMED2;ABC;EXPCEM;BPH8;ESCOP;KAD2;AMODHER;HERCOM;HERSAF;PPP;VACMYR;EP8;BILBVM;GRIN;TNF27";s:21:"field_mono_citation_f";s:96:"HERMED2;ABC;EXPCEM;BPH8;ESCOP;KAD2;AMODHER;HERCOM;HERSAF;PPP;VACMYR;EP8;BILBVM;GRIN;TNF27;CMCROP";s:26:"field_reference_reviewed_e";s:70:"HERCDI;ANTHOVM;A2EPO;ANTOLIG;NIGHT;BOTSAF;NIGVIS;A2EEPO;MIRTOG;EFFANTH";s:26:"field_reference_reviewed_f";s:70:"HERCDI;ANTHOVM;A2EPO;ANTOLIG;NIGHT;BOTSAF;NIGVIS;A2EEPO;MIRTOG;EFFANTH";}i:216503;a:35:{s:5:"title";s:23:"BIL_B_Bilberry - Buccal";s:3:"nid";s:6:"216503";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"BIL_B";s:18:"field_group_name_e";s:8:"Bilberry";s:18:"field_group_name_f";s:8:"Myrtille";s:22:"field_monograph_name_e";s:17:"Bilberry - Buccal";s:22:"field_monograph_name_f";s:18:"Myrtille - Buccale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:619:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.     Note: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:752:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.     Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:273:"The medicinal ingredient may comply with the specifications outlined in the following pharmacopoeial monographs: 'Dried Bilberry' in BP, 'Bilberry Fruit, Dried' and 'Fresh Bilberry Fruit Dry Extract, Refined and Standardised' in Ph. Eur., 'Powdered Bilberry Extract' in USP";s:21:"field_specification_f";s:297:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes: 'Dried Bilberry' dans la BP, 'Bilberry Fruit, Dried' et 'Fresh Bilberry Fruit Dry Extract, Refined and Standardised' dans la Ph. Eur., 'Powdered Bilberry Extract' dans la USP";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2010-06-08";s:16:"field_legacy_nid";s:6:"100809";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:7:"BILB_CW";s:21:"field_mono_citation_e";s:89:"HERMED2;ABC;EXPCEM;BPH8;ESCOP;KAD2;AMODHER;HERCOM;HERSAF;PPP;VACMYR;EP8;BILBVM;GRIN;TNF27";s:21:"field_mono_citation_f";s:96:"HERMED2;ABC;EXPCEM;BPH8;ESCOP;KAD2;AMODHER;HERCOM;HERSAF;PPP;VACMYR;EP8;BILBVM;GRIN;TNF27;CMCROP";s:26:"field_reference_reviewed_e";s:70:"HERCDI;ANTHOVM;A2EPO;ANTOLIG;NIGHT;BOTSAF;NIGVIS;A2EEPO;MIRTOG;EFFANTH";s:26:"field_reference_reviewed_f";s:70:"HERCDI;ANTHOVM;A2EPO;ANTOLIG;NIGHT;BOTSAF;NIGVIS;A2EEPO;MIRTOG;EFFANTH";}i:216504;a:32:{s:5:"title";s:10:"BIO_Biotin";s:3:"nid";s:6:"216504";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"BIO";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:6:"Biotin";s:22:"field_monograph_name_f";s:7:"Biotine";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2007-08-16";s:16:"field_legacy_nid";s:6:"100810";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:12:"ADU14;CH1_13";s:15:"field_dose_note";s:21:"MIN;MAX99;ADUL;BIODEF";s:21:"field_mono_citation_e";s:55:"SULVM;ANHM;NHPDEAC;IOMDRI;FCC;DRITR;MERCK13;MNHD;MART35";s:21:"field_mono_citation_f";s:55:"SULVM;ANHM;NHPDEAC;IOMDRI;FCC;DRITR;MERCK13;MNHD;MART35";}i:216505;a:36:{s:5:"title";s:21:"BIR_PE_Birch, Weeping";s:3:"nid";s:6:"216505";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"BIR_PE";s:18:"field_group_name_e";s:5:"Birch";s:18:"field_group_name_f";s:7:"Bouleau";s:22:"field_monograph_name_e";s:14:"Birch, Weeping";s:22:"field_monograph_name_f";s:16:"Bouleau pleureur";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:150:"The medicinal ingredient may comply with the specifications outlined in the Birch Leaf Monographs published in the European or British Pharmacopoeias.";s:21:"field_specification_f";s:187:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies Birch Leaf publiées dans les Pharmacopées britannique (BP) et européenne (Ph. Eur.).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-04-24";s:16:"field_legacy_nid";s:6:"100811";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:6:"BIRDUR";s:15:"field_mono_risk";s:32:"PERS;WORS;BIR_CW1;BIR_CW2;BIR_AR";s:21:"field_mono_citation_e";s:56:"HBNPD;CGCEM;BHCOM2;HERCDI;PATSC;ESCOP;MEDHER;HERCOM;GRIN";s:21:"field_mono_citation_f";s:73:"HBNPD;CGCEM;BHCOM2;HERCDI;FLORE;PHAPHY;PATSC;ESCOP;MEDHER;HERCOM;GRIN;WEP";s:26:"field_reference_reviewed_e";s:22:"UPHCDI8;AMODHER;BOTSAF";s:26:"field_reference_reviewed_f";s:22:"UPHCDI8;AMODHER;BOTSAF";}i:216506;a:36:{s:5:"title";s:19:"BIR_PU_Birch, White";s:3:"nid";s:6:"216506";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"BIR_PU";s:18:"field_group_name_e";s:5:"Birch";s:18:"field_group_name_f";s:7:"Bouleau";s:22:"field_monograph_name_e";s:12:"Birch, White";s:22:"field_monograph_name_f";s:13:"Bouleau blanc";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:150:"The medicinal ingredient may comply with the specifications outlined in the Birch Leaf Monographs published in the European or British Pharmacopoeias.";s:21:"field_specification_f";s:187:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies Birch Leaf publiées dans les Pharmacopées britannique (BP) et européenne (Ph. Eur.).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-04-24";s:16:"field_legacy_nid";s:6:"100812";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:6:"BIRDUR";s:15:"field_mono_risk";s:32:"PERS;WORS;BIR_CW1;BIR_CW2;BIR_AR";s:21:"field_mono_citation_e";s:56:"HBNPD;CGCEM;BHCOM2;HERCDI;PATSC;ESCOP;MEDHER;HERCOM;GRIN";s:21:"field_mono_citation_f";s:73:"HBNPD;CGCEM;BHCOM2;HERCDI;FLORE;PHAPHY;PATSC;ESCOP;MEDHER;HERCOM;GRIN;WEP";s:26:"field_reference_reviewed_e";s:22:"UPHCDI8;AMODHER;BOTSAF";s:26:"field_reference_reviewed_f";s:22:"UPHCDI8;AMODHER;BOTSAF";}i:216507;a:35:{s:5:"title";s:16:"BCO_Black Cohosh";s:3:"nid";s:6:"216507";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"BCO";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:12:"Black Cohosh";s:22:"field_monograph_name_f";s:12:"Actée noire";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:102:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_cohosh-grappes-eng.php";s:21:"field_monograph_url_f";s:102:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_cohosh-grappes-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:535:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.  Note: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion.Claims for traditional use must include the term “Herbal Medicine”.";s:12:"field_note_f";s:718:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.  Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit.Les allégations concernant l’usage traditionnel doivent inclure le terme « phytothérapie ».";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:1870:"The medicinal ingredient may comply with the specifications outlined in the Black Cohosh, Black Cohosh Fluidextract, Powdered Black Cohosh, Powdered Black Cohosh Extract, or the Black Cohosh Tablets Monographs published in the US Pharmacopeia.;  Health Canada is aware of peer-reviewed published cases where products labelled as containing Black Cohosh were found by laboratory analysis to contain different species. In order to prevent misidentification, the identification of authentic Black Cohosh must be completed by an unambiguous validated method such as the HPLC-ELSD, HPLC-MS or HPLC-MS/MS to determine the presence of a specific marker compound and/or the absence of others. For example, Actaea racemosa contains the triterpene glycoside cimiracemoside C (also called cimigenol-3-O-arabinoside), while most other Actaea/Cimicifuga species do not.  Conversely, other Actaea/Cimicifuga species contain the phenolic acid derivatives cimifugin and (or) cimifigin-3-O-glucoside (e.g. A. cimicifuga and A. yunnanensis, but not A. dahurica) while Black Cohosh does not. The commonly used markers, 23-epi-26-deoxyactein and actein, are found in more than one species of Actaea and therefore their presence is not sufficient evidence alone of the unambiguous identification of Actaea racemosa (Jiang et al. 2006, He et al. 2000). The NHPD recognizes that there are numerous methods which can be used to unambiguously identify Black Cohosh. These methods include, but are not limited to, those cited in the following references: Avula et al. 2007, He et al. 2006, Jiang et al. 2006, Brigham et al. 2004, Zerega et al. 2002, He et al. 2000.  Note: Data relating to the identification of Black Cohosh, using an  unambiguous validated method, is not to be submitted with the  compendial Product Licence Application, although it may be  requested at the NHPD’s discretion.";s:21:"field_specification_f";s:2198:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies Black Cohosh, Black Cohosh Fluidextract, Powdered Black Cohosh, Powdered Black Cohosh Extract, ou Black Cohosh Tablets publiées dans la Pharmacopée américaine (USP).;  Santé Canada est au courant de cas (publiés et revus par des paires) où des analyses de laboratoire ont révélé que certains produits, dont l’étiquette identifiait l’actée noire comme ingrédient, contenaient une toute autre espèce. Afin d’éviter les erreurs d’identification, l’actée noire authentique doit être identifiée en utilisant une méthode validée non équivoque telle que la CLHP-DEDL (HPLC-ELSD), la CLHP-SM (CLHP-MS) ou la CLHP-SM/SM (HPLC-MS/MS) pour détecter la présence d’un marqueur spécifique ou l’absence d’autres marqueurs. Par exemple, Actea racemosa contient un glycoside triterpénique, le cimiracémoside C (aussi appelé cimigénol-3-O-arabinoside), alors que la plupart des autres espèces d’Actea/Cimicifuga n’en contiennent pas.  Réciproquement, d’autres espèces d’Actea/Cimicifuga (e.g. A. cimicifuga et A. yunnanensis, mais pas A. dahurica) renferment de la cimifugine et (ou) du cimifigine-3-O-glucoside, des dérivés d’acide phénolique, tandis que l’actée noire n’en contient pas. Les marqueurs couramment utilisés, la 23-épi-26-déoxyactéine et l’actéine, étant présents sur plus d’une espèce d’Actaea, leur seule présence ne suffit donc pas à identifier de façon non équivoque Actea racemosa (Jiang et al. 2006, He et al. 2000). La DPSN reconnaît qu’il existe de nombreuses méthodes pouvant être utilisées pour identifier sans équivoque l’actée noire et fournit ci-après des références concernant certaines de ces méthodes : Avula et al. 2007, He et al. 2006, Jiang et al. 2006, Brigham et al. 2004, Zerega et al. 2002, He et al. 2000. Nota : Les données relatives à l’identification de l’actée noire en  utilisant une méthode validée et non équivoque ne doivent pas  accompagnées la demande de licence de mise en marché  officinale -- ces données seront soumises à la DPSN sur demande  seulement.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-09-19";s:16:"field_legacy_nid";s:6:"100813";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:32:"PERS;WORS;BCO_CW1;BCO_CW2;BCO_CI";s:21:"field_mono_citation_e";s:169:"ACTAEA;BHP;EXPCEM;BHP2;BHCOM;GPPIHI;UPHCDI8;AUTOHEP;THEPHA;CASEREP;KAD;CRDEE;CIMIID;LCMS;MEDHER;BOTAUTH;FULMHF;HERCOM;HMPL;WSHOP;ENDSAF;HEART;GRIN;PHC;PNCBDP;ETBCEE;AFLP";s:21:"field_mono_citation_f";s:179:"ACTAEA;BHP;EXPCEM;BHP2;BHCOM;GPPIHI;UPHCDI8;AUTOHEP;THEPHA;CASEREP;KAD;CRDEE;NOMEN;CIMIID;LCMS;MEDHER;BOTAUTH;FULMHF;HMPL;WSHOP;PPS;ENDSAF;CMCROP;HEART;GRIN;PHC;PNCBDP;ETBCEE;AFLP";s:26:"field_reference_reviewed_e";s:218:"DECSEP8;COURT;HERCDI;HERBS;BCHEPA;REVNP;EMEAPS;CAPEM;HCP450;P4503A;AWR;TREATHF;MAMMO;RTBC;CAMMS;FULLF;PHYINV;HPBCO;RCDSEMS;BOTSAF;MHRAACT;PPP;ESTRA;ISOPBC;PGNM;MGMTHOT;NLCI;BCRHIZ;REMIFEM;BCOHR;HDPP2;WEP;BONETO;BNO1055";s:26:"field_reference_reviewed_f";s:218:"DECSEP8;COURT;HERCDI;HERBS;BCHEPA;REVNP;EMEAPS;CAPEM;HCP450;P4503A;AWR;TREATHF;MAMMO;RTBC;CAMMS;FULLF;PHYINV;HPBCO;RCDSEMS;BOTSAF;MHRAACT;PPP;ESTRA;ISOPBC;PGNM;MGMTHOT;NLCI;BCRHIZ;REMIFEM;BCOHR;HDPP2;WEP;BONETO;BNO1055";}i:216508;a:35:{s:5:"title";s:19:"BHO_Black Horehound";s:3:"nid";s:6:"216508";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"BHO";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:15:"Black Horehound";s:22:"field_monograph_name_f";s:13:"Ballote noire";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:115:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_blackhorehound-ballotenoire-eng.php";s:21:"field_monograph_url_f";s:115:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_blackhorehound-ballotenoire-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:155:"The medicinal ingredient may comply with the specifications outlined in the Black Horehound Monographs published in the European or British Pharmacopoeias.";s:21:"field_specification_f";s:178:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies de la ballote noire publiées dans les Pharmacopées européenne ou britannique.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-02-14";s:16:"field_legacy_nid";s:6:"100814";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:21:"PERS;WORS;BREC;BHO_CI";s:21:"field_mono_citation_e";s:63:"HERMED2;BHP;BHCOM2;HERCDI;KAD;AMODHER;MEDHER;HERCOM;GRIN;PNCBDP";s:21:"field_mono_citation_f";s:71:"HERMED2;BHP;PMM;BHCOM2;HERCDI;PHAPHY;KAD;AMODHER;MEDHER;GRIN;WEP;PNCBDP";s:26:"field_reference_reviewed_e";s:6:"BOTSAF";s:26:"field_reference_reviewed_f";s:6:"BOTSAF";}i:216509;a:35:{s:5:"title";s:28:"BLT_O_Blessed Thistle - Oral";s:3:"nid";s:6:"216509";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"BLT_O";s:18:"field_group_name_e";s:15:"Blessed Thistle";s:18:"field_group_name_f";s:13:"Chardon béni";s:22:"field_monograph_name_e";s:22:"Blessed Thistle - Oral";s:22:"field_monograph_name_f";s:21:"Chardon béni - Orale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-02-13";s:16:"field_legacy_nid";s:6:"100815";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:36:"PERS;WORS;BREC;BLT_CI;BLTO_CI;BLT_AR";s:21:"field_mono_citation_e";s:52:"EXPCEM;BHCOM;HERCDI;KAD;BOTSAF;HERCOM;GRIN;PHC;PCBDP";s:21:"field_mono_citation_f";s:56:"EXPCEM;BHCOM;HERCDI;PHAPHY;KAD;BOTSAF;GRIN;WEP;PHC;PCBDP";s:26:"field_reference_reviewed_e";s:63:"BHP;CGCEM;PHAPHY;HPIM;ECMM;MEDHER;THEHER;FAMHBL;STED;WEP;PNCBDP";s:26:"field_reference_reviewed_f";s:59:"BHP;CGCEM;PHAPHY;HPIM;ECMM;MEDHER;THEHER;FAMHBL;STED;PNCBDP";}i:216510;a:35:{s:5:"title";s:31:"BLT_T_Blessed Thistle - Topical";s:3:"nid";s:6:"216510";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"BLT_T";s:18:"field_group_name_e";s:15:"Blessed Thistle";s:18:"field_group_name_f";s:13:"Chardon béni";s:22:"field_monograph_name_e";s:25:"Blessed Thistle - Topical";s:22:"field_monograph_name_f";s:23:"Chardon béni - Topique";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-02-13";s:16:"field_legacy_nid";s:6:"100816";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:23:"PERS;WORS;BLT_CI;BLT_AR";s:21:"field_mono_citation_e";s:52:"EXPCEM;BHCOM;HERCDI;KAD;BOTSAF;HERCOM;GRIN;PHC;PCBDP";s:21:"field_mono_citation_f";s:56:"EXPCEM;BHCOM;HERCDI;PHAPHY;KAD;BOTSAF;GRIN;WEP;PHC;PCBDP";s:26:"field_reference_reviewed_e";s:63:"BHP;CGCEM;PHAPHY;HPIM;ECMM;MEDHER;THEHER;FAMHBL;STED;WEP;PNCBDP";s:26:"field_reference_reviewed_f";s:59:"BHP;CGCEM;PHAPHY;HPIM;ECMM;MEDHER;THEHER;FAMHBL;STED;PNCBDP";}i:216511;a:36:{s:5:"title";s:9:"BOL_Boldo";s:3:"nid";s:6:"216511";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"BOL";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:5:"Boldo";s:22:"field_monograph_name_f";s:5:"Boldo";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:93:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_boldo-eng.php";s:21:"field_monograph_url_f";s:93:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_boldo-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-01-15";s:16:"field_legacy_nid";s:6:"100817";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:6:"BOLDUR";s:15:"field_mono_risk";s:23:"PERS;WORS;BOL_CW;BOL_CI";s:21:"field_mono_citation_e";s:82:"HERMED2;EXPCEM;BHCOM2;UPHCDI7;HERCDI;ESCOP;KAD;MEDHER;HERCOM;HERSAF;GRIN;WEP;PCBDP";s:21:"field_mono_citation_f";s:85:"HERMED2;EXPCEM;BHCOM2;UPHCDI7;HERCDI;PHAPHY;ESCOP;KAD;MEDHER;HERCOM;HERSAF;GRIN;PCBDP";s:26:"field_reference_reviewed_e";s:29:"HERMED;BHP;HDPP;AMODHER;HDPP2";s:26:"field_reference_reviewed_f";s:29:"HERMED;BHP;HDPP;AMODHER;HDPP2";}i:216512;a:33:{s:5:"title";s:14:"BOR_Borage Oil";s:3:"nid";s:6:"216512";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"BOR";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:10:"Borage Oil";s:22:"field_monograph_name_f";s:19:"Bourrache, Huile de";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:104:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_borage-bourrache-eng.php";s:21:"field_monograph_url_f";s:104:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_borage-bourrache-fra.php";s:16:"field_nmi_note_e";s:157:"For products providing vitamin E at doses lower than the minima specified in Table 2 of Appendix 1, vitamin E must be declared as a non-medicinal ingredient.";s:16:"field_nmi_note_f";s:209:"La vitamine E doit être déclarée comme ingrédient non médicinal dans le cas des produits fournissant de la vitamine E à des doses inférieures aux doses minimales présentées au tableau 2 de l'annexe 1.";s:12:"field_note_e";s:887:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.      Note: (i) Text in parentheses is additional optional information which can be included on the Product Licence Application and product labels at the applicants’ discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.  (ii)  Vitamin E is an optional medicinal ingredient in borage oil products.  However, no use or purpose statements may be associated with vitamin E.  See Appendix 1 for vitamin E proper name, common name, source material, and dose information.";s:12:"field_note_f";s:1101:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.      Nota: (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.  (ii) Les produits d’huile de bourrache peuvent contenir de la vitamine E comme ingrédient médicinal facultatif. Cependant, aucun énoncé concernant les usage(s) ou fin(s) recommandés ne peut être associé à la vitamine E. Consulter l’annexe 1 pour les noms propres et communs, les matières d’origine et les doses de la vitamine E.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:389:"The medicinal ingredient may comply with the specifications outlined in the Refined Borage Oil Monograph published in the British Pharmacopoeia or the Refined Borage (Starflower) Oil Monograph published in the European Pharmacopoeia;  For products indicating one or more of the optional potencies listed in the dose section, an assay must be performed in order to confirm the potency(ies).";s:21:"field_specification_f";s:458:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie Refined Borage Oil publiée dans la Pharmacopée britannique (BP) ou la monographie Refined Borage (Starflower) Oil publiée dans la Pharmacopée européenne (Ph.Eur.);  Dans le cas des produits affichant une ou plusieurs activités énoncées à la section des doses, une analyse doit être effectuée afin de confirmer la validité de cette (ces) activité(s).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-06-19";s:16:"field_legacy_nid";s:6:"100818";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:21:"field_mono_citation_e";s:89:"BPH8;MEDHER;IOMDRI;FCC;DRIECF;HERCOM;MERCK13;EP8;REGAIN;MART35;ATOPECZ;GRIN;ATOPDER;B4GEN";s:21:"field_mono_citation_f";s:93:"BPH8;PHAPHY;MEDHER;IOMDRI;FCC;DRIECF;MERCK13;EP8;REGAIN;MART35;ATOPECZ;GRIN;ATOPDER;WEP;B4GEN";s:26:"field_reference_reviewed_e";s:41:"UPHCDI8;HERCDI;ATHROMB;N3FA;EPILEP;DIHOMO";s:26:"field_reference_reviewed_f";s:41:"UPHCDI8;HERCDI;ATHROMB;N3FA;EPILEP;DIHOMO";}i:216513;a:33:{s:5:"title";s:18:"BTF_Fennel, Bitter";s:3:"nid";s:6:"216513";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"BTF";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:14:"Fennel, Bitter";s:22:"field_monograph_name_f";s:12:"Fenouil amer";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:112:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_bitterfennel_fenouilamer-eng.php";s:21:"field_monograph_url_f";s:112:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_bitterfennel_fenouilamer-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:179:"The medicinal ingredient may comply with the specifications outlined in the Bitter Fennel or Bitter-Fennel Fruit Oil Monographs published in the European or British Pharmacopoeias";s:21:"field_specification_f";s:214:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies Bitter Fennel ou Bitter-Fennel Fruit Oil publiées dans les Pharmacopées britannique (BP) ou européenne (Ph. Eur.)";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-03-19";s:16:"field_legacy_nid";s:6:"100819";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:16:"ADU;ADU13;CH4_12";s:19:"field_mono_duration";s:15:"BTFDUR1;BTFDUR2";s:15:"field_mono_risk";s:39:"PERS;WORS;BTF_CW1;BTF_CW2;BTF_CI;BTF_AR";s:21:"field_mono_citation_e";s:21:"EMEABTF;EMEABTFO;GRIN";s:21:"field_mono_citation_f";s:35:"PHAPHY;EMEABTF;EMEABTFO;MMPND2;GRIN";}i:216514;a:36:{s:5:"title";s:20:"BUR_O_Burdock - Oral";s:3:"nid";s:6:"216514";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"BUR_O";s:18:"field_group_name_e";s:7:"Burdock";s:18:"field_group_name_f";s:7:"Bardane";s:22:"field_monograph_name_e";s:14:"Burdock - Oral";s:22:"field_monograph_name_f";s:15:"Bardane - Orale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-01-21";s:16:"field_legacy_nid";s:6:"100820";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:6:"BURDUR";s:15:"field_mono_risk";s:46:"PERS;WORS;BURO_CW1;BREC;BUR_CI1;BUR_CI2;BUR_AR";s:21:"field_mono_citation_e";s:95:"HERMED2;HBNPD;BHP2;BHP;BHCOM;UPHCDI7;HERCDI;PATSC;AMODHER;MEDHER;HERCOM;GRIN;HDPP2;PNCBDP;PCBDP";s:21:"field_mono_citation_f";s:105:"HERMED2;HBNPD;BHP2;BHP;BHCOM;UPHCDI7;HERCDI;FLORE;PHAPHY;PATSC;AMODHER;MEDHER;GRIN;HDPP2;WEP;PNCBDP;PCBDP";s:26:"field_reference_reviewed_e";s:29:"HERMED;HDPP;PDRHM;HERSAF;PGNM";s:26:"field_reference_reviewed_f";s:29:"HERMED;HDPP;PDRHM;HERSAF;PGNM";}i:216515;a:35:{s:5:"title";s:23:"BUR_T_Burdock - Topical";s:3:"nid";s:6:"216515";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"BUR_T";s:18:"field_group_name_e";s:7:"Burdock";s:18:"field_group_name_f";s:7:"Bardane";s:22:"field_monograph_name_e";s:17:"Burdock - Topical";s:22:"field_monograph_name_f";s:17:"Bardane - Topique";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-01-21";s:16:"field_legacy_nid";s:6:"100821";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:32:"PERS;WORS;BUR_CI1;BUR_CI2;BUR_AR";s:21:"field_mono_citation_e";s:95:"HERMED2;HBNPD;BHP2;BHP;BHCOM;UPHCDI7;HERCDI;PATSC;AMODHER;MEDHER;HERCOM;GRIN;HDPP2;PNCBDP;PCBDP";s:21:"field_mono_citation_f";s:105:"HERMED2;HBNPD;BHP2;BHP;BHCOM;UPHCDI7;HERCDI;FLORE;PHAPHY;PATSC;AMODHER;MEDHER;GRIN;HDPP2;WEP;PNCBDP;PCBDP";s:26:"field_reference_reviewed_e";s:29:"HERMED;HDPP;PDRHM;HERSAF;PGNM";s:26:"field_reference_reviewed_f";s:29:"HERMED;HDPP;PDRHM;HERSAF;PGNM";}i:216516;a:35:{s:5:"title";s:13:"CAFF_Caffeine";s:3:"nid";s:6:"216516";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"CAFF";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:8:"Caffeine";s:22:"field_monograph_name_f";s:8:"Caféine";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:98:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_caffe-cafe-eng.php";s:21:"field_monograph_url_f";s:98:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_caffe-cafe-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-01-02";s:16:"field_legacy_nid";s:6:"100822";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:19:"field_mono_duration";s:6:"CAFDUR";s:15:"field_mono_risk";s:63:"CAF_CW1;CAF_CW2;CAF_CW3;CAF_CW4;CAF_CW5;CAF_CW6;CAF_AR1;CAF_AR2";s:21:"field_mono_citation_e";s:275:"DETINS;DISBIO;IOPRES;HBNPD;ISCHSTR;BPHREFF;BMES;NONWV;CCCHD;CAFBLAD;PEREXE;CAFDOS;SUPEPH;STDRUG;REMI;ANORCA;HEMODYN;REVREC;CAFHYP;ANACAF;FCC;SUSTAIN;CHRONIC;LITTREM;CAFWITH;PLASMA;INCLIT;HUMHEA;FBBIA;BPRESP;COFNAP;PHRAT;NATRIUR;MOODPER;TNF25;ISCHAEM;CAFSYN;ANADJ;ZIMM;CAFALRT";s:21:"field_mono_citation_f";s:275:"DETINS;DISBIO;IOPRES;HBNPD;ISCHSTR;BPHREFF;BMES;NONWV;CCCHD;CAFBLAD;PEREXE;CAFDOS;SUPEPH;STDRUG;REMI;ANORCA;HEMODYN;REVREC;CAFHYP;ANACAF;FCC;SUSTAIN;CHRONIC;LITTREM;CAFWITH;PLASMA;INCLIT;HUMHEA;FBBIA;BPRESP;COFNAP;PHRAT;NATRIUR;MOODPER;TNF25;ISCHAEM;CAFSYN;ANADJ;ZIMM;CAFALRT";s:26:"field_reference_reviewed_e";s:619:"LUMB;TREADM;THROMB;INTCAF;CAFEST;CAFHV;ALCCAF;SMOKCAF;CAFASTH;QUINO;CAFCONS;DISULF;CAFEPH;10KMRUN;BIOFOOD;SCHOOL;PREPCAF;CAFPHEN;ROWPERF;QUINOL;CAFMED;CAFBPPA;POSTDUR;FLUVO;MATCAF;PREMSYN;SERUMCAF;CAFFI;FRV;FRV2;CNISM;PERFDEC;ACUMIG;CDWC;CCCD;CLOZA;CTCC;GUARA;GSDIS;FLUVOX;MEXIL;CDSUAC;CHDD;STEREO;PHENYL;ANALADJ;GALLW;GALLM;MYTH;MIGHP;CAFCAT;HDCD;CIMETI;FATIG;TENSHA;BITOR;CCHD;BBP;COFINF;NDBP;RCEC;CAFDEP;ERTPW;ANAPH;CCVSDC;CAFVD;PPPS;DIUED;PARKIN;CCBPS;CCBTFSPS;PSSELF;TPSPRC;T2DIAB;CYP1A;CIPO;APNEA;PLPS;HUMBEH;IMPGLUC;SADC;UPDRES;PERIEXT;SHITSP;CHOLRAIS;HCCPH;HEADA;CAFCREA;ADENO;CONTCAF;KETOCO;T1DIA;HABCAF;SODBEN";s:26:"field_reference_reviewed_f";s:619:"LUMB;TREADM;THROMB;INTCAF;CAFEST;CAFHV;ALCCAF;SMOKCAF;CAFASTH;QUINO;CAFCONS;DISULF;CAFEPH;10KMRUN;BIOFOOD;SCHOOL;PREPCAF;CAFPHEN;ROWPERF;QUINOL;CAFMED;CAFBPPA;POSTDUR;FLUVO;MATCAF;PREMSYN;SERUMCAF;CAFFI;FRV;FRV2;CNISM;PERFDEC;ACUMIG;CDWC;CCCD;CLOZA;CTCC;GUARA;GSDIS;FLUVOX;MEXIL;CDSUAC;CHDD;STEREO;PHENYL;ANALADJ;GALLW;GALLM;MYTH;MIGHP;CAFCAT;HDCD;CIMETI;FATIG;TENSHA;BITOR;CCHD;BBP;COFINF;NDBP;RCEC;CAFDEP;ERTPW;ANAPH;CCVSDC;CAFVD;PPPS;DIUED;PARKIN;CCBPS;CCBTFSPS;PSSELF;TPSPRC;T2DIAB;CYP1A;CIPO;APNEA;PLPS;HUMBEH;IMPGLUC;SADC;UPDRES;PERIEXT;SHITSP;CHOLRAIS;HCCPH;HEADA;CAFCREA;ADENO;CONTCAF;KETOCO;T1DIA;HABCAF;SODBEN";}i:216517;a:35:{s:5:"title";s:22:"CAD_O_Calendula - Oral";s:3:"nid";s:6:"216517";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"CAD_O";s:18:"field_group_name_e";s:9:"Calendula";s:18:"field_group_name_f";s:9:"Calendule";s:22:"field_monograph_name_e";s:16:"Calendula - Oral";s:22:"field_monograph_name_f";s:17:"Calendule - Orale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-01-25";s:16:"field_legacy_nid";s:6:"100823";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:37:"PERS;WORS;BREC;CAD_CI;CAD_CI_O;CAD_AR";s:21:"field_mono_citation_e";s:111:"EXPCEM;ENHCI;BHCOM2;UPHCDI7;HERCDI;THEPHA;ESCOP;KAD;MEDHER;HERCOM;HTCH;HERSAF;HMCAL;PPHPP;GRIN;HDPP2;WEP;PNCBDP";s:21:"field_mono_citation_f";s:114:"EXPCEM;ENHCI;PMM;BHCOM2;UPHCDI7;HERCDI;THEPHA;ESCOP;KAD;NOMEN;MEDHER;HTCH;HERSAF;PPS;HMCAL;PPHPP;GRIN;HDPP2;PNCBDP";s:26:"field_reference_reviewed_e";s:30:"HERMED2;BHP;CGCEM;50COM;MART35";s:26:"field_reference_reviewed_f";s:30:"HERMED2;BHP;CGCEM;50COM;MART35";}i:216518;a:35:{s:5:"title";s:24:"CAD_B_Calendula - Buccal";s:3:"nid";s:6:"216518";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"CAD_B";s:18:"field_group_name_e";s:9:"Calendula";s:18:"field_group_name_f";s:9:"Calendule";s:22:"field_monograph_name_e";s:18:"Calendula - Buccal";s:22:"field_monograph_name_f";s:19:"Calendule - Buccale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-01-25";s:16:"field_legacy_nid";s:6:"100824";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:28:"PERS;WORS;PREC;CAD_CI;CAD_AR";s:21:"field_mono_citation_e";s:111:"EXPCEM;ENHCI;BHCOM2;UPHCDI7;HERCDI;THEPHA;ESCOP;KAD;MEDHER;HERCOM;HTCH;HERSAF;HMCAL;PPHPP;GRIN;HDPP2;WEP;PNCBDP";s:21:"field_mono_citation_f";s:114:"EXPCEM;ENHCI;PMM;BHCOM2;UPHCDI7;HERCDI;THEPHA;ESCOP;KAD;NOMEN;MEDHER;HTCH;HERSAF;PPS;HMCAL;PPHPP;GRIN;HDPP2;PNCBDP";s:26:"field_reference_reviewed_e";s:30:"HERMED2;BHP;CGCEM;50COM;MART35";s:26:"field_reference_reviewed_f";s:30:"HERMED2;BHP;CGCEM;50COM;MART35";}i:216519;a:35:{s:5:"title";s:25:"CAD_T_Calendula - Topical";s:3:"nid";s:6:"216519";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"CAD_T";s:18:"field_group_name_e";s:9:"Calendula";s:18:"field_group_name_f";s:9:"Calendule";s:22:"field_monograph_name_e";s:19:"Calendula - Topical";s:22:"field_monograph_name_f";s:19:"Calendule - Topique";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-01-25";s:16:"field_legacy_nid";s:6:"100825";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:4:"ADU2";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:28:"PERS;WORS;PREC;CAD_CI;CAD_AR";s:21:"field_mono_citation_e";s:111:"EXPCEM;ENHCI;BHCOM2;UPHCDI7;HERCDI;THEPHA;ESCOP;KAD;MEDHER;HERCOM;HTCH;HERSAF;HMCAL;PPHPP;GRIN;HDPP2;WEP;PNCBDP";s:21:"field_mono_citation_f";s:114:"EXPCEM;ENHCI;PMM;BHCOM2;UPHCDI7;HERCDI;THEPHA;ESCOP;KAD;NOMEN;MEDHER;HTCH;HERSAF;PPS;HMCAL;PPHPP;GRIN;HDPP2;PNCBDP";s:26:"field_reference_reviewed_e";s:30:"HERMED2;BHP;CGCEM;50COM;MART35";s:26:"field_reference_reviewed_f";s:30:"HERMED2;BHP;CGCEM;50COM;MART35";}i:216520;a:34:{s:5:"title";s:11:"CAL_Calcium";s:3:"nid";s:6:"216520";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"CAL";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:7:"Calcium";s:22:"field_monograph_name_f";s:7:"Calcium";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:95:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_calcium-eng.php";s:21:"field_monograph_url_f";s:95:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_calcium-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:620:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.      Note: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicants’ discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:788:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient (ou des ingrédients) médicinal (médicinaux). La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.     Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:186:"The medicinal ingredient may comply with the specifications outlined in the applicable calcium monographs published in the USA (USP), British (BP) and European (Ph. Eur.) Pharmacopoeias.";s:21:"field_specification_f";s:206:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies du calcium publiées dans les pharmacopées Américaine (USP), Britannique (BP) et Européenne (Ph. Eur.).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-06-23";s:16:"field_legacy_nid";s:6:"100826";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:4:"ADU1";s:15:"field_dose_note";s:12:"MIN;MAX;ADUL";s:21:"field_mono_citation_e";s:133:"HALF;CALSUP;CALABC;AHFS;BPH8;OSTCAN;CVDO;ANHM;DPD;ESE;IOMDRI;FCC;DRICP;PPMEN;OPDT;MERCK14;MERCK13;COMPABS;EP8;MNHD;MART35;CALVD;TNF27";s:21:"field_mono_citation_f";s:133:"HALF;CALSUP;CALABC;AHFS;BPH8;OSTCAN;CVDO;ANHM;DPD;ESE;IOMDRI;FCC;DRICP;PPMEN;OPDT;MERCK14;MERCK13;COMPABS;EP8;MNHD;MART35;CALVD;TNF27";s:26:"field_reference_reviewed_e";s:27:"D3CAL;TOVER;CITRATE;HLTHSUR";s:26:"field_reference_reviewed_f";s:27:"D3CAL;TOVER;CITRATE;HLTHSUR";}i:216521;a:35:{s:5:"title";s:20:"CPO_California poppy";s:3:"nid";s:6:"216521";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"CPO";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:16:"California poppy";s:22:"field_monograph_name_f";s:19:"Pavot de californie";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:98:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_california-eng.php";s:21:"field_monograph_url_f";s:98:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_california-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-03-17";s:16:"field_legacy_nid";s:6:"100827";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:47:"PERS;WORS;CPO_CW1;CPO_CW2;CPO_CW3;CPO_CI;CPO_AR";s:21:"field_mono_citation_e";s:65:"HBNPD;EXPCEM;HERCDI;UPHCDI8;PHARTH;KAD2;MEDHER;HERCOM;HERSAF;GRIN";s:21:"field_mono_citation_f";s:69:"HBNPD;EXPCEM;PMM;HERCDI;UPHCDI8;PHAPHY;PHARTH;KAD2;MEDHER;HERSAF;GRIN";s:26:"field_reference_reviewed_e";s:17:"BOTSAF;MPPW;MOMMP";s:26:"field_reference_reviewed_f";s:17:"BOTSAF;MPPW;MOMMP";}i:216522;a:35:{s:5:"title";s:11:"CAR_Caraway";s:3:"nid";s:6:"216522";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"CAR";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:7:"Caraway";s:22:"field_monograph_name_f";s:5:"Carvi";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:101:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_caraway-carvi-eng.php";s:21:"field_monograph_url_f";s:101:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_caraway-carvi-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:264:"The medicinal ingredient may comply with the specifications outlined in one of the following pharmacopoeial monographs:  Caraway Fruit monograph in British Pharmacopoeia, Caraway Fruit monograph in European Pharmacopoeia, and Caraway monograph in US Pharamcopoeia.";s:21:"field_specification_f";s:283:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes:  'Caraway Fruit' de la Pharmacopée britannique (BP), 'Caraway Fruit' de la Pharmacopée européenne (Ph. Eur.) et 'Caraway' de la Pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-02-28";s:16:"field_legacy_nid";s:6:"100828";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:32:"ADU;INF612;CH13;CH49;ADU10;CHI_4";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:35:"CAR_CW1;CAR_CW2;PREGC;CAR_CI;CAR_AR";s:21:"field_mono_citation_e";s:89:"CGCEM;BHCOM2;HERCDI;THEPHA;ESCOP;KAD;KAD2;AMODHER;MEDHER;HERCOM;HTCH;PPHPP;GRIN;HDPP2;WEP";s:21:"field_mono_citation_f";s:86:"CGCEM;PMM;BHCOM2;HERCDI;THEPHA;ESCOP;KAD;KAD2;AMODHER;MEDHER;HTCH;PPHPP;GRIN;HDPP2;WEP";s:26:"field_reference_reviewed_e";s:21:"BHP;BOTSAF;NAE;PNCBDP";s:26:"field_reference_reviewed_f";s:21:"BHP;BOTSAF;NAE;PNCBDP";}i:216523;a:29:{s:5:"title";s:40:"CDRL_Laxatives, Carbon Dioxide-Releasing";s:3:"nid";s:6:"216523";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"CDRL";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:35:"Laxatives, Carbon Dioxide-Releasing";s:22:"field_monograph_name_f";s:40:"Laxatifs libérant du dioxyde de carbone";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"C;P";s:21:"field_monograph_url_e";s:42:"atReq.do?atid=laxa_carbon_dioxide&lang=eng";s:21:"field_monograph_url_f";s:42:"atReq.do?atid=laxa_carbon_dioxide&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:0:"";s:16:"field_legacy_nid";s:6:"100829";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216524;a:36:{s:5:"title";s:19:"CAS_Cascara Sagrada";s:3:"nid";s:6:"216524";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"CAS";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:15:"Cascara Sagrada";s:22:"field_monograph_name_f";s:15:"Cascara sagrada";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:95:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_cascara-eng.php";s:21:"field_monograph_url_f";s:95:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_cascara-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:567:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.     Note: (i) Text in parentheses is additional optional information which can be included on the Product Licence Application and product labels at the applicant’s discretion.  (ii) Claims for traditional use must include the term “Herbal Medicine”.";s:12:"field_note_f";s:732:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.     Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit.  (ii) Les allégations concernant l’usage traditionnel doivent inclure le terme « phytothérapie ».";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:658:"Bark must be dried and aged for a minimum of one year (Wichtl 2004, Blumenthal et al. 2000) or heated and dried to induce artificial aging to allow oxidation of the anthrones (Blumenthal et al. 2000).  For example, the bark may be heated in hot air at 80-100°C for several hours (Wichtl 2004).;  The medicinal ingredient may comply with the specifications outlined in one of the following pharmacopoeial monographs:  'Cascara' or 'Standardized Cascara Dry Extract' in British Pharmacopoeia, 'Cascara' or 'Cascara Dry Extract, Standardised' in European Pharmacopoeia, and 'Cascara Sagrada', 'Cascara Sagrada Extract' or 'Cascara Tablets' in US Pharamcopoeia.";s:21:"field_specification_f";s:796:"L’écorce doit être séchée et vieillie durant au moins une année (Wichtl 2004, Blumenthal et al. 2000) ou doit être chauffée et séchée pour induire un vieillissement artificiel permettant l’oxydation des anthrones (Blumenthal et al. 2000). Par exemple, l’écorce peut être exposée à l’air chaud à une température de 80 à 100°C durant plusieurs heures (Wichtl 2004).;  L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes:  'Cascara' ou 'Standardized Cascara Dry Extract' de la Pharmacopée britannique (BP), 'Cascara' ou 'Cascara Dry Extract, Standardised' de la Pharmacopée européenne (Ph. Eur.) et ''Cascara Sagrada', 'Cascara Sagrada Extract' ou 'Cascara Tablets' de la Pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-10-31";s:16:"field_legacy_nid";s:6:"100830";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:5:"ADU11";s:15:"field_dose_note";s:11:"APP1;CAS_DR";s:19:"field_mono_duration";s:6:"CASDUR";s:15:"field_mono_risk";s:65:"PERS;WORS;CAS_CW1;CAS_CW2;CAS_CW3;CAS_CW4;CAS_CI1;CAS_CI2;CAS_ADR";s:21:"field_mono_citation_e";s:107:"HBNPD;EXPCEM;BHCOM;HERCDI;BPH8;HMRP;ESCOP;KAD;HERCOM;HERSAF;NAE;EP8;CPS;MART35;GRIN;TNF26;WHOMON2;HDPP2;PHC";s:21:"field_mono_citation_f";s:115:"HBNPD;EXPCEM;PMM;BHCOM;HERCDI;BPH8;PHAPHY;HMRP;ESCOP;KAD;HERSAF;NAE;EP8;CPS;MART35;GRIN;TNF26;WHOMON2;HDPP2;WEP;PHC";s:26:"field_reference_reviewed_e";s:82:"HERMED;BHP2;BHP;THEPHA;LDPOTC;PDRHM3;STIMLAX;GENLAX;MEDHER;PPP;NPPT;DUSA;PATSC;WEP";s:26:"field_reference_reviewed_f";s:82:"HERMED;BHP2;BHP;THEPHA;LDPOTC;PDRHM3;STIMLAX;GENLAX;MEDHER;PPP;NPPT;DUSA;PATSC;WEP";}i:216525;a:35:{s:5:"title";s:10:"CAT_Catnip";s:3:"nid";s:6:"216525";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"CAT";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:6:"Catnip";s:22:"field_monograph_name_f";s:7:"Cataire";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:102:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_catnip-cataire-eng.php";s:21:"field_monograph_url_f";s:102:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_catnip-cataire-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-04-28";s:16:"field_legacy_nid";s:6:"100831";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:21:"PERS;WORS;BREC;CAT_CI";s:21:"field_mono_citation_e";s:60:"BHP;HERCDI;KAD;AMODHER;MEDHER;BOTSAF;HERCOM;DMH;NAE;GRIN;PHC";s:21:"field_mono_citation_f";s:63:"BHP;HERCDI;FLORE;KAD;AMODHER;MEDHER;BOTSAF;DMH;NAE;GRIN;WEP;PHC";s:26:"field_reference_reviewed_e";s:12:"PNCBDP;PCBDP";s:26:"field_reference_reviewed_f";s:12:"PNCBDP;PCBDP";}i:216527;a:34:{s:5:"title";s:45:"CHR_NP_Chromium (from non-picolinate sources)";s:3:"nid";s:6:"216527";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"CHR_NP";s:18:"field_group_name_e";s:8:"Chromium";s:18:"field_group_name_f";s:6:"Chrome";s:22:"field_monograph_name_e";s:38:"Chromium (from non-picolinate sources)";s:22:"field_monograph_name_f";s:31:"Chrome (sources non picolinate)";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:103:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_chromium-chrome-eng.php";s:21:"field_monograph_url_f";s:103:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_chromium-chrome-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:752:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.      Note: (i)Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.  (ii) For Chromium sourced from Chromium picolinate, please refer to the monograph entitled `Chromium (from Chromium picolinate)'";s:12:"field_note_f";s:904:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.      Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués. (ii) Pour du chrome provenant du Picolinate de chrome, veuillez faire référence à la monographie intitulée `Chrome (du Picolinate de chrome)`.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-12-09";s:16:"field_legacy_nid";s:6:"100834";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:29:"MIN;MAXCHR;ADUL;CHR_2;CHR_DEF";s:21:"field_mono_citation_e";s:266:"HALF;CHRMISL;CHRESS;POTANT;ANDERVP;ANTOVP;P242;P93;BUNNVP;CAMPVP;CAMPVP2;CAMPVP3;CEFAVP;CERUVP;NIABND;CUPPVP;EFSAA;CHRPYR;EVM3;GRANVP;ANHM;DPD;IOMDRI;DRIVAVK;KATOVP;KLEEVP;LEENVP;MANYVP;MCCAVP;EFFCIII;ENCNS;MERCK15;PASMVP;CHRSUP;SCF3;MNHD;SUGDVP;MART35;WANIVP;WASSVP";s:21:"field_mono_citation_f";s:266:"HALF;CHRMISL;CHRESS;POTANT;ANDERVP;ANTOVP;P242;P93;BUNNVP;CAMPVP;CAMPVP2;CAMPVP3;CEFAVP;CERUVP;NIABND;CUPPVP;EFSAA;CHRPYR;EVM3;GRANVP;ANHM;DPD;IOMDRI;DRIVAVK;KATOVP;KLEEVP;LEENVP;MANYVP;MCCAVP;EFFCIII;ENCNS;MERCK15;PASMVP;CHRSUP;SCF3;MNHD;SUGDVP;MART35;WANIVP;WASSVP";s:26:"field_reference_reviewed_e";s:614:"ANDEVP;ANDERVP2;ANDERVP3;ANDERVP4;ANDERVP5;ATSDR;BAGCVP;BAILVP;BAILVP2;BAILVP3;BERNVP;BESKVP;BOSCVP;COM4;CRN3;CORYVP;DILLOVP;ENVIRO;EPA8;EVAVP;EVAVP2;FERNVP;FOWLVP;FSA4;GAMMVP;GARGVP;GODAVP;GOODVP;GREENVP;GUIDVP;GUIDVP2;DDLS;HCMC;HCMM;LNHPD;HEPBVP;HEPBVP2;HEPBVP3;HINIVP;HUSZVP;IRIS08;IRIS98;IVANVP;JOVANVP;KERGVP;LAWRVP;LINDVP;MACKVP;MARTIVP;MCLEVP;MEHLVP;MELIVP;MITAVP;MORRIVP;NIH5;NTP8;NTP9;NTP9A;NTP9B;PRESSVP;READVP;RHODVP;ROTHVP;SANVPA;SANVPB;SCFEFSA;SCHRVP;SLESVP;SPEETVP;SPEETVP2;STEARVP;STEARVP2;STEARVWP;SNCWKCH;TZZFXBCH;TGACMEC;TGATGR;VBCJNCH;WJCCPCH;WSCSDCH;WHOTEHN;WHOIARC;WHOICAD;WFPSCH;YUKMCH;YTBBCH";s:26:"field_reference_reviewed_f";s:614:"ANDEVP;ANDERVP2;ANDERVP3;ANDERVP4;ANDERVP5;ATSDR;BAGCVP;BAILVP;BAILVP2;BAILVP3;BERNVP;BESKVP;BOSCVP;COM4;CRN3;CORYVP;DILLOVP;ENVIRO;EPA8;EVAVP;EVAVP2;FERNVP;FOWLVP;FSA4;GAMMVP;GARGVP;GODAVP;GOODVP;GREENVP;GUIDVP;GUIDVP2;DDLS;HCMC;HCMM;LNHPD;HEPBVP;HEPBVP2;HEPBVP3;HINIVP;HUSZVP;IRIS08;IRIS98;IVANVP;JOVANVP;KERGVP;LAWRVP;LINDVP;MACKVP;MARTIVP;MCLEVP;MEHLVP;MELIVP;MITAVP;MORRIVP;NIH5;NTP8;NTP9;NTP9A;NTP9B;PRESSVP;READVP;RHODVP;ROTHVP;SANVPA;SANVPB;SCFEFSA;SCHRVP;SLESVP;SPEETVP;SPEETVP2;STEARVP;STEARVP2;STEARVWP;SNCWKCH;TZZFXBCH;TGACMEC;TGATGR;VBCJNCH;WJCCPCH;WSCSDCH;WHOTEHN;WHOIARC;WHOICAD;WFPSCH;YUKMCH;YTBBCH";}i:216528;a:36:{s:5:"title";s:43:"CHR_PIC_Chromium (from Chromium picolinate)";s:3:"nid";s:6:"216528";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:7:"CHR_PIC";s:18:"field_group_name_e";s:8:"Chromium";s:18:"field_group_name_f";s:6:"Chrome";s:22:"field_monograph_name_e";s:35:"Chromium (from Chromium picolinate)";s:22:"field_monograph_name_f";s:32:"Chrome (du Picolinate de chrome)";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:103:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_chromium-chrome-eng.php";s:21:"field_monograph_url_f";s:103:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_chromium-chrome-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:759:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.      Note: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.  (ii) For Chromium sourced from non-picolinate sources, please refer to the monograph entitled `Chromium (from non-picolinate sources)'";s:12:"field_note_f";s:911:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.      Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.  (ii) Pour du chrome ne provenant pas du Picolinate de chrome, veuillez faire référence à la monographie intitulée `Chrome (sources non picolinate)`.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-12-09";s:16:"field_legacy_nid";s:6:"100835";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:33:"MIN;MAXCHR;ADUL_CHR;CHR_1;CHR_DEF";s:19:"field_mono_duration";s:3:"CHR";s:15:"field_mono_risk";s:13:"CHR_CW;CHR_CI";s:21:"field_mono_citation_e";s:266:"HALF;CHRMISL;CHRESS;POTANT;ANDERVP;ANTOVP;P242;P93;BUNNVP;CAMPVP;CAMPVP2;CAMPVP3;CEFAVP;CERUVP;NIABND;CUPPVP;EFSAA;CHRPYR;EVM3;GRANVP;ANHM;DPD;IOMDRI;DRIVAVK;KATOVP;KLEEVP;LEENVP;MANYVP;MCCAVP;EFFCIII;ENCNS;MERCK15;PASMVP;CHRSUP;SCF3;MNHD;SUGDVP;MART35;WANIVP;WASSVP";s:21:"field_mono_citation_f";s:266:"HALF;CHRMISL;CHRESS;POTANT;ANDERVP;ANTOVP;P242;P93;BUNNVP;CAMPVP;CAMPVP2;CAMPVP3;CEFAVP;CERUVP;NIABND;CUPPVP;EFSAA;CHRPYR;EVM3;GRANVP;ANHM;DPD;IOMDRI;DRIVAVK;KATOVP;KLEEVP;LEENVP;MANYVP;MCCAVP;EFFCIII;ENCNS;MERCK15;PASMVP;CHRSUP;SCF3;MNHD;SUGDVP;MART35;WANIVP;WASSVP";s:26:"field_reference_reviewed_e";s:614:"ANDEVP;ANDERVP2;ANDERVP3;ANDERVP4;ANDERVP5;ATSDR;BAGCVP;BAILVP;BAILVP2;BAILVP3;BERNVP;BESKVP;BOSCVP;COM4;CRN3;CORYVP;DILLOVP;ENVIRO;EPA8;EVAVP;EVAVP2;FERNVP;FOWLVP;FSA4;GAMMVP;GARGVP;GODAVP;GOODVP;GREENVP;GUIDVP;GUIDVP2;DDLS;HCMC;HCMM;LNHPD;HEPBVP;HEPBVP2;HEPBVP3;HINIVP;HUSZVP;IRIS08;IRIS98;IVANVP;JOVANVP;KERGVP;LAWRVP;LINDVP;MACKVP;MARTIVP;MCLEVP;MEHLVP;MELIVP;MITAVP;MORRIVP;NIH5;NTP8;NTP9;NTP9A;NTP9B;PRESSVP;READVP;RHODVP;ROTHVP;SANVPA;SANVPB;SCFEFSA;SCHRVP;SLESVP;SPEETVP;SPEETVP2;STEARVP;STEARVP2;STEARVWP;SNCWKCH;TZZFXBCH;TGACMEC;TGATGR;VBCJNCH;WJCCPCH;WSCSDCH;WHOTEHN;WHOIARC;WHOICAD;WFPSCH;YUKMCH;YTBBCH";s:26:"field_reference_reviewed_f";s:614:"ANDEVP;ANDERVP2;ANDERVP3;ANDERVP4;ANDERVP5;ATSDR;BAGCVP;BAILVP;BAILVP2;BAILVP3;BERNVP;BESKVP;BOSCVP;COM4;CRN3;CORYVP;DILLOVP;ENVIRO;EPA8;EVAVP;EVAVP2;FERNVP;FOWLVP;FSA4;GAMMVP;GARGVP;GODAVP;GOODVP;GREENVP;GUIDVP;GUIDVP2;DDLS;HCMC;HCMM;LNHPD;HEPBVP;HEPBVP2;HEPBVP3;HINIVP;HUSZVP;IRIS08;IRIS98;IVANVP;JOVANVP;KERGVP;LAWRVP;LINDVP;MACKVP;MARTIVP;MCLEVP;MEHLVP;MELIVP;MITAVP;MORRIVP;NIH5;NTP8;NTP9;NTP9A;NTP9B;PRESSVP;READVP;RHODVP;ROTHVP;SANVPA;SANVPB;SCFEFSA;SCHRVP;SLESVP;SPEETVP;SPEETVP2;STEARVP;STEARVP2;STEARVWP;SNCWKCH;TZZFXBCH;TGACMEC;TGATGR;VBCJNCH;WJCCPCH;WSCSDCH;WHOTEHN;WHOIARC;WHOICAD;WFPSCH;YUKMCH;YTBBCH";}i:216529;a:35:{s:5:"title";s:24:"CHS_Chondroitin Sulphate";s:3:"nid";s:6:"216529";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"CHS";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:20:"Chondroitin Sulphate";s:22:"field_monograph_name_f";s:25:"Chondroïtine, Sulfate de";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:99:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_chondroitin-eng.php";s:21:"field_monograph_url_f";s:99:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_chondroitin-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:1173:"The medicinal ingredient must either: i. Comply with the specifications outlined in the Chondroitin Sulfate Sodium Monographs published in the British or European Pharmacopoeiae, or the United States Pharmacopoeia or, ii. Be cited in an approved NHP Master File, authorized by a letter of access issued to the applicant by the NHP Master File's registered owner;  In order to minimize the risk of Transmissible Spongiform Encephalopathies (TSEs) from products sourced from bovine tissues, product licence applicants must have a veterinary certificate on file and must ensure that the following criteria has been met (EP 2008): i. Source animal is fit for human consumption, ii. Source material can be traced back to the herd or animal, iii. Avoidance of cross-contamination with high-infectivity tissues is ensured during sourcing, iv. Manufacturing procedures that are known to reduce infectivity are implemented (e.g. procedures that are in accordance with those outlined in Chapter 5.2.8 of the European Pharmacopoeia).  Note: This information is not to be submitted with the compendial Product Licence Application, although it may be requested at the NHPD's discretion.";s:21:"field_specification_f";s:1437:"L’ingrédient médicinal doit : i. Être conforme aux spécifications énoncées dans les monographies Chondroitin Sulfate Sodium publiées dans les pharmacopées britannique (BP) ou européenne (Ph. Eur.) ou, ii. Faire partie d’un fichier principal de produit de santé naturel (FP-PSN) approuvé par la DPSN. Une lettre d’autorisation d’accès du propriétaire enregistré du FP-PSN doit être fournie par le demandeur;  Afin d’atténuer le risque de maladies du type EST (encéphalopathie spongiforme transmissible) provenant de produits dont la matière d’origine est de source bovine, les demandeurs de licence de mise en marché doivent posséder un certificat d’un vétérinaire et doivent s’assurer que les critères suivants ont été respectés (EP 2008) : i. L’animal source est propre à la consommation humaine, ii. La matière d’origine peut être retracée au troupeau ou à l’animal, iii. La contamination croisée avec des tissus à fort potentiel infectieux est évitée lors de l’obtention de la matière d’origine, iv. Les pratiques de fabrication réduisant le potentiel infectieux sont mises en application (e.g. les pratiques conforment à celles énoncées au chapitre 5.2.8 de la Pharmacopée européenne (Ph. Eur.).  Nota: L’information susmentionnée ne doit pas être remise avec la demande de licence de mise en marché officinale, mais la DPSN peut toutefois en faire la demande.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-07-17";s:16:"field_legacy_nid";s:6:"100836";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:19:"field_mono_duration";s:5:"CSDUR";s:15:"field_mono_risk";s:10:"WORS;PREGC";s:21:"field_mono_citation_e";s:80:"STEPIOKP;EFFTOL;EFFTOL2;EP8;RSKASS;CHSUL;CHSUL2;CHEMIDP;MERCK13;ITKO;EFOCS;TNF26";s:21:"field_mono_citation_f";s:80:"STEPIOKP;EFFTOL;EFFTOL2;EP8;RSKASS;CHSUL;CHSUL2;CHEMIDP;MERCK13;ITKO;EFOCS;TNF26";s:26:"field_reference_reviewed_e";s:149:"CHOSUL1;CHONDR;CHOSUL2;CHOSUL3;CHOSUL4;CHOSUL5;CHOSUL6;CSTGC;CHOSUL7;COMP;ENCNS;CIDPLCHS;CIDPLCS;CHOSUL8;MACOKH;CHOSUL9;GAGO;EFGLCS;CSUL2;CSUL;ORMHKO";s:26:"field_reference_reviewed_f";s:149:"CHOSUL1;CHONDR;CHOSUL2;CHOSUL3;CHOSUL4;CHOSUL5;CHOSUL6;CSTGC;CHOSUL7;COMP;ENCNS;CIDPLCHS;CIDPLCS;CHOSUL8;MACOKH;CHOSUL9;GAGO;EFGLCS;CSUL2;CSUL;ORMHKO";}i:216530;a:36:{s:5:"title";s:28:"CLA_Conjugated Linoleic Acid";s:3:"nid";s:6:"216530";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"CLA";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:24:"Conjugated Linoleic Acid";s:22:"field_monograph_name_f";s:27:"Acide linoléique conjugué";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:2046:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.        Note: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.   (ii) There is insufficient evidence to support the use of Conjugated linoleic acid (CLA) as a weight loss aid. Consumers wishing to achieve weight loss should consult a health care practitioner prior to taking CLA.   (iii) The use of the term “may” in the use or purpose statements reflects the uncertainty of the evidence. For example, some reviews have concluded that CLA does not significantly affect body fat mass.   (iv) The claim “May help to support a modest improvement to body composition” refers to evidence showing that CLA may modestly reduce body fat. Weak evidence also demonstrates that CLA may help to modestly increase lean muscle mass.   (v) The recommendations for decreased caloric intake and increased physical activity are included as components of the use or purpose statements in order to provide a health context.   (vi) Though CLA has been administered to subjects for up to two years, there is insufficient evidence to support any benefits beyond 6 months. As such, a duration of use of 6 months has been included on the monograph.   (vii) CLA does not exert positive effects on any health risk biomarkers (e.g. LDL-cholesterol, HDL-cholesterol, plasma glucose, plasma insulin, etc.) and there is some evidence to suggest that its use may be unsafe in particular subpopulations. As such, mandatory risk information is required on the PLA and label to identify subpopulations at risk.";s:12:"field_note_f";s:2644:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.     Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.   (ii) Il n’y a pas suffisamment de preuves appuyant l’utilisation de l’acide linoléique conjugué (ALC) comme agent favorisant la perte de poids. Tout consommateur souhaitant perdre du poids devrait consulter un praticien de soins de santé avant d’utiliser l’ALC.   (iii) L’usage du verbe « pourrait » dans les énoncés concernant les usages ou fins recommandés dénote l’incertitude des résultats de la recherche. Par exemple, certaines études (y compris les revues systématiques et les méta-analyses) ont conclu que l’ALC n’a pas d’effet significatif sur la masse adipeuse corporelle.   (iv) L’allégation « Pourrait aider à contribuer à une légère amélioration de la composition corporelle » fait référence aux preuves démontrant que l’ALC pourrait légèrement réduire le gras corporel. Des preuves non concluantes ont démontré que l’ALC pourrait aider à augmenter légèrement la masse musculaire.    (v) Afin de fournir un contexte santé aux énoncés concernant les usages ou fins recommandés, des recommandations de diminuer l’apport calorique et d’augmenter l’activité physique ont été ajoutées.   (vi) Il n’y a pas suffisamment de preuves appuyant les bénéfices de l’usage de l’ALC au-delà de 6 mois bien que pour certaines études, les participants ont consommé l’ALC durant 2 ans. La durée d’utilisation indiquée à la monographie est donc de 6 mois.   (vii) L’ALC n’a aucun effet bénéfique sur les marqueurs biologiques indiquant un risque pour la santé (par ex.  les cholestérols LDL et HDL, le glucose sanguin, l’insuline sanguine, etc.). Certaines études ont démontré que l’utilisation de l’ALC pourrait être dangereuse chez certaines sous-populations. Les mentions de risques doivent donc être inclues sur la DLMM et l’étiquette afin de bien cibler les sous-populations à risque.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:607:"The CLA-rich oil must comply with the following chemical specifications: (i) CLA total - greater than 78%, (ii) CLA (c9t11 + t10,c12 isomers) - greater than 74%, (iii) CLA c9,t11 isomers - greater than 36%, (iv) CLA t10,c12 isomers - greater than 36%, (v) CLA trans, trans - less than 3%;      The maximum peroxide value derived from CLA-rich oil must be less or equal to 1 meq O2/kg and be in accordance with the methods set out by the American Oil Chemists’ Society (AOCS) and/or Pharmacopoeial analytical methods. This specification is necessary to ensure the oxidative stability of the CLA (FDA 2007).";s:21:"field_specification_f";s:655:"L’huile riche en ALC doit être conforme aux spécifications chimiques suivantes: (i) ALC total - plus grand que 78%, (ii) ALC (isomères c9t11 + t10,c12) - plus grand que 74%, (iii) ALC isomères c9,t11 - plus grand que 36%, (iv) ALC isomères t10,c12 - plus grand que 36%, (v) ALC trans, trans  - plus petit que 3%;      Le niveau de peroxyde maximal de l’huile riche en ALC doit être  inférieur ou égal à 1 meq O2/kg et doit respecter les méthodes établies par l’« American Oil Chemists’ Society (AOCS) » et/ou par les méthodes analytiques de pharmacopées. Ces spécifications servent à prévenir l’oxydation de l’ALC (FDA 2007).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2010-02-25";s:16:"field_legacy_nid";s:6:"100837";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:13:"CLA_AI;CLA_OF";s:19:"field_mono_duration";s:6:"CLADUR";s:15:"field_mono_risk";s:36:"CLA_CW1;CLA_CW2;PREGC;CLA_CI;CLA_ADR";s:21:"field_mono_citation_e";s:138:"BRTVCL;BSVCL;BSFTJN;BBHBLST;FDAUSDH;GHHSNH;GHHKFJN;GHHKVG;KLSWP;LTGAJCN;PMWAJCN;PPCPLR;PCCEMSSE;RTTBLSC;SBJFBJN;SCMCAHA;TWRJF;TRSLBB;WBCZS";s:21:"field_mono_citation_f";s:138:"BRTVCL;BSVCL;BSFTJN;BBHBLST;FDAUSDH;GHHSNH;GHHKFJN;GHHKVG;KLSWP;LTGAJCN;PMWAJCN;PPCPLR;PCCEMSSE;RTTBLSC;SBJFBJN;SCMCAHA;TWRJF;TRSLBB;WBCZS";s:26:"field_reference_reviewed_e";s:674:"AFTHCL;AHAKCL;AAHDI;AKTCLA;AYDCLA;BMACLA;BMBCLA;BNKCLA;BBRCFCLA;BSNGCLA;BGCCLA;CKCLA;CCAUCLA;CCTCCLA;CCCLA;DTACLA;DWACLA;EMCFCLA;ECSACLA;EMEAEMA;ESDCLA;FCWCLA;FSZLUF;GANB;GKHWMV;HMMST;IKYOKAK;JCBSCLA;KFGWCLA;LGBHCLA;LTAJLR;LBVRBJN;LINDLCA;LSMRS;MMRS;MVMAB;MMBDM;MCOL;MYMNR;MMPRJNB;MLCQAJP;NYJBB;NFOCL;NRNGBJN;NCAJCN;PASPJFS;PASPL;PMBML;PPFRI;PMSL;PMCBD;PSAJCN;PJCJNR;QAMJC;RMDV;RGVDR;RPMAJC;RASCLA;RSBJCN;RVAZD;RVABJCN;RABVDC;RBJFC;RBVRMD;RMFSJN;RPSCCYD;SSMBRFS;SMTPMJA;STBMCR;SKBN;SHSCDB;SCMTPHN;SVBCS;SVBCLAL;SLTSCLA;SGRMSCL;SHHGIJO;TAHMJCN;TAHJON;TWGJIMR;TCHMPNM;TMRCNMC;TBKBAJCN;TBKWAJCN;TBWCYPNS;TYCOCNMC;VNCCA;WJCCPCH2;WJPJCN;WWSJCN;WOMWA;WHOOPMG;YSECATVB;YHOBFL;ZKVGL";s:26:"field_reference_reviewed_f";s:674:"AFTHCL;AHAKCL;AAHDI;AKTCLA;AYDCLA;BMACLA;BMBCLA;BNKCLA;BBRCFCLA;BSNGCLA;BGCCLA;CKCLA;CCAUCLA;CCTCCLA;CCCLA;DTACLA;DWACLA;EMCFCLA;ECSACLA;EMEAEMA;ESDCLA;FCWCLA;FSZLUF;GANB;GKHWMV;HMMST;IKYOKAK;JCBSCLA;KFGWCLA;LGBHCLA;LTAJLR;LBVRBJN;LINDLCA;LSMRS;MMRS;MVMAB;MMBDM;MCOL;MYMNR;MMPRJNB;MLCQAJP;NYJBB;NFOCL;NRNGBJN;NCAJCN;PASPJFS;PASPL;PMBML;PPFRI;PMSL;PMCBD;PSAJCN;PJCJNR;QAMJC;RMDV;RGVDR;RPMAJC;RASCLA;RSBJCN;RVAZD;RVABJCN;RABVDC;RBJFC;RBVRMD;RMFSJN;RPSCCYD;SSMBRFS;SMTPMJA;STBMCR;SKBN;SHSCDB;SCMTPHN;SVBCS;SVBCLAL;SLTSCLA;SGRMSCL;SHHGIJO;TAHMJCN;TAHJON;TWGJIMR;TCHMPNM;TMRCNMC;TBKBAJCN;TBKWAJCN;TBWCYPNS;TYCOCNMC;VNCCA;WJCCPCH2;WJPJCN;WWSJCN;WOMWA;WHOOPMG;YSECATVB;YHOBFL;ZKVGL";}i:216531;a:35:{s:5:"title";s:17:"CLO_Cod Liver Oil";s:3:"nid";s:6:"216531";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"CLO";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:13:"Cod Liver Oil";s:22:"field_monograph_name_f";s:23:"Foie de morue, Huile de";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:36:"atReq.do?atid=cod.liver.oil&lang=eng";s:21:"field_monograph_url_f";s:36:"atReq.do?atid=cod.liver.oil&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:1495:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.       Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.   (ii) Vitamin E is an optional medicinal ingredient in cod liver oil products. However, no use or purpose statements may be associated with vitamin E. See Appendix 4 for vitamin E proper name, common name, source material, and dose information.   (iii) The use(s) or purpose(s) statements in this monograph are based on the efficacy of vitamins A and D, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) that are present in cod liver oil. The references used to support these statements refer to the efficacy of these individual constituents and are not specific to cod liver oil.   (iv) See Appendix 1 for Adequate Intake (AI), Recommended Dietary Allowance (RDA) and Tolerable Upper Intake Level (UL) definitions for nutrient intake. See also Table 8 in Appendix 2 for RDA and AI values for vitamin A, and Table 9 in Appendix 3 for AI values for vitamin D.";s:12:"field_note_f";s:1860:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.      Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.  (ii) Les produits d’huile de foie de morue peuvent contenir de la vitamine E comme ingrédient médicinal facultatif. Cependant, aucun énoncé d’usage(s) ou de fin(s) recommandés ne peut être associé à la vitamine E. Consulter l’annexe 4 pour les noms propres et communs, les matières d’origine et les doses de la vitamine E.   (iii) Les énoncés d’usage(s) ou fin(s) recommandé ce cette monographie sont basés sur l’efficacité des vitamines A et D et des acides eicosapentaénoïque (AEP) et docosahexaénoïque (ADH) présents dans l’huile de foie de morue. Les références utilisées pour soutenir ces énoncés réfèrent à l’efficacité de ces constituants individuels et ne sont pas spécifiques à l’huile de foie de morue.   (iv) Consulter l’annexe 1 pour les définitions de l’apport suffisant (AS), de l’apport nutritionnel recommandé (ANR) et de l’apport maximal tolérable (AMT). Consulter aussi le tableau 8 à l’annexe 2 pour les valeurs d’ANR et d’AS de la vitamine A et le tableau 9 à l’annexe 3 pour les valeurs d’AS de la vitamine D.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:1456:"The medicinal ingredient may comply with the specifications outlined in the following pharmacopoeial monographs:  'Cod-Liver Oil (Type A)' and 'Cod-Liver Oil (Type B)' in the British Pharmacopoeia (BP), 'Cod-Liver Oil, Farmed', 'Cod-Liver Oil (Type A)' and 'Cod-Liver Oil (Type B)' in the European Pharmacopoeia (Ph. Eur.), and 'Cod Liver Oil' in the U.S. Pharmacopoeia (USP).;  Peroxide, anisidine, and totox values of cod liver oil or omega-3 fatty acids derived from cod liver must be in accordance with the methods set out by the Association of Analytical Community (AOAC) and/or Pharmacopoeial analytical methods. These specifications are necessary to ensure the oxidative stability of the cod liver oil/omega-3 fatty acids (HC 2007).  The maximum peroxide value (PV) must be 5 mEq/kg, the maximum anisidine value (AV) must be 20 mEq/kg while the maximum Totox value must be 26 (calculated as 2 X PV + AV) mEq/kg.;  Polychlorinated dibenzo-para-dioxins (PCDD), polychlorinated dibenzofurans (PCDF) and polychlorinated biphenyls (PCB) are contaminants in oils isolated from fish.  Testing for PCDD, PCDF and PCB is required, and must be performed using appropriate analytical methods. Applicants are advised to consult the Evidence for Quality of Finished Natural Health Products Guidance Document (HC 2007). The tolerance limits for PCDD and PCDF are < 2pg/kg body weight/day while for PCB the tolerance limits are < 0.10 microgram/kg body weight/day.";s:21:"field_specification_f";s:1844:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes:  'Cod-Liver Oil (Type A)' et 'Cod-Liver Oil (Type B)' dans la pharmacopée britannique (BP), 'Cod-Liver Oil, Farmed', 'Cod-Liver Oil (Type A)' et 'Cod-Liver Oil (Type B)' dans la pharmacopée européenne (Ph. Eur.), et 'Cod Liver Oil' dans la pharmacopée américaine (USP).;  Les niveaux de peroxyde et d'anisidine, et les niveaux totaux d'oxydation de l'huile de foie de morue ou des dérivés d'acides gras oméga-3 provenant de l'huile de foie de morue doivent respecter les normes établies par l' « Association of Analytical Community (AOAC)» et/ou par les méthodes analytiques de pharmacopées. Ces spécifications assureront la résistance à l'oxydation de l'huile de foie de morue ou des acides gras oméga-3 (SC 2007). Le niveau maximal de l'indice de peroxyde (IP) doit être 5 mEq/kg, le niveau maximal de l'indice de p-anisidine (IPA) doit être 20 mEq/kg tandis que le niveau maximal du total d'oxydation doit être 26 (calculé selon la formule : 2 X IP + IPA) mEq/kg.;   Les polychorodibenzo-para-dioxines (PCDD), les polycholorodibenzofuranes (PCDF) et les polychlorobiphényles (PCB) sont des contaminants dans les produits isolés à partir de poisson. Des analyses pour détecter les PCDD, les PCDF et les PCB sont obligatoires et doivent être effectuées au moyen d'une méthode analytique appropriée. Il est conseillé au demandeur qui désire plus de renseignements à ce sujet de consulter le document de référence Preuves attestant de la qualité des produits de santé naturels finis (SC 2007).  Les seuils de tolérance pour les PCDD et les PCDF sont de < 2 pg/kg poids corporel par jour, tandis que pour les PCB le seuil de tolérance est de < 0.10 microgrammes/kg poids corporel/jour.";s:25:"field_storage_condition_e";s:117:"For all products, except those encapsulated: Refrigerate after opening (USP 32; Ph. Eur. 2008; Wille and Gonus 1989).";s:25:"field_storage_condition_f";s:118:"Tous les produits, sauf ceux encapsulés : Réfrigérer après ouverture (USP 32; Ph. Eur. 2008; Wille et Gonus 1989).";s:10:"field_date";s:10:"2010-02-22";s:16:"field_legacy_nid";s:6:"100838";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:26:"CH03;CH48;AD913;AD1418;ADU";s:15:"field_dose_note";s:31:"CLO;CLO_GR;ADUL;CLO_MAX;CLO_MIN";s:21:"field_mono_citation_e";s:244:"RLCPUFA;BPH9;SRCOD;COGPHY;BLDPRF;174PAT;MRISTD;CHEMDET;ANHM;EFABRAIN;CLOLP;EQUAL;IQ7YR;IOMDRI;DRIECF;DRICP;ITIS;LEMCOD;DOCOSA;EYECHLD;ALZH;PRIMC;COAGU;EP8;RICKETS;DHACOG;MNHD;O3ATHL;EFAHCD;IDCLO;1STYR;VAINCLO;184GRAS;TNF27;EFOCPOS;DIETMO;PREPFO";s:21:"field_mono_citation_f";s:244:"RLCPUFA;BPH9;SRCOD;COGPHY;BLDPRF;174PAT;MRISTD;CHEMDET;ANHM;EFABRAIN;CLOLP;EQUAL;IQ7YR;IOMDRI;DRIECF;DRICP;ITIS;LEMCOD;DOCOSA;EYECHLD;ALZH;PRIMC;COAGU;EP8;RICKETS;DHACOG;MNHD;O3ATHL;EFAHCD;IDCLO;1STYR;VAINCLO;184GRAS;TNF27;EFOCPOS;DIETMO;PREPFO";s:26:"field_reference_reviewed_e";s:45:"COLIFE;SCLO;INFBOW;NSAID;IQ4YR;SEN3N6;CLOPREG";s:26:"field_reference_reviewed_f";s:45:"COLIFE;SCLO;INFBOW;NSAID;IQ4YR;SEN3N6;CLOPREG";}i:216532;a:32:{s:5:"title";s:10:"COP_Copper";s:3:"nid";s:6:"216532";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"COP";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:6:"Copper";s:22:"field_monograph_name_f";s:6:"Cuivre";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2007-11-08";s:16:"field_legacy_nid";s:6:"100839";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:26:"ADU;AD1418;AD913;CH48;CH13";s:15:"field_dose_note";s:12:"MIN;MAX;ADUL";s:21:"field_mono_citation_e";s:58:"HALF;WORDS;ANHM;DPD;IOMDRI;FCC;DRIVAVK;MERCK13;MNHD;MART35";s:21:"field_mono_citation_f";s:58:"HALF;WORDS;ANHM;DPD;IOMDRI;FCC;DRIVAVK;MERCK13;MNHD;MART35";}i:216533;a:29:{s:5:"title";s:26:"CCRE_Corn & Callus Remover";s:3:"nid";s:6:"216533";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"CCRE";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:21:"Corn & Callus Remover";s:22:"field_monograph_name_f";s:49:"Cors et les callosités, Produit pour enlever les";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"C;P";s:21:"field_monograph_url_e";s:31:"atReq.do?atid=cor_call&lang=eng";s:21:"field_monograph_url_f";s:31:"atReq.do?atid=cor_call&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:0:"";s:16:"field_legacy_nid";s:6:"100840";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216534;a:35:{s:5:"title";s:17:"CQ10_Coenzyme Q10";s:3:"nid";s:6:"216534";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"CQ10";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:12:"Coenzyme Q10";s:22:"field_monograph_name_f";s:12:"Coenzyme Q10";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:97:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_coenz-q10-eng.php";s:21:"field_monograph_url_f";s:97:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_coenz-q10-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2007-11-22";s:16:"field_legacy_nid";s:6:"100841";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:19:"field_mono_duration";s:6:"Q10DUR";s:15:"field_mono_risk";s:29:"PREGC;Q10_CW1;Q10_CW2;Q10_CW3";s:21:"field_mono_citation_e";s:205:"ITSTUD;CQ10;PROTCQ;BIOFUN;CQGINK;EP;SUPMIG;ANTIOX;BIOBIO;IWARCQ;INTROCQ;CARDIO;IMPSYN;SYNCQ;MERCK13;BATCH;MITOFUN;TRHYP;MIGPREV;MIGPROP;HYDCQ;WARUBI;PARKDIS;MART35;REVUBI;PROPEFF;TNF25;PRODUBI;DETSOL;TNF26";s:21:"field_mono_citation_f";s:205:"ITSTUD;CQ10;PROTCQ;BIOFUN;CQGINK;EP;SUPMIG;ANTIOX;BIOBIO;IWARCQ;INTROCQ;CARDIO;IMPSYN;SYNCQ;MERCK13;BATCH;MITOFUN;TRHYP;MIGPREV;MIGPROP;HYDCQ;WARUBI;PARKDIS;MART35;REVUBI;PROPEFF;TNF25;PRODUBI;DETSOL;TNF26";s:26:"field_reference_reviewed_e";s:683:"ANTIMIX;LDLLIPO;PIPE;MITRES;EXOQ10;PHOTOAG;Q10CNS;DYSMYO;AEROPOW;DINHP;TRCYC;MITMYO;SYSHYP;MYOSYMP;MITENC;BIOTECH;MITCYT;HMGCOA;ESSHYP;Q10DEF;Q10GINK;Q10T2D;PPLFOOD;PSBAC;Q10ALS;MDNA;MUSDIS;KIDDIS;EVPLAS;SKINPEN;ADLTPER;RSKASS;MEDEFF;PDRNS;GLYCTRL;IBPGC;AAE;NEWB;ANTHRA;CERFLUID;NMCDQ10;DATA;LDL;AAPDPL;ANGPEC;CONGHF;MYOINF;RBAP;CLCARD;STAT;HYPCAR;CLIIIIV;TRESSHYP;STTHER;BRCANC;REMBC;IDNM;DOWNSYN;NONINV;CONHF;OVERV;DOSEREL;Q10SUP;GINGI;Q10HPV;Q10PV;Q10HD;TMME;Q10FEN;TAMOX;MNUTR;VARIMMU;TOLCT;PEHHF;CONCAR;SYSFUN;PHBAC;ASPAC;THERAP;HIGHDOS;EARLY;ILLUM;DAIRY;IDIOP;GOLGI;REMAC;GPI;UBIIDE;CHFAH;UMBI;INTEG;BILARY;LEFTVEN;ENDOTH;Q10PT;ROLE;AOEFF;AOHP;ENDATH;BIOEN;ESHYPER;AMEFF;NANOEM";s:26:"field_reference_reviewed_f";s:683:"ANTIMIX;LDLLIPO;PIPE;MITRES;EXOQ10;PHOTOAG;Q10CNS;DYSMYO;AEROPOW;DINHP;TRCYC;MITMYO;SYSHYP;MYOSYMP;MITENC;BIOTECH;MITCYT;HMGCOA;ESSHYP;Q10DEF;Q10GINK;Q10T2D;PPLFOOD;PSBAC;Q10ALS;MDNA;MUSDIS;KIDDIS;EVPLAS;SKINPEN;ADLTPER;RSKASS;MEDEFF;PDRNS;GLYCTRL;IBPGC;AAE;NEWB;ANTHRA;CERFLUID;NMCDQ10;DATA;LDL;AAPDPL;ANGPEC;CONGHF;MYOINF;RBAP;CLCARD;STAT;HYPCAR;CLIIIIV;TRESSHYP;STTHER;BRCANC;REMBC;IDNM;DOWNSYN;NONINV;CONHF;OVERV;DOSEREL;Q10SUP;GINGI;Q10HPV;Q10PV;Q10HD;TMME;Q10FEN;TAMOX;MNUTR;VARIMMU;TOLCT;PEHHF;CONCAR;SYSFUN;PHBAC;ASPAC;THERAP;HIGHDOS;EARLY;ILLUM;DAIRY;IDIOP;GOLGI;REMAC;GPI;UBIIDE;CHFAH;UMBI;INTEG;BILARY;LEFTVEN;ENDOTH;Q10PT;ROLE;AOEFF;AOHP;ENDATH;BIOEN;ESHYPER;AMEFF;NANOEM";}i:216535;a:36:{s:5:"title";s:13:"CRA_Cranberry";s:3:"nid";s:6:"216535";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"CRA";s:18:"field_group_name_e";s:9:"Cranberry";s:18:"field_group_name_f";s:10:"Canneberge";s:22:"field_monograph_name_e";s:9:"Cranberry";s:22:"field_monograph_name_f";s:10:"Canneberge";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:638:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.      Note: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.  (ii)  Claims for traditional use must include the term “Herbal Medicine”.";s:12:"field_note_f";s:759:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal.      Nota :  (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.   (ii) Les allégations concernant l’usage traditionnel doivent inclure le terme « phytothérapie/herboristerie».";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:298:"The medicinal ingredient may comply with the specifications outlined in the Cranberry Liquid Preparation published in the US Pharmacopeia (USP).; Note: Information detailed in this section is not to be submitted with the compendial PLA, although it may be requested at Health Canada’s discretion.";s:21:"field_specification_f";s:318:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie Cranberry Liquid Preparation publiée dans la pharmacopée américaine (USP).; Nota : L’information susmentionnée ne doit pas être remise avec la DLMM officinale mais Santé Canada peut en faire la demande au besoin.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2011-03-28";s:16:"field_legacy_nid";s:6:"100842";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:7:"CRA_DUR";s:15:"field_mono_risk";s:23:"CRA_CW1;CRA_CW2;CRA_CW3";s:21:"field_mono_citation_e";s:163:"WARCRJ;REDBP;HERMED2;ABC;HIPPU;CHUTI;URISTO;WARCJ;PRVITI3;HERCOM;HERSAF;HYPOPRO;PLASAO;CRAN;NATCRAN;RSKNEPH;CRANHP;GRIN10;BASMU;CRACON;WEP;TURM9;CRANBR;EPBR10;USPN";s:21:"field_mono_citation_f";s:158:"WARCRJ;REDBP;HERMED2;ABC;HIPPU;FLORE;CHUTI;URISTO;WARCJ;PRVITI3;HERSAF;HYPOPRO;PLASAO;CRAN;NATCRAN;RSKNEPH;CRANHP;GRIN10;BASMU;CRACON;TURM9;CRANBR;EPBR10;USPN";s:26:"field_reference_reviewed_e";s:203:"HERMED;URIACID;50COM;COUMADIN;HPBH;HERBS;REDEC;PHCAM;THONEST;LTCFP;HELICO;INTFLU;INTWAR;SUSWAR;REDBAC;FOLK;PLPL;PRVITI;UROPA;WARTIMI;CALOXA;INGCJ;BACURI;BLUEB;CHIMC;PROTON;INHIB;POSINT;CRCRPR;BMCYS;HPINF";s:26:"field_reference_reviewed_f";s:203:"HERMED;URIACID;50COM;COUMADIN;HPBH;HERBS;REDEC;PHCAM;THONEST;LTCFP;HELICO;INTFLU;INTWAR;SUSWAR;REDBAC;FOLK;PLPL;PRVITI;UROPA;WARTIMI;CALOXA;INGCJ;BACURI;BLUEB;CHIMC;PROTON;INHIB;POSINT;CRCRPR;BMCYS;HPINF";}i:216536;a:36:{s:5:"title";s:27:"CRAE_Cranberry juice, dried";s:3:"nid";s:6:"216536";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"CRAE";s:18:"field_group_name_e";s:9:"Cranberry";s:18:"field_group_name_f";s:10:"Canneberge";s:22:"field_monograph_name_e";s:22:"Cranberry juice, dried";s:22:"field_monograph_name_f";s:29:"Canneberge, jus  déshydraté";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:702:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.      Note: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.  (ii)  Claims for traditional use must include the term “Herbal Medicine”.";s:12:"field_note_f";s:759:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal.      Nota :  (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.   (ii) Les allégations concernant l’usage traditionnel doivent inclure le terme « phytothérapie/herboristerie».";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:298:"The medicinal ingredient may comply with the specifications outlined in the Cranberry Liquid Preparation published in the US Pharmacopeia (USP).; Note: Information detailed in this section is not to be submitted with the compendial PLA, although it may be requested at Health Canada’s discretion.";s:21:"field_specification_f";s:318:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie Cranberry Liquid Preparation publiée dans la pharmacopée américaine (USP).; Nota : L’information susmentionnée ne doit pas être remise avec la DLMM officinale mais Santé Canada peut en faire la demande au besoin.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2011-03-28";s:16:"field_legacy_nid";s:6:"100843";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:7:"CRA_DUR";s:15:"field_mono_risk";s:23:"CRA_CW1;CRA_CW2;CRA_CW3";s:21:"field_mono_citation_e";s:168:"WARCRJ;REDBP;HERMED2;ABC;HIPPU;CHUTI;URISTO;WARCJ;PRVITI3;HERCOM;HERSAF;HYPOPRO;PLASAO;CRAN;NATCRAN;RSKNEPH;CRANHP;GRIN10;BASMU;CRACON;WEP;NHPD;TURM9;CRANBR;EPBR10;USPN";s:21:"field_mono_citation_f";s:163:"WARCRJ;REDBP;HERMED2;ABC;HIPPU;FLORE;CHUTI;URISTO;WARCJ;PRVITI3;HERSAF;HYPOPRO;PLASAO;CRAN;NATCRAN;RSKNEPH;CRANHP;GRIN10;BASMU;CRACON;NHPD;TURM9;CRANBR;EPBR10;USPN";s:26:"field_reference_reviewed_e";s:203:"HERMED;URIACID;50COM;COUMADIN;HPBH;HERBS;REDEC;PHCAM;THONEST;LTCFP;HELICO;INTFLU;INTWAR;SUSWAR;REDBAC;FOLK;PLPL;PRVITI;UROPA;WARTIMI;CALOXA;INGCJ;BACURI;BLUEB;CHIMC;PROTON;INHIB;POSINT;CRCRPR;BMCYS;HPINF";s:26:"field_reference_reviewed_f";s:203:"HERMED;URIACID;50COM;COUMADIN;HPBH;HERBS;REDEC;PHCAM;THONEST;LTCFP;HELICO;INTFLU;INTWAR;SUSWAR;REDBAC;FOLK;PLPL;PRVITI;UROPA;WARTIMI;CALOXA;INGCJ;BACURI;BLUEB;CHIMC;PROTON;INHIB;POSINT;CRCRPR;BMCYS;HPINF";}i:216537;a:36:{s:5:"title";s:24:"CRM_Creatine monohydrate";s:3:"nid";s:6:"216537";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"CRM";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:20:"Creatine monohydrate";s:22:"field_monograph_name_f";s:23:"Créatine monohydratée";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:36:"atReq.do?atid=creatine.mono&lang=eng";s:21:"field_monograph_url_f";s:36:"atReq.do?atid=creatine.mono&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:185:"The square brackets in the uses or purposes section indicate optional words of which the applicant must choose at least one option. The parentheses indicate additional optional wording.";s:12:"field_note_f";s:184:"Le demandeur doit choisir au moins un mot parmi ceux donnés entre crochets dans la section des usages ou fins recommandés. Les segments de phrase entre parenthèses sont facultatifs.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:491:"The finished product and/or raw material specifications must have limits for the following impurities: not more than 100 ppm creatinine-- not more than 50 ppm dicyandiamide-- non-detectable dihydrotriazine. The method used to detect dihydrotriazine must have a limit of detection of not more than 5 ppm.   ;Note: Finished product and raw material specifications are not to be submitted with the compendial Product Licence Application, although they may be requested at the NHPD's discretion.";s:21:"field_specification_f";s:592:"Les spécifications du produit fini et/ou des matières premières doivent présenter des valeurs limites quant aux impuretés suivantes : pas plus de 100 ppm de créatinine-- pas plus de 50 ppm de dicyandiamide-- dihydrotriazine non détectable. La limite de détection de la méthode employée pour déceler la présence de dihydrotriazine ne doit pas dépasser 5 ppm.    ;Nota : Les spécifications du produit fini et des matières premières ne doivent pas être présentées avec la demande de licence de mise en marché officinale, même si la DPSN peut les exiger si elle le juge utile";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-07-24";s:16:"field_legacy_nid";s:6:"100844";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"CREA";s:15:"field_mono_risk";s:21:"CRM_CW1;PREGC;CRM_CW2";s:21:"field_mono_citation_e";s:130:"FOOTATL;CROLDA;LCUV;CAFCRE;LOADMEN;FATFREE;CHEMIDP;SUPRAMAX;MERCK14;CREREN;SKEMUS;RENDYS;CAFCREA;LTINT;HEAVY;SCIBAS;PREPCR;CHEMIDP";s:21:"field_mono_citation_f";s:130:"FOOTATL;CROLDA;LCUV;CAFCRE;LOADMEN;FATFREE;CHEMIDP;SUPRAMAX;MERCK14;CREREN;SKEMUS;RENDYS;CAFCREA;LTINT;HEAVY;SCIBAS;PREPCR;CHEMIDP";s:26:"field_reference_reviewed_e";s:258:"SPECREF;EXEPERF;CHMMM;MEDPROD;CRBEN;ERGOM;MBOUT;CMEMC;EVLTE;ERGOG;SPRD;MECI;OLDER;COLLFB;ELEVCR;MEDEFF;MPESP;HYDROXY;NEPHR;CLMARK;TOTALCR;HEPAT;DSLMSG;GASTRO;RENAL;ADVCR;IMPREN;FLUID;INTWORK;DIFFRES;OXYUP;HAEMA;TRANSV;CSHV;RACM;ISCHAEM;HIRE;HEATCR;DEHYDR;UMC";s:26:"field_reference_reviewed_f";s:258:"SPECREF;EXEPERF;CHMMM;MEDPROD;CRBEN;ERGOM;MBOUT;CMEMC;EVLTE;ERGOG;SPRD;MECI;OLDER;COLLFB;ELEVCR;MEDEFF;MPESP;HYDROXY;NEPHR;CLMARK;TOTALCR;HEPAT;DSLMSG;GASTRO;RENAL;ADVCR;IMPREN;FLUID;INTWORK;DIFFRES;OXYUP;HAEMA;TRANSV;CSHV;RACM;ISCHAEM;HIRE;HEATCR;DEHYDR;UMC";}i:216538;a:34:{s:5:"title";s:13:"CURC_Curcumin";s:3:"nid";s:6:"216538";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"CURC";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:8:"Curcumin";s:22:"field_monograph_name_f";s:9:"Curcumine";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:620:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.      Note: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:753:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.      Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:201:"The medicinal ingredient may comply with the specifications outlined in the Curcuminoids, Curcuminoids Capsules and Curcuminoids Tablets monographs published in the United States Pharmacopeia (USP 32).";s:21:"field_specification_f";s:211:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies Curcuminoids, Curcuminoids Capsules and Curcuminoids Tablets, publiées dans la Pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2010-02-26";s:16:"field_legacy_nid";s:6:"100845";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_mono_risk";s:44:"CURC_CW1;CURC_CW2;CURC_CW3;CURC_CW4;CURC_CW5";s:21:"field_mono_citation_e";s:74:"CURC1;CURC2;CURC3;CURC4;CURC5;CURC6;CURC7;CURC8;CURC9;CURC10;CURC11;CURC12";s:21:"field_mono_citation_f";s:74:"CURC1;CURC2;CURC3;CURC4;CURC5;CURC6;CURC7;CURC8;CURC9;CURC10;CURC11;CURC12";s:26:"field_reference_reviewed_e";s:152:"CURCRR1;CURCRR2;CURCRR3;CURCRR4;CURCRR5;CURCRR6;CURCRR7;CURCRR8;CURCRR9;CURCRR10;CURCRR11;CURCRR12;CURCRR13;CURCRR14;CURCRR15;CURCRR16;CURCRR17;CURCRR18";s:26:"field_reference_reviewed_f";s:152:"CURCRR1;CURCRR2;CURCRR3;CURCRR4;CURCRR5;CURCRR6;CURCRR7;CURCRR8;CURCRR9;CURCRR10;CURCRR11;CURCRR12;CURCRR13;CURCRR14;CURCRR15;CURCRR16;CURCRR17;CURCRR18";}i:216539;a:29:{s:5:"title";s:36:"DAN_Dandelion - Taraxacum officinale";s:3:"nid";s:6:"216539";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"DAN";s:18:"field_group_name_e";s:9:"Dandelion";s:18:"field_group_name_f";s:9:"Pissenlit";s:22:"field_monograph_name_e";s:32:"Dandelion - Taraxacum officinale";s:22:"field_monograph_name_f";s:32:"Pissenlit - Taraxacum officinale";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:42:"atReq.do?atid=dandelion.pissenlit&lang=eng";s:21:"field_monograph_url_f";s:42:"atReq.do?atid=dandelion.pissenlit&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-05-21";s:16:"field_legacy_nid";s:6:"100846";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216540;a:29:{s:5:"title";s:43:"DANJ_Dandelion (Taraxacum Officinale) Juice";s:3:"nid";s:6:"216540";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"DANJ";s:18:"field_group_name_e";s:9:"Dandelion";s:18:"field_group_name_f";s:9:"Pissenlit";s:22:"field_monograph_name_e";s:38:"Dandelion (Taraxacum Officinale) Juice";s:22:"field_monograph_name_f";s:39:"Jus De Pissenlit (Taraxacum Officinale)";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:45:"atReq.do?atid=dandelion.ju.pissenlit&lang=eng";s:21:"field_monograph_url_f";s:45:"atReq.do?atid=dandelion.ju.pissenlit&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-05-21";s:16:"field_legacy_nid";s:6:"100847";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216541;a:36:{s:5:"title";s:16:"DEV_Devil's Claw";s:3:"nid";s:6:"216541";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"DEV";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:12:"Devil's Claw";s:22:"field_monograph_name_f";s:16:"Griffe du diable";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:101:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_devils-diable-eng.php";s:21:"field_monograph_url_f";s:101:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_devils-diable-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:156:"The medicinal ingredient may comply with the specifications outlined in the Devil's Claw Root Monograph published in the European or British Pharmacopoeias.";s:21:"field_specification_f";s:192:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies Devil's Claw Root publiées dans les Pharmacopée britannique (BP) et européennes (Ph. Eur.).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-05-09";s:16:"field_legacy_nid";s:6:"100848";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:7:"DEV_DUR";s:15:"field_mono_risk";s:15:"PERS;WORS;PREGC";s:21:"field_mono_citation_e";s:44:"EXPCEM;BHCOM;ESCOP;MEDHER;HERCOM;HERSAF;GRIN";s:21:"field_mono_citation_f";s:51:"EXPCEM;BHCOM;PHAPHY;ESCOP;MEDHER;HERSAF;GRIN;PLATHE";s:26:"field_reference_reviewed_e";s:112:"DCOSTEO;UPHCDI8;HPVSDIA;HAID;DOLOTE;QUALCT;EHECE;DOLOVIOX;OUTMEAS;COCHREV;BPACT;DSOSTEO;LI174;KNEEHIP;BOTSAF;PPP";s:26:"field_reference_reviewed_f";s:112:"DCOSTEO;UPHCDI8;HPVSDIA;HAID;DOLOTE;QUALCT;EHECE;DOLOVIOX;OUTMEAS;COCHREV;BPACT;DSOSTEO;LI174;KNEEHIP;BOTSAF;PPP";}i:216542;a:29:{s:5:"title";s:24:"DIA_Diaper Rash Products";s:3:"nid";s:6:"216542";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"DIA";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:20:"Diaper Rash Products";s:22:"field_monograph_name_f";s:61:"Erythème fessier du nourrisson, Produits de traitement de l'";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"C;P";s:21:"field_monograph_url_e";s:40:"atReq.do?atid=diaprash_erytfess&lang=eng";s:21:"field_monograph_url_f";s:40:"atReq.do?atid=diaprash_erytfess&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:0:"";s:16:"field_legacy_nid";s:6:"100849";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216543;a:36:{s:5:"title";s:26:"ECH_Echinacea Angustifolia";s:3:"nid";s:6:"216543";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"ECH";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:22:"Echinacea Angustifolia";s:22:"field_monograph_name_f";s:23:"Echinacée angustifolia";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:624:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.   Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant. (iii) A claim for traditional use must include the term " Herbal Medicine"";s:12:"field_note_f";s:745:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués. (iii) Une allégation pour un usage traditionnel doit inclure les termes « Phytothérapie/Herboristerie »";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:502:"The finished product specifications must be established in accordance with the requirements described in the NHPD Quality of Natural Health Products Guide.; The medicinal ingredient may comply with the specifications outlined in the following pharmacopoeial monographs:  "Narrow-leaved Coneflower Root" of the European Pharmacopoeia (Ph.Eur.) as well as "Echinacea angustifolia", "Powdered Echinacea angustifolia" and "Powdered Echinacea angustifolia Extract" of the United States (USP) Pharmacopoeias.";s:21:"field_specification_f";s:539:"Les spécifications du produit fini doivent être établies conformément aux exigences décrites dans le Guide de référence sur la qualité des produits de santé naturels de la DPSN.; L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes:  "Narrow-leaved Coneflower Root" de la Pharmacopée européenne (Ph. Eur.) de même que "Echinacea angustifolia", "Powdered Echinacea angustifolia" et "Powdered Echinacea angustifolia Extract" de la Pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-07-10";s:16:"field_legacy_nid";s:6:"100850";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:22:"CH24;CH59;AD1013;ADU14";s:15:"field_dose_note";s:25:"FRAD;ECH1;ECH2;ADUL;APP1R";s:19:"field_mono_duration";s:6:"ECHDUR";s:15:"field_mono_risk";s:29:"ECH_CW1;ECH_CW2;ECH_CW3;PERS2";s:21:"field_mono_citation_e";s:110:"HERMED2;EXPCEM;ENHCI;BHCOM;HERCDI;UPHCDI8;THEPHA;KAD;AMODHER;NHPREG;BOTSAF;HERCOM;HTCH;HERSAF;NAE;PPHPP;GRIN12";s:21:"field_mono_citation_f";s:116:"HERMED2;EXPCEM;ENHCI;BHCOM;HERCDI;UPHCDI8;PHAPHY;THEPHA;KAD;AMODHER;NOMEN;NHPREG;BOTSAF;HTCH;HERSAF;NAE;PPHPP;GRIN12";s:26:"field_reference_reviewed_e";s:563:"MODIR;REVCPCP;HERMED;MEDPROP;UNRECH;QUESLAB;SEVRED;ECHURI;TLCHPLC;ALKECH;BHP2;BHP;PHYTVAR;ISEEGA;ABC;CGCEM;ECHRHIN;ECHWORK;ECHUSED;50COM;HDPP;BHCOM;CAMURTI;REPLY;STRUCT;EMP;MONOANT;ECHPRVC;RISKBEN;ECMM;KAD;PURPCF;GESTEXP;TNFGENE;EVECH;UPRESP;NHPMIF;ECHVC;USEECH;LEUCOP;ETCC;AUTOIMM;ECMV;PRTRCC2;ECHTEA;TABING;ECHALK;CACO2;TAXECH;PRTRCC;IMMUE;IMMUACT;ROOTEXT;ANTIANTI;THEHER;DHINT;PPP;TRTCC;AUSEXP;ECHASS;ECHINA;ECHMED;SEECH;GENEEXP;STUDYHR;PRIRC;PHENET;EVECH2;ESCHIL;NATREM;MOLWT;POLYSAC;RHINO;EXPRI;INEFF;WHOMON;HDPP2;ROLEALK;ENZDEG;BIOPHAR;PCBDP;ECHBAU;EPEDRR11";s:26:"field_reference_reviewed_f";s:563:"MODIR;REVCPCP;HERMED;MEDPROP;UNRECH;QUESLAB;SEVRED;ECHURI;TLCHPLC;ALKECH;BHP2;BHP;PHYTVAR;ISEEGA;ABC;CGCEM;ECHRHIN;ECHWORK;ECHUSED;50COM;HDPP;BHCOM;CAMURTI;REPLY;STRUCT;EMP;MONOANT;ECHPRVC;RISKBEN;ECMM;KAD;PURPCF;GESTEXP;TNFGENE;EVECH;UPRESP;NHPMIF;ECHVC;USEECH;LEUCOP;ETCC;AUTOIMM;ECMV;PRTRCC2;ECHTEA;TABING;ECHALK;CACO2;TAXECH;PRTRCC;IMMUE;IMMUACT;ROOTEXT;ANTIANTI;THEHER;DHINT;PPP;TRTCC;AUSEXP;ECHASS;ECHINA;ECHMED;SEECH;GENEEXP;STUDYHR;PRIRC;PHENET;EVECH2;ESCHIL;NATREM;MOLWT;POLYSAC;RHINO;EXPRI;INEFF;WHOMON;HDPP2;ROLEALK;ENZDEG;BIOPHAR;PCBDP;ECHBAU;EPEDRR11";}i:216544;a:36:{s:5:"title";s:21:"EPA_Echinacea pallida";s:3:"nid";s:6:"216544";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"EPA";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:17:"Echinacea pallida";s:22:"field_monograph_name_f";s:18:"Echinacée pallida";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:624:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.   Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant. (iii) A claim for traditional use must include the term " Herbal Medicine"";s:12:"field_note_f";s:745:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués. (iii) Une allégation pour un usage traditionnel doit inclure les termes « Phytothérapie/Herboristerie »";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:561:"The finished product specifications must be established in accordance with the requirements described in the NHPD Quality of Natural Health Products Guide.;  The medicinal ingredient may comply with the specifications outlined in the following pharmacopoeial monographs: 'Echinacea Pallida Root' of the British Pharmacopoeia(BP), 'Pale Coneflower Root: Echinacea pallidae radix' of the European Pharmacopoeia(Ph Eur) as well as 'Echinacea pallida', 'Powdered Echinacea pallida' and 'Powdered Echinacea pallida Extract' of the United States (USP) Pharmacopoeias.";s:21:"field_specification_f";s:601:"Les spécifications du produit fini doivent être établies conformément aux exigences décrites dans le Guide de référence sur la qualité des produits de santé naturels de la DPSN.;  L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes:  'Echinacea Pallida Root' de la Pharmacopée britannique (BP), 'Pale Coneflower Root: Echinacea pallidae radix' de la Pharmacopée européenne (Ph. Eur.) ainsi que 'Echinacea pallida', 'Powdered Echinacea pallida' et 'Powdered Echinacea pallida Extract' de la Pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-07-10";s:16:"field_legacy_nid";s:6:"100851";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:22:"CH24;CH59;AD1014;ADU15";s:15:"field_dose_note";s:25:"EPAP1;FRAD;EPA1;EPA2;ADUL";s:19:"field_mono_duration";s:6:"EPADUR";s:15:"field_mono_risk";s:29:"EPA_CW1;EPA_CW2;EPA_CW3;PERS2";s:21:"field_mono_citation_e";s:134:"ABC;CGCEM;EXPCEM;ENHCI;BHCOM2;HERCDI;PDSEPR;ESCOP;BOTSAF;HERCOM;HMPL;NAE;PPHPP;GRIN;EPBR10;EPEMA;EPITIS;EPUP10;BP12;USP35;HCOL8;NHPREG";s:21:"field_mono_citation_f";s:140:"ABC;CGCEM;EXPCEM;ENHCI;BHCOM2;HERCDI;PDSEPR;ESCOP;NOMEN;BOTSAF;HMPL;NAE;PPHPP;EPBR10;EPEMA;EPITIS;EPUP10;PPS3;USP35;HCOL8;BP12;NHPREG;GRIN12";s:26:"field_reference_reviewed_e";s:140:"REVCPCP;HERMED2;BHP;ASALIMM;50COM;BHCOM;CYTOTO;ECHVH;GESTEXP;SHMPDES;USEECH;IMMUACT;DHINT;DMH;HERSAF;PPP;HRMED;SEECH;CICATR;WHOMON;HDPP2;WEP";s:26:"field_reference_reviewed_f";s:147:"REVCPCP;HERMED2;BHP;ASALIMM;50COM;BHCOM;CYTOTO;ECHVH;GESTEXP;SHMPDES;USEECH;IMMUACT;DHINT;DMH;HERSAF;PPP;HRMED;SEECH;CICATR;WHOMON;HDPP2;WEP;PHAPHY";}i:216545;a:36:{s:5:"title";s:22:"EPU_Echinacea purpurea";s:3:"nid";s:6:"216545";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"EPU";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:18:"Echinacea purpurea";s:22:"field_monograph_name_f";s:19:"Echinacée purpurea";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:622:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant. (iii) A claim for traditional use must include the term " Herbal Medicine"";s:12:"field_note_f";s:745:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués. (iii) Une allégation pour un usage traditionnel doit inclure les termes « Phytothérapie/Herboristerie »";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:521:"The medicinal ingredient must comply with the requirements outlined in the Natural Health Products Ingredients Database (NHPID).; The medicinal ingredient may comply with the specifications outlined in the following pharmacopoeial monographs: 'Purple Coneflower Herb' and 'Purple Coneflower Root' of the European (Ph.Eur) Pharmacopoeia as well as 'Echinacea purpurea Aerial Parts', 'Echincea purpurea Root', 'Powdered Echinacea purpurea' and 'Powdered Echinacea purpurea Extract' of the United States (USP) Pharmacopoeia.";s:21:"field_specification_f";s:554:"L’ingrédient médicinal doit être conforme aux exigences mentionnées dans la Base de données d’ingrédients de produits de santé naturels (BDIPSN).; L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes:  'Purple Coneflower Herb' et 'Purple Coneflower Root' de la Pharmacopée européenne (Ph. Eur.) ainsi que 'Echinacea purpurea Aerial Parts', 'Echincea purpurea Root', 'Powdered Echinacea purpurea' et 'Powdered Echinacea purpurea Extract' de la Pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-07-10";s:16:"field_legacy_nid";s:6:"100852";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:22:"CH24;CH59;AD1014;ADU15";s:15:"field_dose_note";s:24:"APP1;FRAD;EPU1;EPU2;ADUL";s:19:"field_mono_duration";s:6:"EPUDUR";s:15:"field_mono_risk";s:36:"EPU_CW2;EPU_AR;PERS2;ECH_CW2;ECH_CW1";s:21:"field_mono_citation_e";s:187:"HERMED2;EXPCEM;ENHCI;ABWEHR;EFORCE;UPHCDI8;HERCDI;ESCOP;ECHINIL;MEDHER;ECHINAGA;NHPREG;BOTSAF;HERCOM;HTCH;HERSAF;PPP;PPHPP;EFECPU;EPUEMA;AMODHER;EPUKLI;EPUMHRA;MRSHRT39;EPUUSDA;WHOMON;NAE";s:21:"field_mono_citation_f";s:192:"HERMED2;EXPCEM;ENHCI;ABWEHR;EFORCE;UPHCDI8;HERCDI;PHAPHY;ESCOP;ECHINIL;NOMEN;MEDHER;ECHINAGA;NHPREG;BOTSAF;HTCH;HERSAF;PPP;PPHPP;EFECPU;EPUEMA;EPUKLI;EPUMHRA;MRSHRT39;EPUUSDA;WHOMON;NAE;HERCOM";s:26:"field_reference_reviewed_e";s:691:"MODIR;REVCPCP;HERMED;MEDPROP;UNRECH;QUESLAB;SEVRED;ECHURI;EECC;ALKECH;RAGWD;LMAAEE;ECHTAB;ISEEGA;ABC;CGCEM;AMIDES;ECHWORK;ECHUSED;50COM;HDPP;BHCOM;CAMURTI;STRUCT;CAFFEOYL;EMP;MONOANT;BIOALK;ECHPRVC;RISKBEN;ECMM;KAD;PURPCF;SELCLIN;GESTEXP;TNFGENE;EVECH;PROPEXT;P450;AMODHER;FEEP;UPRESP;NHPMIF;ECHVC;EPSUPP;USEECH;LEUCOP;ETCC;PEDPOP;AUTOIMM;ECMV;PRTRCC2;ECHTEA;MARKER;MACACT;EML;TABING;TAXECH;PRTRCC;IMECH;IMMUACT;ROOTEXT;ANTIANTI;DHINT;AIEEEP;NAE;TRTCC;AUSEXP;ECHASS;SPMOT;ESDOIL;ECHINA;ECHMED;SEECH;MEKC;GLUCURO;GENEEXP;PURPOLY;NAGARD;PRIRC;LYMPHO;PHENET;INFTNCT;EVECH2;PLANTING;EPPERC;MONOCY;MAIMC;PHAGOCY;ESCHIL;NATREM;RHINO;HERPES;REVITO;PURIC;WHOMON;CICHORIC;ROLEALK;PCBDP;EPTHER;LATTICE";s:26:"field_reference_reviewed_f";s:691:"MODIR;REVCPCP;HERMED;MEDPROP;UNRECH;QUESLAB;SEVRED;ECHURI;EECC;ALKECH;RAGWD;LMAAEE;ECHTAB;ISEEGA;ABC;CGCEM;AMIDES;ECHWORK;ECHUSED;50COM;HDPP;BHCOM;CAMURTI;STRUCT;CAFFEOYL;EMP;MONOANT;BIOALK;ECHPRVC;RISKBEN;ECMM;KAD;PURPCF;SELCLIN;GESTEXP;TNFGENE;EVECH;PROPEXT;P450;AMODHER;FEEP;UPRESP;NHPMIF;ECHVC;EPSUPP;USEECH;LEUCOP;ETCC;PEDPOP;AUTOIMM;ECMV;PRTRCC2;ECHTEA;MARKER;MACACT;EML;TABING;TAXECH;PRTRCC;IMECH;IMMUACT;ROOTEXT;ANTIANTI;DHINT;AIEEEP;NAE;TRTCC;AUSEXP;ECHASS;SPMOT;ESDOIL;ECHINA;ECHMED;SEECH;MEKC;GLUCURO;GENEEXP;PURPOLY;NAGARD;PRIRC;LYMPHO;PHENET;INFTNCT;EVECH2;PLANTING;EPPERC;MONOCY;MAIMC;PHAGOCY;ESCHIL;NATREM;RHINO;HERPES;REVITO;PURIC;WHOMON;CICHORIC;ROLEALK;PCBDP;EPTHER;LATTICE";}i:216546;a:36:{s:5:"title";s:13:"ELE_Eleuthero";s:3:"nid";s:6:"216546";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"ELE";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:9:"Eleuthero";s:22:"field_monograph_name_f";s:10:"Eleuthéro";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:97:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_eleuthero-eng.php";s:21:"field_monograph_url_f";s:97:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_eleuthero-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:217:"The medicinal ingredient may comply with the specifications outlined in the Eleuthero Monograph published in the U.S. Pharmacopoeia or the Eleutherococcus Monograph published in the British or European Pharmacopoeias.";s:21:"field_specification_f";s:265:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie Eleuthero publiée dans la Pharmacopée américaine (USP) ou la monographie Eleutherococcus publiée dans les Pharmacopées britannique (BP) ou européenne (Ph. Eur.).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-03-31";s:16:"field_legacy_nid";s:6:"100853";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:7:"ELE_DUR";s:15:"field_mono_risk";s:32:"PERS;WORS;ELE_CW1;ELE_CW2;ELE_CI";s:21:"field_mono_citation_e";s:64:"HERMED2;EXPCEM;BHCOM2;HERCDI;ESCOP;MEDHER;BOTSAF;HERCOM;PPP;GRIN";s:21:"field_mono_citation_f";s:73:"HERMED2;EXPCEM;BHCOM2;HERCDI;PHAPHY;ESCOP;NOMEN;BOTSAF;PPP;PPS;MMPND;GRIN";s:26:"field_reference_reviewed_e";s:79:"WORCAP;FLOCYTO;BHP2;ELDQL;NORVOL;PROLCYC;ESPG;CHRFAG;GLYCO;HMPL;DMH;CDPF;EXPERF";s:26:"field_reference_reviewed_f";s:79:"WORCAP;FLOCYTO;BHP2;ELDQL;NORVOL;PROLCYC;ESPG;CHRFAG;GLYCO;HMPL;DMH;CDPF;EXPERF";}i:216547;a:36:{s:5:"title";s:12:"EPHE_Ephedra";s:3:"nid";s:6:"216547";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"EPHE";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:7:"Ephedra";s:22:"field_monograph_name_f";s:8:"Ephédra";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:995:"COMPLIANCE WITH PRECURSOR CONTROL REGULATIONS:    The Precursor Control Regulations (PCR) (JC 2010) allows Canada to fulfill its international obligations with respect to the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988, and provides a framework for the regulation of activities involving precursor chemicals which can be used in the production of illicit drugs and substances. Under the PCR, regulated chemicals are grouped into two classes: Class A and Class B. For Class A precursors such as ephedra, ephedrine, and/or products containing them, persons wishing to be involved in activities such as importation, exportation, production, packaging, selling, and/or providing must 
first obtain a licence.      Further information regarding compliance with the PCR, including application forms and guidance documents pertaining to the application for a Class A precursor licence, is available at: http://www.healthcanada.gc.ca/precursors.";s:12:"field_note_f";s:1165:"CONFORMITE AVEC LE REGLEMENT SUR LES PRECURSEURS:     Le Règlement sur les précurseurs (le Règlement) (JC 2010) fournit un cadre règlementaire qui permet au Canada de s’acquitter de ses obligations contractées à l’échelle internationale dans le cadre de la Convention des Nations Unies contre le trafic illicite de stupéfiants et de substances psychotropes, 1988, et les clauses spécifiques pour la surveillance et le contrôle des précurseurs utilisés dans la production des drogues illégales. Selon le Règlement, les substances sont classées en deux catégories : catégorie A et catégorie B. Les personnes désirant importer, exporter, produire, emballer, vendre ou fournir des produits contenant des précurseurs de la catégorie A, tel que l’éphédra, l’éphédrine et/ou des produits qui en contiennent, doivent tout d’abord obtenir une licence.     Des renseignements supplémentaires concernant la conformité au Règlement, incluant les formulaires de demandes et les documents d’orientation pour l’obtention d’une licence d’un précurseur de la catégorie A sont disponibles à : http://www.santecanada.gc.ca/precurseurs.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:73:"Store protected from light and moisture (USP 32, BP 2009, Ph. Eur. 2007).";s:25:"field_storage_condition_f";s:91:"Entreposer à l’abri de la lumière et de l’humidité (BP 2009, USP 32, Ph. Eur. 2007).";s:10:"field_date";s:10:"2010-06-08";s:16:"field_legacy_nid";s:6:"100854";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:12:"APP1;EPEDH_1";s:19:"field_mono_duration";s:6:"EPHDUR";s:15:"field_mono_risk";s:248:"PERS;WORS;EPHE_CW1;EPHE_CW2;EPHE_CW3;EPHE_CW4;EPHE_CW5;EPHE_CW6;EPHE_CW7;EPHE_CW8;EPHE_CW9;EPHE_CW10;EPHE_CW11;EPHE_CW12;EPHE_CW13;EPHE_CW14;EPHE_CW15;EPHE_CW16;EPHE_CW17;EPHE_CI;EPHE_ADR1;EPHE_ADR2;EPHE_ADR3;EPHE_ADR4;EPHE_ADR5;EPHE_ADR6;EPHE_ADR7";s:21:"field_mono_citation_e";s:318:"EPEDR1;EPEDR2;EPEDR3;EPEDR4;EPEDR5;EPEDR6;EPEDR7;EPEDR8;EPEDR9;EPEDR10;EPEDR11;EPEDR12;EPEDR13;EPEDR14;EPEDR15;EPEDR16;EPEDR17;EPEDR18;EPEDR19;EPEDR20;EPEDR21;EPEDR22;EPEDR23;EPEDR24;EPEDR25;EPEDR26;EPEDR27;EPEDR28;EPEDR29;EPEDR30;EPEDR31;EPEDR32;EPEDR33;EPEDR34;EPEDR35;EPEDR36;EPEDR37;EPEDR38;EPEDR39;EPEDR40;EPEDR41";s:21:"field_mono_citation_f";s:318:"EPEDR1;EPEDR2;EPEDR3;EPEDR4;EPEDR5;EPEDR6;EPEDR7;EPEDR8;EPEDR9;EPEDR10;EPEDR11;EPEDR12;EPEDR13;EPEDR14;EPEDR15;EPEDR16;EPEDR17;EPEDR18;EPEDR19;EPEDR20;EPEDR21;EPEDR22;EPEDR23;EPEDR24;EPEDR25;EPEDR26;EPEDR27;EPEDR28;EPEDR29;EPEDR30;EPEDR31;EPEDR32;EPEDR33;EPEDR34;EPEDR35;EPEDR36;EPEDR37;EPEDR38;EPEDR39;EPEDR40;EPEDR41";s:26:"field_reference_reviewed_e";s:503:"EPEDRR1;EPEDRR2;EPEDRR3;EPEDRR4;EPEDRR5;EPEDRR6;EPEDRR7;EPEDRR8;EPEDRR9;EPEDRR10;EPEDRR11;EPEDRR12;EPEDRR13;EPEDRR14;EPEDRR15;EPEDRR16;EPEDRR17;EPEDRR18;EPEDRR19;EPEDRR20;EPEDRR21;EPEDRR22;EPEDRR23;EPEDRR24;EPEDRR25;EPEDRR26;EPEDRR27;EPEDRR28;EPEDRR29;EPEDRR30;EPEDRR31;EPEDRR32;EPEDRR33;EPEDRR34;EPEDRR35;EPEDRR36;EPEDRR37;EPEDRR38;EPEDRR39;EPEDRR40;EPEDRR41;EPEDRR42;EPEDRR44;EPEDRR45;EPEDRR46;EPEDRR47;EPEDRR48;EPEDRR49;EPEDRR50;EPEDRR51;EPEDRR52;EPEDRR53;EPEDRR54;EPEDRR55;EPEDRR56;EPEDRR57;EPEDRR58";s:26:"field_reference_reviewed_f";s:503:"EPEDRR1;EPEDRR2;EPEDRR3;EPEDRR4;EPEDRR5;EPEDRR6;EPEDRR7;EPEDRR8;EPEDRR9;EPEDRR10;EPEDRR11;EPEDRR12;EPEDRR13;EPEDRR14;EPEDRR15;EPEDRR16;EPEDRR17;EPEDRR18;EPEDRR19;EPEDRR20;EPEDRR21;EPEDRR22;EPEDRR23;EPEDRR24;EPEDRR25;EPEDRR26;EPEDRR27;EPEDRR28;EPEDRR29;EPEDRR30;EPEDRR31;EPEDRR32;EPEDRR33;EPEDRR34;EPEDRR35;EPEDRR36;EPEDRR37;EPEDRR38;EPEDRR39;EPEDRR40;EPEDRR41;EPEDRR42;EPEDRR44;EPEDRR45;EPEDRR46;EPEDRR47;EPEDRR48;EPEDRR49;EPEDRR50;EPEDRR51;EPEDRR52;EPEDRR53;EPEDRR54;EPEDRR55;EPEDRR56;EPEDRR57;EPEDRR58";}i:216548;a:35:{s:5:"title";s:23:"EPE_European Pennyroyal";s:3:"nid";s:6:"216548";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"EPE";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:19:"European Pennyroyal";s:22:"field_monograph_name_f";s:14:"Menthe pouliot";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:535:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.   Note: Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. The solidus (/) indicates that the terms or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:628:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal.   Nota: Les parenthèses contiennent des éléments d’information facultatifs - il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2012-02-29";s:16:"field_legacy_nid";s:6:"100855";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:5:"APP1R";s:15:"field_mono_risk";s:29:"PERWOR;EPE_CW1;EPE_CW2;EPE_CI";s:21:"field_mono_citation_e";s:70:"HERMED2;BHP;EPE1;TOXBM;AMODHER;MEDHER;HERCOM;BOTSAF;HERSAF;EPE2;PNCBDP";s:21:"field_mono_citation_f";s:67:"HERMED2;BHP;EPE1;TOXBM;AMODHER;MEDHER;BOTSAF;HERSAF;EPE2;WEP;PNCBDP";s:26:"field_reference_reviewed_e";s:62:"MOF;EPE3;POING;PISEIZ;HANDMH;KAD2;PDRHM2;POPH;GLUTA;EOS;PRPOIS";s:26:"field_reference_reviewed_f";s:62:"MOF;EPE3;POING;PISEIZ;HANDMH;KAD2;PDRHM2;POPH;GLUTA;EOS;PRPOIS";}i:216549;a:33:{s:5:"title";s:24:"EVP_Evening Primrose Oil";s:3:"nid";s:6:"216549";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"EVP";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:20:"Evening Primrose Oil";s:22:"field_monograph_name_f";s:16:"Onagre, Huile d'";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:103:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_primrose-onagre-eng.php";s:21:"field_monograph_url_f";s:103:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_primrose-onagre-fra.php";s:16:"field_nmi_note_e";s:157:"For products providing vitamin E at doses lower than the minima specified in Table 2 of Appendix 1, vitamin E must be declared as a non-medicinal ingredient.";s:16:"field_nmi_note_f";s:209:"La vitamine E doit être déclarée comme ingrédient non médicinal dans le cas des produits fournissant de la vitamine E à des doses inférieures aux doses minimales présentées au tableau 2 de l'annexe 1.";s:12:"field_note_e";s:247:"Vitamin E is an optional medicinal ingredient in evening primrose oil products.  However, no use or purpose statements may be associated with vitamin E.  See Appendix 1 for vitamin E proper name, common name, source material, and dose information.";s:12:"field_note_f";s:328:"Les produits d'huile d'onagre peuvent contenir de la vitamine E comme ingrédient médicinal facultatif. Cependant, aucun énoncé concernant les usage(s) ou fin(s) recommandés ne peut être associé à la vitamine E. Consulter l'annexe 1 pour les noms propres et communs, les matières d'origine et les doses de la vitamine E.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:397:"The medicinal ingredient may comply with the specifications outlined in the Refined Evening Primrose Oil Monograph published in the British Pharmacopoeia or the Evening Primrose Oil, Refined Monograph published in the European Pharmacopoeia.  For products indicating one or more of the optional potencies listed in the dose section, an assay must be performed in order to confirm the potency(ies).";s:21:"field_specification_f";s:503:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie Refined Evening Primrose Oil publiée dans la Pharmacopée britannique (BP) ou dans la Huile d’onagre Page 2 de 9 monographie Evening Primrose Oil, Refined publiée dans la Pharmacopée européenne (Ph. Eur.).  Dans le cas des produits affichant une ou plusieurs activités énoncées à la section des doses, une analyse doit être effectuée afin de confirmer la validité de cette (ces) activité(s).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-07-16";s:16:"field_legacy_nid";s:6:"100856";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:21:"field_mono_citation_e";s:62:"EP8;IOMDRI;FCC;TRDIA;HERCOM;HERSAF;MERCK13;MART35;GRIN;WHOMON2";s:21:"field_mono_citation_f";s:70:"PMM;PHAPHY;EP8;IOMDRI;FCC;TRDIA;HERSAF;MERCK13;PPS;MART35;GRIN;WHOMON2";s:26:"field_reference_reviewed_e";s:245:"HERMED2;HBNPD;BPH8;HERCDI;LTERM2;MEDHER;DRIECF;ATOPIC;DELTA6;EFAPL;CYCBP;LAGLA;BOTSAF;PPP;EFAMOL;EPOGAM;EPOPMS;EPIDER;EPOMO;MASTA;BCLEFF;SAFEPO;SUPEPO;TRAECZ;EPOECZ;BCRCT;GLALA;OREFA;PSOART;ELDER;PROSPRE;MASTAL;CHDERM;WEP;PNCBDP;OEPO;TEEPO;OS6WK";s:26:"field_reference_reviewed_f";s:245:"HERMED2;HBNPD;BPH8;HERCDI;LTERM2;MEDHER;DRIECF;ATOPIC;DELTA6;EFAPL;CYCBP;LAGLA;BOTSAF;PPP;EFAMOL;EPOGAM;EPOPMS;EPIDER;EPOMO;MASTA;BCLEFF;SAFEPO;SUPEPO;TRAECZ;EPOECZ;BCRCT;GLALA;OREFA;PSOART;ELDER;PROSPRE;MASTAL;CHDERM;WEP;PNCBDP;OEPO;TEEPO;OS6WK";}i:216550;a:35:{s:5:"title";s:22:"FEN_O_Fenugreek - Oral";s:3:"nid";s:6:"216550";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"FEN_O";s:18:"field_group_name_e";s:9:"Fenugreek";s:18:"field_group_name_f";s:8:"Fenugrec";s:22:"field_monograph_name_e";s:16:"Fenugreek - Oral";s:22:"field_monograph_name_f";s:16:"Fenugrec - Orale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:703:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.      Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.  (ii) Claims for traditional use must include the term “Herbal Medicine”.";s:12:"field_note_f";s:859:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.     Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués. (ii) Les allégations concernant l’usage traditionnel doivent inclure le terme « phytothérapie ».";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:180:"The medicinal ingredient may comply with the specifications outlined in the Fenugreek monograph published in the British Pharmacopoeia (BP) or the European Pharmacopoeia (Ph.Eur.).";s:21:"field_specification_f";s:197:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie Fenugreek publiée dans la pharmacopée européenne (Ph. Eur.) ou la pharmacopée britannique (BP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-06-24";s:16:"field_legacy_nid";s:6:"100857";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:27:"PERS;WORS;FENO_CW1;FENO_CW2";s:21:"field_mono_citation_e";s:159:"ANTIHYPO;APIP1V1;EXPCEM;BHCOM2;HERCDI;UPHCDI;KAD;AMODHER;MEDHER;MMIT;BOTSAF;HERCOM;THEHER;EBHM;DMH;HERSAF;HMPL;HYPOGL;GRIN;HDPP2;PHC;MHAY;PNCBDP;PCBDP;BPH8;EP8";s:21:"field_mono_citation_f";s:156:"ANTIHYPO;APIP1V1;EXPCEM;BHCOM2;HERCDI;UPHCDI;PHAPHY;KAD;AMODHER;MEDHER;MMIT;BOTSAF;EBHM;DMH;HERSAF;HMPL;HYPOGL;GRIN;HDPP2;WEP;PHC;MHAY;PNCBDP;PCBDP;BPH8;EP8";s:26:"field_reference_reviewed_e";s:172:"APIP1V2;HERMED2;HERMED;BEHM;BHP2;HDPP;GINFEN;BHCOM;GLYOXA;THEPHA;ECMM;VANAD;PDRHM3;PDRHM2;EFFTFG;POLYPH;PSMAP;PPP;PPS;LIPPER;FENSDS;SHRTCOM;FENDIA;SCHYPO;RHBPE;ETHTOX;PECOD";s:26:"field_reference_reviewed_f";s:172:"APIP1V2;HERMED2;HERMED;BEHM;BHP2;HDPP;GINFEN;BHCOM;GLYOXA;THEPHA;ECMM;VANAD;PDRHM3;PDRHM2;EFFTFG;POLYPH;PSMAP;PPP;PPS;LIPPER;FENSDS;SHRTCOM;FENDIA;SCHYPO;RHBPE;ETHTOX;PECOD";}i:216551;a:35:{s:5:"title";s:25:"FEN_T_Fenugreek - Topical";s:3:"nid";s:6:"216551";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"FEN_T";s:18:"field_group_name_e";s:9:"Fenugreek";s:18:"field_group_name_f";s:8:"Fenugrec";s:22:"field_monograph_name_e";s:19:"Fenugreek - Topical";s:22:"field_monograph_name_f";s:18:"Fenugrec - Topique";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:701:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.     Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant. (ii) Claims for traditional use must include the term “Herbal Medicine”.";s:12:"field_note_f";s:859:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.     Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués. (ii) Les allégations concernant l’usage traditionnel doivent inclure le terme « phytothérapie ».";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:180:"The medicinal ingredient may comply with the specifications outlined in the Fenugreek monograph published in the British Pharmacopoeia (BP) or the European Pharmacopoeia (Ph.Eur.).";s:21:"field_specification_f";s:197:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie Fenugreek publiée dans la pharmacopée européenne (Ph. Eur.) ou la pharmacopée britannique (BP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-06-24";s:16:"field_legacy_nid";s:6:"100858";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:9:"PERS;WORS";s:21:"field_mono_citation_e";s:159:"ANTIHYPO;APIP1V1;EXPCEM;BHCOM2;HERCDI;UPHCDI;KAD;AMODHER;MEDHER;MMIT;BOTSAF;HERCOM;THEHER;EBHM;DMH;HERSAF;HMPL;HYPOGL;GRIN;HDPP2;PHC;MHAY;PNCBDP;PCBDP;BPH8;EP8";s:21:"field_mono_citation_f";s:156:"ANTIHYPO;APIP1V1;EXPCEM;BHCOM2;HERCDI;UPHCDI;PHAPHY;KAD;AMODHER;MEDHER;MMIT;BOTSAF;EBHM;DMH;HERSAF;HMPL;HYPOGL;GRIN;HDPP2;WEP;PHC;MHAY;PNCBDP;PCBDP;BPH8;EP8";s:26:"field_reference_reviewed_e";s:172:"APIP1V2;HERMED2;HERMED;BEHM;BHP2;HDPP;GINFEN;BHCOM;GLYOXA;THEPHA;ECMM;VANAD;PDRHM3;PDRHM2;EFFTFG;POLYPH;PSMAP;PPP;PPS;LIPPER;FENSDS;SHRTCOM;FENDIA;SCHYPO;RHBPE;ETHTOX;PECOD";s:26:"field_reference_reviewed_f";s:172:"APIP1V2;HERMED2;HERMED;BEHM;BHP2;HDPP;GINFEN;BHCOM;GLYOXA;THEPHA;ECMM;VANAD;PDRHM3;PDRHM2;EFFTFG;POLYPH;PSMAP;PPP;PPS;LIPPER;FENSDS;SHRTCOM;FENDIA;SCHYPO;RHBPE;ETHTOX;PECOD";}i:216552;a:36:{s:5:"title";s:12:"FEV_Feverfew";s:3:"nid";s:6:"216552";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"FEV";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:8:"Feverfew";s:22:"field_monograph_name_f";s:16:"Grande camomille";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:106:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_feverfew-camomille-eng.php";s:21:"field_monograph_url_f";s:106:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_feverfew-camomille-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:701:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.     Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant. (ii) Claims for traditional use must include the term “Herbal Medicine”.";s:12:"field_note_f";s:873:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.     Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués. (ii) Les allégations concernant l’usage traditionnel doivent inclure le terme « phytothérapie/herboristerie ».";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:629:"Migraine prevention/prophylaxis products must contain a minimum of 90% dried leaf (Awang 1993);  The medicinal ingredient may comply with the specifications outlined in the following pharmacopoeial monographs: 'Feverfew' from the British Pharmacopoeia (BP), 'Feverfew' of the European Pharmacopoeia (Ph. Eur.) or 'Feverfew' and 'Powdered Feverfew' of the US Pharamcopoeia (USP).; For migraine prevention/prophylaxis: Products must contain a minimum of 90% dried leaf (Awang 1993).; Note: Information detailed in this section is not to be submitted with the compendial PLA, although it may be requested at the NHPD’s discretion.";s:21:"field_specification_f";s:647:"Les produits de prévention/réduction des migraines doivent contenir un minimum de 90% de feuilles séchées (Awang 1993);  L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes: 'Feverfew' de la Pharmacopée Britannique, 'Feverfew' de la Pharmacopée Européenne ou 'Feverfew' et 'Powdered Feverfew' de la Pharmacopée Américaine.; Prévention de la migraine : Les produits doivent contenir un minimum de 90% de feuilles séchées (Awang 1993); Nota : L’information susmentionnée ne doit pas être remise avec la DLMM officinale -- la DPSN peut toutefois en faire la demande.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2010-10-15";s:16:"field_legacy_nid";s:6:"100859";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:8:"FEV;APP1";s:19:"field_mono_duration";s:17:"FEVDUR;FEVDUR_MIG";s:15:"field_mono_risk";s:57:"PERS;WORS;FEV_CW1;FEV_CW2;FEV_CI1;FEV_CI2;FEV_AR1;FEV_AR2";s:21:"field_mono_citation_e";s:157:"FEVAW;FEVFEV;HERMED2;PLATAGG;FFEW;BHCOM;HERCDI;PHASEI;ESCOP;KAD;6YEAR;MEDHER;EFFFF;BOTSAF;HERCOM;PPP;FFMP;FFPRO;DANISH;FFPMR;MART35;GRIN;PHC;COOK;ASTR1;50COM";s:21:"field_mono_citation_f";s:164:"FEVAW;FEVFEV;HERMED2;PLATAGG;FFEW;BHCOM;HERCDI;PHAPHY;PHASEI;ESCOP;KAD;6YEAR;MEDHER;EFFFF;BOTSAF;PPP;FFMP;FFPRO;DANISH;FFPMR;MART35;GRIN;PLATHE;PHC;COOK;ASTR1;50COM";s:26:"field_reference_reviewed_e";s:229:"ANALG;SISTER;1HNMR;FFMPRO;FACES;BHP2;ABC;UPHCDI8;PHACTFF;CLAPPNM;MAFFRIB;HMMP;MIG99;LABEL;UPDSR;ANTIFERT;USEFF;AMODHER;CONTACT;ANCIENT;PARTHE;UNSAFE;IKAPPAB;ANTINO;PLATELET;THEHER;DHINT;DMH;VARPAR;RHEUM;COMPDER;HEART;PNCBDP;PCBDP";s:26:"field_reference_reviewed_f";s:229:"ANALG;SISTER;1HNMR;FFMPRO;FACES;BHP2;ABC;UPHCDI8;PHACTFF;CLAPPNM;MAFFRIB;HMMP;MIG99;LABEL;UPDSR;ANTIFERT;USEFF;AMODHER;CONTACT;ANCIENT;PARTHE;UNSAFE;IKAPPAB;ANTINO;PLATELET;THEHER;DHINT;DMH;VARPAR;RHEUM;COMPDER;HEART;PNCBDP;PCBDP";}i:216553;a:36:{s:5:"title";s:11:"FIG_Figwort";s:3:"nid";s:6:"216553";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"FIG";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:7:"Figwort";s:22:"field_monograph_name_f";s:19:"Scrofulaire noueuse";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:107:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_figwort-scrofulaire-eng.php";s:21:"field_monograph_url_f";s:107:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_figwort-scrofulaire-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:718:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.     Note: (i) Text in parentheses is additional optional information which can be included on the Product Licence Application and product labels at the applicants’ discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant. (ii) Claims for traditional use must include the term “Herbal Medicine”.";s:12:"field_note_f";s:910:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient (ou des ingrédients) médicinal (médicinaux). La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.     Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués. (ii) Les allégations relatives à l’utilisation traditionnelle doivent inclure les termes « en phytothérapie ».";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2011-01-25";s:16:"field_legacy_nid";s:6:"100860";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:6:"FIGOCC";s:15:"field_mono_risk";s:22:"PERS;WORS;PREGC;FIG_CW";s:21:"field_mono_citation_e";s:90:"BEHM;HBNPD;BHP;HERCDI;PATSC;KAD;AMODHER;MEDHER;HERCOM;DMH;FIGGRIN;PNCBDP;PCBDP;PPS3;PHAPHY";s:21:"field_mono_citation_f";s:94:"BEHM;HBNPD;BHP;PMM;HERCDI;PATSC;KAD;AMODHER;MEDHER;HERCOM;DMH;FIGGRIN;PNCBDP;PCBDP;PPS3;PHAPHY";s:26:"field_reference_reviewed_e";s:6:"PDRHM2";s:26:"field_reference_reviewed_f";s:6:"PDRHM2";}i:216554;a:34:{s:5:"title";s:12:"FIS_Fish Oil";s:3:"nid";s:6:"216554";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"FIS";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:8:"Fish Oil";s:22:"field_monograph_name_f";s:17:"Poisson, Huile de";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:810:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.   There are many N-3 polyunsaturated fatty acids, popularly known as omega-3 acids/ω-3 fatty acids (Ph.Eur. 2012). This monograph is specific to eicosapentaenoic acid (C20:5 n-3, EPA) and docosahexaenoic acid (C22:6 n-3, DHA).    Notes: (i) Text in parentheses is additional optional information which can be included on the Product Licence Application and product labels at the applicants’ discretion. (ii) The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:924:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal.   Il existe plusieurs acides gras polyinsaturés N-3, mieux connus sous les noms d’acides gras omega-3/acides gras ω-3 (Ph.Eur. 2012). Cette monographie est spécifique à l’acide eicosapentaénoïque (C20:5 n-3, AEP) et à l’acide docosahexaénoïque (C22:6 n-3, ADH).     Nota :   (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit.  (ii) La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:2694:"The medicinal ingredient must comply with the requirements outlined in the Natural Health Products Ingredients Database (NHPID). In addition, the medicinal ingredient may comply with the specifications outlined in the Fish Oil, Rich in Omega-3-Acids Monographs published in the European and British Pharmacopoeias or Fish oil containing Omega-3 Acids from the USP (Refer to Appendix 1 Table 2);  Peroxide, anisidine, and totox values of fish oil or omega-3 fatty acids derived from fish oil must be in accordance with the methods set out by the Association of Analytical Community (AOAC) and/or Pharmacopoeial analytical methods. These specifications are necessary to ensure the oxidative stability of the fish oil and the omega-3 fatty acids from seal oil (HC 2007).  The maximum peroxide value (PV) must be 5 mEq/kg, the maximum anisidine value (AV) must be 20 while the maximum Totox value must be 26 (calculated as 2 X PV + AV). (Refer to Appendix 1 Table 3);  The dioxins, polychlorinated dibenzo-para-dioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs), and the polychlorinated biphenyls (PCBs), which include the dioxin-like polychlorinated biphenyls (DL PCBs), and the non dioxin-like polychlorinated biphenyls (NDL-PCBs) are contaminants in oils from marine sources. Testing for these contaminants are required, and must be performed using either the analytical method of the European Commission Regulation EU 252/2012 (EU 2012) or the U.S. Environmental Protection Agency’s method 1613B for PCDDs and PCDFs and method 1668A for PCBs (USP 35, US EPA 2010, 2008,1994). Applicants are advised to consult the Council of the European Union document on these contaminants for further information (EU 2011).  The maximum limits from EU1259/2011 are: for dioxins (sum of PCDDs and PCDFs) -- a maximum of 1.75 pg/g, for the sum of dioxins and DL-PCBs -- a maximum of 6 pg/g, and for PCBs -- a maximum of 200 ng/g. The maximum limits from USP 35 are  for dioxins (sum of PCDDs and PCDFs) -- a maximum of 1.0 pg/g, and for PCBs -- a maximum of 0.5ppm (Refer to Appendix 1 Table 4) [(i)Maximums levels are expressed in World Health Organization (WHO 2005) toxic equivalents using WHO-toxic equivalent factors (TEFs). Analytical results relating to 17 individual dioxin congeners of toxicological concern are expressed in a single quantifiable unit: 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) toxic equivalent concentration (TEQ) (USP 35; EU 2011).(ii) Sum of dioxins: WHO-PCDD/F-TEQ (USP 35; EU 2011) (iii) Sum of dioxins and dioxin-like PCBs: WHO-PCDD/F-PCB-TEQ (EU 2011) (iv) Sum of PCB congeners 28, 52, 101, 118, 138, 153 and 180 (USP 35; EU 2011) (v) Equivalence: 0.5 ppm = 500 ng/g.";s:21:"field_specification_f";s:3165:"L’ingrédient médicinal doit être conforme aux exigences mentionnées dans la Base de données d’ingrédients de produits de santé naturels (BDIPSN). De plus, l’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales 'Fish Oil, Rich in Omega-3-Acids' publiées dans les pharmacopées européenne et britannique ou 'Fish Oil Containing Omega-3 Acids' de USP (Consulter le Appendice 1 tableau 2);  Les niveaux de peroxyde, d’anisidine et les niveaux totaux d’oxydation de l’huile de poisson et des dérivés d’acides gras oméga-3 provenant de l’huile de poisson doivent respecter les normes établies par l’Association of Analytical Community (AOAC) et/ou les méthodes analytiques des pharmacopées. Ces spécifications assureront la résistance à l'oxydation de l'huile de phoque et des acides gras oméga-3 provenant de l'huile de poisson (SC 2007). Le niveau maximal de l'indice de peroxyde (IP) doit être 5 mEq/kg, le niveau maximal de l'indice d'anisidine (IA) doit être 20 tandis que le niveau maximal du total d'oxydation doit être 26 (calculé selon la formule : 2 X IP + IA).(Consulter le Appendice 1 tableau 3); Les dioxines polychlorodibenzo-para-dioxines (PCDD) et polychlorodibenzofuranes (PCDF), et les polychlorobiphényles (PCB) qui comprennent les polychlorobiphényles de type dioxine (PCB-TD) et les polychlorobiphényles de type non-dioxine (PCB-TND), sont des contaminants présents dans les huiles marines. Des analyses pour détecter ces contaminants sont obligatoires et doivent être effectuées soit au moyen de la méthode analytique du Règlement EU 252/2012 de la Commission européenne (UE 2012), soit au moyen de la méthode 1613B de la U.S. Environmental Protection Agency pour les PCDD et les PCDF et la méthode 1668A pour les PCB (USP 35, US EPA 1999, 1994). Les demandeurs sont avisés de consulter le document du Conseil de l’Union européenne sur ces contaminants pour de plus amples informations (UE 2011). Les teneurs maximales de UE 1259/2011:  pour les dioxines (somme des PCDD et des PCDF) --  un maximum de 1,75 pg/g, pour la somme des dioxines et des PCB-TD -- un maximum de 6 pg/g, et pour le Somme des indicateurs PCBs -- un maximum de 200 ng/g. Les teneurs maximales de USP 35:  pour les dioxines (somme des PCDD et des PCDF) --  un maximum de 1,0 pg/g, et pour les PCBs -- 0,5 ppm (Consulter le Appendice 1 tableau 4)[(i)Exprimée en équivalents toxiques tels que définis par l’Organisation mondiale de la santé (WHO 2005), en appliquant les facteurs d’équivalence toxique de l’OMS (TEF-OMS). Les résultats de l’analyse de 17 congénères de dioxines représentant un risque toxicologique sont exprimés sous la forme d’une seule unité quantifiable : la concentration en équivalents toxiques (TEQ) de 2,3,7,8-tétrachlorodibenzo-p-dioxine (TCDD) (USP 35; UE 2011). (ii) Somme des dioxines : OMS-PCDD/F-TEQ (USP 35; UE 2011). (iii) Somme des dioxines et des PCBTD : OMS-PCDD/F-PCB-TEQ (UE 2011). (iv) Somme des congénères 28, 52, 101, 118, 138, 153 et 180 de PCB (USP 35; UE 2011). (v) Equivalence : 0,5 ppm = 500 ng/g.";s:25:"field_storage_condition_e";s:187:"For all products: Store in airtight container, protected from light (Ph.Eur. 2012, USP 34).; For all products, except those encapsulated: Refrigerate after opening (Wille and Gonus 1989).";s:25:"field_storage_condition_f";s:212:"Pour tous les produits: Entreposer dans un contenant hermétique à l’abri de la lumière (Ph.Eur. 2012, USP 34).; Tous les produits, sauf ceux encapsulés: Réfrigérer après ouverture (Willie et Gonus 1989).";s:10:"field_date";s:10:"2013-07-10";s:16:"field_legacy_nid";s:6:"100861";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:21:"CH18;AD913;AD1418;ADU";s:15:"field_dose_note";s:22:"RESMIN;FOIL;FOIL1;ADUL";s:21:"field_mono_citation_e";s:296:"O3FA;MAROIL1;MAROIL42;MAROIL4;COGPHY;BLDPRF;174PAT;MAROIL5;MRISTD;EFABRAIN;MAROIL6;O3CD;MAROIL7;CONSUM;N3POLY;DOCOSA;EYECHLD;ALZH;CHHDDEP;HIDOSE;PRIMC;ETHYLEPA;MAROIL8;O3ATHL;EFAHCD;ONEYR;RHARTH;FADEP;FABIP;MAROIL12;MAROIL13;MAROIL14;EFOCPOS;FOCONC;CARDIS;PREPFO;BORDPD;MAROIL43;MAROIL46;EFSA2012";s:21:"field_mono_citation_f";s:287:"O3FA;MAROIL1;MAROIL42;MAROIL4;COGPHY;BLDPRF;174PAT;MAROIL5;MRISTD;EFABRAIN;MAROIL6;O3CD;MAROIL7;CONSUM;N3POLY;DOCOSA;EYECHLD;ALZH;CHHDDEP;HIDOSE;PRIMC;ETHYLEPA;MAROIL8;O3ATHL;EFAHCD;ONEYR;RHARTH;FADEP;FABIP;MAROIL12;MAROIL13;MAROIL14;EFOCPOS;FOCONC;CARDIS;PREPFO;BORDPD;MAROIL43;MAROIL46";s:26:"field_reference_reviewed_e";s:1876:"ABSFOC;MAROIL15;PASSCL;HYPERPH;BTPAFAC;PARTUR;CAROTID;NONINSU;REDBLP;BPSL;EVOKED;MOTOR;ANTICO;FOOO;THEORY;VISUAL;TERMINF;6WK;DOSERES;PLASMAPH;SUPOO;NUTRI;MAROIL16;HERCDI;FOIW;CIRC;LCADHD;EMPAR;FAIID;FACD;ATRIAL;DENPAT;ARACHI;FRSTYR;CDPROT;EPARICH;MARINE;PHENK;CLBIOEF;FASBS;MAROIL17;MAROIL18;MAROIL19;MAROIL20;GRAY;HTGPAT;GLUCTRL;MAROIL21;MAROIL22;AGEING;PHPHLPD;PUFA;TRIAL;ATOPY;CD14;FCBCR;EARLY2;SAFPUFA;LTME;HAEVAR;SLGC;MAROIL23;SSDHAARA;SSALALA;ICFA;VALMA;DEGENE;EEBIP;PTCA;ALAMLC;TRNSCR;FOGCD;EPAOCD;COGDYS;RESTEN;PRVCOM;BPRES;ACTRA;PLCOMP;HIPUR;LTERM2;FOV;FNIRMWB;FGRET;LIPPRE;AGGRES;AGYA;DYSMEN;MAROIL24;INTREC;SECPR;MEDEFF;EPADHA;PLGD;ESE;INCSTRK;PDRNS;OPPOR;ENDOTH2;EYEHLTH;ASTHMA;XLINK;FOVSSO;NEONATE;VENOUS;PLIST;DFABD;SFSEL;STRKWM;MAROIL25;CART;SUPLUT;MIDAGE;OLDMEN;CORANG;FASTING;DECBM;NAPROX;DSADA;EMDFA;DFOOO;HDFO;ETHEST;EPIC;PLFIB;NONST;CYTOK;COING;DOFO;DIFASS;EOFACMH;RECSIN;PPDIP;PRIMER;THRMBX;ADND;LIPGC;EOFACAN;LOWERED;TH1LIKE;SERZNC;N3N6;COMMENT;PPDEP;DHATMD;ESPRIT;MFPH;DEVNBF;MAROIL26;VESLPW;AIRWAY;BRONCH;18MTH;MATDHA;OWMW;AMBUL;PURED;REGBP;SDASP;BRASTH;MAJSUR;MAROIL27;DIETDHA;RESDEP;CHHDDEP;UNIPOL;N3LONG;EDSN3P;MAROIL28;CRSSNAT;ABSN3;FLAXR29;ONCOPDS;MARTFO;BRTHWT;SEAFOOD;OMACOR;HRPREG;OPLBL;OFAMD;STRMAT;ETHANOL;3YEAR;N3FARF;SCHDEP;FOED;HYPSUB;TACHY;COLOREC;TWOTYP;AUTIST;OXFDUR;LEARNING;FAADHD;CHEMOP;DHACOG;IRRIT;FACFOC;DEMRSK;MALEVOL;7YEARS;MTLHLT;LTSN3;MODEST;ADVFC;ABSEFF;TRIALFO;HIMEGA;WRKSHP;EFADHB;MICRONUT;MILDCI;INTCLAUD;BIOIND;O3BOYS;EFABOYS;DISRUPT;O3FABD;ANTILIP;MAJDEP;SITNF;SECPREV;LORISK;TOKORO;14YEAR;ATOPECZ;FINLAND;BRPROS;DIASTO;DFACC;55Y;PERIOP;VERA;FOPF;DHAARA;DGAMER;MAROIL29;MAROIL30;MAROIL31;CORREL;GISSI;RBVER;MAROIL32;OLDRSUB;EFOSRA;ZUTPHEN2;ATOPDER;FREELIV;3LODOSE;INCORP;DIF;INBORN;ADHD;EICOSA;METEFF;PROSPRE;NUTBIO;PASSCL2;COGAG;MAOSFI;RSSEFO;CEN3FA;EPEADA;EPEADA2;COURSE;FOCCHD;FCC7;MAROIL44;MAROIL45;MAROIL10;MAROIL11";s:26:"field_reference_reviewed_f";s:1885:"ABSFOC;MAROIL15;PASSCL;HYPERPH;BTPAFAC;PARTUR;CAROTID;NONINSU;REDBLP;BPSL;EVOKED;MOTOR;ANTICO;FOOO;THEORY;VISUAL;TERMINF;6WK;DOSERES;PLASMAPH;SUPOO;NUTRI;MAROIL16;HERCDI;FOIW;CIRC;LCADHD;EMPAR;FAIID;FACD;ATRIAL;DENPAT;ARACHI;FRSTYR;CDPROT;EPARICH;MARINE;PHENK;CLBIOEF;FASBS;MAROIL17;MAROIL18;MAROIL19;MAROIL20;GRAY;HTGPAT;GLUCTRL;MAROIL21;MAROIL22;AGEING;PHPHLPD;PUFA;TRIAL;ATOPY;CD14;FCBCR;EARLY2;SAFPUFA;LTME;HAEVAR;SLGC;MAROIL23;SSDHAARA;SSALALA;ICFA;VALMA;DEGENE;EEBIP;PTCA;ALAMLC;TRNSCR;FOGCD;EPAOCD;COGDYS;RESTEN;PRVCOM;BPRES;ACTRA;PLCOMP;HIPUR;LTERM2;FOV;FNIRMWB;FGRET;LIPPRE;AGGRES;AGYA;DYSMEN;MAROIL24;INTREC;SECPR;MEDEFF;EPADHA;PLGD;ESE;INCSTRK;PDRNS;OPPOR;ENDOTH2;EYEHLTH;ASTHMA;XLINK;FOVSSO;NEONATE;VENOUS;PLIST;DFABD;SFSEL;STRKWM;MAROIL25;CART;SUPLUT;MIDAGE;OLDMEN;CORANG;FASTING;DECBM;NAPROX;DSADA;EMDFA;DFOOO;HDFO;ETHEST;EPIC;PLFIB;NONST;CYTOK;COING;DOFO;DIFASS;EOFACMH;RECSIN;PPDIP;PRIMER;THRMBX;ADND;LIPGC;EOFACAN;LOWERED;TH1LIKE;SERZNC;N3N6;COMMENT;PPDEP;DHATMD;ESPRIT;MFPH;DEVNBF;MAROIL26;VESLPW;AIRWAY;BRONCH;18MTH;MATDHA;OWMW;AMBUL;PURED;REGBP;SDASP;BRASTH;MAJSUR;MAROIL27;DIETDHA;RESDEP;CHHDDEP;UNIPOL;N3LONG;EDSN3P;MAROIL28;CRSSNAT;ABSN3;FLAXR29;ONCOPDS;MARTFO;BRTHWT;SEAFOOD;OMACOR;HRPREG;OPLBL;OFAMD;MAROIL33;STRMAT;ETHANOL;3YEAR;N3FARF;SCHDEP;FOED;HYPSUB;TACHY;COLOREC;TWOTYP;AUTIST;OXFDUR;LEARNING;FAADHD;CHEMOP;DHACOG;IRRIT;FACFOC;DEMRSK;MALEVOL;7YEARS;MTLHLT;LTSN3;MODEST;ADVFC;ABSEFF;TRIALFO;HIMEGA;WRKSHP;EFADHB;MICRONUT;MILDCI;INTCLAUD;BIOIND;O3BOYS;EFABOYS;DISRUPT;O3FABD;ANTILIP;MAJDEP;SITNF;SECPREV;LORISK;TOKORO;14YEAR;ATOPECZ;FINLAND;BRPROS;DIASTO;DFACC;55Y;PERIOP;VERA;FOPF;DHAARA;DGAMER;MAROIL29;MAROIL30;MAROIL31;CORREL;GISSI;RBVER;MAROIL32;OLDRSUB;EFOSRA;ZUTPHEN2;ATOPDER;FREELIV;3LODOSE;INCORP;DIF;INBORN;ADHD;EICOSA;METEFF;PROSPRE;NUTBIO;PASSCL2;COGAG;MAOSFI;RSSEFO;CEN3FA;EPEADA;EPEADA2;COURSE;FOCCHD;FCC7;MAROIL44;MAROIL45;MAROIL10;MAROIL11";}i:216555;a:35:{s:5:"title";s:14:"FLAXS_Flaxseed";s:3:"nid";s:6:"216555";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"FLAXS";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:8:"Flaxseed";s:22:"field_monograph_name_f";s:13:"Graine de lin";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:616:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.   Note: Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:749:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.  Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:118:"For all products, except those encapsulated: 
Refrigerate after opening (Nykter et al. 2006; Lukaszewicz et al. 2004).";s:25:"field_storage_condition_f";s:119:"Tous les produits, sauf ceux encapsulés :
Réfrigérer après ouverture (Nykter et al. 2006; Lukaszewicz et al. 2004).";s:10:"field_date";s:10:"2010-04-13";s:16:"field_legacy_nid";s:6:"100862";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:12:"CH6_12;ADU13";s:15:"field_dose_note";s:56:"FLAXS_1;FLAXS_2;FLAXS_3;FLAXS_4;FLAXS_DR1;FLAXS_DR2;APP1";s:15:"field_mono_risk";s:91:"FLAXS_CW1;FLAXS_CW2;FLAXS_CW3;FLAXS_CW4;FLAXS_CW5;FLAXS_CW6;FLAXS_CW7;FLAXS_ADR1;FLAXS_ADR2";s:21:"field_mono_citation_e";s:350:"FLAXR1;FLAXR2;FLAXR3;FLAXR4;FLAXR5;FLAXR6;FLAXR7;FLAXR8;FLAXR9;FLAXR10;FLAXR11;FLAXR12;FLAXR13;FLAXR14;FLAXR15;FLAXR16;FLAXR17;FLAXR18;FLAXR19;FLAXR20;FLAXR21;FLAXR22;FLAXR23;FLAXR24;FLAXR25;FLAXR26;FLAXR27;FLAXR28;FLAXR29;FLAXR30;FLAXR31;FLAXR32;FLAXR33;FLAXR34;FLAXR35;FLAXR36;FLAXR37;FLAXR38;FLAXR39;FLAXR40;FLAXR41;FLAXR42;FLAXR43;FLAXR44;FLAXR45";s:21:"field_mono_citation_f";s:350:"FLAXR1;FLAXR2;FLAXR3;FLAXR4;FLAXR5;FLAXR6;FLAXR7;FLAXR8;FLAXR9;FLAXR10;FLAXR11;FLAXR12;FLAXR13;FLAXR14;FLAXR15;FLAXR16;FLAXR17;FLAXR18;FLAXR19;FLAXR20;FLAXR21;FLAXR22;FLAXR23;FLAXR24;FLAXR25;FLAXR26;FLAXR27;FLAXR28;FLAXR29;FLAXR30;FLAXR31;FLAXR32;FLAXR33;FLAXR34;FLAXR35;FLAXR36;FLAXR37;FLAXR38;FLAXR39;FLAXR40;FLAXR41;FLAXR42;FLAXR43;FLAXR44;FLAXR45";s:26:"field_reference_reviewed_e";s:215:"FLAXRR1;FLAXRR2;FLAXRR3;FLAXRR4;FLAXRR5;FLAXRR6;FLAXRR7;FLAXRR8;FLAXRR9;FLAXRR10;FLAXRR11;FLAXRR12;FLAXRR13;FLAXRR14;FLAXRR15;FLAXRR16;FLAXRR17;FLAXRR18;FLAXRR19;FLAXRR20;FLAXRR21;FLAXRR22;FLAXRR23;FLAXRR24;FLAXRR25";s:26:"field_reference_reviewed_f";s:215:"FLAXRR1;FLAXRR2;FLAXRR3;FLAXRR4;FLAXRR5;FLAXRR6;FLAXRR7;FLAXRR8;FLAXRR9;FLAXRR10;FLAXRR11;FLAXRR12;FLAXRR13;FLAXRR14;FLAXRR15;FLAXRR16;FLAXRR17;FLAXRR18;FLAXRR19;FLAXRR20;FLAXRR21;FLAXRR22;FLAXRR23;FLAXRR24;FLAXRR25";}i:216556;a:34:{s:5:"title";s:18:"FLAXO_Flaxseed oil";s:3:"nid";s:6:"216556";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"FLAXO";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:12:"Flaxseed oil";s:22:"field_monograph_name_f";s:12:"Huile de Lin";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:157:"For products providing vitamin E at doses lower than the minima specified in Table 2 of Appendix 1, vitamin E must be declared as a non-medicinal ingredient.";s:16:"field_nmi_note_f";s:209:"La vitamine E doit être déclarée comme ingrédient non médicinal dans le cas des produits fournissant de la vitamine E à des doses inférieures aux doses minimales présentées au tableau 2 de l'annexe 1.";s:12:"field_note_e";s:863:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.  Note:  (I) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.     (II) Vitamin E is an optional medicinal ingredient in flax oil products. However, no use or purpose statements may be associated with vitamin E. See Appendix 2 for vitamin E proper name, common name, source material, and dose information.";s:12:"field_note_f";s:1087:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.  Nota : (I) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.  (ii ) Les produits d'huile de lin peuvent contenir de la vitamine E comme ingrédient médicinal facultatif. Cependant, aucun énoncé concernant les usage(s) ou fin(s) recommandés ne peut être associé à la vitamine E. Consulter l'annexe 2 pour les noms propres et communs, les matières d'origine et les doses de la vitamine E.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:404:"For products indicating one or more of the optional potencies listed in the dose section, an assay must be performed in order to confirm the potency(ies). ; The medicinal ingredient may comply with the specifications outlined in the Linseed or Linseed Oil, Virgin, monographs published in the European Pharmacopoeia, or the Linseed or Virgin Linseed Oil monographs published in the British Pharmacopoeia.";s:21:"field_specification_f";s:503:"Dans le cas des produits affichant une ou plusieurs activités facultatives énumérées dans la section des doses, une analyse doit être effectuée afin de confirmer la validité de cette (ces) activité(s).;  
 L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies Linseed et/ou Linseed oil, Virgin publiées dans la Pharmacopée européenne (Ph.Eur.), ou les monographies Linseed et/ou Virgin Linseed Oil publiées dans la Pharmacopée britannique (BP).";s:25:"field_storage_condition_e";s:118:"For all products, except those encapsulated: 
Refrigerate after opening (Nykter et al. 2006; Lukaszewicz et al. 2004).";s:25:"field_storage_condition_f";s:119:"Tous les produits, sauf ceux encapsulés :
Réfrigérer après ouverture (Nykter et al. 2006; Lukaszewicz et al. 2004).";s:10:"field_date";s:10:"2010-04-13";s:16:"field_legacy_nid";s:6:"100863";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:22:"CH24;CH59;AD1014;ADU15";s:15:"field_dose_note";s:44:"FLAXO_1;FLAXO_2;FLAXO_3;FLAXO_4;FLAXO_5;APP1";s:21:"field_mono_citation_e";s:350:"FLAXR1;FLAXR2;FLAXR3;FLAXR4;FLAXR5;FLAXR6;FLAXR7;FLAXR8;FLAXR9;FLAXR10;FLAXR11;FLAXR12;FLAXR13;FLAXR14;FLAXR15;FLAXR16;FLAXR17;FLAXR18;FLAXR19;FLAXR20;FLAXR21;FLAXR22;FLAXR23;FLAXR24;FLAXR25;FLAXR26;FLAXR27;FLAXR28;FLAXR29;FLAXR30;FLAXR31;FLAXR32;FLAXR33;FLAXR34;FLAXR35;FLAXR36;FLAXR37;FLAXR38;FLAXR39;FLAXR40;FLAXR41;FLAXR42;FLAXR43;FLAXR44;FLAXR45";s:21:"field_mono_citation_f";s:350:"FLAXR1;FLAXR2;FLAXR3;FLAXR4;FLAXR5;FLAXR6;FLAXR7;FLAXR8;FLAXR9;FLAXR10;FLAXR11;FLAXR12;FLAXR13;FLAXR14;FLAXR15;FLAXR16;FLAXR17;FLAXR18;FLAXR19;FLAXR20;FLAXR21;FLAXR22;FLAXR23;FLAXR24;FLAXR25;FLAXR26;FLAXR27;FLAXR28;FLAXR29;FLAXR30;FLAXR31;FLAXR32;FLAXR33;FLAXR34;FLAXR35;FLAXR36;FLAXR37;FLAXR38;FLAXR39;FLAXR40;FLAXR41;FLAXR42;FLAXR43;FLAXR44;FLAXR45";s:26:"field_reference_reviewed_e";s:215:"FLAXRR1;FLAXRR2;FLAXRR3;FLAXRR4;FLAXRR5;FLAXRR6;FLAXRR7;FLAXRR8;FLAXRR9;FLAXRR10;FLAXRR11;FLAXRR12;FLAXRR13;FLAXRR14;FLAXRR15;FLAXRR16;FLAXRR17;FLAXRR18;FLAXRR19;FLAXRR20;FLAXRR21;FLAXRR22;FLAXRR23;FLAXRR24;FLAXRR25";s:26:"field_reference_reviewed_f";s:215:"FLAXRR1;FLAXRR2;FLAXRR3;FLAXRR4;FLAXRR5;FLAXRR6;FLAXRR7;FLAXRR8;FLAXRR9;FLAXRR10;FLAXRR11;FLAXRR12;FLAXRR13;FLAXRR14;FLAXRR15;FLAXRR16;FLAXRR17;FLAXRR18;FLAXRR19;FLAXRR20;FLAXRR21;FLAXRR22;FLAXRR23;FLAXRR24;FLAXRR25";}i:216557;a:32:{s:5:"title";s:10:"FOL_Folate";s:3:"nid";s:6:"216557";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"FOL";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:6:"Folate";s:22:"field_monograph_name_f";s:6:"Folate";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:94:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_folate-eng.php";s:21:"field_monograph_url_f";s:94:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_folate-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:267:"The medicinal ingredient may comply with the specifications outlined in the following pharmacopoeial monographs:  'Folic Acid' of the British Pharmacopoeia, 'Folic Acid' of the European Pharmacopoeia, and 'Folic Acid' and 'Folic Acid Tablets' of the US Pharmacopoeia.";s:21:"field_specification_f";s:305:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes:  'Folic Acid' de la Pharmacopée britannique (BP), 'Folic Acid' de la Pharmacopée européenne (Ph. Eur.), et 'Folic Acid' et 'Folic Acid Tablets' de la Pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-06-24";s:16:"field_legacy_nid";s:6:"100865";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:12:"ADU14;CH1_13";s:15:"field_dose_note";s:12:"FOL;MIN;ADUL";s:21:"field_mono_citation_e";s:56:"BPH8;ANHM;IOMDRI;FCC;DRITR;MERCK14;EP8;MNHD;MART35;TNF27";s:21:"field_mono_citation_f";s:56:"BPH8;ANHM;IOMDRI;FCC;DRITR;MERCK14;EP8;MNHD;MART35;TNF27";}i:216558;a:34:{s:5:"title";s:25:"FRA_O_Frankincense - Oral";s:3:"nid";s:6:"216558";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"FRA_O";s:18:"field_group_name_e";s:12:"Frankincense";s:18:"field_group_name_f";s:15:"Arbre à encens";s:22:"field_monograph_name_e";s:19:"Frankincense - Oral";s:22:"field_monograph_name_f";s:23:"Arbre à encens - Orale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:106:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_frankincense-arbre-eng.php";s:21:"field_monograph_url_f";s:106:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_frankincense-arbre-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2004-03-05";s:16:"field_legacy_nid";s:6:"100866";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:3:"FRA";s:19:"field_mono_duration";s:4:"PROL";s:15:"field_mono_risk";s:4:"PREG";s:21:"field_mono_citation_e";s:59:"CHMMM;ENCHU;PDRHM;HAMP;ENCCNI;CMH;CMM;CTCH;HERCOM;GRIN;MHAY";s:21:"field_mono_citation_f";s:59:"CHMMM;ENCHU;PDRHM;HAMP;ENCCNI;CMH;CMM;CTCH;HERCOM;GRIN;MHAY";}i:216559;a:35:{s:5:"title";s:28:"FRA_T_Frankincense - Topical";s:3:"nid";s:6:"216559";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"FRA_T";s:18:"field_group_name_e";s:12:"Frankincense";s:18:"field_group_name_f";s:15:"Arbre à encens";s:22:"field_monograph_name_e";s:22:"Frankincense - Topical";s:22:"field_monograph_name_f";s:25:"Arbre à encens - Topique";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:45:"atReq.do?atid=frankincense_arbre_top&lang=eng";s:21:"field_monograph_url_f";s:45:"atReq.do?atid=frankincense_arbre_top&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2004-03-05";s:16:"field_legacy_nid";s:6:"100867";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:3:"FRA";s:19:"field_mono_duration";s:4:"PROL";s:15:"field_mono_risk";s:4:"PREG";s:21:"field_mono_citation_e";s:59:"CHMMM;ENCHU;PDRHM;HAMP;ENCCNI;CMH;CMM;CTCH;HERCOM;GRIN;MHAY";s:21:"field_mono_citation_f";s:59:"CHMMM;ENCHU;PDRHM;HAMP;ENCCNI;CMH;CMM;CTCH;HERCOM;GRIN;MHAY";}i:216560;a:35:{s:5:"title";s:27:"FRA_B_Frankincense - Buccal";s:3:"nid";s:6:"216560";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"FRA_B";s:18:"field_group_name_e";s:12:"Frankincense";s:18:"field_group_name_f";s:15:"Arbre à encens";s:22:"field_monograph_name_e";s:21:"Frankincense - Buccal";s:22:"field_monograph_name_f";s:25:"Arbre à encens - Buccale";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:45:"atReq.do?atid=frankincense_arbre_buc&lang=eng";s:21:"field_monograph_url_f";s:45:"atReq.do?atid=frankincense_arbre_buc&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2004-03-05";s:16:"field_legacy_nid";s:6:"100868";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:3:"FRA";s:19:"field_mono_duration";s:4:"PROL";s:15:"field_mono_risk";s:4:"PREG";s:21:"field_mono_citation_e";s:59:"CHMMM;ENCHU;PDRHM;HAMP;ENCCNI;CMH;CMM;CTCH;HERCOM;GRIN;MHAY";s:21:"field_mono_citation_f";s:59:"CHMMM;ENCHU;PDRHM;HAMP;ENCCNI;CMH;CMM;CTCH;HERCOM;GRIN;MHAY";}i:216561;a:36:{s:5:"title";s:10:"GAR_Garlic";s:3:"nid";s:6:"216561";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"GAR";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:6:"Garlic";s:22:"field_monograph_name_f";s:3:"Ail";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:33:"atReq.do?atid=garlic_ail&lang=eng";s:21:"field_monograph_url_f";s:33:"atReq.do?atid=garlic_ail&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:1059:"The medicinal ingredient may comply with the specifications outlined in the following pharmacopoeial monographs: Garlic, Powdered Garlic, Powdered Garlic Extract or Garlic Fluid Extract of the British Pharmacopoeia, Garlic Powder Monograph of the European Pharmacopoeia and Garlic Powder Monograph of the US Pharmacopoeia ;  For products containing fresh garlic in oil, the preparations must meet at least one of the following conditions in order to prevent the growth of the bacterial spores associated with botulism: (i) Products are subjected to a validated treatment, such as heat treatment, with equivalent effect to the 12 D canning process (a thermal process designed to reduce the probability of survival of a single, heat-resistant spore of Clostridium botulinum by a factor of 1012) to inactivate spores of C. botulinum (FAO 1985), or (ii) The water activity of the garlic bulb is reduced to 0.94 or less before adding it to the oil, or (iii) Ensure that the pH of the plant material is adjusted to 4.6 or less before adding it to the oil (HC 2007).";s:21:"field_specification_f";s:1141:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes:  Garlic, Powdered Garlic, Powdered Garlic Extract ou Garlic Fluid Extract de la Pharmacopée britannique (BP), Garlic Powder Monograph de la Pharmaacopée européenne (Ph. Eur.) et Garlic Powder Monograph de la Pharmacopée américaine (USP);  Pour les produits à base d'ail frais macéré dans l'huile, les préparations doivent être conforme à une ou plusieurs des conditions suivantes afin de prévenir la germination des spores bactériennes associées au botulisme : (i) Le produit est soumis à un procédé validé, tel que le traitement thermique, dont l'effet est équivalent à la mise en conserve 12 D (un procédé thermique conçu pour réduire la probabilité de survie d'une seule spore thermorésistante de Clostridium botulinum par un facteur de 1012) visant à inactiver les spores de C. botulinum (FAO 1985), ou (ii) L'activité de l'eau du bulbe d'ail est réduite à 0,94 ou moins avant l'ajout de l'huile, ou (ii) Le pH du bulbe a été ajusté à 4,6 ou moins avant l'ajout de l'huile (SC 2007)";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-05-09";s:16:"field_legacy_nid";s:6:"100869";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:26:"CH24;CH59;AD1014;ADU15;ADU";s:15:"field_dose_note";s:34:"APP1;FRAD;GARCH;GARADU;ADBR;CINIIN";s:15:"field_mono_risk";s:38:"GAR_CW1;GAR_CW2;GAR_CW3;GAR_CW4;GAR_AR";s:21:"field_mono_citation_e";s:112:"EXPCEM;ENHCI2;BHCOM;UPHCDI8;ESCOP;CANNING;KAD;NHPDCOM;FDREG;HYPOCHO;ANETHUM;AGEDGE;HERCOM;HTCH;HERSAF;PPHPP;GRIN";s:21:"field_mono_citation_f";s:112:"EXPCEM;ENHCI2;BHCOM;UPHCDI8;PHAPHY;ESCOP;CANNING;KAD;NHPDCOM;FDREG;HYPOCHO;ANETHUM;AGEDGE;HTCH;HERSAF;PPHPP;GRIN";s:26:"field_reference_reviewed_e";s:72:"BHP2;BHP;ARTCALC;UIORAB;RAWVSCOM;EQUAL;SAFFOOD;CLOSBOT;PPP;CHEMIDP;PREEC";s:26:"field_reference_reviewed_f";s:72:"BHP2;BHP;ARTCALC;UIORAB;RAWVSCOM;EQUAL;SAFFOOD;CLOSBOT;PPP;CHEMIDP;PREEC";}i:216562;a:35:{s:5:"title";s:30:"GEC_O_Chamomile, German - Oral";s:3:"nid";s:6:"216562";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"GEC_O";s:18:"field_group_name_e";s:16:"German Chamomile";s:18:"field_group_name_f";s:19:"Camomille allemande";s:22:"field_monograph_name_e";s:24:"Chamomile, German - Oral";s:22:"field_monograph_name_f";s:27:"Camomille allemande - Orale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:612:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.    Note: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicants’ discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:751:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.     Nota :Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:312:"The medicinal ingredient may comply with the specifications outlined in the following pharmacopoeial monographs:  'Matricaria Flowers' from British Pharmacopoeia (BP), 'Matricaria Flower' and 'Matricaria Liquid Extract' from European Pharmacopoeia (Ph.Eur.) or 'Chamomile' from United States Pharmacopoeia (USP).";s:21:"field_specification_f";s:326:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes:  'Matricaria Flowers' de la pharmacopée britannique (BP), 'Matricaria Flower' et 'Matricaria Liquid Extract' de la pharmacopée européenne (Ph.Eur.) ou 'Chamomile' de la pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-07-31";s:16:"field_legacy_nid";s:6:"100870";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:22:"CH24;CH59;AD1014;ADU15";s:15:"field_dose_note";s:14:"APP1;FRAD;ADAD";s:15:"field_mono_risk";s:23:"PERS;WORS;GEC_CI;GEC_AR";s:21:"field_mono_citation_e";s:109:"EXPCEM;ENHCI;BPH8;BHCOM;UPHCDI8;HERCDI;THEPHA;ESCOP;ECMM;KAD2;FDREG;HERCOM;HERSAF;EP8;PPHPP;GRIN;TNF27;WHOMON";s:21:"field_mono_citation_f";s:109:"EXPCEM;ENHCI;BPH8;BHCOM;UPHCDI8;HERCDI;THEPHA;ESCOP;ECMM;KAD2;FDREG;HERCOM;HERSAF;EP8;PPHPP;GRIN;TNF27;WHOMON";s:26:"field_reference_reviewed_e";s:84:"SEHM;HERMED2;BTIC;AMODHER;POTIN;INHIA;IAPT;JACI;TFDP;BOTSAF;NHM;CDCT;HNPA;CMAJM;GRIN";s:26:"field_reference_reviewed_f";s:84:"SEHM;HERMED2;BTIC;AMODHER;POTIN;INHIA;IAPT;JACI;TFDP;BOTSAF;NHM;CDCT;HNPA;CMAJM;GRIN";}i:216563;a:36:{s:5:"title";s:33:"GEC_T_Chamomile, German - Topical";s:3:"nid";s:6:"216563";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"GEC_T";s:18:"field_group_name_e";s:16:"German Chamomile";s:18:"field_group_name_f";s:19:"Camomille allemande";s:22:"field_monograph_name_e";s:27:"Chamomile, German - Topical";s:22:"field_monograph_name_f";s:29:"Camomille allemande - Topique";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:40:"atReq.do?atid=germ_chamom_allem&lang=eng";s:21:"field_monograph_url_f";s:40:"atReq.do?atid=germ_chamom_allem&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:612:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.    Note: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicants’ discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:751:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.     Nota :Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:312:"The medicinal ingredient may comply with the specifications outlined in the following pharmacopoeial monographs:  'Matricaria Flowers' from British Pharmacopoeia (BP), 'Matricaria Flower' and 'Matricaria Liquid Extract' from European Pharmacopoeia (Ph.Eur.) or 'Chamomile' from United States Pharmacopoeia (USP).";s:21:"field_specification_f";s:326:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes:  'Matricaria Flowers' de la pharmacopée britannique (BP), 'Matricaria Flower' et 'Matricaria Liquid Extract' de la pharmacopée européenne (Ph.Eur.) ou 'Chamomile' de la pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-07-31";s:16:"field_legacy_nid";s:6:"100871";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:4:"ADU2";s:15:"field_dose_note";s:14:"APP1;FRAD;ADAD";s:15:"field_mono_risk";s:23:"PERS;WORS;GEC_CI;GEC_AR";s:21:"field_mono_citation_e";s:109:"EXPCEM;ENHCI;BPH8;BHCOM;UPHCDI8;HERCDI;THEPHA;ESCOP;ECMM;KAD2;FDREG;HERCOM;HERSAF;EP8;PPHPP;GRIN;TNF27;WHOMON";s:21:"field_mono_citation_f";s:109:"EXPCEM;ENHCI;BPH8;BHCOM;UPHCDI8;HERCDI;THEPHA;ESCOP;ECMM;KAD2;FDREG;HERCOM;HERSAF;EP8;PPHPP;GRIN;TNF27;WHOMON";s:26:"field_reference_reviewed_e";s:84:"SEHM;HERMED2;BTIC;AMODHER;POTIN;INHIA;IAPT;JACI;TFDP;BOTSAF;NHM;CDCT;HNPA;CMAJM;GRIN";s:26:"field_reference_reviewed_f";s:84:"SEHM;HERMED2;BTIC;AMODHER;POTIN;INHIA;IAPT;JACI;TFDP;BOTSAF;NHM;CDCT;HNPA;CMAJM;GRIN";}i:216564;a:36:{s:5:"title";s:32:"GEC_B_Chamomile, German - Buccal";s:3:"nid";s:6:"216564";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"GEC_B";s:18:"field_group_name_e";s:16:"German Chamomile";s:18:"field_group_name_f";s:19:"Camomille allemande";s:22:"field_monograph_name_e";s:26:"Chamomile, German - Buccal";s:22:"field_monograph_name_f";s:29:"Camomille allemande - Buccale";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:47:"atReq.do?atid=germ_chamom_allem_buccal&lang=eng";s:21:"field_monograph_url_f";s:47:"atReq.do?atid=germ_chamom_allem_buccal&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:612:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.    Note: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicants’ discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:751:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.     Nota :Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:312:"The medicinal ingredient may comply with the specifications outlined in the following pharmacopoeial monographs:  'Matricaria Flowers' from British Pharmacopoeia (BP), 'Matricaria Flower' and 'Matricaria Liquid Extract' from European Pharmacopoeia (Ph.Eur.) or 'Chamomile' from United States Pharmacopoeia (USP).";s:21:"field_specification_f";s:326:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes:  'Matricaria Flowers' de la pharmacopée britannique (BP), 'Matricaria Flower' et 'Matricaria Liquid Extract' de la pharmacopée européenne (Ph.Eur.) ou 'Chamomile' de la pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-07-31";s:16:"field_legacy_nid";s:6:"100872";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:4:"ADU2";s:15:"field_dose_note";s:14:"APP1;FRAD;ADAD";s:15:"field_mono_risk";s:23:"PERS;WORS;GEC_CI;GEC_AR";s:21:"field_mono_citation_e";s:109:"EXPCEM;ENHCI;BPH8;BHCOM;UPHCDI8;HERCDI;THEPHA;ESCOP;ECMM;KAD2;FDREG;HERCOM;HERSAF;EP8;PPHPP;GRIN;TNF27;WHOMON";s:21:"field_mono_citation_f";s:109:"EXPCEM;ENHCI;BPH8;BHCOM;UPHCDI8;HERCDI;THEPHA;ESCOP;ECMM;KAD2;FDREG;HERCOM;HERSAF;EP8;PPHPP;GRIN;TNF27;WHOMON";s:26:"field_reference_reviewed_e";s:84:"SEHM;HERMED2;BTIC;AMODHER;POTIN;INHIA;IAPT;JACI;TFDP;BOTSAF;NHM;CDCT;HNPA;CMAJM;GRIN";s:26:"field_reference_reviewed_f";s:84:"SEHM;HERMED2;BTIC;AMODHER;POTIN;INHIA;IAPT;JACI;TFDP;BOTSAF;NHM;CDCT;HNPA;CMAJM;GRIN";}i:216565;a:35:{s:5:"title";s:11:"GEN_Gentian";s:3:"nid";s:6:"216565";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"GEN";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:7:"Gentian";s:22:"field_monograph_name_f";s:14:"Gentiane jaune";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:95:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_gentian-eng.php";s:21:"field_monograph_url_f";s:95:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_gentian-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:203:"The medicinal ingredient may comply with the specifications outlined in the Gentian Monograph published in the British Pharmacopoeia or the Gentian Root Monograph published in the European Pharmacopoeia.";s:21:"field_specification_f";s:240:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie Gentian publiée dans la Pharmacopée britannique (BP) ou dans la monographie Gentian Root publiée dans la Pharmacopée européenne (Ph. Eur.).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-02-27";s:16:"field_legacy_nid";s:6:"100873";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:37:"PERS;WORS;BREC;GEN_CI1;GEN_CI2;GEN_AR";s:21:"field_mono_citation_e";s:87:"EXPCEM;BHCOM;HERCDI;ESCOP;KAD;AMODHER;MEDHER;HERCOM;HERSAF;MUTAGE;GRIN;HDPP2;WEP;PNCBDP";s:21:"field_mono_citation_f";s:87:"EXPCEM;PMM;BHCOM;HERCDI;PHAPHY;ESCOP;KAD;AMODHER;MEDHER;HERSAF;MUTAGE;GRIN;HDPP2;PNCBDP";s:26:"field_reference_reviewed_e";s:11:"HERMED2;BHP";s:26:"field_reference_reviewed_f";s:11:"HERMED2;BHP";}i:216566;a:35:{s:5:"title";s:10:"GIN_Ginger";s:3:"nid";s:6:"216566";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"GIN";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:6:"Ginger";s:22:"field_monograph_name_f";s:9:"Gingembre";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:104:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_ginger-gingembre-eng.php";s:21:"field_monograph_url_f";s:104:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_ginger-gingembre-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-01-18";s:16:"field_legacy_nid";s:6:"100874";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:4:"ADU6";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:9:"PERS;WORS";s:21:"field_mono_citation_e";s:103:"BHCOM;THEPHA;ESCOP;KAD;HYPGRA;OPENSEA;SLOWAVE;HERCOM;PPP;HERSAF;MSGPP;RANDB;COMP7;GRIN;WHOMON;WEP;PCBDP";s:21:"field_mono_citation_f";s:110:"BHCOM;PHAPHY;THEPHA;ESCOP;KAD;HYPGRA;OPENSEA;SLOWAVE;HERCOM;PPP;HERSAF;MSGPP;RANDB;COMP7;GRIN;WHOMON;WEP;PCBDP";s:26:"field_reference_reviewed_e";s:49:"ANTIEME;GINFEN;MOTSIC;GINGIN;OACOAG;DRGING;ONIGIN";s:26:"field_reference_reviewed_f";s:49:"ANTIEME;GINFEN;MOTSIC;GINGIN;OACOAG;DRGING;ONIGIN";}i:216567;a:36:{s:5:"title";s:18:"GINK_Ginkgo Biloba";s:3:"nid";s:6:"216567";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"GINK";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:13:"Ginkgo Biloba";s:22:"field_monograph_name_f";s:13:"Ginkgo Biloba";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:100:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_ginko_biloba-eng.php";s:21:"field_monograph_url_f";s:100:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_ginko_biloba-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:621:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.      Notes: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:789:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient (ou des ingrédients) médicinal (médicinaux). La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.      Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:341:"The medicinal ingredient may comply with the specifications outlined in the following pharmacopoeial monographs: 'Ginkgo Leaf' published in the British Pharmacopoeia, 'Ginkgo Leaf (Ginkgonis folium)' published in the European Pharmacopoeia, or 'Ginkgo', 'Powdered Ginkgo Extract', 'Ginkgo Capsules' and 'Ginkgo Tablets' published in the USP.";s:21:"field_specification_f";s:397:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes: 'Ginkgo Leaf' publiée dans la Pharmacopée britannique (BP), 'Ginkgo Leaf (Ginkgonis folium)' publiée dans la pharmacopée européenne (Ph. Eur.), ou 'Ginkgo', 'Powdered Ginkgo Extract', 'Ginkgo Capsules' et 'Ginkgo Tablets' publiées dans la pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-06-24";s:16:"field_legacy_nid";s:6:"100875";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:26:"GINKDUR1;GINKDUR2;GINKDUR3";s:15:"field_mono_risk";s:25:"GINK_CW1;GINK_CW2;GINK_CI";s:21:"field_mono_citation_e";s:150:"SPONT;COGIMP;EXPCEM;URIMET;BPH8;UPHCDI;MENFUN;NPEFF;DIFFER;MENPER;DDCOG;GBDEM;HERCOM;FOREARM;CIOA;CIOA2;MEMHMV;EP8;INTERM;CPBV;30DAY;GRIN;TNF27;WHOMON";s:21:"field_mono_citation_f";s:162:"SPONT;COGIMP;EXPCEM;URIMET;PMM;BPH8;UPHCDI;PHAPHY;MENFUN;NPEFF;DIFFER;MENPER;DDCOG;GBDEM;FOREARM;CIOA;CIOA2;MEMHMV;PPS;EP8;INTERM;CPBV;30DAY;GRIN;TNF27;WHOMON;WEP";s:26:"field_reference_reviewed_e";s:469:"TWODOS;6MTH;MMDT;CERHAEM;ABC;CGCEM;THROM;AGMEM;ADVINT;NOOTR;SEGINK;PAQUID;BILHAE;MCIND;CPCAWM;CERINS;THEPHA;LAPCHO;RETROB;DRUGTH;LTGINK;GINKBI;EPISEIZ;FLURBI;VASORI;SENDEM;POBS;IMPHAE;NMCDGB;GINGIN;PROOF;HPIM2;BETACELL;METF;SEVER;GBEPLA;CHEMOS;INTRAHEM;DEMAT;DONEPE;BOTSAF;FATAL;REM;EGB761;SPEXT;GLANCE;EFFGB;INTCLAU;TANAKAN;STDGB;HYPHEMA;BILAT;2DOSES;ALZCOOP;ARTOCC;P300;SCAG;GINKGO;EXTBH;MEMENH;CERAG;TOLMID;GINKHP;SUBARA;GINKELD;100PAT;PPMHS;GBVSPL;IDIOCI;OCUBF;CFBP";s:26:"field_reference_reviewed_f";s:469:"TWODOS;6MTH;MMDT;CERHAEM;ABC;CGCEM;THROM;AGMEM;ADVINT;NOOTR;SEGINK;PAQUID;BILHAE;MCIND;CPCAWM;CERINS;THEPHA;LAPCHO;RETROB;DRUGTH;LTGINK;GINKBI;EPISEIZ;FLURBI;VASORI;SENDEM;POBS;IMPHAE;NMCDGB;GINGIN;PROOF;HPIM2;BETACELL;METF;SEVER;GBEPLA;CHEMOS;INTRAHEM;DEMAT;DONEPE;BOTSAF;FATAL;REM;EGB761;SPEXT;GLANCE;EFFGB;INTCLAU;TANAKAN;STDGB;HYPHEMA;BILAT;2DOSES;ALZCOOP;ARTOCC;P300;SCAG;GINKGO;EXTBH;MEMENH;CERAG;TOLMID;GINKHP;SUBARA;GINKELD;100PAT;PPMHS;GBVSPL;IDIOCI;OCUBF;CFBP";}i:216568;a:35:{s:5:"title";s:19:"GLA_Globe artichoke";s:3:"nid";s:6:"216568";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"GLA";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:15:"Globe artichoke";s:22:"field_monograph_name_f";s:9:"Artichaut";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:107:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_artichoke-artichaut-eng.php";s:21:"field_monograph_url_f";s:107:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_artichoke-artichaut-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:140:"The medicinal ingredient may comply with the specifications outlined in the Artichoke Leaf Monograph published in the British Pharmacopoeia.";s:21:"field_specification_f";s:158:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie Artichoke Leaf publiée dans la Pharmacopée britannique (BP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-04-10";s:16:"field_legacy_nid";s:6:"100876";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:48:"PERS;WORS;GLA_CW1;GLA_CW2;GLA_CI1;GLA_CI2;GLA_AR";s:21:"field_mono_citation_e";s:68:"HERMED2;EXPCEM;BHCOM2;UPHCDI8;HERCDI;ESCOP;MEDHER;HERCOM;HERSAF;GRIN";s:21:"field_mono_citation_f";s:79:"HERMED2;EXPCEM;BHCOM2;UPHCDI8;HERCDI;PHAPHY;ESCOP;MEDHER;HERSAF;GRIN;PLATHE;WEP";s:26:"field_reference_reviewed_e";s:5:"INGAE";s:26:"field_reference_reviewed_f";s:5:"INGAE";}i:216569;a:35:{s:5:"title";s:23:"GL1_Glucosamine sulfate";s:3:"nid";s:6:"216569";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"GL1";s:18:"field_group_name_e";s:11:"Glucosamine";s:18:"field_group_name_f";s:11:"Glucosamine";s:22:"field_monograph_name_e";s:19:"Glucosamine sulfate";s:22:"field_monograph_name_f";s:23:"Glucosamine, Sulfate de";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:99:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_glucosamine-eng.php";s:21:"field_monograph_url_f";s:99:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_glucosamine-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:636:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.    Note: Text in parentheses is additional optional information which can be included on the Product Licence Application and product labels at the applicants’ discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:750:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.    Nota: Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:223:"The medicinal ingredient may comply with the specifications outlined in the Glucosamine Tablets, Glucosamine Sulfate Potassium Chloride and Glucosamine Sulfate Sodium Chloride monographs published in the U.S. Pharmacopoeia.";s:21:"field_specification_f";s:258:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies suivantes publiées dans la Pharmacopée américaine (USP) : Glucosamine Tablets, Glucosamine Sulfate Potassium Chloride ou Glucosamine Sulfate Sodium Chloride.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-06-11";s:16:"field_legacy_nid";s:6:"100877";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:19:"field_mono_duration";s:5:"GLDUR";s:15:"field_mono_risk";s:11:"WORS;GLU_CW";s:21:"field_mono_citation_e";s:112:"GLUCO;EFGLSUP;PHCAM;ACETAM;EFGLHY;ITIS;GPHB;POLYHRBL;GSUSE;ESGS;LTERM;GUP;MART35;EVGS;GLTH2;RDBPPC;TNF27;CHEMIDP";s:21:"field_mono_citation_f";s:112:"GLUCO;EFGLSUP;PHCAM;ACETAM;EFGLHY;ITIS;GPHB;POLYHRBL;GSUSE;ESGS;LTERM;GUP;MART35;EVGS;GLTH2;RDBPPC;TNF27;CHEMIDP";s:26:"field_reference_reviewed_e";s:316:"DLYJNT;HYPE;APOLIPO;GEH;TESIO;PROTEO;JURY;COLIFE;NONSF;GTO;EGSTPO;WHERENOW;NATMIN;OLINKED;SFALL;CHITIN;CADRMP;GSANALG;HCGE;CLININQ;MESANG;GANGLIO;EGSKO;SHLLFSH;COMBPKO;OG6WK;EGAPRA;HEXOSA;GSOK;AIGUE;GAATH;CRYSGS;ENSAI;FINANC;INTRAM;SYNKIN3;GSHIP;GSUOS;AGGRCN;NIGER;GLCSSUP;FSTNG;GSE;GLTH;GLPAIN;SHRIMP;INSSEN;OGLCNAC";s:26:"field_reference_reviewed_f";s:316:"DLYJNT;HYPE;APOLIPO;GEH;TESIO;PROTEO;JURY;COLIFE;NONSF;GTO;EGSTPO;WHERENOW;NATMIN;OLINKED;SFALL;CHITIN;CADRMP;GSANALG;HCGE;CLININQ;MESANG;GANGLIO;EGSKO;SHLLFSH;COMBPKO;OG6WK;EGAPRA;HEXOSA;GSOK;AIGUE;GAATH;CRYSGS;ENSAI;FINANC;INTRAM;SYNKIN3;GSHIP;GSUOS;AGGRCN;NIGER;GLCSSUP;FSTNG;GSE;GLTH;GLPAIN;SHRIMP;INSSEN;OGLCNAC";}i:216570;a:35:{s:5:"title";s:29:"GL2_Glucosamine hydrochloride";s:3:"nid";s:6:"216570";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"GL2";s:18:"field_group_name_e";s:11:"Glucosamine";s:18:"field_group_name_f";s:11:"Glucosamine";s:22:"field_monograph_name_e";s:25:"Glucosamine hydrochloride";s:22:"field_monograph_name_f";s:28:"Glucosamine, Chlorhydrate de";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:99:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_glucosamine-eng.php";s:21:"field_monograph_url_f";s:99:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_glucosamine-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:636:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.    Note: Text in parentheses is additional optional information which can be included on the Product Licence Application and product labels at the applicants’ discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:750:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.    Nota: Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:173:"The medicinal ingredient may comply with the specifications outlined in the Glucosamine Hydrochloride and Glucosamine Tablets monographs published in the U.S. Pharmacopoeia.";s:21:"field_specification_f";s:208:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies suivantes publiées dans la Pharmacopée américaine (USP) : Glucosamine Hydrochloride ou Glucosamine Tablets.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-06-11";s:16:"field_legacy_nid";s:6:"100878";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:19:"field_mono_duration";s:5:"GLDUR";s:15:"field_mono_risk";s:11:"WORS;GLU_CW";s:21:"field_mono_citation_e";s:112:"GLUCO;EFGLSUP;PHCAM;ACETAM;EFGLHY;ITIS;GPHB;POLYHRBL;GSUSE;ESGS;LTERM;GUP;MART35;EVGS;GLTH2;RDBPPC;TNF27;CHEMIDP";s:21:"field_mono_citation_f";s:112:"GLUCO;EFGLSUP;PHCAM;ACETAM;EFGLHY;ITIS;GPHB;POLYHRBL;GSUSE;ESGS;LTERM;GUP;MART35;EVGS;GLTH2;RDBPPC;TNF27;CHEMIDP";s:26:"field_reference_reviewed_e";s:316:"DLYJNT;HYPE;APOLIPO;GEH;TESIO;PROTEO;JURY;COLIFE;NONSF;GTO;EGSTPO;WHERENOW;NATMIN;OLINKED;SFALL;CHITIN;CADRMP;GSANALG;HCGE;CLININQ;MESANG;GANGLIO;EGSKO;SHLLFSH;COMBPKO;OG6WK;EGAPRA;HEXOSA;GSOK;AIGUE;GAATH;CRYSGS;ENSAI;FINANC;INTRAM;SYNKIN3;GSHIP;GSUOS;AGGRCN;NIGER;GLCSSUP;FSTNG;GSE;GLTH;GLPAIN;SHRIMP;INSSEN;OGLCNAC";s:26:"field_reference_reviewed_f";s:316:"DLYJNT;HYPE;APOLIPO;GEH;TESIO;PROTEO;JURY;COLIFE;NONSF;GTO;EGSTPO;WHERENOW;NATMIN;OLINKED;SFALL;CHITIN;CADRMP;GSANALG;HCGE;CLININQ;MESANG;GANGLIO;EGSKO;SHLLFSH;COMBPKO;OG6WK;EGAPRA;HEXOSA;GSOK;AIGUE;GAATH;CRYSGS;ENSAI;FINANC;INTRAM;SYNKIN3;GSHIP;GSUOS;AGGRCN;NIGER;GLCSSUP;FSTNG;GSE;GLTH;GLPAIN;SHRIMP;INSSEN;OGLCNAC";}i:216571;a:36:{s:5:"title";s:27:"GLUCC_Glucomannan - Capsule";s:3:"nid";s:6:"216571";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"GLUCC";s:18:"field_group_name_e";s:11:"Glucomannan";s:18:"field_group_name_f";s:12:"Glucomannane";s:22:"field_monograph_name_e";s:21:"Glucomannan - Capsule";s:22:"field_monograph_name_f";s:22:"Glucomannane - Capsule";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:619:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.      Note: Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:753:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.      Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2010-05-11";s:16:"field_legacy_nid";s:6:"100879";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:4:"GLUC";s:15:"field_mono_risk";s:41:"PREGC;GLUC1;GLUC2;GLUC3;GLUC4;GLUC5;GLUC6";s:21:"field_mono_citation_e";s:147:"KGHM;HBNPD;GLUC01;GLUC02;KONSUP;GLUC03;GLUC04;FCHMP;GLUC05;GREO;GLUC06;GLUC07;DSGLUC;CHEMIDP;MERCK14;NPPT;GLUC08;MART35;GLUC09;GLUC10;GLUC11;GLUCOB";s:21:"field_mono_citation_f";s:147:"KGHM;HBNPD;GLUC01;GLUC02;KONSUP;GLUC03;GLUC04;FCHMP;GLUC05;GREO;GLUC06;GLUC07;DSGLUC;CHEMIDP;MERCK14;NPPT;GLUC08;MART35;GLUC09;GLUC10;GLUC11;GLUCOB";s:26:"field_reference_reviewed_e";s:154:"GLUC12;GLUC13;EXP3FS;GLUC14;GLUC15;GLUC16;GLUC17;GLUC18;GLUC19;GLUC20;LNHPD;DPD;GLUC21;GLUC22;GLUC23;GLUC24;NUTRA;CDSWL;GLUC25;GLUC26;GLUC27;GLUC28;PSGLIP";s:26:"field_reference_reviewed_f";s:154:"GLUC12;GLUC13;EXP3FS;GLUC14;GLUC15;GLUC16;GLUC17;GLUC18;GLUC19;GLUC20;LNHPD;DPD;GLUC21;GLUC22;GLUC23;GLUC24;NUTRA;CDSWL;GLUC25;GLUC26;GLUC27;GLUC28;PSGLIP";}i:216572;a:36:{s:5:"title";s:26:"GLUCP_Glucomannan - Powder";s:3:"nid";s:6:"216572";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"GLUCP";s:18:"field_group_name_e";s:11:"Glucomannan";s:18:"field_group_name_f";s:12:"Glucomannane";s:22:"field_monograph_name_e";s:20:"Glucomannan - Powder";s:22:"field_monograph_name_f";s:21:"Glucomannane - Poudre";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:619:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.      Note: Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:753:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.      Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2010-05-11";s:16:"field_legacy_nid";s:6:"100880";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:4:"GLUC";s:15:"field_mono_risk";s:41:"PREGC;GLUC1;GLUC2;GLUC3;GLUC4;GLUC5;GLUC6";s:21:"field_mono_citation_e";s:147:"KGHM;HBNPD;GLUC01;GLUC02;KONSUP;GLUC03;GLUC04;FCHMP;GLUC05;GREO;GLUC06;GLUC07;DSGLUC;CHEMIDP;MERCK14;NPPT;GLUC08;MART35;GLUC09;GLUC10;GLUC11;GLUCOB";s:21:"field_mono_citation_f";s:147:"KGHM;HBNPD;GLUC01;GLUC02;KONSUP;GLUC03;GLUC04;FCHMP;GLUC05;GREO;GLUC06;GLUC07;DSGLUC;CHEMIDP;MERCK14;NPPT;GLUC08;MART35;GLUC09;GLUC10;GLUC11;GLUCOB";s:26:"field_reference_reviewed_e";s:154:"GLUC12;GLUC13;EXP3FS;GLUC14;GLUC15;GLUC16;GLUC17;GLUC18;GLUC19;GLUC20;LNHPD;DPD;GLUC21;GLUC22;GLUC23;GLUC24;NUTRA;CDSWL;GLUC25;GLUC26;GLUC27;GLUC28;PSGLIP";s:26:"field_reference_reviewed_f";s:154:"GLUC12;GLUC13;EXP3FS;GLUC14;GLUC15;GLUC16;GLUC17;GLUC18;GLUC19;GLUC20;LNHPD;DPD;GLUC21;GLUC22;GLUC23;GLUC24;NUTRA;CDSWL;GLUC25;GLUC26;GLUC27;GLUC28;PSGLIP";}i:216573;a:36:{s:5:"title";s:23:"GOL_O_Goldenseal - Oral";s:3:"nid";s:6:"216573";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"GOL_O";s:18:"field_group_name_e";s:10:"Goldenseal";s:18:"field_group_name_f";s:8:"Hydraste";s:22:"field_monograph_name_e";s:17:"Goldenseal - Oral";s:22:"field_monograph_name_f";s:16:"Hydraste - Orale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:622:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.        Note: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:749:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.   Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:1458:"The manufacturer must have proof of sale or a permit of the cultivated Hydrastis canadensis (Goldenseal) because the wild population is threatened: (i) Hydrastis canadensis is listed in Schedule 1 of the Species at Risk Act (SARA) as a “threatened” species and is afforded protection under this Act. Under section 32(2) of SARA, no person shall possess, collect, buy, sell or trade an individual of a wildlife species that is listed as an extirpated species, an endangered species or a threatened species, or any part or derivative of such an individual (JC 2003). Proof of purchase of cultivated Hydrastis canadensis is required. (ii) The Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) sets controls on the movement of animal and plant species that are, or may be, “threatened” due to excessive commercial exploitation. To import Hydrastis canadensis (including the whole, part of, or the powdered root and/or rhizome) into Canada requires an accompanying CITES export permit from exporting countries. For permit information see http://www.cites.ec.gc.ca/eng/sct3/sct3_4_e.cfm (EC 2005). ; The medicinal ingredient may comply with the specifications outlined in the 'Goldenseal root' monograph of the British Pharmacopoeia, the 'Goldenseal rhizome' monograph of the European Pharmacopoeia and the 'Goldenseal', 'Powdered Goldenseal' and 'Powdered Goldenseal Extract' monographs of the American Pharmacopoeia.";s:21:"field_specification_f";s:1869:"Le fabricant doit avoir en sa possession une preuve de vente ou un permis indiquant que l’hydraste (Hydrastis canadensis) utilisée est cultivée, les populations sauvages étant menacées : (i) Hydrastis canadensis est inscrite à l’annexe 1 de la Loi sur les espèces en péril en tant qu’espèce menacée et est donc protégée par cette loi. Selon l’article 32(2) de la Loi sur les espèces en péril, il est interdit de posséder, de collectionner, d’acheter, de vendre ou d’échanger un individu — notamment partie d’un individu ou produit qui en provient — d’une espèce sauvage inscrite comme espèce disparue du pays, en voie de disparition ou menacée (JC 2003). Une preuve d’achat de la plante cultivée Hydrastis canadensis est requise. (ii) La Convention sur le commerce international des espèces de faune et de flore sauvages menacées d’extinction (CITES (Convention on International Trade in Endangered Species of wild Fauna an Flora)) contrôle les échanges internationaux d’espèces animales et végétales qui sont, ou pourraient être, menacées de surexploitation commerciale. Afin d’importer au Canada l’Hydrastis canadensis (les racines ou les rhizomes, des parties de racines ou de rhizomes, ou les racines ou le rhizomes en poudre), un permis d’exportation de CITES provenant du pays exportateur est exigé. Afin d’obtenir de plus amples informations au sujet des permis d’exportation, consulter http://www.cites.ec.gc.ca/fra/sct3/sct3_4_f.cfm (EC 2005).;  L'ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie 'Goldenseal' de la Pharmacopé britannique (BP), la monographie 'Goldenseal rhizome' de la Pharmacopée européenne (Ph. Eur.) ou les monographies 'Goldenseal', 'Powdered Goldenseal' et 'Powdered Goldenseal Extract' de la Pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2010-01-11";s:16:"field_legacy_nid";s:6:"100881";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:6:"GOLDUR";s:15:"field_mono_risk";s:40:"PERS;WORS;GOL_CW1;GOL_CW2;GOL_CW3;GOL_CI";s:21:"field_mono_citation_e";s:134:"HERMED2;ABC;50COM;BPH9;BHCOM;UPHCDI8;HERCDI;CITESGOL;SARAGOL;THEPHA;AMODHER;MEDHER;SARA;HERCOM;HERSAF;NAE;EPC8;GRINGOL;TNF27;WEP;PCBDP";s:21:"field_mono_citation_f";s:151:"HERMED2;ABC;50COM;BPH9;BHCOM;UPHCDI8;HERCDI;CITESGOL;SARAGOL;THEPHA;AMODHER;MEDHER;SARA;HERCOM;HERSAF;NAE;EPC8;GRINGOL;TNF27;WEP;PCBDP;NOMEN;PPS;CMCROP";s:26:"field_reference_reviewed_e";s:46:"HERMED;ENCHU;EMP;HANDMH;KAD2;BOTSAF;PPP;CMCROP";s:26:"field_reference_reviewed_f";s:50:"HERMED;PMM;ENCHU;PHAPHY;EMP;HANDMH;KAD2;BOTSAF;PPP";}i:216574;a:36:{s:5:"title";s:25:"GOL_B_Goldenseal - Buccal";s:3:"nid";s:6:"216574";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"GOL_B";s:18:"field_group_name_e";s:10:"Goldenseal";s:18:"field_group_name_f";s:8:"Hydraste";s:22:"field_monograph_name_e";s:19:"Goldenseal - Buccal";s:22:"field_monograph_name_f";s:18:"Hydraste - Buccale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:622:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.        Note: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:749:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.   Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:1458:"The manufacturer must have proof of sale or a permit of the cultivated Hydrastis canadensis (Goldenseal) because the wild population is threatened: (i) Hydrastis canadensis is listed in Schedule 1 of the Species at Risk Act (SARA) as a “threatened” species and is afforded protection under this Act. Under section 32(2) of SARA, no person shall possess, collect, buy, sell or trade an individual of a wildlife species that is listed as an extirpated species, an endangered species or a threatened species, or any part or derivative of such an individual (JC 2003). Proof of purchase of cultivated Hydrastis canadensis is required. (ii) The Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) sets controls on the movement of animal and plant species that are, or may be, “threatened” due to excessive commercial exploitation. To import Hydrastis canadensis (including the whole, part of, or the powdered root and/or rhizome) into Canada requires an accompanying CITES export permit from exporting countries. For permit information see http://www.cites.ec.gc.ca/eng/sct3/sct3_4_e.cfm (EC 2005). ; The medicinal ingredient may comply with the specifications outlined in the 'Goldenseal root' monograph of the British Pharmacopoeia, the 'Goldenseal rhizome' monograph of the European Pharmacopoeia and the 'Goldenseal', 'Powdered Goldenseal' and 'Powdered Goldenseal Extract' monographs of the American Pharmacopoeia.";s:21:"field_specification_f";s:1869:"Le fabricant doit avoir en sa possession une preuve de vente ou un permis indiquant que l’hydraste (Hydrastis canadensis) utilisée est cultivée, les populations sauvages étant menacées : (i) Hydrastis canadensis est inscrite à l’annexe 1 de la Loi sur les espèces en péril en tant qu’espèce menacée et est donc protégée par cette loi. Selon l’article 32(2) de la Loi sur les espèces en péril, il est interdit de posséder, de collectionner, d’acheter, de vendre ou d’échanger un individu — notamment partie d’un individu ou produit qui en provient — d’une espèce sauvage inscrite comme espèce disparue du pays, en voie de disparition ou menacée (JC 2003). Une preuve d’achat de la plante cultivée Hydrastis canadensis est requise. (ii) La Convention sur le commerce international des espèces de faune et de flore sauvages menacées d’extinction (CITES (Convention on International Trade in Endangered Species of wild Fauna an Flora)) contrôle les échanges internationaux d’espèces animales et végétales qui sont, ou pourraient être, menacées de surexploitation commerciale. Afin d’importer au Canada l’Hydrastis canadensis (les racines ou les rhizomes, des parties de racines ou de rhizomes, ou les racines ou le rhizomes en poudre), un permis d’exportation de CITES provenant du pays exportateur est exigé. Afin d’obtenir de plus amples informations au sujet des permis d’exportation, consulter http://www.cites.ec.gc.ca/fra/sct3/sct3_4_f.cfm (EC 2005).;  L'ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie 'Goldenseal' de la Pharmacopé britannique (BP), la monographie 'Goldenseal rhizome' de la Pharmacopée européenne (Ph. Eur.) ou les monographies 'Goldenseal', 'Powdered Goldenseal' et 'Powdered Goldenseal Extract' de la Pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2010-01-11";s:16:"field_legacy_nid";s:6:"100882";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:6:"GOLDUR";s:15:"field_mono_risk";s:40:"PERS;WORS;GOL_CW1;GOL_CW2;GOL_CW3;GOL_CI";s:21:"field_mono_citation_e";s:134:"HERMED2;ABC;50COM;BPH9;BHCOM;UPHCDI8;HERCDI;CITESGOL;SARAGOL;THEPHA;AMODHER;MEDHER;SARA;HERCOM;HERSAF;NAE;EPC8;GRINGOL;TNF27;WEP;PCBDP";s:21:"field_mono_citation_f";s:151:"HERMED2;ABC;50COM;BPH9;BHCOM;UPHCDI8;HERCDI;CITESGOL;SARAGOL;THEPHA;AMODHER;MEDHER;SARA;HERCOM;HERSAF;NAE;EPC8;GRINGOL;TNF27;WEP;PCBDP;NOMEN;PPS;CMCROP";s:26:"field_reference_reviewed_e";s:46:"HERMED;ENCHU;EMP;HANDMH;KAD2;BOTSAF;PPP;CMCROP";s:26:"field_reference_reviewed_f";s:50:"HERMED;PMM;ENCHU;PHAPHY;EMP;HANDMH;KAD2;BOTSAF;PPP";}i:216575;a:36:{s:5:"title";s:23:"GRI_O_Ground Ivy - Oral";s:3:"nid";s:6:"216575";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"GRI_O";s:18:"field_group_name_e";s:10:"Ground Ivy";s:18:"field_group_name_f";s:16:"Lierre terrestre";s:22:"field_monograph_name_e";s:17:"Ground Ivy - Oral";s:22:"field_monograph_name_f";s:24:"Lierre terrestre - Orale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-03-05";s:16:"field_legacy_nid";s:6:"100883";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:6:"GIVDUR";s:15:"field_mono_risk";s:16:"PERS;WORS;GIV_CW";s:21:"field_mono_citation_e";s:57:"HERMED2;BEHM;HBNPD;BHCOM;PATSC;AMODHER;HERCOM;GRIN;PNCBDP";s:21:"field_mono_citation_f";s:60:"HERMED2;BEHM;HBNPD;PMM;BHCOM;FLORE;PATSC;AMODHER;GRIN;PNCBDP";s:26:"field_reference_reviewed_e";s:65:"BHP2;HERCDI;TPMD;KAD2;PDRHM2;CIHH;HPBCO;NAE;DUSA;MOMMP;HPBCO2;WEP";s:26:"field_reference_reviewed_f";s:65:"BHP2;HERCDI;TPMD;KAD2;PDRHM2;CIHH;HPBCO;NAE;DUSA;MOMMP;HPBCO2;WEP";}i:216576;a:35:{s:5:"title";s:26:"GRI_T_Ground Ivy - Topical";s:3:"nid";s:6:"216576";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"GRI_T";s:18:"field_group_name_e";s:10:"Ground Ivy";s:18:"field_group_name_f";s:16:"Lierre terrestre";s:22:"field_monograph_name_e";s:20:"Ground Ivy - Topical";s:22:"field_monograph_name_f";s:26:"Lierre terrestre - Topique";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-03-05";s:16:"field_legacy_nid";s:6:"100884";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:16:"PERS;WORS;GIV_CW";s:21:"field_mono_citation_e";s:57:"HERMED2;BEHM;HBNPD;BHCOM;PATSC;AMODHER;HERCOM;GRIN;PNCBDP";s:21:"field_mono_citation_f";s:60:"HERMED2;BEHM;HBNPD;PMM;BHCOM;FLORE;PATSC;AMODHER;GRIN;PNCBDP";s:26:"field_reference_reviewed_e";s:65:"BHP2;HERCDI;TPMD;KAD2;PDRHM2;CIHH;HPBCO;NAE;DUSA;MOMMP;HPBCO2;WEP";s:26:"field_reference_reviewed_f";s:65:"BHP2;HERCDI;TPMD;KAD2;PDRHM2;CIHH;HPBCO;NAE;DUSA;MOMMP;HPBCO2;WEP";}i:216577;a:36:{s:5:"title";s:22:"GSE_Grape Seed Extract";s:3:"nid";s:6:"216577";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"GSE";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:18:"Grape Seed Extract";s:22:"field_monograph_name_f";s:30:"Pépins de raisin, Extraits de";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:117:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_grape_seed_extra_pepin_raisin-eng.php";s:21:"field_monograph_url_f";s:117:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_grape_seed_extra_pepin_raisin-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:620:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.      Note: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicants’ discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:754:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.       Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-06-24";s:16:"field_legacy_nid";s:6:"100885";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:15:"GSEDUR1;GSEDUR2";s:15:"field_mono_risk";s:12:"PREGC;GSE_CW";s:21:"field_mono_citation_e";s:64:"FREERAD;TPAIND;CVINS;4729PAT;PERVI;PPOXST;MMLDL;LOWER;MANIF;GRIN";s:21:"field_mono_citation_f";s:64:"FREERAD;TPAIND;CVINS;4729PAT;PERVI;PPOXST;MMLDL;LOWER;MANIF;GRIN";s:26:"field_reference_reviewed_e";s:507:"NADPH;PROCY;30CASES;IH636;HERMED2;HERMED;HCTHR;POEDEMA;RHINIT;CAIAAI;CGCEM;VITIS;BHCOM2;UPHCDI;VINEPA;GSPE;GRAPE;INHIBPA;QUERC;REDGRP;REDWINE;REVNP;HANDMH;ESCOP;KAD;RHINOC;LIPIDPER;LYCHEE;CHAPRO;CMBP;MHERBS;PDRHM;MEDHER;ASYMP;SKINC;NEPHRO;ANTIINF;PHLEBO;BOTSAF;HERCOM;BOTMED;IDNM;PAGRAPES;HERSAF;FLAVON;NSGS;CONSRW;AOACT;MERCK14;MERCK13;PTEDEMAS;REPERF;TNM2;FLRICH;NBCHROM;AGCS;EGSEC;PGSBF;MART35;MART33;CYTEXP;GRN125;GRN124;MPW;GRPHYP;LDLSUS;MNGOLD;ROINT;24HEI;ANTIPICA;AOBOT;ATTCOG;VCGSP;CHLOA;SEPRE;GSEOS";s:26:"field_reference_reviewed_f";s:507:"NADPH;PROCY;30CASES;IH636;HERMED2;HERMED;HCTHR;POEDEMA;RHINIT;CAIAAI;CGCEM;VITIS;BHCOM2;UPHCDI;VINEPA;GSPE;GRAPE;INHIBPA;QUERC;REDGRP;REDWINE;REVNP;HANDMH;ESCOP;KAD;RHINOC;LIPIDPER;LYCHEE;CHAPRO;CMBP;MHERBS;PDRHM;MEDHER;ASYMP;SKINC;NEPHRO;ANTIINF;PHLEBO;BOTSAF;HERCOM;BOTMED;IDNM;PAGRAPES;HERSAF;FLAVON;NSGS;CONSRW;AOACT;MERCK14;MERCK13;PTEDEMAS;REPERF;TNM2;FLRICH;NBCHROM;AGCS;EGSEC;PGSBF;MART35;MART33;CYTEXP;GRN125;GRN124;MPW;GRPHYP;LDLSUS;MNGOLD;ROINT;24HEI;ANTIPICA;AOBOT;ATTCOG;VCGSP;CHLOA;SEPRE;GSEOS";}i:216578;a:36:{s:5:"title";s:9:"HTP_5-HTP";s:3:"nid";s:6:"216578";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"HTP";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:5:"5-HTP";s:22:"field_monograph_name_f";s:5:"5-HTP";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:27:"atReq.do?atid=5htp&lang=eng";s:21:"field_monograph_url_f";s:27:"atReq.do?atid=5htp&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2007-12-18";s:16:"field_legacy_nid";s:6:"100886";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:19:"field_mono_duration";s:34:"HTP1;HTP2;HTP3;HTP4;HTP5;HTP6;HTP7";s:15:"field_mono_risk";s:62:"PREGC;PERS;WORS;HTP_CW1;HTP_CW2;HTP_CW3;HTP_CI;HTP_AR1;HTP_AR2";s:21:"field_mono_citation_e";s:205:"DEPSEN;HBNPD;SERPRE;PRIMHEAD;REVANTI;EATBEH;ENINT;PRFIBRO;FEEDBEH;SAF5HTP;PHARTH;INGRIF;SCLERO;HPLC;SEROSYN;ADDRUG;FIBMIG;MERCK13;TNM;FUNDIM;PFSYN;INGES;SLPDIS;EFF5HTP;SCLLIKE;MEAS;5VSM;ALACAR;EFFSLP;ALONE";s:21:"field_mono_citation_f";s:205:"DEPSEN;HBNPD;SERPRE;PRIMHEAD;REVANTI;EATBEH;ENINT;PRFIBRO;FEEDBEH;SAF5HTP;PHARTH;INGRIF;SCLERO;HPLC;SEROSYN;ADDRUG;FIBMIG;MERCK13;TNM;FUNDIM;PFSYN;INGES;SLPDIS;EFF5HTP;SCLLIKE;MEAS;5VSM;ALACAR;EFFSLP;ALONE";s:26:"field_reference_reviewed_e";s:437:"IBSPD;FDSR;POIKI;JUVHA;MMDT;ADVREA;5OHTRY;E5ACT;SERPRE2;DNP;MONO;EATBEH2;PRIMHA;SDCHIL;LABILE;EMA;EOSINO;MWOVR;INFOPAP;IMPUR;DEAR;NEWSYN;DSNPPA;MIAN;EFFL5;PLACE;PSYTR;BSLES;DOGS;5HT;MEDEFF;RATS;SAD;NMCD;FSP;ANXDIS;ANDI;EMSYN;PANATT;SERSYN;OBES;NPTD;MHRA;EXPL5;PREP5D;CIDPL;PDRH;DOWNS;EVID;CONVTRY;L5HYDRO;L5VSPL;ACUTE;DEPRES;H9772;CERVAS;BRMONO;TGAADRU;SCLER;5HYDRO;SEARCH;MGTDEP;CENTRAL;CHEMOPRO;PILOT;PANDIS;PTINS;KINET;UMC;MICE;INDOLE";s:26:"field_reference_reviewed_f";s:437:"IBSPD;FDSR;POIKI;JUVHA;MMDT;ADVREA;5OHTRY;E5ACT;SERPRE2;DNP;MONO;EATBEH2;PRIMHA;SDCHIL;LABILE;EMA;EOSINO;MWOVR;INFOPAP;IMPUR;DEAR;NEWSYN;DSNPPA;MIAN;EFFL5;PLACE;PSYTR;BSLES;DOGS;5HT;MEDEFF;RATS;SAD;NMCD;FSP;ANXDIS;ANDI;EMSYN;PANATT;SERSYN;OBES;NPTD;MHRA;EXPL5;PREP5D;CIDPL;PDRH;DOWNS;EVID;CONVTRY;L5HYDRO;L5VSPL;ACUTE;DEPRES;H9772;CERVAS;BRMONO;TGAADRU;SCLER;5HYDRO;SEARCH;MGTDEP;CENTRAL;CHEMOPRO;PILOT;PANDIS;PTINS;KINET;UMC;MICE;INDOLE";}i:216579;a:37:{s:5:"title";s:36:"HAWT_La_Hawthorn-Crataegus laevigata";s:3:"nid";s:6:"216579";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:7:"HAWT_La";s:18:"field_group_name_e";s:8:"Hawthorn";s:18:"field_group_name_f";s:9:"Aubépine";s:22:"field_monograph_name_e";s:28:"Hawthorn-Crataegus laevigata";s:22:"field_monograph_name_f";s:29:"Aubépine-Crataegus laevigata";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:42:"atReq.do?atid=crataegus.laevigata&lang=eng";s:21:"field_monograph_url_f";s:42:"atReq.do?atid=crataegus.laevigata&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:640:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.    Note: (i) Text in parentheses is additional optional information which can be included on the Product Licence Application and product labels at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:789:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient (ou des ingrédients) médicinal (médicinaux). La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.      Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:429:"The medicinal ingredient may comply with the specifications outlined in the following pharmacopoeial monographs: 'Hawthorn Berries', 'Hawthorn Leaf and Flower', 'Hawthorn Leaf and Flower Dry Extract', 'Hawthorn Leaf and Flower Liquid Extract Quantified' of the British Pharmacopoeia(BP) and European Pharmacopoeia(Ph. Eur) as well as 'Hawthorn Leaf with Flower', 'Powdered Hawthorn Leaf with Flower' of the US Pharmacopoeia(USP).";s:21:"field_specification_f";s:444:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales ci-dessous: 'Hawthorn Berries', 'Hawthorn Leaf and Flower', 'Hawthorn Leaf and Flower Dry Extract', 'Hawthorn Leaf and Flower Liquid Extract Quantified' des pharmacopées britanniques et européennes (BP) et (Ph. Eur.), et aussi 'Hawthorn Leaf with Flower', 'Powdered Hawthorn Leaf with Flower' de la pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-07-18";s:16:"field_legacy_nid";s:6:"100887";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:4:"HAWR";s:15:"field_mono_risk";s:18:"HAWR_CW1;PERS;WORS";s:21:"field_mono_citation_e";s:110:"HAWR1;HAWR2;HAWR3;HAWR4;HAWR6;HAWR7;HAWR8;HAWR9;HAWR10;HAWR11;HAWR12;HAWR13;HAWR14;HAWR15;HAWR16;HAWR17;HAWR18";s:21:"field_mono_citation_f";s:110:"HAWR1;HAWR2;HAWR3;HAWR4;HAWR6;HAWR7;HAWR8;HAWR9;HAWR10;HAWR11;HAWR12;HAWR13;HAWR14;HAWR15;HAWR16;HAWR17;HAWR18";s:26:"field_reference_reviewed_e";s:55:"HAWRR1;HAWRR2;HAWRR3;HAWRR4;HAWRR5;HAWRR6;HAWRR7;HAWRR8";s:26:"field_reference_reviewed_f";s:55:"HAWRR1;HAWRR2;HAWRR3;HAWRR4;HAWRR5;HAWRR6;HAWRR7;HAWRR8";}i:216580;a:37:{s:5:"title";s:35:"HAWT_Mo_Hawthorn-Crataegus monogyna";s:3:"nid";s:6:"216580";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:7:"HAWT_Mo";s:18:"field_group_name_e";s:8:"Hawthorn";s:18:"field_group_name_f";s:9:"Aubépine";s:22:"field_monograph_name_e";s:27:"Hawthorn-Crataegus monogyna";s:22:"field_monograph_name_f";s:28:"Aubépine-Crataegus monogyna";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:41:"atReq.do?atid=crataegus.monogyna&lang=eng";s:21:"field_monograph_url_f";s:41:"atReq.do?atid=crataegus.monogyna&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:640:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.    Note: (i) Text in parentheses is additional optional information which can be included on the Product Licence Application and product labels at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:789:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient (ou des ingrédients) médicinal (médicinaux). La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.      Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:429:"The medicinal ingredient may comply with the specifications outlined in the following pharmacopoeial monographs: 'Hawthorn Berries', 'Hawthorn Leaf and Flower', 'Hawthorn Leaf and Flower Dry Extract', 'Hawthorn Leaf and Flower Liquid Extract Quantified' of the British Pharmacopoeia(BP) and European Pharmacopoeia(Ph. Eur) as well as 'Hawthorn Leaf with Flower', 'Powdered Hawthorn Leaf with Flower' of the US Pharmacopoeia(USP).";s:21:"field_specification_f";s:444:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales ci-dessous: 'Hawthorn Berries', 'Hawthorn Leaf and Flower', 'Hawthorn Leaf and Flower Dry Extract', 'Hawthorn Leaf and Flower Liquid Extract Quantified' des pharmacopées britanniques et européennes (BP) et (Ph. Eur.), et aussi 'Hawthorn Leaf with Flower', 'Powdered Hawthorn Leaf with Flower' de la pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-07-18";s:16:"field_legacy_nid";s:6:"100888";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:4:"HAWR";s:15:"field_mono_risk";s:18:"HAWR_CW1;PERS;WORS";s:21:"field_mono_citation_e";s:110:"HAWR1;HAWR2;HAWR3;HAWR4;HAWR6;HAWR7;HAWR8;HAWR9;HAWR10;HAWR11;HAWR12;HAWR13;HAWR14;HAWR15;HAWR16;HAWR17;HAWR18";s:21:"field_mono_citation_f";s:110:"HAWR1;HAWR2;HAWR3;HAWR4;HAWR6;HAWR7;HAWR8;HAWR9;HAWR10;HAWR11;HAWR12;HAWR13;HAWR14;HAWR15;HAWR16;HAWR17;HAWR18";s:26:"field_reference_reviewed_e";s:55:"HAWRR1;HAWRR2;HAWRR3;HAWRR4;HAWRR5;HAWRR6;HAWRR7;HAWRR8";s:26:"field_reference_reviewed_f";s:55:"HAWRR1;HAWRR2;HAWRR3;HAWRR4;HAWRR5;HAWRR6;HAWRR7;HAWRR8";}i:216581;a:35:{s:5:"title";s:21:"HEA_O_Heal-all - Oral";s:3:"nid";s:6:"216581";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"HEA_O";s:18:"field_group_name_e";s:8:"Heal-all";s:18:"field_group_name_f";s:8:"Prunelle";s:22:"field_monograph_name_e";s:15:"Heal-all - Oral";s:22:"field_monograph_name_f";s:16:"Prunelle - Orale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:566:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.    Note: (i) Text in parentheses is additional optional information which can be included on the Product Licence Application and product labels at the applicant’s discretion.  (ii) Claims for traditional use must include the term “Herbal Medicine”.";s:12:"field_note_f";s:732:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.     Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit.  (ii) Les allégations concernant l’usage traditionnel doivent inclure le terme « phytothérapie ».";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-02-27";s:16:"field_legacy_nid";s:6:"100889";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:9:"PERS;WORS";s:21:"field_mono_citation_e";s:75:"BEHM;EMP;COMHER;KAD;AMODHER;CIHH;HERBBK;HERCOM;THEHER;FAMHBL;GRIN;PHC;PCBDP";s:21:"field_mono_citation_f";s:70:"BEHM;FLORE;EMP;COMHER;KAD;NOMEN;AMODHER;CIHH;FAMHBL;GRIN;WEP;PHC;PCBDP";s:26:"field_reference_reviewed_e";s:73:"CHMMM;HANDMH;HPIM;PHCAM;HGHP;MEDHER;BOTSAF;TCBP;DFMM;WEP;PNCBDP;PDCM;HCHF";s:26:"field_reference_reviewed_f";s:73:"CHMMM;HANDMH;HPIM;PHCAM;HGHP;MEDHER;BOTSAF;TCBP;DFMM;WEP;PNCBDP;PDCM;HCHF";}i:216582;a:35:{s:5:"title";s:24:"HEA_T_Heal-all - Topical";s:3:"nid";s:6:"216582";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"HEA_T";s:18:"field_group_name_e";s:8:"Heal-all";s:18:"field_group_name_f";s:8:"Prunelle";s:22:"field_monograph_name_e";s:18:"Heal-all - Topical";s:22:"field_monograph_name_f";s:18:"Prunelle - Topique";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:567:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.     Note: (i) Text in parentheses is additional optional information which can be included on the Product Licence Application and product labels at the applicant’s discretion.  (ii) Claims for traditional use must include the term “Herbal Medicine”.";s:12:"field_note_f";s:732:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.     Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit.  (ii) Les allégations concernant l’usage traditionnel doivent inclure le terme « phytothérapie ».";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-02-27";s:16:"field_legacy_nid";s:6:"100890";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:9:"PERS;WORS";s:21:"field_mono_citation_e";s:75:"BEHM;EMP;COMHER;KAD;AMODHER;CIHH;HERBBK;HERCOM;THEHER;FAMHBL;GRIN;PHC;PCBDP";s:21:"field_mono_citation_f";s:70:"BEHM;FLORE;EMP;COMHER;KAD;NOMEN;AMODHER;CIHH;FAMHBL;GRIN;WEP;PHC;PCBDP";s:26:"field_reference_reviewed_e";s:73:"CHMMM;HANDMH;HPIM;PHCAM;HGHP;MEDHER;BOTSAF;TCBP;DFMM;WEP;PNCBDP;PDCM;HCHF";s:26:"field_reference_reviewed_f";s:73:"CHMMM;HANDMH;HPIM;PHCAM;HGHP;MEDHER;BOTSAF;TCBP;DFMM;WEP;PNCBDP;PDCM;HCHF";}i:216583;a:35:{s:5:"title";s:23:"HEA_B_Heal-all - Buccal";s:3:"nid";s:6:"216583";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"HEA_B";s:18:"field_group_name_e";s:8:"Heal-all";s:18:"field_group_name_f";s:8:"Prunelle";s:22:"field_monograph_name_e";s:17:"Heal-all - Buccal";s:22:"field_monograph_name_f";s:18:"Prunelle - Buccale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:564:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.  Note: (i) Text in parentheses is additional optional information which can be included on the Product Licence Application and product labels at the applicant’s discretion.  (ii) Claims for traditional use must include the term “Herbal Medicine”.";s:12:"field_note_f";s:729:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.  Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit.  (ii) Les allégations concernant l’usage traditionnel doivent inclure le terme « phytothérapie ».";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-02-27";s:16:"field_legacy_nid";s:6:"100891";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:9:"PERS;WORS";s:21:"field_mono_citation_e";s:75:"BEHM;EMP;COMHER;KAD;AMODHER;CIHH;HERBBK;HERCOM;THEHER;FAMHBL;GRIN;PHC;PCBDP";s:21:"field_mono_citation_f";s:70:"BEHM;FLORE;EMP;COMHER;KAD;NOMEN;AMODHER;CIHH;FAMHBL;GRIN;WEP;PHC;PCBDP";s:26:"field_reference_reviewed_e";s:73:"CHMMM;HANDMH;HPIM;PHCAM;HGHP;MEDHER;BOTSAF;TCBP;DFMM;WEP;PNCBDP;PDCM;HCHF";s:26:"field_reference_reviewed_f";s:73:"CHMMM;HANDMH;HPIM;PHCAM;HGHP;MEDHER;BOTSAF;TCBP;DFMM;WEP;PNCBDP;PDCM;HCHF";}i:216584;a:35:{s:5:"title";s:8:"HOP_Hops";s:3:"nid";s:6:"216584";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"HOP";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:4:"Hops";s:22:"field_monograph_name_f";s:7:"Houblon";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:100:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_hops-houblon-eng.php";s:21:"field_monograph_url_f";s:100:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_hops-houblon-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:152:"The medicinal ingredient may comply with the specifications outlined in the Hop Strobile Monographs published in the European or British Pharmacopoeias.";s:21:"field_specification_f";s:181:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies du strobile du houblon publiées dans les Pharmacopées européenne ou britannique.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-02-12";s:16:"field_legacy_nid";s:6:"100892";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:5:"ADU12";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:48:"PERS;WORS;HOP_CW1;HOP_CW2;HOP_CW3;HOP_CW4;HOP_AR";s:21:"field_mono_citation_e";s:103:"HERMED2;HBNPD;EXPCEM;BHCOM;HERCDI;UPHCDI7;PHARTH;EMA;ESCOP;KAD;AMODHER;MEDHER;HERSAF;HERCOM;BOTSAF;GRIN";s:21:"field_mono_citation_f";s:107:"HERMED2;HBNPD;EXPCEM;PMM;BHCOM;HERCDI;UPHCDI7;PHAPHY;PHARTH;EMA;ESCOP;KAD;AMODHER;MEDHER;HERSAF;BOTSAF;GRIN";s:26:"field_reference_reviewed_e";s:42:"HERMED;BHP;BOTPHA;EMP;PCH;CMCROP;HDPP2;WEP";s:26:"field_reference_reviewed_f";s:42:"HERMED;BHP;BOTPHA;EMP;PCH;CMCROP;HDPP2;WEP";}i:216585;a:35:{s:5:"title";s:18:"HOC_Horse Chestnut";s:3:"nid";s:6:"216585";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"HOC";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:14:"Horse Chestnut";s:22:"field_monograph_name_f";s:16:"Marronier d'Inde";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:107:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_chestnut-marronnier-eng.php";s:21:"field_monograph_url_f";s:107:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_chestnut-marronnier-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:478:"The medicinal ingredient must conform to one of the following criteria: (i). the horse chestnut seed has been adequately processed, such that the outer capsule (pericarp) has been completely removed and discarded, to ensure that the finished product does not contain esculin or (ii). the horse chestnut seed complies with the specifications outlined in the Horse Chestnut, Powdered Horse Chestnut, or Powdered Horse Chestnut Extract Monographs published in the US Pharmacopoeia.";s:21:"field_specification_f";s:562:"L’ingrédient médicinal doit être conforme à l’une des spécifications suivantes : (i) la graine du marronnier d’Inde a subit les transformations nécessaires de telle sorte que la capsule entourant la graine (le péricarpe) a été entièrement enlevée et jetée, car le produit final ne doit contenir aucune esculine, ou (ii) la graine du marronnier d’Inde est conforme aux spécifications énoncées dans les monographies Horse Chestnut, Powdered Horse Chestnut ou Powdered Horse Chestnut Extract  publiées dans la Pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-03-27";s:16:"field_legacy_nid";s:6:"100893";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:23:"PERS;WORS;HOC_CW;HOC_AR";s:21:"field_mono_citation_e";s:66:"EXPCEM;BHCOM2;UPHCDI8;ESCOP;KAD2;AMODHER;MEDHER;HERSAF;HERCOM;GRIN";s:21:"field_mono_citation_f";s:70:"EXPCEM;PMM;BHCOM2;UPHCDI8;PHAPHY;ESCOP;KAD2;AMODHER;MEDHER;HERSAF;GRIN";s:26:"field_reference_reviewed_e";s:11:"HERCDI;ECMM";s:26:"field_reference_reviewed_f";s:11:"HERCDI;ECMM";}i:216586;a:36:{s:5:"title";s:15:"HOR_Horseradish";s:3:"nid";s:6:"216586";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"HOR";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:11:"Horseradish";s:22:"field_monograph_name_f";s:7:"Raifort";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:107:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_horseradish-raifort-eng.php";s:21:"field_monograph_url_f";s:107:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_horseradish-raifort-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-02-15";s:16:"field_legacy_nid";s:6:"100894";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:6:"HOROCC";s:15:"field_mono_risk";s:57:"PERS;WORS;HOR_CW1;HOR_CW2;HOR_CW3;HOR_CI1;HOR_CI2;HOR_CI3";s:21:"field_mono_citation_e";s:93:"HERMED2;HBNPD;EXPCEM;UPHCDI7;HERCDI;PATSC;KAD;AMODHER;BOTSAF;HERCOM;THEHER;DMH;NAE;GRIN;PCBDP";s:21:"field_mono_citation_f";s:94:"HERMED2;HBNPD;EXPCEM;PMM;UPHCDI7;HERCDI;PATSC;KAD;AMODHER;BOTSAF;THEHER;DMH;NAE;GRIN;WEP;PCBDP";s:26:"field_reference_reviewed_e";s:21:"MEDHER;PPP;PHC;PNCBDP";s:26:"field_reference_reviewed_f";s:21:"MEDHER;PPP;PHC;PNCBDP";}i:216587;a:29:{s:5:"title";s:27:"HCTO_Hydrocortisone Topical";s:3:"nid";s:6:"216587";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"HCTO";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:22:"Hydrocortisone Topical";s:22:"field_monograph_name_f";s:22:"Hydrocortisone topique";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"C;P";s:21:"field_monograph_url_e";s:37:"atReq.do?atid=hydrocortisone&lang=eng";s:21:"field_monograph_url_f";s:37:"atReq.do?atid=hydrocortisone&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:0:"";s:16:"field_legacy_nid";s:6:"100895";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216588;a:29:{s:5:"title";s:28:"HOLA_Laxatives, Hyperosmotic";s:3:"nid";s:6:"216588";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"HOLA";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:23:"Laxatives, Hyperosmotic";s:22:"field_monograph_name_f";s:24:"Laxatifs hyperosmotiques";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"C;P";s:21:"field_monograph_url_e";s:37:"atReq.do?atid=laxa_hyperosmo&lang=eng";s:21:"field_monograph_url_f";s:37:"atReq.do?atid=laxa_hyperosmo&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:0:"";s:16:"field_legacy_nid";s:6:"100896";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216589;a:35:{s:5:"title";s:10:"HYS_Hyssop";s:3:"nid";s:6:"216589";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"HYS";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:6:"Hyssop";s:22:"field_monograph_name_f";s:6:"Hysope";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:94:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_hyssop-eng.php";s:21:"field_monograph_url_f";s:94:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_hyssop-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:617:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.   Notes: Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:750:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.   Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-08-19";s:16:"field_legacy_nid";s:6:"100897";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:16:"PERS;WORS;HYS_CW";s:21:"field_mono_citation_e";s:60:"BHP;CGCEM;BHCOM2;KAD;AMODHER;BOTSAF;HERCOM;GRINHYS;PHC;PCBDP";s:21:"field_mono_citation_f";s:64:"BHP;CGCEM;BHCOM2;PHAPHY;KAD;AMODHER;BOTSAF;GRINHYS;WEP;PHC;PCBDP";s:26:"field_reference_reviewed_e";s:80:"BEHM;BHP2;ENHCI2;UPHCDI;HERCDI;PISEIZ;ECMM;MEDHER;ENCCNI;TEPO;HMPL;NAE;HEART;EOS";s:26:"field_reference_reviewed_f";s:80:"BEHM;BHP2;ENHCI2;UPHCDI;HERCDI;PISEIZ;ECMM;MEDHER;ENCCNI;TEPO;HMPL;NAE;HEART;EOS";}i:216590;a:32:{s:5:"title";s:10:"IOD_Iodine";s:3:"nid";s:6:"216590";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"IOD";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:6:"Iodine";s:22:"field_monograph_name_f";s:4:"Iode";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2007-11-08";s:16:"field_legacy_nid";s:6:"100898";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:21:"ADU14;AD913;CH48;CH13";s:15:"field_dose_note";s:19:"MIN;MAX;ADUL;IODDEF";s:21:"field_mono_citation_e";s:52:"MAC;ANHM;AB42;IOMDRI;FCC;DRIVAVK;MERCK13;MNHD;MART35";s:21:"field_mono_citation_f";s:52:"MAC;ANHM;AB42;IOMDRI;FCC;DRIVAVK;MERCK13;MNHD;MART35";}i:216591;a:34:{s:5:"title";s:8:"IRO_Iron";s:3:"nid";s:6:"216591";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"IRO";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:4:"Iron";s:22:"field_monograph_name_f";s:3:"Fer";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:31:"atReq.do?atid=iron_fer&lang=eng";s:21:"field_monograph_url_f";s:31:"atReq.do?atid=iron_fer&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:638:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.      Note: Text in parentheses is additional optional information which can be included on the Product Licence Application and product labels at the applicants’ discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:789:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient (ou des ingrédients) médicinal (médicinaux). La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.      Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:509:"If the package contains more than 250 mg of equivalent iron, the package must display the following text: 'Keep out of reach of children. There is enough drug in this package to seriously harm a child.'  (Note: This must be preceded by a prominently displayed symbol that is octagonal in shape, conspicuous in colour and on a background of a contrasting colour) (As per Section 97 of the Natural Health Product Regulations, citing Sections C.01.029 and C.01.031 of the Food and Drug Regulations (JC 2009a,b)).";s:17:"field_risk_note_f";s:598:"Lorsque l'emballage contient plus que l'équivalent de 250 mg de fer élémentaire, l'emballage doit inclure le texte suivant: 'Garder hors de portée des enfants. Ce contenant contient assez de médicament pouvant causer des torts sérieux à un enfant'.  (Nota : Cette mise en garde doit être précédée d'un symbole bien en évidence de forme octogonale et de couleur frappante sur fond de couleur contrastante ) (Selon l'Article 97 du Règlement sur les produits de santé naturels qui fait référence aux articles C.01.029 et C.01.031 du Règlement sur les aliments et drogues (JC 2009a,b))";s:21:"field_specification_e";s:182:"The medicinal ingredient may comply with the specifications outlined in the applicable iron monographs published in the USA (USP), British (BP) and European (Ph.Eur.) Pharmacopoeias.";s:21:"field_specification_f";s:214:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales du fer publiées dans les Pharmacopées américaine (USP), britannique (BP) ou européenne (Ph. Eur.).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-06-23";s:16:"field_legacy_nid";s:6:"100899";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:11:"ADU14;CH013";s:15:"field_dose_note";s:20:"IRON;MIN;MAXIRO;ADUL";s:15:"field_mono_risk";s:23:"IRO_AR1;IRO_AR2;IRO_PCK";s:21:"field_mono_citation_e";s:118:"CONUN;HALF;BADRAP;SAFISS;ITRFL;IRFORT;AHFS;ANHM;DPD;IOMDRI;FCC;DRIVAVK;ICCOMP;NHPREG;FDREG;MERCK14;MERCK13;MNHD;MART35";s:21:"field_mono_citation_f";s:118:"CONUN;HALF;BADRAP;SAFISS;ITRFL;IRFORT;AHFS;ANHM;DPD;IOMDRI;FCC;DRIVAVK;ICCOMP;NHPREG;FDREG;MERCK14;MERCK13;MNHD;MART35";}i:216592;a:36:{s:5:"title";s:11:"JUN_Juniper";s:3:"nid";s:6:"216592";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"JUN";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:7:"Juniper";s:22:"field_monograph_name_f";s:10:"Genévrier";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:105:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_juniper-genevrier-eng.php";s:21:"field_monograph_url_f";s:105:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_juniper-genevrier-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:147:"The medicinal ingredient may comply with the specifications outlined in the Juniper Monographs published in the European or British Pharmacopoeias.";s:21:"field_specification_f";s:184:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies Juniper publiées dans les Pharmacopées britannique (BP) et européenne (Ph. Eur.).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-04-21";s:16:"field_legacy_nid";s:6:"100900";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:14:"JUNDUR;JUNDUR2";s:15:"field_mono_risk";s:32:"PERS;WORS;JUN_CW;JUN_CI1;JUN_CI2";s:21:"field_mono_citation_e";s:81:"HBNPD;EXPCEM;BHCOM2;HERCDI;PATSC;ESCOP;KAD2;AMODHER;MEDHER;HERCOM;HMPL;HDPP2;GRIN";s:21:"field_mono_citation_f";s:95:"HBNPD;EXPCEM;PMM;BHCOM2;FLORE;HERCDI;PHAPHY;PATSC;ESCOP;KAD2;AMODHER;MEDHER;HMPL;HDPP2;WEP;GRIN";s:26:"field_reference_reviewed_e";s:19:"HERMED2;THC;HYPOGLY";s:26:"field_reference_reviewed_f";s:19:"HERMED2;THC;HYPOGLY";}i:216593;a:36:{s:5:"title";s:17:"LARG_Arginine, L-";s:3:"nid";s:6:"216593";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"LARG";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:12:"Arginine, L-";s:22:"field_monograph_name_f";s:12:"Arginine, L-";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:614:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.       Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:753:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.      Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:321:"The medicinal ingredient may comply with the specifications outlined in the following pharmacopoeial monographs : (i) 'Arginine' from British Pharmacopoeia (BP), (ii) 'Arginine' and 'Arginine Hydrochloride' from European Pharmacopoeia (Ph. Eur.), (iii) 'Arginine' and 'Arginine Hydrochloride' from US Pharmacopoeia (USP).";s:21:"field_specification_f";s:344:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes: (i) 'Arginine' de la pharmacopée britannique (BP), (ii) 'Arginine' et 'Arginine Hydrochloride' de la pharmacopée américaine (Ph. Eur.), (iii) 'Arginine' et 'Arginine Hydrochloride' de la pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2010-05-25";s:16:"field_legacy_nid";s:6:"100901";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:26:"LARGDUR1;LARGDUR2;LARGDUR3";s:15:"field_mono_risk";s:57:"PREGC;LARG_CW1;LARG_CW2;LARG_CW3;LARG_CW4;LARG_CI;LARG_AR";s:21:"field_mono_citation_e";s:228:"LARG1;LARG2;LARG3;LARG4;LARG5;BPH9;LARG6;LARG7;LARG8;LARG9;LARG10;LARG11;CTM;LARG12;ANHM;LARG13;LARG14;IOMDRI;LARG15;LARG16;LARG17;LARG18;LARG19;TURM15;LARG20;LARG21;EP8;LARG22;AATLL;MNHD;LARG23;LARG24;LARG25;LARG26;TNF27;LARG27";s:21:"field_mono_citation_f";s:228:"LARG1;LARG2;LARG3;LARG4;LARG5;BPH9;LARG6;LARG7;LARG8;LARG9;LARG10;LARG11;CTM;LARG12;ANHM;LARG13;LARG14;IOMDRI;LARG15;LARG16;LARG17;LARG18;LARG19;TURM15;LARG20;LARG21;EP8;LARG22;AATLL;MNHD;LARG23;LARG24;LARG25;LARG26;TNF27;LARG27";s:26:"field_reference_reviewed_e";s:466:"LARR1;LARR2;LARR3;LARR4;LARR5;LARR6;LARR7;LARR8;LARR9;LARR10;LARR11;LARR12;LARR13;LARR14;LARR15;LARR16;LARR17;LARR18;LARR19;LARR20;LARR21;LARR22;LARR23;LARR24;LARR25;LARR26;LARR27;LARR28;LARR29;LARR30;LARR31;LARR32;LARR33;LARR34;LARR35;LARR36;LARR37;LARR38;LARR39;LARR40;LARR41;LARR42;LARR43;LARR44;LARR45;LARR46;LARR47;LARR48;LARR49;LARR50;LARR51;LARR52;LARR53;LARR54;LARR55;LARR56;LARR57;LARR58;LARR59;LARR60;LARR61;LARR62;LARR63;LARR64;LARR65;LARR66;LARR67;LARR68";s:26:"field_reference_reviewed_f";s:466:"LARR1;LARR2;LARR3;LARR4;LARR5;LARR6;LARR7;LARR8;LARR9;LARR10;LARR11;LARR12;LARR13;LARR14;LARR15;LARR16;LARR17;LARR18;LARR19;LARR20;LARR21;LARR22;LARR23;LARR24;LARR25;LARR26;LARR27;LARR28;LARR29;LARR30;LARR31;LARR32;LARR33;LARR34;LARR35;LARR36;LARR37;LARR38;LARR39;LARR40;LARR41;LARR42;LARR43;LARR44;LARR45;LARR46;LARR47;LARR48;LARR49;LARR50;LARR51;LARR52;LARR53;LARR54;LARR55;LARR56;LARR57;LARR58;LARR59;LARR60;LARR61;LARR62;LARR63;LARR64;LARR65;LARR66;LARR67;LARR68";}i:216594;a:33:{s:5:"title";s:14:"LEM_Lemon Balm";s:3:"nid";s:6:"216594";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"LEM";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:10:"Lemon Balm";s:22:"field_monograph_name_f";s:19:"Mélisse officinale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:105:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_lemonbalm_melisse-eng.php";s:21:"field_monograph_url_f";s:105:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_lemonbalm_melisse-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:206:"The medicinal ingredient may comply with the specifications outlined in the Lemon Balm Monograph published in the British Pharmacopoeia or the Melissa Leaf Monograph published in the European Pharmacopoeia.";s:21:"field_specification_f";s:239:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie Lemon Balm publiée dans la Pharmacopée britannique (BP) ou la monographie Melissa Leaf, publiée dans la Pharmacopée européenne (Ph. Eur.).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-03-17";s:16:"field_legacy_nid";s:6:"100902";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:5:"ADU13";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:40:"LEM_CW1;LEM_CW2;LEM_CW3;LEM_AR;PERS;WORS";s:21:"field_mono_citation_e";s:26:"HBNPD;PHARTH;EMEALEMB;GRIN";s:21:"field_mono_citation_f";s:37:"HBNPD;PHARTH;EMEALEMB;GRIN;PHAPHY;WEP";}i:216595;a:34:{s:5:"title";s:18:"LGLU_Glutamine, L-";s:3:"nid";s:6:"216595";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"LGLU";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:13:"Glutamine, L-";s:22:"field_monograph_name_f";s:13:"Glutamine, L-";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:98:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_lglutamine-eng.php";s:21:"field_monograph_url_f";s:98:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_lglutamine-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:324:"The medicinal ingredient must be pharmacopoeial grade (for a list of acceptable pharmacopoeia, see the NHPD Evidence for Quality of Finished Natural Health Products Guidance Document) or cited in an approved NHP Master File, authorized by a letter of access issued to the applicant by the NHP Master File's registered owner.";s:21:"field_specification_f";s:481:"L'ingrédient médicinal doit être conforme aux normes des pharmacopées (pour une liste des pharmacopées acceptables, consulter le document de référence de la DPSN des Preuves attestant de l'innocuité et de l'efficacité des produits de santé naturels finis) ou doit faire partie d'un fichier principal de produit de santé naturel (FP-PSN) approuvé par la DPSN. Une lettre d'autorisation d'accès du propriétaire enregistré du FP-PSN doit être fournie par le demandeur.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-02-11";s:16:"field_legacy_nid";s:6:"100903";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_mono_risk";s:13:"LGLU_CW;PREGC";s:21:"field_mono_citation_e";s:84:"ORGLU;PREXEX;GLUDIP;CTM;GLUECI;DRIECF;SALIGA;LGLUMET;GLUGLU;CIDPL;MERCK13;MNHD;TNF25";s:21:"field_mono_citation_f";s:84:"ORGLU;PREXEX;GLUDIP;CTM;GLUECI;DRIECF;SALIGA;LGLUMET;GLUGLU;CIDPL;MERCK13;MNHD;TNF25";s:26:"field_reference_reviewed_e";s:105:"SUPATH;GLUSUP;GASDIS;ASSSAF;DEPR;CONDEAA;GLNM;ABNINT;CIRRHO;GIS;EXCGLU;SEVBP;CPME;SHORT;GASUP;GEIM;ADVESO";s:26:"field_reference_reviewed_f";s:105:"SUPATH;GLUSUP;GASDIS;ASSSAF;DEPR;CONDEAA;GLNM;ABNINT;CIRRHO;GIS;EXCGLU;SEVBP;CPME;SHORT;GASUP;GEIM;ADVESO";}i:216596;a:36:{s:5:"title";s:12:"LIC_Licorice";s:3:"nid";s:6:"216596";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"LIC";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:8:"Licorice";s:22:"field_monograph_name_f";s:9:"Réglisse";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:105:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_licorice-reglisse-eng.php";s:21:"field_monograph_url_f";s:105:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_licorice-reglisse-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:419:"The medicinal ingredient may comply with the specifications outlined in the following pharmacopoeial monographs : (i) Liquorice, Liquorice Root for use in THM, Liquorice Root for use in THMP monographs from British Pharmacopoeia, (ii) Liquorice Root, Liquorice Ethanolic Liquid Extract monographs from European Pharmacopoeia, (iii) Licorice, Powdered Licorice, Powdered Licorice Extract monographs from US Pharmacopoeia";s:21:"field_specification_f";s:432:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes: (i) Liquorice, Liquorice Root for use in THM, Liquorice Root for use in THMP de la Pharmacopé britannique (BP), (ii) Liquorice Root, Liquorice Ethanolic Liquid Extract de la Pharmacopée européenne (Ph. Eur.), (iii) Licorice, Powdered Licorice, Powdered Licorice Extract de la Pharmacopée américaine (USP)";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-02-25";s:16:"field_legacy_nid";s:6:"100904";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:21:"CH4;CH59;AD1014;ADU15";s:15:"field_dose_note";s:24:"FRAD;LIC1;LIC2;ADAD;APP1";s:19:"field_mono_duration";s:6:"LICDUR";s:15:"field_mono_risk";s:41:"PERS;WORS;LIC_CW1;LIC_CW2;LIC_CI1;LIC_CI2";s:21:"field_mono_citation_e";s:94:"EXPCEM;ENHCI;BHCOM;UPHCDI8;ESCOP;KAD;AMODHER;MEDHER;FDREG;BOTSAF;HERCOM;HTCH;HERSAF;PPHPP;GRIN";s:21:"field_mono_citation_f";s:98:"EXPCEM;ENHCI;PMM;BHCOM;UPHCDI8;PHAPHY;ESCOP;KAD;AMODHER;MEDHER;FDREG;BOTSAF;HTCH;HERSAF;PPHPP;GRIN";s:26:"field_reference_reviewed_e";s:6:"HERCDI";s:26:"field_reference_reviewed_f";s:6:"HERCDI";}i:216597;a:35:{s:5:"title";s:24:"LINSL_Linden, Small-leaf";s:3:"nid";s:6:"216597";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"LINSL";s:18:"field_group_name_e";s:6:"Linden";s:18:"field_group_name_f";s:7:"Tilleul";s:22:"field_monograph_name_e";s:18:"Linden, Small-leaf";s:22:"field_monograph_name_f";s:27:"Tilleul à petites feuilles";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:102:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_linden-tilleul-eng.php";s:21:"field_monograph_url_f";s:102:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_linden-tilleul-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-02-13";s:16:"field_legacy_nid";s:6:"100905";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:21:"CH4;CH59;AD1014;ADU15";s:15:"field_dose_note";s:24:"FRAD;LIN1;LIN2;ADAD;APP1";s:15:"field_mono_risk";s:16:"PERS;WORS;LIN_AR";s:21:"field_mono_citation_e";s:86:"BHP2;EXPCEM;ENHCI;BHCOM;AEHD2;KAD;MEDHER;FDREG;HERCOM;HTCH;HERSAF;PPHPP;GRIN;HDPP2;WEP";s:21:"field_mono_citation_f";s:93:"BHP2;EXPCEM;PMM;ENHCI;BHCOM;PHAPHY;AEHD2;KAD;MEDHER;FDREG;MONHER;HTCH;HERSAF;PPHPP;GRIN;HDPP2";s:26:"field_reference_reviewed_e";s:23:"HERMED2;IHNA;BOTSAF;PPP";s:26:"field_reference_reviewed_f";s:23:"HERMED2;IHNA;HERCOM;PPP";}i:216598;a:35:{s:5:"title";s:24:"LINLL_Linden, Large-leaf";s:3:"nid";s:6:"216598";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"LINLL";s:18:"field_group_name_e";s:6:"Linden";s:18:"field_group_name_f";s:7:"Tilleul";s:22:"field_monograph_name_e";s:18:"Linden, Large-leaf";s:22:"field_monograph_name_f";s:27:"Tilleul à grandes feuilles";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:102:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_linden-tilleul-eng.php";s:21:"field_monograph_url_f";s:102:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_linden-tilleul-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-02-13";s:16:"field_legacy_nid";s:6:"100906";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:21:"CH4;CH59;AD1014;ADU15";s:15:"field_dose_note";s:19:"LIN1;LIN2;ADAD;APP1";s:15:"field_mono_risk";s:16:"PERS;WORS;LIN_AR";s:21:"field_mono_citation_e";s:86:"BHP2;EXPCEM;ENHCI;BHCOM;AEHD2;KAD;MEDHER;FDREG;HERCOM;HTCH;HERSAF;PPHPP;GRIN;HDPP2;WEP";s:21:"field_mono_citation_f";s:93:"BHP2;EXPCEM;PMM;ENHCI;BHCOM;PHAPHY;AEHD2;KAD;MEDHER;FDREG;MONHER;HTCH;HERSAF;PPHPP;GRIN;HDPP2";s:26:"field_reference_reviewed_e";s:23:"HERMED2;IHNA;BOTSAF;PPP";s:26:"field_reference_reviewed_f";s:23:"HERMED2;IHNA;HERCOM;PPP";}i:216599;a:35:{s:5:"title";s:22:"LINEU_Linden, European";s:3:"nid";s:6:"216599";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"LINEU";s:18:"field_group_name_e";s:6:"Linden";s:18:"field_group_name_f";s:7:"Tilleul";s:22:"field_monograph_name_e";s:16:"Linden, European";s:22:"field_monograph_name_f";s:16:"Tilleul d'Europe";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:102:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_linden-tilleul-eng.php";s:21:"field_monograph_url_f";s:102:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_linden-tilleul-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:63:"T. x europaea L. is a hybrid of T. cordata and T. platyphyllos.";s:12:"field_note_f";s:65:"T. x europaea L. est un hybride de T. cordata et T. platyphyllos.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-02-13";s:16:"field_legacy_nid";s:6:"100907";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:21:"CH4;CH59;AD1014;ADU15";s:15:"field_dose_note";s:19:"LIN1;LIN2;ADAD;APP1";s:15:"field_mono_risk";s:16:"PERS;WORS;LIN_AR";s:21:"field_mono_citation_e";s:86:"BHP2;EXPCEM;ENHCI;BHCOM;AEHD2;KAD;MEDHER;FDREG;HERCOM;HTCH;HERSAF;PPHPP;GRIN;HDPP2;WEP";s:21:"field_mono_citation_f";s:93:"BHP2;EXPCEM;PMM;ENHCI;BHCOM;PHAPHY;AEHD2;KAD;MEDHER;FDREG;MONHER;HTCH;HERSAF;PPHPP;GRIN;HDPP2";s:26:"field_reference_reviewed_e";s:23:"HERMED2;IHNA;BOTSAF;PPP";s:26:"field_reference_reviewed_f";s:23:"HERMED2;IHNA;HERCOM;PPP";}i:216600;a:35:{s:5:"title";s:16:"LTY_Tyrosine, L-";s:3:"nid";s:6:"216600";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"LTY";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:12:"Tyrosine, L-";s:22:"field_monograph_name_f";s:12:"Tyrosine, L-";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:98:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_l_tyrosine-eng.php";s:21:"field_monograph_url_f";s:98:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_l_tyrosine-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:324:"The medicinal ingredient must be pharmacopoeial grade (for a list of acceptable pharmacopoeia, see the NHPD Evidence for Quality of Finished Natural Health Products Guidance Document) or cited in an approved NHP Master File, authorized by a letter of access issued to the applicant by the NHP Master File's registered owner.";s:21:"field_specification_f";s:481:"L'ingrédient médicinal doit être conforme aux normes des pharmacopées (pour une liste des pharmacopées acceptables, consulter le document de référence de la DPSN des Preuves attestant de l'innocuité et de l'efficacité des produits de santé naturels finis) ou doit faire partie d'un fichier principal de produit de santé naturel (FP-PSN) approuvé par la DPSN. Une lettre d'autorisation d'accès du propriétaire enregistré du FP-PSN doit être fournie par le demandeur.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-03-17";s:16:"field_legacy_nid";s:6:"100908";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:19:"field_mono_duration";s:6:"LTYDUR";s:15:"field_mono_risk";s:12:"PREGC;LTY_CW";s:21:"field_mono_citation_e";s:57:"LBNPS;CTM;TPCP;COLDEXP;EFTYR2;CIDPL;BODCOOL;TYRIMP3;TNF25";s:21:"field_mono_citation_f";s:57:"LBNPS;CTM;TPCP;COLDEXP;EFTYR2;CIDPL;BODCOOL;TYRIMP3;TNF25";s:26:"field_reference_reviewed_e";s:131:"TYRIMP;TRTMNT;DOPBIO;LTCI;DECARB;EFTYR;TYRIMP2;TRTNAR;DRIECF;VASOD;READY;ABSORP;TYRPOT;DRDI;TYRREV;INGTYR;TYRPHAR;PHEN;AMINO;CPMAOI";s:26:"field_reference_reviewed_f";s:131:"TYRIMP;TRTMNT;DOPBIO;LTCI;DECARB;EFTYR;TYRIMP2;TRTNAR;DRIECF;VASOD;READY;ABSORP;TYRPOT;DRDI;TYRREV;INGTYR;TYRPHAR;PHEN;AMINO;CPMAOI";}i:216601;a:36:{s:5:"title";s:21:"LUN_O_Lungwort - Oral";s:3:"nid";s:6:"216601";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"LUN_O";s:18:"field_group_name_e";s:8:"Lungwort";s:18:"field_group_name_f";s:10:"Pulmonaire";s:22:"field_monograph_name_e";s:15:"Lungwort - Oral";s:22:"field_monograph_name_f";s:18:"Pulmonaire - Orale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-04-24";s:16:"field_legacy_nid";s:6:"100909";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:6:"LUNDUR";s:15:"field_mono_risk";s:15:"PREGC;PERS;WORS";s:21:"field_mono_citation_e";s:64:"HBNPD;BHP;HDPP;PATSC;HERBBK;HERCOM;DUSA;MOMMP;GRIN;HDPP2;WEP;PHC";s:21:"field_mono_citation_f";s:68:"PMM;HBNPD;BHP;HDPP;PATSC;HERBBK;DUSA;MOMMP;GRIN;HDPP2;PLATHE;WEP;PHC";s:26:"field_reference_reviewed_e";s:37:"CGCEM;EMP;HANDMH;PDRHM3;BOTSAF;PNCBDP";s:26:"field_reference_reviewed_f";s:37:"CGCEM;EMP;HANDMH;PDRHM3;BOTSAF;PNCBDP";}i:216602;a:36:{s:5:"title";s:24:"LUN_T_Lungwort - Topical";s:3:"nid";s:6:"216602";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"LUN_T";s:18:"field_group_name_e";s:8:"Lungwort";s:18:"field_group_name_f";s:10:"Pulmonaire";s:22:"field_monograph_name_e";s:18:"Lungwort - Topical";s:22:"field_monograph_name_f";s:20:"Pulmonaire - Topique";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:42:"atReq.do?atid=lungwort_pulmonaire&lang=eng";s:21:"field_monograph_url_f";s:42:"atReq.do?atid=lungwort_pulmonaire&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-04-24";s:16:"field_legacy_nid";s:6:"100910";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:9:"PERS;WORS";s:21:"field_mono_citation_e";s:64:"HBNPD;BHP;HDPP;PATSC;HERBBK;HERCOM;DUSA;MOMMP;GRIN;HDPP2;WEP;PHC";s:21:"field_mono_citation_f";s:68:"PMM;HBNPD;BHP;HDPP;PATSC;HERBBK;DUSA;MOMMP;GRIN;HDPP2;PLATHE;WEP;PHC";s:26:"field_reference_reviewed_e";s:37:"CGCEM;EMP;HANDMH;PDRHM3;BOTSAF;PNCBDP";s:26:"field_reference_reviewed_f";s:37:"CGCEM;EMP;HANDMH;PDRHM3;BOTSAF;PNCBDP";}i:216603;a:35:{s:5:"title";s:10:"LYS_Lysine";s:3:"nid";s:6:"216603";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"LYS";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:6:"Lysine";s:22:"field_monograph_name_f";s:6:"Lysine";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:94:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_lysine-eng.php";s:21:"field_monograph_url_f";s:94:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_lysine-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-01-02";s:16:"field_legacy_nid";s:6:"100911";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:19:"field_mono_duration";s:6:"LYSDUR";s:15:"field_mono_risk";s:15:"LYS_CW1;LYS_CW2";s:21:"field_mono_citation_e";s:92:"CTM;HSINF;SUCLT;ANHM;DRIECF;HERP;RECOH;MERCK13;MNHD;FAILRH;MART35;HERP2;TNF25;SUBLYS;CLINEFF";s:21:"field_mono_citation_f";s:92:"CTM;HSINF;SUCLT;ANHM;DRIECF;HERP;RECOH;MERCK13;MNHD;FAILRH;MART35;HERP2;TNF25;SUBLYS;CLINEFF";s:26:"field_reference_reviewed_e";s:208:"CANOLA;CYSFIB;GROWTH;DIET;INTRAP;REVNP;FAILLYS;WALNUTS;METABO;HPGPDS3;LYSCOL;PREG;TNDF;PDRNS;NUTSTA;PHRICE;FANC;PREADO;WILL;EXCESS;CARIO;LYSPRO;FAILLT;MTHWSH;RADIOCS;CALMET;MICROB;TNF;CELLCUL;CAL45;MERCK;LHCC";s:26:"field_reference_reviewed_f";s:208:"CANOLA;CYSFIB;GROWTH;DIET;INTRAP;REVNP;FAILLYS;WALNUTS;METABO;HPGPDS3;LYSCOL;PREG;TNDF;PDRNS;NUTSTA;PHRICE;FANC;PREADO;WILL;EXCESS;CARIO;LYSPRO;FAILLT;MTHWSH;RADIOCS;CALMET;MICROB;TNF;CELLCUL;CAL45;MERCK;LHCC";}i:216604;a:33:{s:5:"title";s:13:"MAG_Magnesium";s:3:"nid";s:6:"216604";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"MAG";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:9:"Magnesium";s:22:"field_monograph_name_f";s:10:"Magnésium";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2007-11-15";s:16:"field_legacy_nid";s:6:"100912";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:26:"ADU;AD1418;AD913;CH48;CH13";s:15:"field_dose_note";s:30:"MAGSPEC;MIN;MAXMAG;ADUL;MAGDEF";s:15:"field_mono_risk";s:6:"MAG_AR";s:21:"field_mono_citation_e";s:98:"THEASTH;CHBSWL;HALF;MMLE;BIOAV;ANHM;DPD;IOMDRI;FCC;DRICP;MAGDIAB;PERDIS;MERCK13;MAGDEF;MNHD;MART35";s:21:"field_mono_citation_f";s:98:"THEASTH;CHBSWL;HALF;MMLE;BIOAV;ANHM;DPD;IOMDRI;FCC;DRICP;MAGDIAB;PERDIS;MERCK13;MAGDEF;MNHD;MART35";}i:216605;a:29:{s:5:"title";s:33:"MSCP_Medicated Skin Care Products";s:3:"nid";s:6:"216605";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"MSCP";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:28:"Medicated Skin Care Products";s:22:"field_monograph_name_f";s:48:"Peau, Produits médicamenteux pour le soin de la";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"C;P";s:21:"field_monograph_url_e";s:32:"atReq.do?atid=skin_peau&lang=eng";s:21:"field_monograph_url_f";s:32:"atReq.do?atid=skin_peau&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:0:"";s:16:"field_legacy_nid";s:6:"100913";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216606;a:36:{s:5:"title";s:22:"MEL_O_Melatonin - Oral";s:3:"nid";s:6:"216606";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"MEL_O";s:18:"field_group_name_e";s:9:"Melatonin";s:18:"field_group_name_f";s:11:"Mélatonine";s:22:"field_monograph_name_e";s:16:"Melatonin - Oral";s:22:"field_monograph_name_f";s:19:"Mélatonine - Orale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:667:"For Melatonin products with a sublingual route of administration, please use the 'Melatonin-Sublingual' monograph.    This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.   Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:789:"Pour les produits de Mélatonine avec une voie d'administration sublinguale, veuillez faire référence à la monographie 'Mélatonine-Sublinguale'.    La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:267:"The medicinal ingredient must comply with the requirements outlined in the Natural Health Products Ingredients Database (NHPID). In addition, the medicinal ingredient may comply with the specifications outlined in the Melatonin monograph of the British Pharmacopoeia.";s:21:"field_specification_f";s:305:"L’ingrédient médicinal doit être conforme aux exigences mentionnées dans la Base de données d’ingrédients de produits de santé naturels (BDIPSN). De plus, l’ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie Melatonin de la pharmacopée britannique.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-05-13";s:16:"field_legacy_nid";s:6:"100914";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:3:"MEL";s:19:"field_mono_duration";s:16:"MEL_DUR;MEL_DUR2";s:15:"field_mono_risk";s:56:"MEL_CW1;MEL_CW2;MEL_CI;MEL_ADR2;MEL_ADR3;MEL_CW3;MEL_CW4";s:21:"field_mono_citation_e";s:405:"MEMCURE;MEL1;MEL10;MEL11;MEL12;MEL13;MEL14;MEL15;MEL16;MEL17;MEL18;MEL19;MEL2;MEL20;MEL21;MEL3;MEL4;MEL5;MEL6;MEL7;MEL8;MEL9;ILLPAT;LOWDOS;GUIDE;EFMEL;EFEXO;MELTRT;INFMEL;NEGEFF;FIBRO;JETLAG;DELAY;PHARTH;SLPDIST;ILLUMI;IMPSQ;REPLAC;MONMEL;NORMAL;SUBJ;CROSS;APPTHE;REDREM;WINTER;DECTOX;CARDIOV;HYPNO;EXOMEL;NHPD;MERCK13;DBJET;LONGHAUL;ENTRAIN;BLIND;MELA;MELIMP;CIRCA;CHILD;OPTMEL;DRIV;MART33;TIMEDEP;AGEREL";s:21:"field_mono_citation_f";s:405:"ILLPAT;LOWDOS;GUIDE;EFMEL;EFEXO;MELTRT;INFMEL;NEGEFF;FIBRO;JETLAG;DELAY;PHARTH;SLPDIST;ILLUMI;IMPSQ;REPLAC;MONMEL;NORMAL;SUBJ;CROSS;APPTHE;REDREM;WINTER;DECTOX;CARDIOV;HYPNO;EXOMEL;NHPD;MERCK13;DBJET;LONGHAUL;ENTRAIN;BLIND;MELA;MELIMP;CIRCA;CHILD;OPTMEL;DRIV;MART33;TIMEDEP;AGEREL;MEMCURE;MEL1;MEL10;MEL11;MEL12;MEL13;MEL14;MEL15;MEL16;MEL17;MEL18;MEL19;MEL2;MEL20;MEL21;MEL3;MEL4;MEL5;MEL6;MEL7;MEL8;MEL9";s:26:"field_reference_reviewed_e";s:484:"ILLPAT;LOWDOS;GUIDE;EFMEL;EFEXO;MELTRT;INFMEL;NEGEFF;FIBRO;JETLAG;DELAY;PHARTH;SLPDIST;ILLUMI;IMPSQ;REPLAC;MONMEL;NORMAL;SUBJ;CROSS;APPTHE;REDREM;WINTER;DECTOX;CARDIOV;HYPNO;EXOMEL;NHPD;MERCK13;DBJET;LONGHAUL;ENTRAIN;BLIND;MELA;MELIMP;CIRCA;CHILD;OPTMEL;DRIV;MART33;TIMEDEP;AGEREL;MEL22;MEL23;MEL24;MEL25;MEL26;MEL27;MEL28;MEL29;MEL30;MEL31;MEL32;MEL33;MEL34;MEL35;MEL36;MEL37;MEL38;MEL39;MEL40;MEL41;MEL42;MEL43;MEL44;MEL45;MEL46;MEL47;MEL48;MEL49;MEL50;MEL51;MEL52;MEL53;MEL54;MEL55";s:26:"field_reference_reviewed_f";s:484:"MEL22;MEL23;MEL24;MEL25;MEL26;MEL27;MEL28;MEL29;MEL30;MEL31;MEL32;MEL33;MEL34;MEL35;MEL36;MEL37;MEL38;MEL39;MEL40;MEL41;MEL42;MEL43;MEL44;MEL45;MEL46;MEL47;MEL48;MEL49;MEL50;MEL51;MEL52;MEL53;MEL54;MEL55;ILLPAT;LOWDOS;GUIDE;EFMEL;EFEXO;MELTRT;INFMEL;NEGEFF;FIBRO;JETLAG;DELAY;PHARTH;SLPDIST;ILLUMI;IMPSQ;REPLAC;MONMEL;NORMAL;SUBJ;CROSS;APPTHE;REDREM;WINTER;DECTOX;CARDIOV;HYPNO;EXOMEL;NHPD;MERCK13;DBJET;LONGHAUL;ENTRAIN;BLIND;MELA;MELIMP;CIRCA;CHILD;OPTMEL;DRIV;MART33;TIMEDEP;AGEREL";}i:216607;a:36:{s:5:"title";s:28:"MEL_S_Melatonin - Sublingual";s:3:"nid";s:6:"216607";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"MEL_S";s:18:"field_group_name_e";s:9:"Melatonin";s:18:"field_group_name_f";s:11:"Mélatonine";s:22:"field_monograph_name_e";s:22:"Melatonin - Sublingual";s:22:"field_monograph_name_f";s:25:"Mélatonine - Sublinguale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:669:"For Melatonin products with an oral route of administration, please use the 'Melatonin-Oral' monograph.   This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.   Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:779:"Pour les produits de Mélatonine avec une voie d'administration orale, veuillez faire référence à la monographie 'Mélatonine-Orale'.   La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal.  Nota: (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:267:"The medicinal ingredient must comply with the requirements outlined in the Natural Health Products Ingredients Database (NHPID). In addition, the medicinal ingredient may comply with the specifications outlined in the Melatonin monograph of the British Pharmacopoeia.";s:21:"field_specification_f";s:305:"L’ingrédient médicinal doit être conforme aux exigences mentionnées dans la Base de données d’ingrédients de produits de santé naturels (BDIPSN). De plus, l’ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie Melatonin de la pharmacopée britannique.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-05-14";s:16:"field_legacy_nid";s:6:"100915";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:3:"MEL";s:19:"field_mono_duration";s:16:"MEL_DUR;MEL_DUR2";s:15:"field_mono_risk";s:56:"MEL_CW1;MEL_CW2;MEL_CI;MEL_CW3;MEL_CW4;MEL_ADR2;MEL_ADR3";s:21:"field_mono_citation_e";s:370:"ILLPAT;MEL1;LOWDOS;GUIDE;MEL2;EFMEL;EFEXO;MELTRT;INFMEL;MEL3;MEL4;NEGEFF;MEL5;FIBRO;JETLAG;DELAY;MEL6;PHARTH;SLPDIST;ILLUMI;MEL7;IMPSQ;REPLAC;MEL8;MEL9;MEL10;MONMEL;NORMAL;SUBJ;CROSS;APPTHE;REDREM;WINTER;DECTOX;CARDIOV;MEL11;MEL12;HYPNO;MEL13;MEL14;MEL15;DBJET;LONGHAUL;ENTRAIN;BLIND;MELA;MEL16;MELIMP;MEL17;CIRCA;CHILD;OPTMEL;DRIV;MEL18;MEL19;TIMEDEP;MEL20;MEL21;AGEREL";s:21:"field_mono_citation_f";s:335:"ILLPAT;LOWDOS;GUIDE;EFMEL;EFEXO;MELTRT;INFMEL;NEGEFF;FIBRO;JETLAG;DELAY;PHARTH;SLPDIST;ILLUMI;IMPSQ;REPLAC;MONMEL;NORMAL;SUBJ;CROSS;APPTHE;REDREM;WINTER;DECTOX;CARDIOV;HYPNO;DBJET;LONGHAUL;ENTRAIN;BLIND;MELA;MELIMP;CIRCA;CHILD;OPTMEL;DRIV;TIMEDEP;AGEREL;MEL1;MEL10;MEL11;MEL12;MEL13;MEL14;MEL15;MEL16;MEL17;MEL18;MEL19;MEL2;MEL20;MEL21";s:26:"field_reference_reviewed_e";s:222:"MEL22;MEL23;MEL24;MEL25;MEL26;MEL27;MEL28;MEL29;MEL30;MEL31;MEL32;MEL33;MEL34;MEL35;MEL36;MEL37;MEL38;MEL39;MEL40;MEL41;MEL42;MEL43;MEL44;MEL45;MEL46;MEL47;MEL48;MEL49;MEL50;MEL51;MEL52;MEL53;MEL54;MEL55;EFEXO;FIBRO;EXOMEL";s:26:"field_reference_reviewed_f";s:222:"MEL22;MEL23;MEL24;MEL25;MEL26;MEL27;MEL28;MEL29;MEL30;MEL31;MEL32;MEL33;MEL34;MEL35;MEL36;MEL37;MEL38;MEL39;MEL40;MEL41;MEL42;MEL43;MEL44;MEL45;MEL46;MEL47;MEL48;MEL49;MEL50;MEL51;MEL52;MEL53;MEL54;MEL55;EFEXO;FIBRO;EXOMEL";}i:216608;a:37:{s:5:"title";s:16:"MIT_Milk Thistle";s:3:"nid";s:6:"216608";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"MIT";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:12:"Milk Thistle";s:22:"field_monograph_name_f";s:13:"Chardon-Marie";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:40:"atReq.do?atid=milk.thistle.oral&lang=eng";s:21:"field_monograph_url_f";s:40:"atReq.do?atid=milk.thistle.oral&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:718:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.     Note: (i) Text in parentheses is additional optional information which can be included on the Product Licence Application and product labels at the applicants’ discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant. (ii) Claims for traditional use must include the term “Herbal Medicine”.";s:12:"field_note_f";s:910:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient (ou des ingrédients) médicinal (médicinaux). La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.     Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués. (ii) Les allégations relatives à l’utilisation traditionnelle doivent inclure les termes « en phytothérapie ».";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:439:"The medicinal ingredient may comply with the specifications outlined in the following pharmacopoeial monographs : (i) 'Milk-thistle Fruit' of the British Pharmacopoeia, (ii) 'Milk-Thistle Fruit', 'Milk Thistle Dry Extract, Refined and Standardised' from the European Pharmacopoeia, or (iii) 'Milk Thistle', "Powdered Milk Thistle', 'Powdered Milk Thistle Extract', 'Milk Thistle Capsules', 'Milk Thistle Tablets' from the US Pharmacopoeia.";s:21:"field_specification_f";s:454:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes: (i) 'Milk-thistle Fruit' de la Pharmacopée britannique, (ii) 'Milk-Thistle Fruit', 'Milk Thistle Dry Extract, Refined and Standardised' de la Pharmacopée européenne, ou (iii) 'Milk Thistle', "Powdered Milk Thistle', 'Powdered Milk Thistle Extract', 'Milk Thistle Capsules', 'Milk Thistle Tablets' de la Pharmacopée américaine.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-06-19";s:16:"field_legacy_nid";s:6:"100916";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:6:"MT_DUR";s:15:"field_mono_risk";s:21:"PERS;WORS;MT_CW;MT_AR";s:21:"field_mono_citation_e";s:140:"HERMED2;ABC;EXPCEM;BHCOM2;UPHCDI;THEPHA;LIVPRO;KAD;THELD;ANAPHY;MEDHER;VIRHEP;HERCOM;HMPL;EBHM;HERSAF;PPP;URTICA;EFFSIL;GRIN;CIRRH;PHC;PCBDP";s:21:"field_mono_citation_f";s:150:"HERMED2;ABC;EXPCEM;BHCOM2;UPHCDI;FLORE;THEPHA;LIVPRO;KAD;THELD;ANAPHY;MEDHER;VIRHEP;HMPL;EBHM;HERSAF;PPP;URTICA;EFFSIL;GRIN;CIRRH;PLATHE;WEP;PHC;PCBDP";s:26:"field_reference_reviewed_e";s:211:"ADRMT;HERMED;BEHM;BHP2;BPH8;MTTLD;HERCDI;ALCLD;HERBS;SRSM;SODAP;PATCIR;PHCAM;AMODHER;SCILFT;MZ80;BOTSAF;DMH;ALCPAT;EP8;HEPBC;HYPERLP;CHRHEPC;LEGALON;EGYVIL;ROMANIAN;HEART;TTCHHC;116PAT;TNF26;EXACER;CMCROP;PNCBDP";s:26:"field_reference_reviewed_f";s:211:"ADRMT;HERMED;BEHM;BHP2;BPH8;MTTLD;HERCDI;ALCLD;HERBS;SRSM;SODAP;PATCIR;PHCAM;AMODHER;SCILFT;MZ80;BOTSAF;DMH;ALCPAT;EP8;HEPBC;HYPERLP;CHRHEPC;LEGALON;EGYVIL;ROMANIAN;HEART;TTCHHC;116PAT;TNF26;EXACER;CMCROP;PNCBDP";}i:216609;a:35:{s:5:"title";s:7:"MSM_MSM";s:3:"nid";s:6:"216609";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"MSM";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:3:"MSM";s:22:"field_monograph_name_f";s:3:"MSM";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:91:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_msm-eng.php";s:21:"field_monograph_url_f";s:91:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_msm-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:153:"The medicinal ingredient may comply with the specifications outlined in the Methylsulfonylmethane Monograph published in the United States Pharmacopoeia.";s:21:"field_specification_f";s:166:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie Methylsulfonylmethane publiée dans la Pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-06-26";s:16:"field_legacy_nid";s:6:"100917";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:19:"field_mono_duration";s:7:"MSM_DUR";s:15:"field_mono_risk";s:18:"PREGC;WORS;MSM_ADR";s:21:"field_mono_citation_e";s:29:"CHEMIDP;EFFMSM;MERCK13;RDBPPC";s:21:"field_mono_citation_f";s:29:"CHEMIDP;EFFMSM;MERCK13;RDBPPC";s:26:"field_reference_reviewed_e";s:30:"DCCTP;TOXMSM;ACCMSM;35SMSM;HAP";s:26:"field_reference_reviewed_f";s:30:"DCCTP;TOXMSM;ACCMSM;35SMSM;HAP";}i:216610;a:35:{s:5:"title";s:11:"MUG_Mugwort";s:3:"nid";s:6:"216610";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"MUG";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:7:"Mugwort";s:22:"field_monograph_name_f";s:15:"Armoise commune";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:110:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_mugwort-armoisecommune-eng.php";s:21:"field_monograph_url_f";s:110:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_mugwort-armoisecommune-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-01-15";s:16:"field_legacy_nid";s:6:"100918";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:32:"PERS;WORS;MUG_CI1;MUG_CI2;MUG_AR";s:21:"field_mono_citation_e";s:59:"CGCEM;BHCOM2;HERCDI;AMODHER;MEDHER;HERCOM;GRIN;HDPP2;PNCBDP";s:21:"field_mono_citation_f";s:69:"CGCEM;PMM;BHCOM2;HERCDI;FLORE;AMODHER;MEDHER;HERCOM;GRIN;HDPP2;PNCBDP";s:26:"field_reference_reviewed_e";s:60:"BEHM;BHP;BOTPHA;HANDMH;PDRHM;6YEAR;HUMSER;EXTINT;DANISH;PGNM";s:26:"field_reference_reviewed_f";s:60:"BEHM;BHP;BOTPHA;HANDMH;PDRHM;6YEAR;HUMSER;EXTINT;DANISH;PGNM";}i:216611;a:33:{s:5:"title";s:10:"NIA_Niacin";s:3:"nid";s:6:"216611";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"NIA";s:18:"field_group_name_e";s:6:"Niacin";s:18:"field_group_name_f";s:7:"Niacine";s:22:"field_monograph_name_e";s:6:"Niacin";s:22:"field_monograph_name_f";s:7:"Niacine";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:92:"For products containing Nicotinamide/Niacinamide, please refer to the Niacinamide monograph.";s:12:"field_note_f";s:123:"Pour les produits contenant de la Nicotinamide/Niacinamide, veuillez faire référence à la monographie de la Niacinamide.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-12-23";s:16:"field_legacy_nid";s:6:"100919";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:26:"ADU;AD1418;AD913;CH48;CH13";s:15:"field_dose_note";s:20:"NIA;MIN2;MAXNIA;ADUL";s:15:"field_mono_risk";s:11:"NIACI;NIAAR";s:21:"field_mono_citation_e";s:88:"OPNIA;SULVM;ANHM;NHPDEAC4;IOMDRI;FCC;DRITR;SAFNIA;MERCK13;MNHD;MART35;TNF27;CHEMIDP;BPH8";s:21:"field_mono_citation_f";s:88:"OPNIA;SULVM;ANHM;NHPDEAC4;IOMDRI;FCC;DRITR;SAFNIA;MERCK13;MNHD;MART35;TNF27;CHEMIDP;BPH8";}i:216612;a:32:{s:5:"title";s:16:"NIA2_Niacinamide";s:3:"nid";s:6:"216612";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"NIA2";s:18:"field_group_name_e";s:6:"Niacin";s:18:"field_group_name_f";s:7:"Niacine";s:22:"field_monograph_name_e";s:11:"Niacinamide";s:22:"field_monograph_name_f";s:11:"Niacinamide";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:77:"For products containing Nicotinic acid, please refer to the Niacin monograph.";s:12:"field_note_f";s:111:"Pour les produits contenant de l'Acide nicotinique, veuillez faire référence à la monographie de la Niacine.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-12-23";s:16:"field_legacy_nid";s:6:"100920";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:26:"ADU;AD1418;AD913;CH48;CH13";s:15:"field_dose_note";s:21:"NIA2;MIN2;MAXNIA;ADUL";s:21:"field_mono_citation_e";s:88:"OPNIA;SULVM;ANHM;NHPDEAC4;IOMDRI;FCC;DRITR;SAFNIA;MERCK13;MNHD;MART35;TNF27;CHEMIDP;BPH8";s:21:"field_mono_citation_f";s:88:"OPNIA;SULVM;ANHM;NHPDEAC4;IOMDRI;FCC;DRITR;SAFNIA;MERCK13;MNHD;MART35;TNF27;CHEMIDP;BPH8";}i:216613;a:32:{s:5:"title";s:20:"PAA_Pantothenic Acid";s:3:"nid";s:6:"216613";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"PAA";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:16:"Pantothenic Acid";s:22:"field_monograph_name_f";s:21:"Pantothénique, Acide";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:99:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_pantothenic-eng.php";s:21:"field_monograph_url_f";s:99:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_pantothenic-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2007-08-16";s:16:"field_legacy_nid";s:6:"100921";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:12:"ADU14;CH1_13";s:15:"field_dose_note";s:23:"MIN2;MAXPAA;ADUL;CONPAA";s:21:"field_mono_citation_e";s:56:"ANHM;NHPDEAC6;IOMDRI;FCC;DRITR;MERCK13;MNHD;MART35;TNF25";s:21:"field_mono_citation_f";s:56:"ANHM;NHPDEAC6;IOMDRI;FCC;DRITR;MERCK13;MNHD;MART35;TNF25";}i:216614;a:33:{s:5:"title";s:14:"PEP_Peppermint";s:3:"nid";s:6:"216614";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"PEP";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:10:"Peppermint";s:22:"field_monograph_name_f";s:15:"Menthe poivrée";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:112:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_peppermint-menthepoivree-eng.php";s:21:"field_monograph_url_f";s:112:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_peppermint-menthepoivree-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:292:"The medicinal ingredient may comply with the specifications outlined in the Peppermint, Peppermint Oil, Peppermint Spirit, or Peppermint Water Monographs published in the US Pharmacopoeia or the Peppermint Leaf or Peppermint Oil Monographs published in the European or British Pharmacopoeias.";s:21:"field_specification_f";s:375:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies suivantes publiées dans la Pharmacopée américaine (USP) : Peppermint, Peppermint Oil, Peppermint Spirit ou Peppermint Water, ou dans les monographies suivantes publiées dans les Pharmacopées européenne (Ph. Eur.) ou britannique (BP) : Peppermint Leaf ou Peppermint Oil.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-02-20";s:16:"field_legacy_nid";s:6:"100922";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:22:"CH24;CH59;AD1014;ADU15";s:15:"field_dose_note";s:24:"FRAD;PEP1;PEP2;PEP3;APP1";s:15:"field_mono_risk";s:57:"PERS;WORS;PEP_CW1;PEP_CW2;PEP_CW3;PEP_CW4;PEP_AR1;PEP_AR2";s:21:"field_mono_citation_e";s:86:"EXPCEM;50COM;ENHCI;BHCOM;HERCDI;UPHCDI7;ESCOP;KAD;MEDHER;FDREG;HERCOM;HTCH;HERSAF;GRIN";s:21:"field_mono_citation_f";s:90:"EXPCEM;50COM;ENHCI;BHCOM;HERCDI;UPHCDI7;PHAPHY;ESCOP;KAD;MEDHER;FDREG;HTCH;HERSAF;GRIN;WEP";}i:216615;a:35:{s:5:"title";s:17:"PFL_Passionflower";s:3:"nid";s:6:"216615";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"PFL";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:13:"Passionflower";s:22:"field_monograph_name_f";s:10:"Passiflore";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:112:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_passionflower_passiflore-eng.php";s:21:"field_monograph_url_f";s:112:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_passionflower_passiflore-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:157:"The medicinal ingredient may comply with the specifications outlined in the Passion Flower Monograph published in the British or the European Pharmacopoeias.";s:21:"field_specification_f";s:186:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie Passion Flower publiée dans les Pharmacopées britannique (BP) ou européenne (Ph. Eur.).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-03-20";s:16:"field_legacy_nid";s:6:"100923";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:5:"ADU13";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:49:"PERS;WORS;PFL_CW1;PFL_CW2;PFL_CW3;PFL_AR1;PFL_AR2";s:21:"field_mono_citation_e";s:33:"HBNPD;UPHCDI8;PHARTH;EMEAPFL;GRIN";s:21:"field_mono_citation_f";s:62:"HBNPD;PMM;UPHCDI8;PHAPHY;PHARTH;EMEAPFL;MMPND3;GRIN;PLATHE;WEP";s:26:"field_reference_reviewed_e";s:5:"ESCOP";s:26:"field_reference_reviewed_f";s:5:"ESCOP";}i:216616;a:36:{s:5:"title";s:18:"PGI_Ginseng, Panax";s:3:"nid";s:6:"216616";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"PGI";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:14:"Ginseng, Panax";s:22:"field_monograph_name_f";s:14:"Ginseng, Panax";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:101:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_panax_ginseng-eng.php";s:21:"field_monograph_url_f";s:101:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_panax_ginseng-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:737:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.      Note: (i) Text in parentheses is additional optional information which can be included on the Product Licence Application and product labels at the applicants’ discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.  (ii) Claims for traditional use (other than TCM) must include the term “Herbal Medicine”.";s:12:"field_note_f";s:918:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.      Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.  (ii) Les allégations relatives à l’utilisation traditionnelle doivent inclure les termes « en phytothérapie/herboristerie », sauf dans le cas de la MTC.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:335:"The medicinal ingredient may comply with the specifications outlined in the following pharmacopoeial monographs:  'Ginseng' iin the British Pharmacopoeia, 'Ginseng' in the European Pharmacopoeia as well as 'Asian Ginseng', 'Powdered Asian Ginseng', 'Powdered Asian Ginseng Extract' or 'Asian Ginseng Tablets' in the U.S. Pharmacopoeia.";s:21:"field_specification_f";s:377:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes:  'Ginseng' de la pharmacopée britannique (BP), 'Ginseng' de la pharmacopée européenne (Ph. Eur.), de même que 'Asian Ginseng', 'Powdered Asian Ginseng', 'Powdered Asian Ginseng Extract' ou 'Asian Ginseng Tablets' de la pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-11-04";s:16:"field_legacy_nid";s:6:"100924";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:5:"PGDUR";s:15:"field_mono_risk";s:39:"PG_CW1;PG_CW2;PG_CW3;PG_CW4;PG_CI;PG_AR";s:21:"field_mono_citation_e";s:380:"PEAK;CHMMM;BHP;BPH8;EXPCEM;BHCOM;UPHCDI;GCPD;PGSYSREV;PSYCHOM;BISANA;KRGED;PGQUAL;INTEXE;SUPRA;WRKPRF;NOERG;ESCOP;MANIC;G115;KRGADJ;MEDHER;WARGIN;PHENELZ;ICPHV;MODCOG;DDCCP;EXIND;WARPG;PGECP;BOTSAF;HERCOM;HERSAF;LMPC;EP8;CCMM2;PPRC97;PGGLUC;POTVAC;ALVEOL;2EXTPG;CHRBRON;SPORTIF;GBPG;SEPGPL;BGMR;DREAM;GASPP;PPGLYC;HPLCPG;DMSEGCF;GTNIDDP;400MGPG;GRIN;TNF27;GLINREG;WHOMON;PHC;PCBDP";s:21:"field_mono_citation_f";s:377:"PEAK;CHMMM;BHP;BPH8;EXPCEM;BHCOM;UPHCDI;GCPD;PGSYSREV;PSYCHOM;BISANA;KRGED;PGQUAL;INTEXE;SUPRA;WRKPRF;NOERG;ESCOP;MANIC;G115;KRGADJ;MEDHER;WARGIN;PHENELZ;ICPHV;MODCOG;DDCCP;EXIND;WARPG;PGECP;BOTSAF;HERSAF;PPS;LMPC;EP8;CCMM2;PPRC97;PGGLUC;POTVAC;ALVEOL;2EXTPG;CHRBRON;SPORTIF;GBPG;SEPGPL;BGMR;DREAM;GASPP;PPGLYC;HPLCPG;DMSEGCF;GTNIDDP;400MGPG;GRIN;TNF27;GLINREG;WHOMON;PHC;PCBDP";s:26:"field_reference_reviewed_e";s:605:"HICD;COMMANIC;EEPGU;EEPG;BEHM;BHP2;ABC;ENHCI2;BHCOM2;SHHEP;SREGCRF;PSYWB;EASG;ZIDOVU;SSPENO;CEKRGED;GCSJS;EPGQL;GES;TCMTD;GCSJS2;GINMAST;THEPHA;GIMANIA;GCSJS3;ECMM;KAD;PHSATH;PWRKCAP;GONADAL;TOPSP;DURG115;ESPG;NITRIC;AMODHER;COPD;NURSES;CADRMP;KRGEDPR;CPHM;RGTED;PPPMA;SJWGIN;MYSEFF;ROUJIN;GINING;GPECPM;EEESD;SUNGIN;UNSAFE;ECGS;LACTATE;ECCEN;INSAM;EPGBACM;OLIGO;HERBBK;BIOMAR;PPP;HMPL;NAE;GSBNO;APHROD;GINMAST2;MEMENHA;ROOTS;GLYCAE;GLUREG;GACA;EPGSMF;PPHPP;DFMM;8POPGIN;DOSEESC;ISGIN;LEULYM;HPLCSEP;CD4T;REDGIN;BOUTS;HEART;CLIMSYN;HBO2;AIM;EFFGIN;HERMEDI;WHOMON3;WHOMON2;WEP;PNCBDP;PDCM;SRHDS;HCHF;GRADED";s:26:"field_reference_reviewed_f";s:605:"HICD;COMMANIC;EEPGU;EEPG;BEHM;BHP2;ABC;ENHCI2;BHCOM2;SHHEP;SREGCRF;PSYWB;EASG;ZIDOVU;SSPENO;CEKRGED;GCSJS;EPGQL;GES;TCMTD;GCSJS2;GINMAST;THEPHA;GIMANIA;GCSJS3;ECMM;KAD;PHSATH;PWRKCAP;GONADAL;TOPSP;DURG115;ESPG;NITRIC;AMODHER;COPD;NURSES;CADRMP;KRGEDPR;CPHM;RGTED;PPPMA;SJWGIN;MYSEFF;ROUJIN;GINING;GPECPM;EEESD;SUNGIN;UNSAFE;ECGS;LACTATE;ECCEN;INSAM;EPGBACM;OLIGO;HERBBK;BIOMAR;PPP;HMPL;NAE;GSBNO;APHROD;GINMAST2;MEMENHA;ROOTS;GLYCAE;GLUREG;GACA;EPGSMF;PPHPP;DFMM;8POPGIN;DOSEESC;ISGIN;LEULYM;HPLCSEP;CD4T;REDGIN;BOUTS;HEART;CLIMSYN;HBO2;AIM;EFFGIN;HERMEDI;WHOMON3;WHOMON2;WEP;PNCBDP;PDCM;SRHDS;HCHF;GRADED";}i:216617;a:36:{s:5:"title";s:24:"PRO_T_Propolis - Topical";s:3:"nid";s:6:"216617";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"PRO_T";s:18:"field_group_name_e";s:8:"Propolis";s:18:"field_group_name_f";s:8:"Propolis";s:22:"field_monograph_name_e";s:18:"Propolis - Topical";s:22:"field_monograph_name_f";s:18:"Propolis - Topique";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:35:"atReq.do?atid=propolis_top&lang=eng";s:21:"field_monograph_url_f";s:35:"atReq.do?atid=propolis_top&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:466:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.   Notes: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion.";s:12:"field_note_f";s:622:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.   Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:162:"The medicinal ingredient may comply with the specifications outlined in the Propolis monograph published in the Pharmacopoeia of the People’s Republic of China.";s:21:"field_specification_f";s:174:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie Propolis publiée dans la Pharmacopée de la République Populaire de Chine.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-07-31";s:16:"field_legacy_nid";s:6:"100926";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:19:"field_mono_duration";s:6:"PRODUR";s:15:"field_mono_risk";s:24:"PRO_CW1;PERS;WORS;PRO_AR";s:21:"field_mono_citation_e";s:141:"HERCDI;OLDREM;11DIME;EDEMA;SCAVEN;PROPSUP;KAINITE;BABPHD;605CON;CCBPTA;OCCDER;PPP;PGNM;CCMM2;DERPRO;BRAZPRO;APHTH;BACKGR;GRANUL;HEART;DERMPRO";s:21:"field_mono_citation_f";s:141:"HERCDI;OLDREM;11DIME;EDEMA;SCAVEN;PROPSUP;KAINITE;BABPHD;605CON;CCBPTA;OCCDER;PPP;PGNM;CCMM2;DERPRO;BRAZPRO;APHTH;BACKGR;GRANUL;HEART;DERMPRO";s:26:"field_reference_reviewed_e";s:201:"PRORES;SILICAT;RBPTBP;GRNPRO;PYLORI;NIVCRI;AQUPRO;INRATS;FREEAA;CHRYSIN;ADJUV;PROREV;SULFAD;1255CH;VAGIN;ITIS;RINSE;VAP;PROFOOD;SULCO;ADRPRO;EICOPR;NOVOPL;BEEPROD;NMCD;NMQS;PPS;CANDID;IMMUNE;FPHPRJ;HSV";s:26:"field_reference_reviewed_f";s:201:"PRORES;SILICAT;RBPTBP;GRNPRO;PYLORI;NIVCRI;AQUPRO;INRATS;FREEAA;CHRYSIN;ADJUV;PROREV;SULFAD;1255CH;VAGIN;ITIS;RINSE;VAP;PROFOOD;SULCO;ADRPRO;EICOPR;NOVOPL;BEEPROD;NMCD;NMQS;PPS;CANDID;IMMUNE;FPHPRJ;HSV";}i:216618;a:36:{s:5:"title";s:23:"PRO_B_Propolis - Buccal";s:3:"nid";s:6:"216618";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"PRO_B";s:18:"field_group_name_e";s:8:"Propolis";s:18:"field_group_name_f";s:8:"Propolis";s:22:"field_monograph_name_e";s:17:"Propolis - Buccal";s:22:"field_monograph_name_f";s:18:"Propolis - Buccale";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:35:"atReq.do?atid=propolis_buc&lang=eng";s:21:"field_monograph_url_f";s:35:"atReq.do?atid=propolis_buc&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:466:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.   Notes: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion.";s:12:"field_note_f";s:622:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.   Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:162:"The medicinal ingredient may comply with the specifications outlined in the Propolis monograph published in the Pharmacopoeia of the People’s Republic of China.";s:21:"field_specification_f";s:174:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie Propolis publiée dans la Pharmacopée de la République Populaire de Chine.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-07-31";s:16:"field_legacy_nid";s:6:"100927";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:19:"field_mono_duration";s:6:"PRODUR";s:15:"field_mono_risk";s:32:"PRO_CW1;PERS;WORS;PRO_CW3;PRO_AR";s:21:"field_mono_citation_e";s:141:"HERCDI;OLDREM;11DIME;EDEMA;SCAVEN;PROPSUP;KAINITE;BABPHD;605CON;CCBPTA;OCCDER;PPP;PGNM;CCMM2;DERPRO;BRAZPRO;APHTH;BACKGR;GRANUL;HEART;DERMPRO";s:21:"field_mono_citation_f";s:141:"HERCDI;OLDREM;11DIME;EDEMA;SCAVEN;PROPSUP;KAINITE;BABPHD;605CON;CCBPTA;OCCDER;PPP;PGNM;CCMM2;DERPRO;BRAZPRO;APHTH;BACKGR;GRANUL;HEART;DERMPRO";s:26:"field_reference_reviewed_e";s:201:"PRORES;SILICAT;RBPTBP;GRNPRO;PYLORI;NIVCRI;AQUPRO;INRATS;FREEAA;CHRYSIN;ADJUV;PROREV;SULFAD;1255CH;VAGIN;ITIS;RINSE;VAP;PROFOOD;SULCO;ADRPRO;EICOPR;NOVOPL;BEEPROD;NMCD;NMQS;PPS;CANDID;IMMUNE;FPHPRJ;HSV";s:26:"field_reference_reviewed_f";s:201:"PRORES;SILICAT;RBPTBP;GRNPRO;PYLORI;NIVCRI;AQUPRO;INRATS;FREEAA;CHRYSIN;ADJUV;PROREV;SULFAD;1255CH;VAGIN;ITIS;RINSE;VAP;PROFOOD;SULCO;ADRPRO;EICOPR;NOVOPL;BEEPROD;NMCD;NMQS;PPS;CANDID;IMMUNE;FPHPRJ;HSV";}i:216619;a:35:{s:5:"title";s:31:"PSY_AF_Psyllium - Plantago afra";s:3:"nid";s:6:"216619";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"PSY_AF";s:18:"field_group_name_e";s:8:"Psyllium";s:18:"field_group_name_f";s:8:"Psyllium";s:22:"field_monograph_name_e";s:24:"Psyllium - Plantago afra";s:22:"field_monograph_name_f";s:24:"Psyllium - Plantago afra";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:96:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_psyllium-eng.php";s:21:"field_monograph_url_f";s:96:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_psyllium-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:465:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.  Notes: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion.";s:12:"field_note_f";s:621:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.  Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:400:"The medicinal ingredient may comply with the specifications outlined in one of the following pharmacopoeial monographs:  'Psyllium Seed' or 'Ispaghula Seed' monograph in British Pharmacopoeia, 'Psyllium Seed' or 'Ispaghula Seed' monograph in European Pharmacopoeia, and 'Plantago Seed' or 'Psyllium Hydrophilic Mucilloid for Oral Suspension' or 'Psyllium Hemicellulose' monograph in US Pharamcopoeia.";s:21:"field_specification_f";s:414:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes:   'Psyllium Seed' ou 'Ispaghula Seed' de la Pharmacopée britannique (BP), 'Psyllium Seed' ou 'Ispaghula Seed' de la Pharmacopée européenne (Ph. Eur.) et 'Plantago Seed' ou 'Psyllium Hydrophilic Mucilloid for Oral Suspension' ou 'Psyllium Hemicellulose' de la Pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-06-18";s:16:"field_legacy_nid";s:6:"100928";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:12:"CH6_12;ADU13";s:15:"field_dose_note";s:11:"PSYSED;APP1";s:15:"field_mono_risk";s:71:"PSY_CW1;PSY_CW2;PSY_CW3;PSY_CW4;PSY_CI1;PSY_CI2;PSY_CI3;PSY_AR1;PSY_AR2";s:21:"field_mono_citation_e";s:97:"EXPCEM;BHCOM;HMPAPI;HMPOT;HMPO;ESCOP;LDPOTC;REMI;HERCOM;NPPT;PATSC;MART35;GRIN;WHOMON3;WHOMON;PHC";s:21:"field_mono_citation_f";s:97:"EXPCEM;BHCOM;PHAPHY;HMPAPI;HMPOT;HMPO;ESCOP;LDPOTC;REMI;NPPT;PATSC;MART35;GRIN;WHOMON3;WHOMON;PHC";s:26:"field_reference_reviewed_e";s:79:"CONSTIP;HBNPD;BHP;BPH8;MECHCP;BFLAX;GENLAX;LEVOTHY;DIGEST;SUPDS;EP8;TNF27;HDPP2";s:26:"field_reference_reviewed_f";s:79:"CONSTIP;HBNPD;BHP;BPH8;MECHCP;BFLAX;GENLAX;LEVOTHY;DIGEST;SUPDS;EP8;TNF27;HDPP2";}i:216620;a:35:{s:5:"title";s:35:"PSY_AR_Psyllium - Plantago arenaria";s:3:"nid";s:6:"216620";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"PSY_AR";s:18:"field_group_name_e";s:8:"Psyllium";s:18:"field_group_name_f";s:8:"Psyllium";s:22:"field_monograph_name_e";s:28:"Psyllium - Plantago arenaria";s:22:"field_monograph_name_f";s:28:"Psyllium - Plantago arenaria";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:96:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_psyllium-eng.php";s:21:"field_monograph_url_f";s:96:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_psyllium-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:468:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.     Notes: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion.";s:12:"field_note_f";s:625:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.      Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:459:"The medicinal ingredient may comply with the specifications outlined in one of the following pharmacopoeial monographs:  'Psyllium Seed' or 'Ispaghula Seed' or 'Ispaghula Husk' monograph in British Pharmacopoeia, 'Psyllium Seed' or 'Ispaghula Seed' or 'Ispaghula Husk' monograph in European Pharmacopoeia, and 'Plantago Seed' or 'Psyllium Husk' or 'Psyllium Hydrophilic Mucilloid for Oral Suspension' or 'Psyllium Hemicellulose' monograph in US Pharamcopoeia.";s:21:"field_specification_f";s:474:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes:   'Psyllium Seed' ou 'Ispaghula Seed' ou 'Ispaghula Husk'  de la Pharmacopée britannique (BP), 'Psyllium Seed' ou 'Ispaghula Seed' ou 'Ispaghula Husk' de la Pharmacopée européenne (Ph. Eur.) et 'Plantago Seed' ou 'Psyllium Husk' ou 'Psyllium Hydrophilic Mucilloid for Oral Suspension' ou 'Psyllium Hemicellulose' de la Pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-02-18";s:16:"field_legacy_nid";s:6:"100929";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:12:"CH6_12;ADU13";s:15:"field_dose_note";s:18:"PSYSED;PSYHSK;APP1";s:15:"field_mono_risk";s:71:"PSY_CW1;PSY_CW2;PSY_CW3;PSY_CW4;PSY_CI1;PSY_CI2;PSY_CI3;PSY_AR1;PSY_AR2";s:21:"field_mono_citation_e";s:97:"EXPCEM;BHCOM;HMPAPI;HMPOT;HMPO;ESCOP;LDPOTC;REMI;HERCOM;NPPT;PATSC;MART35;GRIN;WHOMON3;WHOMON;PHC";s:21:"field_mono_citation_f";s:97:"EXPCEM;BHCOM;PHAPHY;HMPAPI;HMPOT;HMPO;ESCOP;LDPOTC;REMI;NPPT;PATSC;MART35;GRIN;WHOMON3;WHOMON;PHC";s:26:"field_reference_reviewed_e";s:79:"CONSTIP;HBNPD;BHP;BPH8;MECHCP;BFLAX;GENLAX;LEVOTHY;DIGEST;SUPDS;EP8;TNF27;HDPP2";s:26:"field_reference_reviewed_f";s:79:"CONSTIP;HBNPD;BHP;BPH8;MECHCP;BFLAX;GENLAX;LEVOTHY;DIGEST;SUPDS;EP8;TNF27;HDPP2";}i:216621;a:35:{s:5:"title";s:32:"PSY_OV_Psyllium - Plantago ovata";s:3:"nid";s:6:"216621";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"PSY_OV";s:18:"field_group_name_e";s:8:"Psyllium";s:18:"field_group_name_f";s:8:"Psyllium";s:22:"field_monograph_name_e";s:25:"Psyllium - Plantago ovata";s:22:"field_monograph_name_f";s:25:"Psyllium - Plantago ovata";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:96:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_psyllium-eng.php";s:21:"field_monograph_url_f";s:96:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_psyllium-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:468:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.     Notes: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion.";s:12:"field_note_f";s:624:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.     Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:459:"The medicinal ingredient may comply with the specifications outlined in one of the following pharmacopoeial monographs:  'Psyllium Seed' or 'Ispaghula Seed' or 'Ispaghula Husk' monograph in British Pharmacopoeia, 'Psyllium Seed' or 'Ispaghula Seed' or 'Ispaghula Husk' monograph in European Pharmacopoeia, and 'Plantago Seed' or 'Psyllium Husk' or 'Psyllium Hydrophilic Mucilloid for Oral Suspension' or 'Psyllium Hemicellulose' monograph in US Pharamcopoeia.";s:21:"field_specification_f";s:474:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes:   'Psyllium Seed' ou 'Ispaghula Seed' ou 'Ispaghula Husk'  de la Pharmacopée britannique (BP), 'Psyllium Seed' ou 'Ispaghula Seed' ou 'Ispaghula Husk' de la Pharmacopée européenne (Ph. Eur.) et 'Plantago Seed' ou 'Psyllium Husk' ou 'Psyllium Hydrophilic Mucilloid for Oral Suspension' ou 'Psyllium Hemicellulose' de la Pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-02-18";s:16:"field_legacy_nid";s:6:"100930";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:12:"CH6_12;ADU13";s:15:"field_dose_note";s:18:"PSYSED;PSYHSK;APP1";s:15:"field_mono_risk";s:71:"PSY_CW1;PSY_CW2;PSY_CW3;PSY_CW4;PSY_CI1;PSY_CI2;PSY_CI3;PSY_AR1;PSY_AR2";s:21:"field_mono_citation_e";s:97:"EXPCEM;BHCOM;HMPAPI;HMPOT;HMPO;ESCOP;LDPOTC;REMI;HERCOM;NPPT;PATSC;MART35;GRIN;WHOMON3;WHOMON;PHC";s:21:"field_mono_citation_f";s:97:"EXPCEM;BHCOM;PHAPHY;HMPAPI;HMPOT;HMPO;ESCOP;LDPOTC;REMI;NPPT;PATSC;MART35;GRIN;WHOMON3;WHOMON;PHC";s:26:"field_reference_reviewed_e";s:79:"CONSTIP;HBNPD;BHP;BPH8;MECHCP;BFLAX;GENLAX;LEVOTHY;DIGEST;SUPDS;EP8;TNF27;HDPP2";s:26:"field_reference_reviewed_f";s:79:"CONSTIP;HBNPD;BHP;BPH8;MECHCP;BFLAX;GENLAX;LEVOTHY;DIGEST;SUPDS;EP8;TNF27;HDPP2";}i:216622;a:35:{s:5:"title";s:21:"RCHA_Chamomile, Roman";s:3:"nid";s:6:"216622";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"RCHA";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:16:"Chamomile, Roman";s:22:"field_monograph_name_f";s:17:"Camomille romaine";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:620:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.      Note: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicants’ discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:753:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.      Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:208:"The medicinal ingredient may comply with the specifications outlined in the 'Chamomile Flowers' monograph of the British Pharmacopoeia or the 'Chamomile Flower, Roman' monograph of the European Pharmacopoeia.";s:21:"field_specification_f";s:245:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie 'Chamomile Flowers' de la pharmacopée britannique (BP) ou dans la monographie 'Chamomile Flower, Roman' de la Pharmacopée européenne (Ph. Eur.).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-08-05";s:16:"field_legacy_nid";s:6:"100931";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:25:"PERS;WORS;RCHA_CI;RCHA_AR";s:21:"field_mono_citation_e";s:72:"BPH8;BHP;CGCEM;BHCOM;HERCDI;THEPHA;ECMM;HERCOM;BOTSAF;PPP;EP8;GRIN;HDPP2";s:21:"field_mono_citation_f";s:72:"BPH8;BHP;CGCEM;BHCOM;HERCDI;THEPHA;ECMM;BOTSAF;PPP;EP8;GRIN;HDPP2;PLATHE";s:26:"field_reference_reviewed_e";s:29:"HERMED2;UPHCDI8;APCRCT;HERSAF";s:26:"field_reference_reviewed_f";s:29:"HERMED2;UPHCDI8;APCRCT;HERSAF";}i:216623;a:32:{s:5:"title";s:14:"RIB_Riboflavin";s:3:"nid";s:6:"216623";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"RIB";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:10:"Riboflavin";s:22:"field_monograph_name_f";s:11:"Riboflavine";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2007-08-16";s:16:"field_legacy_nid";s:6:"100932";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:12:"ADU14;CH1_13";s:15:"field_dose_note";s:15:"MIN;MAXRIB;ADUL";s:21:"field_mono_citation_e";s:63:"HDRIB;RIBOFL;ANHM;NHPDEAC2;IOMDRI;FCC;DRITR;MERCK13;MNHD;MART35";s:21:"field_mono_citation_f";s:63:"HDRIB;RIBOFL;ANHM;NHPDEAC2;IOMDRI;FCC;DRITR;MERCK13;MNHD;MART35";}i:216624;a:33:{s:5:"title";s:21:"ROS_O_Rosemary - Oral";s:3:"nid";s:6:"216624";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"ROS_O";s:18:"field_group_name_e";s:8:"Rosemary";s:18:"field_group_name_f";s:7:"Romarin";s:22:"field_monograph_name_e";s:15:"Rosemary - Oral";s:22:"field_monograph_name_f";s:15:"Romarin - Orale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-01-23";s:16:"field_legacy_nid";s:6:"100933";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:17:"PERS;WORS;ROSO_CI";s:21:"field_mono_citation_e";s:98:"HERMED2;BHP;EXPCEM;BHCOM2;HERCDI;ESCOP;AMODHER;MEDHER;BOTSAF;HERCOM;HERSAF;HEART;GRIN;HDPP2;PNCBDP";s:21:"field_mono_citation_f";s:102:"HERMED2;BHP;EXPCEM;PMM;BHCOM2;HERCDI;PHAPHY;ESCOP;AMODHER;MEDHER;BOTSAF;HERSAF;HEART;GRIN;HDPP2;PNCBDP";}i:216625;a:33:{s:5:"title";s:24:"ROS_T_Rosemary - Topical";s:3:"nid";s:6:"216625";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"ROS_T";s:18:"field_group_name_e";s:8:"Rosemary";s:18:"field_group_name_f";s:7:"Romarin";s:22:"field_monograph_name_e";s:18:"Rosemary - Topical";s:22:"field_monograph_name_f";s:17:"Romarin - Topique";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-01-23";s:16:"field_legacy_nid";s:6:"100934";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:35:"PERS;WORS;ROST_CW1;ROST_CW2;ROST_AR";s:21:"field_mono_citation_e";s:98:"HERMED2;BHP;EXPCEM;BHCOM2;HERCDI;ESCOP;AMODHER;MEDHER;BOTSAF;HERCOM;HERSAF;HEART;GRIN;HDPP2;PNCBDP";s:21:"field_mono_citation_f";s:102:"HERMED2;BHP;EXPCEM;PMM;BHCOM2;HERCDI;PHAPHY;ESCOP;AMODHER;MEDHER;BOTSAF;HERSAF;HEART;GRIN;HDPP2;PNCBDP";}i:216626;a:35:{s:5:"title";s:16:"SAP_Saw Palmetto";s:3:"nid";s:6:"216626";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"SAP";s:18:"field_group_name_e";s:12:"Saw Palmetto";s:18:"field_group_name_f";s:5:"Sabal";s:22:"field_monograph_name_e";s:12:"Saw Palmetto";s:22:"field_monograph_name_f";s:5:"Sabal";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:613:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and label for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.  Note: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant's discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:749:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.  Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:625:"The finished product must comply with the minimum specifications outlined in the current NHPD Compendium of Monographs. The medicinal ingredient may comply with the specifications outlined in the Saw Palmetto Fruit monograph published in the British Pharmacopoeia, the Saw Palmetto Fruit monograph published in the European Pharmacopoeia, the Saw Palmetto monograph published in the US Pharmacopoeia or the Powdered Saw Palmetto monograph published in the US Pharmacopoeia.;Note: Information detailed in this section is not to be submitted with the compendial PLA, although it may be requested at Health Canada’s discretion";s:21:"field_specification_f";s:725:"Le produit fini doit être conforme aux spécifications minimales énoncées dans la version actuelle du Compendium des monographies de la DPSN. L'ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie 'Saw Palmetto Fruit' publiée dans la Pharmacopée britannique (BP), dans la monographie 'Saw Palmetto Fruit' publiée dans la Pharmacopée européenne (Ph. Eur.), dans la monographie 'Saw Palmetto' publiée dans la Pharmacopée américaine (USP) ou dans la monographie 'Powdered Saw Palmetto' publiée dans la Pharmacopée américaine (USP).;Nota : L’information susmentionnée ne doit pas être remise avec la DLMM officinale mais Santé Canada peut en faire la demande au besoin.";s:25:"field_storage_condition_e";s:93:"Store in a tightly closed, light-resistant container in a cool, dry place (USP 32, WHO 2002).";s:25:"field_storage_condition_f";s:120:"Entreposer dans un contenant fermé hermétiquement et photorésistant, dans un endroit frais et sec (USP 32, WHO 2002).";s:10:"field_date";s:10:"2010-12-23";s:16:"field_legacy_nid";s:6:"100935";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"MAL";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:16:"PERS;WORS;SAW_CW";s:21:"field_mono_citation_e";s:133:"EXPCEM;BHCOM2;HERCOM;HERSAF;PPP;GRIN;SERREP;SAWPLEXR1;SAWPLEXR2;SAWPLEXR3;SAWPLEXR4;SAWPLEXR5;SAWPLEXR6;SAWPLEXR7;SAWPLEXR8;SAWPLEXR9";s:21:"field_mono_citation_f";s:140:"EXPCEM;BHCOM2;NOMEN;HERSAF;PPS2;GRIN;PLATHE;SERREP;SAWPLEXR1;SAWPLEXR2;SAWPLEXR3;SAWPLEXR4;SAWPLEXR5;SAWPLEXR6;SAWPLEXR7;SAWPLEXR8;SAWPLEXR9";s:26:"field_reference_reviewed_e";s:179:"PLATFUN;SPBPH;SPCR;PERMIX;ESRBPH;UPHCDI8;HERCDI;INTRA;HHEPA;BIOEQ;PERTAM;ANTIEST;ANDROGEN;RISKBEN;HMCAE;LUTS;LIPIDO;SAWP;ALFUZ;MEDHER;FINAS;CURBIC;SAWPLEXRR1;SAWPLEXRR2;SAWPLEXRR3";s:26:"field_reference_reviewed_f";s:183:"PLATFUN;SPBPH;SPCR;PERMIX;ESRBPH;UPHCDI8;HERCDI;INTRA;HHEPA;BIOEQ;PERTAM;ANTIEST;ANDROGEN;RISKBEN;HMCAE;LUTS;LIPIDO;SAWP;ALFUZ;MEDHER;FINAS;PPP;CURBIC;SAWPLEXRR1;SAWPLEXRR2;SAWPLEXRR3";}i:216627;a:35:{s:5:"title";s:39:"SAPE_Saw palmetto, liposterolic extract";s:3:"nid";s:6:"216627";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"SAPE";s:18:"field_group_name_e";s:12:"Saw Palmetto";s:18:"field_group_name_f";s:5:"Sabal";s:22:"field_monograph_name_e";s:34:"Saw palmetto, liposterolic extract";s:22:"field_monograph_name_f";s:30:"Sabal, Extrait lipostérolique";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:613:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and label for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.  Note: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant's discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:749:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.  Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:910:"The finished product must comply with the minimum specifications outlined in the current NHPD Compendium of Monographs.; The medicinal ingredient may comply with the specifications outlined in the Saw Palmetto Fruit monograph published in the British Pharmacopoeia, the Saw Palmetto Fruit monograph published in the European Pharmacopoeia, the Saw Palmetto monograph published in the US Pharmacopeia, Powdered Saw Palmetto monograph published in the US Pharmacopeia, or the Saw Palmetto Extract monograph published in the US Pharmacopeia.; Acceptable lipophilic extraction methods of the dried saw palmetto fruit (Croom and Chan 2010, USP Verified 2010, derMarderosian and Beutler 2009) are as follows: N-hexane, Supercritical carbon dioxide, 90 % ethanol.; Note: Information detailed in this section is not to be submitted with the compendial PLA, although it may be requested at Health Canada’s discretion.";s:21:"field_specification_f";s:961:"Le produit fini doit être conforme aux spécifications minimales énoncées dans la version actuelle du Compendium des monographies de la DPSN.; L'ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie 'Saw Palmetto Fruit' publiée dans la Pharmacopée britannique (BP), dans la monographie 'Saw Palmetto Fruit' publiée dans la Pharmacopée européenne (Ph. Eur.), dans la monographie 'Saw Palmetto' publiée dans la Pharmacopée américaine (USP) ou dans la monographie 'Powdered Saw Palmetto' publiée dans la Pharmacopée américaine (USP).; Les méthodes d’extraction lipophiles acceptables du fruit séché du sabal (Croom et Chan 2010, USP Verified 2010, derMarderosian et Beutler 2009) sont les suivantes : N-hexane, Dioxyde de carbone supercritique,  Éthanol à 90%.; Nota : L’information susmentionnée ne doit pas être remise avec la DLMM officinale mais Santé Canada peut en faire la demande au besoin.";s:25:"field_storage_condition_e";s:93:"Store in a tightly closed, light-resistant container in a cool, dry place (USP 32, WHO 2002).";s:25:"field_storage_condition_f";s:120:"Entreposer dans un contenant fermé hermétiquement et photorésistant, dans un endroit frais et sec (USP 32, WHO 2002).";s:10:"field_date";s:10:"2010-12-23";s:16:"field_legacy_nid";s:6:"100936";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"MAL";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:16:"PERS;WORS;SAW_CW";s:21:"field_mono_citation_e";s:133:"EXPCEM;BHCOM2;HERCOM;HERSAF;PPP;GRIN;SERREP;SAWPLEXR1;SAWPLEXR2;SAWPLEXR3;SAWPLEXR4;SAWPLEXR5;SAWPLEXR6;SAWPLEXR7;SAWPLEXR8;SAWPLEXR9";s:21:"field_mono_citation_f";s:140:"EXPCEM;BHCOM2;NOMEN;HERSAF;PPS2;GRIN;PLATHE;SERREP;SAWPLEXR1;SAWPLEXR2;SAWPLEXR3;SAWPLEXR4;SAWPLEXR5;SAWPLEXR6;SAWPLEXR7;SAWPLEXR8;SAWPLEXR9";s:26:"field_reference_reviewed_e";s:179:"PLATFUN;SPBPH;SPCR;PERMIX;ESRBPH;UPHCDI8;HERCDI;INTRA;HHEPA;BIOEQ;PERTAM;ANTIEST;ANDROGEN;RISKBEN;HMCAE;LUTS;LIPIDO;SAWP;ALFUZ;MEDHER;FINAS;CURBIC;SAWPLEXRR1;SAWPLEXRR2;SAWPLEXRR3";s:26:"field_reference_reviewed_f";s:183:"PLATFUN;SPBPH;SPCR;PERMIX;ESRBPH;UPHCDI8;HERCDI;INTRA;HHEPA;BIOEQ;PERTAM;ANTIEST;ANDROGEN;RISKBEN;HMCAE;LUTS;LIPIDO;SAWP;ALFUZ;MEDHER;FINAS;PPP;CURBIC;SAWPLEXRR1;SAWPLEXRR2;SAWPLEXRR3";}i:216628;a:35:{s:5:"title";s:12:"SCU_Skullcap";s:3:"nid";s:6:"216628";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"SCU";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:8:"Skullcap";s:22:"field_monograph_name_f";s:11:"Scutellaire";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:108:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_scullcap-scutellaire-eng.php";s:21:"field_monograph_url_f";s:108:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_scullcap-scutellaire-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-01-18";s:16:"field_legacy_nid";s:6:"100937";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:39:"SCU_CW1;SCU_CW2;SCU_CI;SCU_AR;PERS;WORS";s:21:"field_mono_citation_e";s:103:"HERMED2;HBNPD;50COM;BHP;BHCOM2;HERCDI;PHARTH;THEPHA;KAD;REMI;MEDHER;HERCOM;PPP;HERSAF;HEART;PNCBDP;GRIN";s:21:"field_mono_citation_f";s:100:"HERMED2;HBNPD;50COM;BHP;BHCOM2;HERCDI;PHARTH;THEPHA;KAD;REMI;MEDHER;PPP;HERSAF;PPS;HEART;PNCBDP;GRIN";s:26:"field_reference_reviewed_e";s:6:"BOTSAF";s:26:"field_reference_reviewed_f";s:6:"BOTSAF";}i:216629;a:33:{s:5:"title";s:12:"SEL_Selenium";s:3:"nid";s:6:"216629";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"SEL";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:8:"Selenium";s:22:"field_monograph_name_f";s:10:"Sélénium";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:96:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_selenium-eng.php";s:21:"field_monograph_url_f";s:96:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_selenium-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2007-09-11";s:16:"field_legacy_nid";s:6:"100939";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:22:"MIN;MAXSEL;ADUL;SELDEF";s:15:"field_mono_risk";s:6:"SEL_CW";s:21:"field_mono_citation_e";s:50:"SELSUP;ANHM;DPD;IOMDRI;DRIVVSC;MERCK13;MNHD;MART35";s:21:"field_mono_citation_f";s:50:"SELSUP;ANHM;DPD;IOMDRI;DRIVVSC;MERCK13;MNHD;MART35";}i:216630;a:36:{s:5:"title";s:9:"SEN_Senna";s:3:"nid";s:6:"216630";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"SEN";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:5:"Senna";s:22:"field_monograph_name_f";s:6:"Séné";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:98:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_senna_sene-eng.php";s:21:"field_monograph_url_f";s:98:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_senna_sene-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:702:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.      Note: (i) Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicants’ discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.  (ii) Claims for traditional use must include the term “Herbal Medicine”.";s:12:"field_note_f";s:858:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.      Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.  (ii) Les allégations concernant l’usage traditionnel doivent inclure le terme « phytothérapie.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:612:"The medicinal ingredient may comply with the specifications outlined in the following pharmacopoeial monographs: (i) 'Senna Leaf', 'Senna Leaf Dry Extract, Standardised', 'Alexandrian senna fruit', 'Tinnevelly senna fruit', 'Senna Liquid Extract', 'Standardised Senna Granules', 'Senna Tablets' monographs from the British Pharmacopoeia, (ii) 'Senna Leaf', 'Senna Leaf Dry Extract, Standardized',  'Senna Pods, Alexandrian', 'Senna Pods, Tinnevelly' monographs from the European Pharmacopoeia and (iii) 'Senna Leaf', 'Senna Fluid Extract', 'Senna Pods', 'Senna Oral Solution' monographs from the US Pharmacopoeia";s:21:"field_specification_f";s:613:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes:  (i) 'Senna Leaf', 'Senna Leaf Dry Extract, Standardised', 'Alexandrian senna fruit', 'Tinnevelly senna fruit', 'Senna Liquid Extract', 'Standardised Senna Granules', 'Senna Tablets' de la Pharmacopée britannique (BP), (ii) 'Senna Leaf', 'Senna Leaf Dry Extract, Standardized',  'Senna Pods, Alexandrian', 'Senna Pods, Tinnevelly' de la Pharmacopée européenne (Ph. Eur.) et (iii) 'Senna Leaf', 'Senna Fluid Extract', 'Senna Pods', 'Senna Oral Solution' de la Pharmacopée américaine (USP)";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-06-24";s:16:"field_legacy_nid";s:6:"100940";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:5:"ADU11";s:15:"field_dose_note";s:10:"APP1;SENNA";s:19:"field_mono_duration";s:6:"SENDUR";s:15:"field_mono_risk";s:64:"PERS;WORS;SEN_CW1;SEN_CW2;SEN_CW3;SEN_CW4;SEN_CI1;SEN_CI2;SEN_AR";s:21:"field_mono_citation_e";s:121:"HBNPD;EXPCEM;BPH8;HERCDI;EMEASEN1;EMEASEN2;ESCOP;KAD;BOTSAF;HERCOM;HERSAF;EP8;NPPT;CPS;MART35;GRIN;TNF27;WHOMON;HDPP2;PHC";s:21:"field_mono_citation_f";s:128:"HBNPD;EXPCEM;BPH8;HERCDI;PHAPHY;EMEASEN1;EMEASEN2;ESCOP;KAD;BOTSAF;HERSAF;EP8;NPPT;CPS;MART35;GRIN;TNF27;WHOMON;HDPP2;PLATHE;PHC";s:26:"field_reference_reviewed_e";s:35:"BHCOM;UPHCDI;STIMLAX;THEPHA;NAE;WEP";s:26:"field_reference_reviewed_f";s:35:"BHCOM;UPHCDI;STIMLAX;THEPHA;NAE;WEP";}i:216631;a:36:{s:5:"title";s:28:"SJW_O_St. John's Wort - Oral";s:3:"nid";s:6:"216631";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"SJW_O";s:18:"field_group_name_e";s:15:"St. John's Wort";s:18:"field_group_name_f";s:12:"Millepertuis";s:22:"field_monograph_name_e";s:22:"St. John's Wort - Oral";s:22:"field_monograph_name_f";s:20:"Millepertuis - Orale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:112:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_stjohnswort-millepertuis-eng.php";s:21:"field_monograph_url_f";s:112:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_stjohnswort-millepertuis-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:700:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.     Note: (i) Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant. (ii) Claims for traditional use must include the term “Herbal Medicine”.";s:12:"field_note_f";s:860:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.     Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.  (ii) Les allégations concernant l’usage traditionnel doivent inclure le terme « phytothérapie ».";s:17:"field_risk_note_e";s:106:"See Appendix 2 to find the references of the Caution and Contraindication statements about medication use.";s:17:"field_risk_note_f";s:131:"Consulter l'Annexe 2 pour trouver les références des énoncés de mise en garde et de contre-indication reliés aux médicaments.";s:21:"field_specification_e";s:301:"The medicinal ingredient may comply with the specifications outlined in one of the following pharmacopoeial monographs: (i) 'St. John's wort' from European Pharmacopoeia (Ph. Eur.) and (ii) 'St. John's wort' or 'Powdered St. John's wort' or 'Powdered St. John's wort extract' in US Pharmacopoeia (USP)";s:21:"field_specification_f";s:314:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes: (i) 'St. John's wort' de la Pharmacopée européenne (Ph. Eur) et (ii) 'St. John's wort' ou 'Powdered St. John's wort' ou 'Powdered St. John's wort extract' de la Pharmacopée américaine (USP)";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-11-12";s:16:"field_legacy_nid";s:6:"100941";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:15:"SJWDUR1;SJWDUR2";s:15:"field_mono_risk";s:58:"SJW_CW1;SJW_CW2;SJW_CW3;PERS;WORS;SJW_CI;SJW_ADR1;SJW_ADR2";s:21:"field_mono_citation_e";s:586:"CYCLOS;DRUGINT;WS5570;HERMED2;DISWCY;ALTCYCA;BHP;EXPCEM;CYP3A4;ENHCI2;BHCOM2;1YRSAF;UPHCDI8;HERCDI;CARBAZ;DAB6;BUSPSJW;NEVIRA;COORD;MDR1;METHAD;ESCOP;SECOND;CANNING;FLUOXE;KAD;DTMMDE;IMATI;STW3V1;ORAL;AMODHER;CYTOCH;INTORAL;NHPDCOM;TACROL;MEDHER;MAJDD;SJWOILS;SJWGIN;DIGOXIN;WS5572;SJWCYC;WS55702;QUAZE;EFFSJWE;HAZARD;ASHO;3A4ENZ;IRINO;PHENPRO;BOTSAF;HERCOM;HERSAF;THEOPH;ORGAN;EFFDIG;BLEEDING;POTMET;TIMING;ADRSJW;INTSJW;EP8;INDINA;DYSTHY;PEST;DEXDEX;ACUHT;HTMMD;UNWANT;IMMES;TOPICAL;ACANCER;HYPOM;SIMPRA;PAROXE;VERAPA;HIDDEN;MODDEP;GRIN;TNF27;LI160;FEXO;HUMCYT;HSAD;HDPP2;PCBDP;ETHNIC";s:21:"field_mono_citation_f";s:592:"CYCLOS;DRUGINT;WS5570;HERMED2;DISWCY;ALTCYCA;BHP;EXPCEM;CYP3A4;ENHCI2;BHCOM2;1YRSAF;UPHCDI8;HERCDI;FLORE;PHAPHY;CARBAZ;DAB6;BUSPSJW;NEVIRA;COORD;MDR1;METHAD;ESCOP;SECOND;CANNING;FLUOXE;KAD;DTMMDE;IMATI;STW3V1;ORAL;AMODHER;CYTOCH;INTORAL;NHPDCOM;TACROL;MEDHER;MAJDD;SJWOILS;SJWGIN;DIGOXIN;WS5572;SJWCYC;WS55702;QUAZE;EFFSJWE;HAZARD;ASHO;3A4ENZ;IRINO;PHENPRO;BOTSAF;HERSAF;THEOPH;ORGAN;EFFDIG;BLEEDING;POTMET;TIMING;ADRSJW;INTSJW;EP8;INDINA;DYSTHY;PEST;DEXDEX;ACUHT;HTMMD;UNWANT;IMMES;TOPICAL;ACANCER;HYPOM;SIMPRA;PAROXE;VERAPA;HIDDEN;MODDEP;GRIN;TNF27;LI160;FEXO;HUMCYT;HSAD;HDPP2;PCBDP;ETHNIC";s:26:"field_reference_reviewed_e";s:200:"LOWHF;MILDMOD;SERTRA;FINREP;DELEM;JUVDEP;STW3;CARCOL;AMITRI;EPISODE;SJWOCD;DELIRI;SJWDEP2;DISJW;HPVSFL;SOMATO;EIGHT;HCREAM;SOLARSR;SLPEEG;EFFSJW;ADODEP;ORSER;ICD10;2C19;SJWADHD;XANOX;WEP;SJWIMI;SAFSJW";s:26:"field_reference_reviewed_f";s:200:"LOWHF;MILDMOD;SERTRA;FINREP;DELEM;JUVDEP;STW3;CARCOL;AMITRI;EPISODE;SJWOCD;DELIRI;SJWDEP2;DISJW;HPVSFL;SOMATO;EIGHT;HCREAM;SOLARSR;SLPEEG;EFFSJW;ADODEP;ORSER;ICD10;2C19;SJWADHD;XANOX;WEP;SJWIMI;SAFSJW";}i:216632;a:36:{s:5:"title";s:54:"SJW_HE_St. John's Wort - Oral - Hydroalcoholic Extract";s:3:"nid";s:6:"216632";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"SJW_HE";s:18:"field_group_name_e";s:15:"St. John's Wort";s:18:"field_group_name_f";s:12:"Millepertuis";s:22:"field_monograph_name_e";s:47:"St. John's Wort - Oral - Hydroalcoholic Extract";s:22:"field_monograph_name_f";s:46:"Millepertuis - Orale - Extrait hydroalcoolique";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:112:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_stjohnswort-millepertuis-eng.php";s:21:"field_monograph_url_f";s:112:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_stjohnswort-millepertuis-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:700:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.     Note: (i) Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant. (ii) Claims for traditional use must include the term “Herbal Medicine”.";s:12:"field_note_f";s:860:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.     Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.  (ii) Les allégations concernant l’usage traditionnel doivent inclure le terme « phytothérapie ».";s:17:"field_risk_note_e";s:106:"See Appendix 2 to find the references of the Caution and Contraindication statements about medication use.";s:17:"field_risk_note_f";s:131:"Consulter l'Annexe 2 pour trouver les références des énoncés de mise en garde et de contre-indication reliés aux médicaments.";s:21:"field_specification_e";s:407:"The medicinal ingredient may comply with the specifications outlined in one of the following pharmacopoeial monographs: (i) 'St. John's wort' from the European Pharmacopoeia (Ph. Eur.), (ii) 'St. John's wort' or 'Powdered St. John's wort' or 'Powdered St. John's wort extract' from the US Pharmacopoeia (USP), (iii) 'Oleum Hyperici (Johannisöl)' from DAB 6 (EB-6), a supplement to the German Pharmacopoeia.";s:21:"field_specification_f";s:412:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes: (i) 'St. John's wort' de la Pharmacopée européenne (Ph. Eur), (ii) 'St. John's wort' ou 'Powdered St. John's wort' ou 'Powdered St. John's wort extract' de la Pharmacopée américaine (USP), (iii) 'Oleum Hyperici (Johannisöl)' de DAB 6 (EB-6), un supplément à la pharmacopée allemande.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-11-12";s:16:"field_legacy_nid";s:6:"100942";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:15:"SJWDUR1;SJWDUR2";s:15:"field_mono_risk";s:58:"SJW_CW1;SJW_CW2;SJW_CW3;PERS;WORS;SJW_CI;SJW_ADR1;SJW_ADR2";s:21:"field_mono_citation_e";s:586:"CYCLOS;DRUGINT;WS5570;HERMED2;DISWCY;ALTCYCA;BHP;EXPCEM;CYP3A4;ENHCI2;BHCOM2;1YRSAF;UPHCDI8;HERCDI;CARBAZ;DAB6;BUSPSJW;NEVIRA;COORD;MDR1;METHAD;ESCOP;SECOND;CANNING;FLUOXE;KAD;DTMMDE;IMATI;STW3V1;ORAL;AMODHER;CYTOCH;INTORAL;NHPDCOM;TACROL;MEDHER;MAJDD;SJWOILS;SJWGIN;DIGOXIN;WS5572;SJWCYC;WS55702;QUAZE;EFFSJWE;HAZARD;ASHO;3A4ENZ;IRINO;PHENPRO;BOTSAF;HERCOM;HERSAF;THEOPH;ORGAN;EFFDIG;BLEEDING;POTMET;TIMING;ADRSJW;INTSJW;EP8;INDINA;DYSTHY;PEST;DEXDEX;ACUHT;HTMMD;UNWANT;IMMES;TOPICAL;ACANCER;HYPOM;SIMPRA;PAROXE;VERAPA;HIDDEN;MODDEP;GRIN;TNF27;LI160;FEXO;HUMCYT;HSAD;HDPP2;PCBDP;ETHNIC";s:21:"field_mono_citation_f";s:592:"CYCLOS;DRUGINT;WS5570;HERMED2;DISWCY;ALTCYCA;BHP;EXPCEM;CYP3A4;ENHCI2;BHCOM2;1YRSAF;UPHCDI8;HERCDI;FLORE;PHAPHY;CARBAZ;DAB6;BUSPSJW;NEVIRA;COORD;MDR1;METHAD;ESCOP;SECOND;CANNING;FLUOXE;KAD;DTMMDE;IMATI;STW3V1;ORAL;AMODHER;CYTOCH;INTORAL;NHPDCOM;TACROL;MEDHER;MAJDD;SJWOILS;SJWGIN;DIGOXIN;WS5572;SJWCYC;WS55702;QUAZE;EFFSJWE;HAZARD;ASHO;3A4ENZ;IRINO;PHENPRO;BOTSAF;HERSAF;THEOPH;ORGAN;EFFDIG;BLEEDING;POTMET;TIMING;ADRSJW;INTSJW;EP8;INDINA;DYSTHY;PEST;DEXDEX;ACUHT;HTMMD;UNWANT;IMMES;TOPICAL;ACANCER;HYPOM;SIMPRA;PAROXE;VERAPA;HIDDEN;MODDEP;GRIN;TNF27;LI160;FEXO;HUMCYT;HSAD;HDPP2;PCBDP;ETHNIC";s:26:"field_reference_reviewed_e";s:200:"LOWHF;MILDMOD;SERTRA;FINREP;DELEM;JUVDEP;STW3;CARCOL;AMITRI;EPISODE;SJWOCD;DELIRI;SJWDEP2;DISJW;HPVSFL;SOMATO;EIGHT;HCREAM;SOLARSR;SLPEEG;EFFSJW;ADODEP;ORSER;ICD10;2C19;SJWADHD;XANOX;WEP;SJWIMI;SAFSJW";s:26:"field_reference_reviewed_f";s:200:"LOWHF;MILDMOD;SERTRA;FINREP;DELEM;JUVDEP;STW3;CARCOL;AMITRI;EPISODE;SJWOCD;DELIRI;SJWDEP2;DISJW;HPVSFL;SOMATO;EIGHT;HCREAM;SOLARSR;SLPEEG;EFFSJW;ADODEP;ORSER;ICD10;2C19;SJWADHD;XANOX;WEP;SJWIMI;SAFSJW";}i:216633;a:35:{s:5:"title";s:31:"SJW_T_St. John's Wort - Topical";s:3:"nid";s:6:"216633";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"SJW_T";s:18:"field_group_name_e";s:15:"St. John's Wort";s:18:"field_group_name_f";s:12:"Millepertuis";s:22:"field_monograph_name_e";s:25:"St. John's Wort - Topical";s:22:"field_monograph_name_f";s:22:"Millepertuis - Topique";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:112:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_stjohnswort-millepertuis-eng.php";s:21:"field_monograph_url_f";s:112:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_stjohnswort-millepertuis-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:700:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.     Note: (i) Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant. (ii) Claims for traditional use must include the term “Herbal Medicine”.";s:12:"field_note_f";s:860:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.     Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.  (ii) Les allégations concernant l’usage traditionnel doivent inclure le terme « phytothérapie ».";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:1169:"The medicinal ingredient may comply with the specifications outlined in one of the following pharmacopoeial monographs: (i) 'St. John's wort' from European Pharmacopoeia (Ph. Eur.) and (ii) 'St. John's wort' or 'Powdered St. John's wort' or 'Powdered St. John's wort extract' in US Pharmacopoeia (USP).;     The preparations must meet at least one of the following conditions in order to prevent the growth of the bacterial spores associated with botulism:  (i) Products are subjected to a validated treatment, such as heat treatment, with equivalent effect to the 12 D canning process (a thermal process designed to reduce the probability of survival of a single, heat-resistant spore of Clostridium botulinum by a factor of 10 exponent 12) to inactivate spores of C. botulinum (FAO 1985), or   (ii) The water activity of the plant material is reduced to 0.94 or less before adding it to the oil, or  (iii) Ensure that the pH of the plant material is adjusted to 4.6 or less before adding it to the oil (HC 2007).      Note: This information is not to be submitted with the compendial Product Licence Application, although it may be requested at the NHPD's discretion.";s:21:"field_specification_f";s:1317:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes: (i) 'St. John's wort' de la Pharmacopée européenne (Ph. Eur) et (ii) 'St. John's wort' ou 'Powdered St. John's wort' ou 'Powdered St. John's wort extract' de la Pharmacopée américaine (USP).;   Les préparations doivent être conformes à au moins l’une des conditions suivantes, afin de prévenir la germination des spores bactériennes associées au botulisme :   (i) Le produit est soumis à un procédé validé, tel que le traitement thermique, dont l’effet est équivalent à celui de la mise en conserve 12 D (procédé thermique conçu pour réduire la probabilité de survie d’une seule spore thermorésistante de Clostridium botulinum par un facteur de 10 exposant 12) visant à inactiver les spores de C. botulinum (FAO 1985), ou  (ii) L’activité hydrique de l’élément végétal est réduite à 0,94, ou moins, avant que celui-ci ne soit ajouté à l’huile, ou  (iii) Le pH de l’élément végétal est ajusté à 4,6, ou moins, avant que celui-ci ne soit ajouté à l’huile (SC 2007).    Nota : Cette information ne doit pas être présentée avec la demande de licence de mise en marché officinale, mais elle peut être exigée par la DPSN, à sa discrétion.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-11-12";s:16:"field_legacy_nid";s:6:"100943";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ALL";s:15:"field_dose_note";s:8:"APP1;SJW";s:15:"field_mono_risk";s:9:"PERS;WORS";s:21:"field_mono_citation_e";s:586:"CYCLOS;DRUGINT;WS5570;HERMED2;DISWCY;ALTCYCA;BHP;EXPCEM;CYP3A4;ENHCI2;BHCOM2;1YRSAF;UPHCDI8;HERCDI;CARBAZ;DAB6;BUSPSJW;NEVIRA;COORD;MDR1;METHAD;ESCOP;SECOND;CANNING;FLUOXE;KAD;DTMMDE;IMATI;STW3V1;ORAL;AMODHER;CYTOCH;INTORAL;NHPDCOM;TACROL;MEDHER;MAJDD;SJWOILS;SJWGIN;DIGOXIN;WS5572;SJWCYC;WS55702;QUAZE;EFFSJWE;HAZARD;ASHO;3A4ENZ;IRINO;PHENPRO;BOTSAF;HERCOM;HERSAF;THEOPH;ORGAN;EFFDIG;BLEEDING;POTMET;TIMING;ADRSJW;INTSJW;EP8;INDINA;DYSTHY;PEST;DEXDEX;ACUHT;HTMMD;UNWANT;IMMES;TOPICAL;ACANCER;HYPOM;SIMPRA;PAROXE;VERAPA;HIDDEN;MODDEP;GRIN;TNF27;LI160;FEXO;HUMCYT;HSAD;HDPP2;PCBDP;ETHNIC";s:21:"field_mono_citation_f";s:592:"CYCLOS;DRUGINT;WS5570;HERMED2;DISWCY;ALTCYCA;BHP;EXPCEM;CYP3A4;ENHCI2;BHCOM2;1YRSAF;UPHCDI8;HERCDI;FLORE;PHAPHY;CARBAZ;DAB6;BUSPSJW;NEVIRA;COORD;MDR1;METHAD;ESCOP;SECOND;CANNING;FLUOXE;KAD;DTMMDE;IMATI;STW3V1;ORAL;AMODHER;CYTOCH;INTORAL;NHPDCOM;TACROL;MEDHER;MAJDD;SJWOILS;SJWGIN;DIGOXIN;WS5572;SJWCYC;WS55702;QUAZE;EFFSJWE;HAZARD;ASHO;3A4ENZ;IRINO;PHENPRO;BOTSAF;HERSAF;THEOPH;ORGAN;EFFDIG;BLEEDING;POTMET;TIMING;ADRSJW;INTSJW;EP8;INDINA;DYSTHY;PEST;DEXDEX;ACUHT;HTMMD;UNWANT;IMMES;TOPICAL;ACANCER;HYPOM;SIMPRA;PAROXE;VERAPA;HIDDEN;MODDEP;GRIN;TNF27;LI160;FEXO;HUMCYT;HSAD;HDPP2;PCBDP;ETHNIC";s:26:"field_reference_reviewed_e";s:200:"LOWHF;MILDMOD;SERTRA;FINREP;DELEM;JUVDEP;STW3;CARCOL;AMITRI;EPISODE;SJWOCD;DELIRI;SJWDEP2;DISJW;HPVSFL;SOMATO;EIGHT;HCREAM;SOLARSR;SLPEEG;EFFSJW;ADODEP;ORSER;ICD10;2C19;SJWADHD;XANOX;WEP;SJWIMI;SAFSJW";s:26:"field_reference_reviewed_f";s:200:"LOWHF;MILDMOD;SERTRA;FINREP;DELEM;JUVDEP;STW3;CARCOL;AMITRI;EPISODE;SJWOCD;DELIRI;SJWDEP2;DISJW;HPVSFL;SOMATO;EIGHT;HCREAM;SOLARSR;SLPEEG;EFFSJW;ADODEP;ORSER;ICD10;2C19;SJWADHD;XANOX;WEP;SJWIMI;SAFSJW";}i:216634;a:29:{s:5:"title";s:33:"SOY_Soybean Extracts and Isolates";s:3:"nid";s:6:"216634";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"SOY";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:29:"Soybean Extracts and Isolates";s:22:"field_monograph_name_f";s:38:"Soya, Extraits et isolats de fèves de";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:40:"atReq.do?atid=soy_extra_isolate&lang=eng";s:21:"field_monograph_url_f";s:40:"atReq.do?atid=soy_extra_isolate&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:0:"";s:16:"field_legacy_nid";s:6:"100944";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216635;a:34:{s:5:"title";s:19:"STN_Stinging Nettle";s:3:"nid";s:6:"216635";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"STN";s:18:"field_group_name_e";s:15:"Stinging Nettle";s:18:"field_group_name_f";s:5:"Ortie";s:22:"field_monograph_name_e";s:15:"Stinging Nettle";s:22:"field_monograph_name_f";s:5:"Ortie";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-01-30";s:16:"field_legacy_nid";s:6:"100945";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:6:"STNDUR";s:15:"field_mono_risk";s:13:"STN_CW;STN_CI";s:21:"field_mono_citation_e";s:95:"HERMED2;HBNPD;HDPP;EXPCEM;BHCOM;BHCOM2;HERCDI;PATSC;ESCOP;MEDHER;HERCOM;HERSAF;HEART;GRIN;PCBDP";s:21:"field_mono_citation_f";s:98:"HERMED2;HBNPD;HDPP;EXPCEM;PMM;BHCOM;BHCOM2;HERCDI;FLORE;PATSC;ESCOP;MEDHER;HERSAF;HEART;GRIN;PCBDP";}i:216636;a:34:{s:5:"title";s:26:"STNJ_Stinging Nettle Juice";s:3:"nid";s:6:"216636";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"STNJ";s:18:"field_group_name_e";s:15:"Stinging Nettle";s:18:"field_group_name_f";s:5:"Ortie";s:22:"field_monograph_name_e";s:21:"Stinging Nettle Juice";s:22:"field_monograph_name_f";s:13:"Ortie, Jus d'";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-01-30";s:16:"field_legacy_nid";s:6:"100946";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:6:"STNDUR";s:15:"field_mono_risk";s:14:"STNJ_CW;STN_CI";s:21:"field_mono_citation_e";s:95:"HERMED2;HBNPD;HDPP;EXPCEM;BHCOM;BHCOM2;HERCDI;PATSC;ESCOP;MEDHER;HERCOM;HERSAF;HEART;GRIN;PCBDP";s:21:"field_mono_citation_f";s:98:"HERMED2;HBNPD;HDPP;EXPCEM;PMM;BHCOM;BHCOM2;HERCDI;FLORE;PATSC;ESCOP;MEDHER;HERSAF;HEART;GRIN;PCBDP";}i:216637;a:29:{s:5:"title";s:24:"SBPR_Sunscreen monograph";s:3:"nid";s:6:"216637";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"SBPR";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:19:"Sunscreen monograph";s:22:"field_monograph_name_f";s:36:"Ecrans solaires, monographie sur les";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"C;P";s:21:"field_monograph_url_e";s:45:"atReq.do?atid=sunscreen-ecransolaire&lang=eng";s:21:"field_monograph_url_f";s:45:"atReq.do?atid=sunscreen-ecransolaire&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:0:"";s:16:"field_legacy_nid";s:6:"100947";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216638;a:33:{s:5:"title";s:17:"SWF_Fennel, Sweet";s:3:"nid";s:6:"216638";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"SWF";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:13:"Fennel, Sweet";s:22:"field_monograph_name_f";s:12:"Fenouil doux";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:111:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_sweetfennel_fenouildoux-eng.php";s:21:"field_monograph_url_f";s:111:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_sweetfennel_fenouildoux-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:152:"The medicinal ingredient may comply with the specifications outlined in the Sweet Fennel Monographs published in the European or British Pharmacopoeias.";s:21:"field_specification_f";s:187:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies Sweet Fennel publiées dans les Pharmacopées britannique (BP) ou européenne (Ph. Eur.).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-03-13";s:16:"field_legacy_nid";s:6:"100948";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:12:"ADU13;CH4_12";s:19:"field_mono_duration";s:15:"SWFDUR1;SWFDUR2";s:15:"field_mono_risk";s:29:"SWF_CW1;SWF_CW2;SWF_CI;SWF_AR";s:21:"field_mono_citation_e";s:12:"EMEASWF;GRIN";s:21:"field_mono_citation_f";s:16:"EMEASWF;GRIN;WEP";}i:216639;a:36:{s:5:"title";s:22:"TEA_Green Tea Extracts";s:3:"nid";s:6:"216639";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"TEA";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:18:"Green Tea Extracts";s:22:"field_monograph_name_f";s:22:"Thé vert, Extraits de";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:39:"atReq.do?atid=greentea_thevert&lang=eng";s:21:"field_monograph_url_f";s:39:"atReq.do?atid=greentea_thevert&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-04-18";s:16:"field_legacy_nid";s:6:"100949";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:19:"field_mono_duration";s:6:"TEADUR";s:15:"field_mono_risk";s:23:"TEA_CW1;TEA_CW2;TEA_CW3";s:21:"field_mono_citation_e";s:126:"DYSLIP;EXOLISE;OXIDSTR;CANADO;24HENERG;FULHEP;GLITE;IYHCAF;BIOAVA;HERCOM;ACLVR;LDLMEN;PPLIPID;UKREVI;GRIN;CONSGBT;HABCAF;IRABS";s:21:"field_mono_citation_f";s:126:"PHAPHY;DYSLIP;EXOLISE;OXIDSTR;CANADO;24HENERG;FULHEP;GLITE;IYHCAF;BIOAVA;ACLVR;LDLMEN;PPLIPID;UKREVI;GRIN;CONSGBT;HABCAF;IRABS";s:26:"field_reference_reviewed_e";s:818:"INVREL;OXIDAM;ABC;HEPATOTO;VITK1;CATECHOL;UPHCDI8;HERCDI;BEGT;EXVIVO;PASKIN;PPE;NONWV;SPONAB;BETACAT;OWFEM;WTLOSS;PEREXE;ENDODYS;SYMDEF;THRMGN;MODGT;JURKAT;DENIAL;PETITION;FINRULE;KAD;MALOND;HOTBEV;HELPFUL;TEAFLAV;GROUND;CHEMIST;ANORCA;AMODHER;SAUDI;4MTHTEA;REDBLOOD;ZUTPHEN;7COUNTRY;SLPQUAL;JAPPAT;REGING;EBPDGBT;LPOXID;SOWARF;BEVER;CROSS2;OXIMOD;CONCERN;ACUHEP;PLASMA;SMOKERS;KYUSHU;BDYWT;JAPAN;MILK;ELICITS;BIOMARK;SDTEA;THEAFL;HOTWT;ERK;APBT;COLITIS;LOWDENS;BOTSAF;FRENCH;GALLAT;INFARCT;TCMAAMI;REVERS;TEATIME;PREEFF;HUMHEA;MAJCAT;DTACD;COFNAP;NOEFF;CAFLEV;ESSOB;CHAMB;BWGAIN;SAAR;ARTERY;WHITET;JAPMW;PHRAT;IVANTI;INHIBLDL;ALUMNI;ANTIMU;EPIGA;MOODPER;PSYCHO;MOOD;TWOPAT;FOURWKS;IVAEGT;PAWGT;TCIS;LETTER;GREEN;GTINTAK;POSTPRAN;MECHAN;THEDAY;METABO2;WHOPN;HDPP2;PNCBDP;SCOTTISH;PCBDP;HABITUAL;PARDEC;FLAVFREE;CAFALRT";s:26:"field_reference_reviewed_f";s:818:"INVREL;OXIDAM;ABC;HEPATOTO;VITK1;CATECHOL;UPHCDI8;HERCDI;BEGT;EXVIVO;PASKIN;PPE;NONWV;SPONAB;BETACAT;OWFEM;WTLOSS;PEREXE;ENDODYS;SYMDEF;THRMGN;MODGT;JURKAT;DENIAL;PETITION;FINRULE;KAD;MALOND;HOTBEV;HELPFUL;TEAFLAV;GROUND;CHEMIST;ANORCA;AMODHER;SAUDI;4MTHTEA;REDBLOOD;ZUTPHEN;7COUNTRY;SLPQUAL;JAPPAT;REGING;EBPDGBT;LPOXID;SOWARF;BEVER;CROSS2;OXIMOD;CONCERN;ACUHEP;PLASMA;SMOKERS;KYUSHU;BDYWT;JAPAN;MILK;ELICITS;BIOMARK;SDTEA;THEAFL;HOTWT;ERK;APBT;COLITIS;LOWDENS;BOTSAF;FRENCH;GALLAT;INFARCT;TCMAAMI;REVERS;TEATIME;PREEFF;HUMHEA;MAJCAT;DTACD;COFNAP;NOEFF;CAFLEV;ESSOB;CHAMB;BWGAIN;SAAR;ARTERY;WHITET;JAPMW;PHRAT;IVANTI;INHIBLDL;ALUMNI;ANTIMU;EPIGA;MOODPER;PSYCHO;MOOD;TWOPAT;FOURWKS;IVAEGT;PAWGT;TCIS;LETTER;GREEN;GTINTAK;POSTPRAN;MECHAN;THEDAY;METABO2;WHOPN;HDPP2;PNCBDP;SCOTTISH;PCBDP;HABITUAL;PARDEC;FLAVFREE;CAFALRT";}i:216640;a:36:{s:5:"title";s:18:"THU_O_Thuja - Oral";s:3:"nid";s:6:"216640";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"THU_O";s:18:"field_group_name_e";s:5:"Thuja";s:18:"field_group_name_f";s:5:"Thuya";s:22:"field_monograph_name_e";s:12:"Thuja - Oral";s:22:"field_monograph_name_f";s:13:"Thuya - Orale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-04-25";s:16:"field_legacy_nid";s:6:"100950";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:6:"THUDUR";s:15:"field_mono_risk";s:35:"PERS;WORS;THUO_CW1;THUO_CW2;THUO_CI";s:21:"field_mono_citation_e";s:66:"HBNPD;BHP;UPHCDI8;HERCDI;KAD2;MEDHER;BOTSAF;HERCOM;MOLMEC;GRIN;PHC";s:21:"field_mono_citation_f";s:69:"HBNPD;BHP;UPHCDI8;HERCDI;FLORE;KAD2;MEDHER;BOTSAF;MOLMEC;GRIN;WEP;PHC";s:26:"field_reference_reviewed_e";s:26:"PISEIZ;SEIZ7M;THUJONE;FLAV";s:26:"field_reference_reviewed_f";s:26:"PISEIZ;SEIZ7M;THUJONE;FLAV";}i:216641;a:36:{s:5:"title";s:21:"THU_T_Thuja - Topical";s:3:"nid";s:6:"216641";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"THU_T";s:18:"field_group_name_e";s:5:"Thuja";s:18:"field_group_name_f";s:5:"Thuya";s:22:"field_monograph_name_e";s:15:"Thuja - Topical";s:22:"field_monograph_name_f";s:15:"Thuya - Topique";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:28:"atReq.do?atid=thuja&lang=eng";s:21:"field_monograph_url_f";s:28:"atReq.do?atid=thuja&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-04-25";s:16:"field_legacy_nid";s:6:"100951";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:17:"PERS;WORS;THUT_CW";s:21:"field_mono_citation_e";s:66:"HBNPD;BHP;UPHCDI8;HERCDI;KAD2;MEDHER;BOTSAF;HERCOM;MOLMEC;GRIN;PHC";s:21:"field_mono_citation_f";s:69:"HBNPD;BHP;UPHCDI8;HERCDI;FLORE;KAD2;MEDHER;BOTSAF;MOLMEC;GRIN;WEP;PHC";s:26:"field_reference_reviewed_e";s:26:"PISEIZ;SEIZ7M;THUJONE;FLAV";s:26:"field_reference_reviewed_f";s:26:"PISEIZ;SEIZ7M;THUJONE;FLAV";}i:216642;a:35:{s:5:"title";s:18:"THY_O_Thyme - Oral";s:3:"nid";s:6:"216642";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"THY_O";s:18:"field_group_name_e";s:5:"Thyme";s:18:"field_group_name_f";s:4:"Thym";s:22:"field_monograph_name_e";s:12:"Thyme - Oral";s:22:"field_monograph_name_f";s:12:"Thym - Orale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:145:"The medicinal ingredient may comply with the specifications outlined in the Thyme Monographs published in the European or British Pharmacopoeias.";s:21:"field_specification_f";s:166:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies du thym publiées dans les Pharmacopées européenne ou britannique.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-02-12";s:16:"field_legacy_nid";s:6:"100952";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:4:"ADU1";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:15:"PERS;WORS;PREGC";s:21:"field_mono_citation_e";s:77:"HBNPD;EXPCEM;ENHCI;BHCOM2;EMA;ESCOP;MEDHER;HERCOM;HTCH;HERSAF;GRIN;WHOMON;WEP";s:21:"field_mono_citation_f";s:81:"HBNPD;EXPCEM;PMM;ENHCI;BHCOM2;PHAPHY;EMA;ESCOP;MEDHER;HTCH;HERSAF;GRIN;WHOMON;WEP";s:26:"field_reference_reviewed_e";s:65:"THYME;HERCDI;TOXBM;BHP;FIXED;FIXED2;FECOMB;BOTSAF;PPP;PPHPP;HDPP2";s:26:"field_reference_reviewed_f";s:65:"THYME;HERCDI;TOXBM;BHP;FIXED;FIXED2;FECOMB;BOTSAF;PPP;PPHPP;HDPP2";}i:216643;a:35:{s:5:"title";s:21:"THY_T_Thyme - Topical";s:3:"nid";s:6:"216643";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"THY_T";s:18:"field_group_name_e";s:5:"Thyme";s:18:"field_group_name_f";s:4:"Thym";s:22:"field_monograph_name_e";s:15:"Thyme - Topical";s:22:"field_monograph_name_f";s:14:"Thym - Topique";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:145:"The medicinal ingredient may comply with the specifications outlined in the Thyme Monographs published in the European or British Pharmacopoeias.";s:21:"field_specification_f";s:166:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies du thym publiées dans les Pharmacopées européenne ou britannique.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-02-12";s:16:"field_legacy_nid";s:6:"100953";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:4:"ADU1";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:9:"PERS;WORS";s:21:"field_mono_citation_e";s:77:"HBNPD;EXPCEM;ENHCI;BHCOM2;EMA;ESCOP;MEDHER;HERCOM;HTCH;HERSAF;GRIN;WHOMON;WEP";s:21:"field_mono_citation_f";s:81:"HBNPD;EXPCEM;PMM;ENHCI;BHCOM2;PHAPHY;EMA;ESCOP;MEDHER;HTCH;HERSAF;GRIN;WHOMON;WEP";s:26:"field_reference_reviewed_e";s:65:"THYME;HERCDI;TOXBM;BHP;FIXED;FIXED2;FECOMB;BOTSAF;PPP;PPHPP;HDPP2";s:26:"field_reference_reviewed_f";s:65:"THYME;HERCDI;TOXBM;BHP;FIXED;FIXED2;FECOMB;BOTSAF;PPP;PPHPP;HDPP2";}i:216644;a:35:{s:5:"title";s:20:"THY_B_Thyme - Buccal";s:3:"nid";s:6:"216644";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"THY_B";s:18:"field_group_name_e";s:5:"Thyme";s:18:"field_group_name_f";s:4:"Thym";s:22:"field_monograph_name_e";s:14:"Thyme - Buccal";s:22:"field_monograph_name_f";s:14:"Thym - Buccale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:145:"The medicinal ingredient may comply with the specifications outlined in the Thyme Monographs published in the European or British Pharmacopoeias.";s:21:"field_specification_f";s:166:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies du thym publiées dans les Pharmacopées européenne ou britannique.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-02-12";s:16:"field_legacy_nid";s:6:"100954";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:4:"ADU6";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:9:"PERS;WORS";s:21:"field_mono_citation_e";s:77:"HBNPD;EXPCEM;ENHCI;BHCOM2;EMA;ESCOP;MEDHER;HERCOM;HTCH;HERSAF;GRIN;WHOMON;WEP";s:21:"field_mono_citation_f";s:81:"HBNPD;EXPCEM;PMM;ENHCI;BHCOM2;PHAPHY;EMA;ESCOP;MEDHER;HTCH;HERSAF;GRIN;WHOMON;WEP";s:26:"field_reference_reviewed_e";s:65:"THYME;HERCDI;TOXBM;BHP;FIXED;FIXED2;FECOMB;BOTSAF;PPP;PPHPP;HDPP2";s:26:"field_reference_reviewed_f";s:65:"THYME;HERCDI;TOXBM;BHP;FIXED;FIXED2;FECOMB;BOTSAF;PPP;PPHPP;HDPP2";}i:216645;a:36:{s:5:"title";s:24:"TUR_T_Turmeric - Topical";s:3:"nid";s:6:"216645";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"TUR_T";s:18:"field_group_name_e";s:8:"Turmeric";s:18:"field_group_name_f";s:7:"Curcuma";s:22:"field_monograph_name_e";s:18:"Turmeric - Topical";s:22:"field_monograph_name_f";s:17:"Curcuma  -Topique";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:39:"atReq.do?atid=turmeric.topical&lang=eng";s:21:"field_monograph_url_f";s:39:"atReq.do?atid=turmeric.topical&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:617:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.   Note: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:750:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.   Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:167:"The medicinal ingredient may comply with the specifications outlined in the Turmeric, Powdered Turmeric Monographs published in the United States Pharmacopeia (USP 32)";s:21:"field_specification_f";s:180:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies Turmeric et Powdered Turmeric, publiées dans la Pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2010-02-25";s:16:"field_legacy_nid";s:6:"100955";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:8:"TURT_CW1";s:21:"field_mono_citation_e";s:158:"TURM1;TURM2;TURM3;TURM4;TURM5;TURM6;TURM7;TURM8;TURM9;TURM10;TURM11;TURM12;TURM13;TURM14;TURM15;TURM16;TURM17;TURM18;TURM19;TURM20;TURM21;TURM22;TURM23;TURM24";s:21:"field_mono_citation_f";s:165:"TURM1;TURM2;TURM3;TURM4;TURM5;TURM6;TURM7;TURM8;TURM9;TURM10;TURM11;TURM12;TURM13;TURM14;TURM15;TURM16;TURM17;TURM18;TURM19;TURM20;TURM21;TURM22;TURM23;TURM24;TURM25";s:26:"field_reference_reviewed_e";s:150:"TURMR1;TURMR2;TURMR3;TURMR4;TURMR5;TURMR6;TURMR7;TURMR8;TURMR9;TURMR10;TURMR11;TURMR12;TURMR13;TURMR14;TURMR15;TURMR16;TURMR17;TURMR18;TURMR19;TURMR20";s:26:"field_reference_reviewed_f";s:150:"TURMR1;TURMR2;TURMR3;TURMR4;TURMR5;TURMR6;TURMR7;TURMR8;TURMR9;TURMR10;TURMR11;TURMR12;TURMR13;TURMR14;TURMR15;TURMR16;TURMR17;TURMR18;TURMR19;TURMR20";}i:216646;a:35:{s:5:"title";s:21:"TUR_O_Turmeric - Oral";s:3:"nid";s:6:"216646";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"TUR_O";s:18:"field_group_name_e";s:8:"Turmeric";s:18:"field_group_name_f";s:7:"Curcuma";s:22:"field_monograph_name_e";s:15:"Turmeric - Oral";s:22:"field_monograph_name_f";s:15:"Curcuma - Orale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:617:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.   Note: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:750:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.   Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:167:"The medicinal ingredient may comply with the specifications outlined in the Turmeric, Powdered Turmeric Monographs published in the United States Pharmacopeia (USP 32)";s:21:"field_specification_f";s:180:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies Turmeric et Powdered Turmeric, publiées dans la Pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2010-02-25";s:16:"field_legacy_nid";s:6:"100956";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:35:"TURO_CW1;TURO_CW2;TURO_CW3;TURO_CW4";s:21:"field_mono_citation_e";s:158:"TURM1;TURM2;TURM3;TURM4;TURM5;TURM6;TURM7;TURM8;TURM9;TURM10;TURM11;TURM12;TURM13;TURM14;TURM15;TURM16;TURM17;TURM18;TURM19;TURM20;TURM21;TURM22;TURM23;TURM24";s:21:"field_mono_citation_f";s:165:"TURM1;TURM2;TURM3;TURM4;TURM5;TURM6;TURM7;TURM8;TURM9;TURM10;TURM11;TURM12;TURM13;TURM14;TURM15;TURM16;TURM17;TURM18;TURM19;TURM20;TURM21;TURM22;TURM23;TURM24;TURM25";s:26:"field_reference_reviewed_e";s:150:"TURMR1;TURMR2;TURMR3;TURMR4;TURMR5;TURMR6;TURMR7;TURMR8;TURMR9;TURMR10;TURMR11;TURMR12;TURMR13;TURMR14;TURMR15;TURMR16;TURMR17;TURMR18;TURMR19;TURMR20";s:26:"field_reference_reviewed_f";s:150:"TURMR1;TURMR2;TURMR3;TURMR4;TURMR5;TURMR6;TURMR7;TURMR8;TURMR9;TURMR10;TURMR11;TURMR12;TURMR13;TURMR14;TURMR15;TURMR16;TURMR17;TURMR18;TURMR19;TURMR20";}i:216647;a:35:{s:5:"title";s:12:"VAL_Valerian";s:3:"nid";s:6:"216647";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"VAL";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:8:"Valerian";s:22:"field_monograph_name_f";s:10:"Valériane";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:36:"atReq.do?atid=valerian.oral&lang=eng";s:21:"field_monograph_url_f";s:36:"atReq.do?atid=valerian.oral&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:704:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.     Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.    (ii) Claims for traditional use must include the term “Herbal Medicine”.";s:12:"field_note_f";s:859:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.     Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués. (ii) Les allégations concernant l’usage traditionnel doivent inclure le terme « phytothérapie ».";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:411:"The medicinal ingredient may comply with the specifications outlined in one of the following pharmacopoeial monographs: (i) 'Valerian'  monograph in the British Pharmacopoeia, (ii) 'Valerian Dry Hydroalcoholic Extract', 'Valerian Root' or 'Valerian Tincture' from the European Pharmacopoeia, and (iii) 'Valerian', 'Powdered Valerian', 'Powdered Valerian Extract' or 'Valerian Tablets' from the US Pharmacopoeia.";s:21:"field_specification_f";s:427:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes: (i) 'Valerian' de la Pharmacopée britannique (BP), (ii) 'Valerian Dry Hydroalcoholic Extract', 'Valerian Root' ou 'Valerian Tincture' de la Pharmacopée européenne (Ph. Eur.) et (iii) 'Valerian', 'Powdered Valerian', 'Powdered Valerian Extract' ou 'Valerian Tablets' de la Pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2008-10-31";s:16:"field_legacy_nid";s:6:"100957";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:8:"APP1;VAL";s:15:"field_mono_risk";s:33:"PERS;WORS;VAL_CW1;VAL_CW2;VAL_ADR";s:21:"field_mono_citation_e";s:167:"VALSLP;HBNPD;BHP;BHP2;EXPCEM;BHCOM;HERCDI;TOXBM;PHARTH;HYPHIS;SLPSTQU;THEPHA;CMVAL;ESCOP;ECMM;KAD2;REMI;VIGDEC;MEDHER;AQEXT;AQEXT2;HERCOM;HERSAF;EP8;GRIN;TNF26;EFTLVAL";s:21:"field_mono_citation_f";s:180:"VALSLP;HBNPD;BHP;BHP2;EXPCEM;BHCOM;HERCDI;TOXBM;FLORE;PHAPHY;PHARTH;HYPHIS;SLPSTQU;THEPHA;CMVAL;ESCOP;ECMM;KAD2;REMI;VIGDEC;MEDHER;AQEXT;AQEXT2;HERSAF;EP8;GRIN;TNF26;PLATHE;EFTLVAL";s:26:"field_reference_reviewed_e";s:318:"VALEPO;HERMED2;VALSL;INSOMN;ABC;CGCEM;50COM;ENHCI2;BPH8;UPHCDI8;HERBS;TPMD;NOF1;SLPDIST2;BALDR;MENWMN;CAMSDOA;PREGOUT;FDREG;VALPROP;RTAC;MILDSED;VALTALC;BOTSAF;HMPL;EBHM;DMH;PPP;VALAD;TRADUSE;THOPT;TELEV;BENZWD;DUSA;HDSTAD;PPHPP;QUEEG;SLPPOLY;HRBLAG;POTINT;SRVSA;OLDERWMN;PTFI;HEART;AHPTC;NEUREXAN;WHOMON;WEP;PHC;PCBDP";s:26:"field_reference_reviewed_f";s:318:"VALEPO;HERMED2;VALSL;INSOMN;ABC;CGCEM;50COM;ENHCI2;BPH8;UPHCDI8;HERBS;TPMD;NOF1;SLPDIST2;BALDR;MENWMN;CAMSDOA;PREGOUT;FDREG;VALPROP;RTAC;MILDSED;VALTALC;BOTSAF;HMPL;EBHM;DMH;PPP;VALAD;TRADUSE;THOPT;TELEV;BENZWD;DUSA;HDSTAD;PPHPP;QUEEG;SLPPOLY;HRBLAG;POTINT;SRVSA;OLDERWMN;PTFI;HEART;AHPTC;NEUREXAN;WHOMON;WEP;PHC;PCBDP";}i:216648;a:34:{s:5:"title";s:13:"VIA_Vitamin A";s:3:"nid";s:6:"216648";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"VIA";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:9:"Vitamin A";s:22:"field_monograph_name_f";s:10:"Vitamine A";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:621:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.       Note: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:754:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.       Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:290:"The medicinal ingredient may comply with the specifications outlined in the Vitamin A and Vitamin A Capsules monographs published in the U.S. Pharmacopeia (USP 32), and the Vitamin A monographs published in the European Pharmacopoeia (Ph. Eur. 2007) and the British Pharmacopoeia (BP 2008).";s:21:"field_specification_f";s:325:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales Vitamin A et Vitamin A Capsules publiées dans la pharmacopée américaine (USP 32), et les monographies officinales Vitamin A publiées dans les pharmacopées européenne (Ph. Eur. 2007) et britannique (BP 2008).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2010-03-01";s:16:"field_legacy_nid";s:6:"100958";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:26:"ADU;AD1418;AD913;CH48;CH03";s:15:"field_dose_note";s:41:"ADUL;VIARAE;MIN_VIA;MAXVIA;CONVIA;CONVIA2";s:21:"field_mono_citation_e";s:63:"ANHM;IOMDRI;FCC;MERCK13;MNHD;MART35;VITAR1;VITAR2;VITAR3;VITAR4";s:21:"field_mono_citation_f";s:63:"ANHM;IOMDRI;FCC;MERCK13;MNHD;MART35;VITAR1;VITAR2;VITAR3;VITAR4";s:26:"field_reference_reviewed_e";s:34:"VITRR1;VITRR2;VITRR3;VITRR4;VITRR5";s:26:"field_reference_reviewed_f";s:34:"VITRR1;VITRR2;VITRR3;VITRR4;VITRR5";}i:216649;a:32:{s:5:"title";s:12:"VB1_Thiamine";s:3:"nid";s:6:"216649";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"VB1";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:8:"Thiamine";s:22:"field_monograph_name_f";s:8:"Thiamine";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:96:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_thiamine-eng.php";s:21:"field_monograph_url_f";s:96:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_thiamine-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2007-08-16";s:16:"field_legacy_nid";s:6:"100959";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:12:"ADU14;CH1_13";s:15:"field_dose_note";s:22:"MIN;MAXVB1;ADUL;THIDEF";s:21:"field_mono_citation_e";s:57:"CURTRE;ANHM;NHPDEAC7;IOMDRI;FCC;DRITR;MERCK13;MNHD;MART35";s:21:"field_mono_citation_f";s:57:"CURTRE;ANHM;NHPDEAC7;IOMDRI;FCC;DRITR;MERCK13;MNHD;MART35";}i:216650;a:32:{s:5:"title";s:14:"VB6_Vitamin B6";s:3:"nid";s:6:"216650";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"VB6";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:10:"Vitamin B6";s:22:"field_monograph_name_f";s:11:"Vitamine B6";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2007-11-08";s:16:"field_legacy_nid";s:6:"100960";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:26:"ADU;AD1418;AD913;CH48;CH13";s:15:"field_dose_note";s:15:"MIN;MAXVB6;ADUL";s:21:"field_mono_citation_e";s:41:"ANHM;IOMDRI;FCC;DRITR;MERCK13;MNHD;MART35";s:21:"field_mono_citation_f";s:41:"ANHM;IOMDRI;FCC;DRITR;MERCK13;MNHD;MART35";}i:216651;a:32:{s:5:"title";s:15:"V12_Vitamin B12";s:3:"nid";s:6:"216651";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"V12";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:11:"Vitamin B12";s:22:"field_monograph_name_f";s:12:"Vitamine B12";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:99:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_vitamin_b12-eng.php";s:21:"field_monograph_url_f";s:99:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_vitamin_b12-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2007-11-08";s:16:"field_legacy_nid";s:6:"100961";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:12:"ADU14;CH1_13";s:15:"field_dose_note";s:14:"MIN;MAX99;ADUL";s:21:"field_mono_citation_e";s:88:"ORCOB;OPB12;RAB12;ANHM;NHPDEAC3;IOMDRI;FCC;DRITR;MERCK13;MNHD;MART35;HYDROX;OAHYD;HOMOZY";s:21:"field_mono_citation_f";s:88:"ORCOB;OPB12;RAB12;ANHM;NHPDEAC3;IOMDRI;FCC;DRITR;MERCK13;MNHD;MART35;HYDROX;OAHYD;HOMOZY";}i:216652;a:32:{s:5:"title";s:13:"VIC_Vitamin C";s:3:"nid";s:6:"216652";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"VIC";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:9:"Vitamin C";s:22:"field_monograph_name_f";s:10:"Vitamine C";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:97:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_vitamin_c-eng.php";s:21:"field_monograph_url_f";s:97:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_vitamin_c-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2007-09-13";s:16:"field_legacy_nid";s:6:"100962";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:26:"ADU;AD1418;AD913;CH48;CH13";s:15:"field_dose_note";s:22:"MIN;MAXVIC;ADUL;VICDEF";s:21:"field_mono_citation_e";s:50:"ANHM;IOMDRI;FCC;DRIVVSC;WNDHEA;MERCK13;MNHD;MART35";s:21:"field_mono_citation_f";s:50:"ANHM;IOMDRI;FCC;DRIVVSC;WNDHEA;MERCK13;MNHD;MART35";}i:216653;a:32:{s:5:"title";s:13:"VID_Vitamin D";s:3:"nid";s:6:"216653";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"VID";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:9:"Vitamin D";s:22:"field_monograph_name_f";s:10:"Vitamine D";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2007-08-16";s:16:"field_legacy_nid";s:6:"100963";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:11:"ADU14;CH013";s:15:"field_dose_note";s:22:"MIN;MAXVID;ADUL;CONVID";s:21:"field_mono_citation_e";s:52:"ANHM;FDREG;IOMDRI;FCC;DRICP;OPDT;MERCK13;MNHD;MART35";s:21:"field_mono_citation_f";s:52:"ANHM;FDREG;IOMDRI;FCC;DRICP;OPDT;MERCK13;MNHD;MART35";}i:216654;a:35:{s:5:"title";s:52:"VIE_Vitamin E (from RRR-alpha-tocopherol and esters)";s:3:"nid";s:6:"216654";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"VIE";s:18:"field_group_name_e";s:9:"Vitamin E";s:18:"field_group_name_f";s:10:"Vitamine E";s:22:"field_monograph_name_e";s:48:"Vitamin E (from RRR-alpha-tocopherol and esters)";s:22:"field_monograph_name_f";s:47:"Vitamine E (de RRR-alpha-tocophérol et esters)";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:914:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.      Note: (i) Text in parentheses is additional optional information which can be included on the Product Licence Application and product labels at the applicants’ discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.  (ii) This monograph is only applicable when the source of Vitamin E is RRR-alpha-tocopherol and its esters.  When rac-alpha-tocopherol and its esters are the source of Vitamin E, please refer to the monograph named 'Vitamin E (from rac-alpha-tocopherol and its esters)'.";s:12:"field_note_f";s:1113:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.      Nota: (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.   (ii) Cette monographie est pertinente seulement lorsque la matière d'origine de la Vitamine E est RRR-alpha-tocophérol et ses esters.  Lorsque alpha-tocophérol totalement rac et ses esters sont la matière d'origine de la Vitamine E, veuillez vous référer à la monographie intitulée 'Vitamine E (d'alpha-tocophérol totalement rac et ses esters)'.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:358:"The medicinal ingredient may comply with the specifications outlined in the following pharmacopoeial monographs:   'RRR-alpha-Tocopherol', ''RRR-alpha-Tocopheryl Acetate', and 'RRR-alpha-Tocopheryl Hydrogen Succinate' from the European Pharmacopoeia (Ph. Eur.) or 'Vitamin E', 'Vitamin E Preparation' and 'Vitamin E Capsules' from the US Pharmacopoeia (USP).";s:21:"field_specification_f";s:370:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes:  ' 'RRR-alpha-Tocopherol', ''RRR-alpha-Tocopheryl Acetate' et 'RRR-alpha-Tocopheryl Hydrogen Succinate' de la Pharmacopée européenne (Ph. Eur.) ou 'Vitamin E', 'Vitamin E Preparation' et 'Vitamin E Capsules' de la Pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-06-18";s:16:"field_legacy_nid";s:6:"100964";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:26:"CH13;CH48;AD913;AD1418;ADU";s:15:"field_dose_note";s:30:"VIE_RRR;MIN3;MAXVE;ADUL;VIEDEF";s:15:"field_mono_risk";s:23:"VIE_CW1;VIE_CW2;VIE_CW3";s:21:"field_mono_citation_e";s:92:"AOVIT;HDNCK;VKSTAT;HERCDI;TCDRHP;COAGVE;ANHM;IOMDRI;LTVESUP;AOVCIG;EP8;MNHD;TNF27;VEBP;PROOX";s:21:"field_mono_citation_f";s:92:"AOVIT;HDNCK;VKSTAT;HERCDI;TCDRHP;COAGVE;ANHM;IOMDRI;LTVESUP;AOVCIG;EP8;MNHD;TNF27;VEBP;PROOX";s:26:"field_reference_reviewed_e";s:811:"HDSUP;CTFINL;COREV;VEPREV;CISPLA;LDLHDL;LUNGC;VECSAFE;HDNCK2;REDPCI;TIPS;NUTBIO2;FRAM;MORTOAS;GASTC;FEMTYP2;FLAWED;SPACE;LOWDENS2;MEDONC;LONGROM;HOPEVE;SIMVAS;DUTCH;MUCOSA;CCS08;MENUS;ABSURD;HVM;AOVCVE;WHIOS;POORLY;LDASP;HDAT;ENVTOB;ADENOC;PREVAC;NUMBERS;CHAP20;RTRIALS;SULVM;VEBETA;XIRRAD;HINTAKE;GISSI;PHARYN;MPHYS;STATIS;MRCBHF;SUPAT;GAMMAT;VEAPS;MEANT;ASCD;PATYRS;AOMICRO;GDTOCO;VCEA;DRIVVSC;BLADDER;LDAVE;DESERV;PROBUC;TIEN;EPICN;APPLE;PROTEOM;VEWARF;9COHO;STATCD;WHSTUDY;STROKE;LINXIAN;FIVECH;RAMIPR;MAVET;SECHNC;ANNUAL;POLYPS;NUMRES;LIPPEROX;RADTHER;ALLCAUSE;HAPTO;CHAOS;NNT;AORAD;CMCAVE;RECTAL;CARCIN;VITAL;VESCDCP;AOUSE;DIACAN;RACES;ONCOL;VECONS;CPTUAV;DFVACE;MALCELLS;ASAP;TACC;SUBFR;VCVEFOL;EDUCA;VECONS2;CHAOS2;PCCL;STGIII;VEREV;NHPUC;POSTINT;USEAOV;GTUV;DESCR;COLON;SUAMPC;SERUM;VEINT;AMTOCO;HOPESI";s:26:"field_reference_reviewed_f";s:811:"HDSUP;CTFINL;COREV;VEPREV;CISPLA;LDLHDL;LUNGC;VECSAFE;HDNCK2;REDPCI;TIPS;NUTBIO2;FRAM;MORTOAS;GASTC;FEMTYP2;FLAWED;SPACE;LOWDENS2;MEDONC;LONGROM;HOPEVE;SIMVAS;DUTCH;MUCOSA;CCS08;MENUS;ABSURD;HVM;AOVCVE;WHIOS;POORLY;LDASP;HDAT;ENVTOB;ADENOC;PREVAC;NUMBERS;CHAP20;RTRIALS;SULVM;VEBETA;XIRRAD;HINTAKE;GISSI;PHARYN;MPHYS;STATIS;MRCBHF;SUPAT;GAMMAT;VEAPS;MEANT;ASCD;PATYRS;AOMICRO;GDTOCO;VCEA;DRIVVSC;BLADDER;LDAVE;DESERV;PROBUC;TIEN;EPICN;APPLE;PROTEOM;VEWARF;9COHO;STATCD;WHSTUDY;STROKE;LINXIAN;FIVECH;RAMIPR;MAVET;SECHNC;ANNUAL;POLYPS;NUMRES;LIPPEROX;RADTHER;ALLCAUSE;HAPTO;CHAOS;NNT;AORAD;CMCAVE;RECTAL;CARCIN;VITAL;VESCDCP;AOUSE;DIACAN;RACES;ONCOL;VECONS;CPTUAV;DFVACE;MALCELLS;ASAP;TACC;SUBFR;VCVEFOL;EDUCA;VECONS2;CHAOS2;PCCL;STGIII;VEREV;NHPUC;POSTINT;USEAOV;GTUV;DESCR;COLON;SUAMPC;SERUM;VEINT;AMTOCO;HOPESI";}i:216655;a:35:{s:5:"title";s:53:"VIE2_Vitamin E (from rac-alpha-tocopherol and esters)";s:3:"nid";s:6:"216655";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"VIE2";s:18:"field_group_name_e";s:9:"Vitamin E";s:18:"field_group_name_f";s:10:"Vitamine E";s:22:"field_monograph_name_e";s:48:"Vitamin E (from rac-alpha-tocopherol and esters)";s:22:"field_monograph_name_f";s:57:"Vitamine E (d'alpha-tocophérol totalement rac et esters)";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:914:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.      Note: (i) Text in parentheses is additional optional information which can be included on the Product Licence Application and product labels at the applicants’ discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.  (ii) This monograph is only applicable when the source of Vitamin E is rac-alpha-tocopherol and its esters.  When RRR-alpha-tocopherol and its esters are the source of Vitamin E, please refer to the monograph named 'Vitamin E (from RRR-alpha-tocopherol and its esters)'.";s:12:"field_note_f";s:1103:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.      Nota: (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.   (ii) Cette monographie est pertinente seulement lorsque la matière d'origine de la Vitamine E est alpha-tocophérol totalement rac et ses esters.  Lorsque RRR-alpha-tocophérol et ses esters sont la matière d'origine de la Vitamine E, veuillez vous référer à la monographie intitulée 'Vitamine E (de RRR-alpha-tocophérol et ses esters)'.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:365:"The medicinal ingredient may comply with the specifications outlined in the following pharmacopoeial monographs:  'All-rac-alpha-Tocopherol',  'All-rac-alpha-Tocopheryl Acetate', and 'DL-alpha-Tocopheryl Hydrogen Succinate'  from the European Pharmacopoeia (Ph. Eur.) or 'Vitamin E', 'Vitamin E Preparation' and 'Vitamin E Capsules' from the US Pharmacopoeia (USP).";s:21:"field_specification_f";s:376:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes:  'All-rac-alpha-Tocopherol',  'All-rac-alpha-Tocopheryl Acetate' et 'DL-alpha-Tocopheryl Hydrogen Succinate'  de la Pharmacopée européenne (Ph. Eur.) ou 'Vitamin E', 'Vitamin E Preparation' et 'Vitamin E Capsules' de la Pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-06-18";s:16:"field_legacy_nid";s:6:"100965";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:26:"CH13;CH48;AD913;AD1418;ADU";s:15:"field_dose_note";s:31:"VIE_RAC;MIN3;MAXVE2;ADUL;VIEDEF";s:15:"field_mono_risk";s:23:"VIE_CW1;VIE_CW2;VIE_CW3";s:21:"field_mono_citation_e";s:92:"AOVIT;HDNCK;VKSTAT;HERCDI;TCDRHP;COAGVE;ANHM;IOMDRI;LTVESUP;AOVCIG;EP8;MNHD;TNF27;VEBP;PROOX";s:21:"field_mono_citation_f";s:92:"AOVIT;HDNCK;VKSTAT;HERCDI;TCDRHP;COAGVE;ANHM;IOMDRI;LTVESUP;AOVCIG;EP8;MNHD;TNF27;VEBP;PROOX";s:26:"field_reference_reviewed_e";s:811:"HDSUP;CTFINL;COREV;VEPREV;CISPLA;LDLHDL;LUNGC;VECSAFE;HDNCK2;REDPCI;TIPS;NUTBIO2;FRAM;MORTOAS;GASTC;FEMTYP2;FLAWED;SPACE;LOWDENS2;MEDONC;LONGROM;HOPEVE;SIMVAS;DUTCH;MUCOSA;CCS08;MENUS;ABSURD;HVM;AOVCVE;WHIOS;POORLY;LDASP;HDAT;ENVTOB;ADENOC;PREVAC;NUMBERS;CHAP20;RTRIALS;SULVM;VEBETA;XIRRAD;HINTAKE;GISSI;PHARYN;MPHYS;STATIS;MRCBHF;SUPAT;GAMMAT;VEAPS;MEANT;ASCD;PATYRS;AOMICRO;GDTOCO;VCEA;DRIVVSC;BLADDER;LDAVE;DESERV;PROBUC;TIEN;EPICN;APPLE;PROTEOM;VEWARF;9COHO;STATCD;WHSTUDY;STROKE;LINXIAN;FIVECH;RAMIPR;MAVET;SECHNC;ANNUAL;POLYPS;NUMRES;LIPPEROX;RADTHER;ALLCAUSE;HAPTO;CHAOS;NNT;AORAD;CMCAVE;RECTAL;CARCIN;VITAL;VESCDCP;AOUSE;DIACAN;RACES;ONCOL;VECONS;CPTUAV;DFVACE;MALCELLS;ASAP;TACC;SUBFR;VCVEFOL;EDUCA;VECONS2;CHAOS2;PCCL;STGIII;VEREV;NHPUC;POSTINT;USEAOV;GTUV;DESCR;COLON;SUAMPC;SERUM;VEINT;AMTOCO;HOPESI";s:26:"field_reference_reviewed_f";s:811:"HDSUP;CTFINL;COREV;VEPREV;CISPLA;LDLHDL;LUNGC;VECSAFE;HDNCK2;REDPCI;TIPS;NUTBIO2;FRAM;MORTOAS;GASTC;FEMTYP2;FLAWED;SPACE;LOWDENS2;MEDONC;LONGROM;HOPEVE;SIMVAS;DUTCH;MUCOSA;CCS08;MENUS;ABSURD;HVM;AOVCVE;WHIOS;POORLY;LDASP;HDAT;ENVTOB;ADENOC;PREVAC;NUMBERS;CHAP20;RTRIALS;SULVM;VEBETA;XIRRAD;HINTAKE;GISSI;PHARYN;MPHYS;STATIS;MRCBHF;SUPAT;GAMMAT;VEAPS;MEANT;ASCD;PATYRS;AOMICRO;GDTOCO;VCEA;DRIVVSC;BLADDER;LDAVE;DESERV;PROBUC;TIEN;EPICN;APPLE;PROTEOM;VEWARF;9COHO;STATCD;WHSTUDY;STROKE;LINXIAN;FIVECH;RAMIPR;MAVET;SECHNC;ANNUAL;POLYPS;NUMRES;LIPPEROX;RADTHER;ALLCAUSE;HAPTO;CHAOS;NNT;AORAD;CMCAVE;RECTAL;CARCIN;VITAL;VESCDCP;AOUSE;DIACAN;RACES;ONCOL;VECONS;CPTUAV;DFVACE;MALCELLS;ASAP;TACC;SUBFR;VCVEFOL;EDUCA;VECONS2;CHAOS2;PCCL;STGIII;VEREV;NHPUC;POSTINT;USEAOV;GTUV;DESCR;COLON;SUAMPC;SERUM;VEINT;AMTOCO;HOPESI";}i:216656;a:29:{s:5:"title";s:17:"WARE_Wart Remover";s:3:"nid";s:6:"216656";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"WARE";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:12:"Wart Remover";s:22:"field_monograph_name_f";s:21:"Anti-verrues, produit";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"C;P";s:21:"field_monograph_url_e";s:48:"atReq.do?atid=wart_remover_anti_verrues&lang=eng";s:21:"field_monograph_url_f";s:48:"atReq.do?atid=wart_remover_anti_verrues&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:0:"";s:16:"field_legacy_nid";s:6:"100966";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216657;a:35:{s:5:"title";s:24:"WHZ_O_Witch Hazel - Oral";s:3:"nid";s:6:"216657";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"WHZ_O";s:18:"field_group_name_e";s:11:"Witch Hazel";s:18:"field_group_name_f";s:10:"Hamamélis";s:22:"field_monograph_name_e";s:18:"Witch Hazel - Oral";s:22:"field_monograph_name_f";s:18:"Hamamélis - Orale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:616:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.   Notes: Text in parentheses is additional optional information which can be included on PLA and on product label at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:786:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient (ou des ingrédients) médicinal (médicinaux). La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.   Nota : La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués. Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:244:"The medicinal ingredient may comply with the specifications outlined in the Hamamelis Leaf Monograph published in the British Pharmacopoeia or the European Pharmacopoeia or the Witch hazel monograph published in the United States Pharmacopoeia.";s:21:"field_specification_f";s:253:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies Hamamelis Leaf publiées dans les pharmacopées britannique (BP) ou européenne (Ph. Eur.) et Witch Hazel publiée par la pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2010-05-17";s:16:"field_legacy_nid";s:6:"100967";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:25:"PERS;WORS;WHZO_CW;WHZO_AR";s:21:"field_mono_citation_e";s:130:"HERMED2;HBNPD;EXPCEM;ENHCI;BPH8;BHCOM;UPHCDI8;THEPHA;CHMHV;ESCOP;ECMM;AMODHER;MEDHER;BOTSAF;HERCOM;HTCH;PPP;EP8;PPHPP;GRINHV;TNF27";s:21:"field_mono_citation_f";s:130:"HERMED2;HBNPD;EXPCEM;ENHCI;BPH8;BHCOM;UPHCDI8;FLORE;PHAPHY;THEPHA;CHMHV;ESCOP;ECMM;AMODHER;MEDHER;BOTSAF;HTCH;PPP;EP8;PPHPP;GRINHV";s:26:"field_reference_reviewed_e";s:75:"BHP2;BPC;BPC2;HERCDI;KAD;THEHER;EBHM;DMH;NAE;MART35;PHC;PNCBDP;PCBDP;HAMVIR";s:26:"field_reference_reviewed_f";s:81:"BHP2;BPC;BPC2;HERCDI;KAD;THEHER;EBHM;DMH;NAE;MART35;TNF27;PHC;PNCBDP;PCBDP;HAMVIR";}i:216658;a:36:{s:5:"title";s:27:"WHZ_T_Witch Hazel - Topical";s:3:"nid";s:6:"216658";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"WHZ_T";s:18:"field_group_name_e";s:11:"Witch Hazel";s:18:"field_group_name_f";s:10:"Hamamélis";s:22:"field_monograph_name_e";s:21:"Witch Hazel - Topical";s:22:"field_monograph_name_f";s:20:"Hamamélis - Topique";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:42:"atReq.do?atid=witch.hazel.topical&lang=eng";s:21:"field_monograph_url_f";s:42:"atReq.do?atid=witch.hazel.topical&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:616:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.   Notes: Text in parentheses is additional optional information which can be included on PLA and on product label at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:786:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient (ou des ingrédients) médicinal (médicinaux). La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.   Nota : La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués. Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:244:"The medicinal ingredient may comply with the specifications outlined in the Hamamelis Leaf Monograph published in the British Pharmacopoeia or the European Pharmacopoeia or the Witch hazel monograph published in the United States Pharmacopoeia.";s:21:"field_specification_f";s:253:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies Hamamelis Leaf publiées dans les pharmacopées britannique (BP) ou européenne (Ph. Eur.) et Witch Hazel publiée par la pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2010-05-17";s:16:"field_legacy_nid";s:6:"100968";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:4:"ADU2";s:15:"field_dose_note";s:9:"APP1;SSPR";s:15:"field_mono_risk";s:17:"PERS;WORS;WHZT_AR";s:21:"field_mono_citation_e";s:130:"HERMED2;HBNPD;EXPCEM;ENHCI;BPH8;BHCOM;UPHCDI8;THEPHA;CHMHV;ESCOP;ECMM;AMODHER;MEDHER;BOTSAF;HERCOM;HTCH;PPP;EP8;PPHPP;GRINHV;TNF27";s:21:"field_mono_citation_f";s:130:"HERMED2;HBNPD;EXPCEM;ENHCI;BPH8;BHCOM;UPHCDI8;FLORE;PHAPHY;THEPHA;CHMHV;ESCOP;ECMM;AMODHER;MEDHER;BOTSAF;HTCH;PPP;EP8;PPHPP;GRINHV";s:26:"field_reference_reviewed_e";s:75:"BHP2;BPC;BPC2;HERCDI;KAD;THEHER;EBHM;DMH;NAE;MART35;PHC;PNCBDP;PCBDP;HAMVIR";s:26:"field_reference_reviewed_f";s:81:"BHP2;BPC;BPC2;HERCDI;KAD;THEHER;EBHM;DMH;NAE;MART35;TNF27;PHC;PNCBDP;PCBDP;HAMVIR";}i:216659;a:35:{s:5:"title";s:26:"WHZ_B_Witch Hazel - Buccal";s:3:"nid";s:6:"216659";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"WHZ_B";s:18:"field_group_name_e";s:11:"Witch Hazel";s:18:"field_group_name_f";s:10:"Hamamélis";s:22:"field_monograph_name_e";s:20:"Witch Hazel - Buccal";s:22:"field_monograph_name_f";s:20:"Hamamélis - Buccale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:616:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.   Notes: Text in parentheses is additional optional information which can be included on PLA and on product label at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:786:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient (ou des ingrédients) médicinal (médicinaux). La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.   Nota : La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués. Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:244:"The medicinal ingredient may comply with the specifications outlined in the Hamamelis Leaf Monograph published in the British Pharmacopoeia or the European Pharmacopoeia or the Witch hazel monograph published in the United States Pharmacopoeia.";s:21:"field_specification_f";s:253:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies Hamamelis Leaf publiées dans les pharmacopées britannique (BP) ou européenne (Ph. Eur.) et Witch Hazel publiée par la pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2010-05-17";s:16:"field_legacy_nid";s:6:"100969";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:15:"field_mono_risk";s:9:"PERS;WORS";s:21:"field_mono_citation_e";s:130:"HERMED2;HBNPD;EXPCEM;ENHCI;BPH8;BHCOM;UPHCDI8;THEPHA;CHMHV;ESCOP;ECMM;AMODHER;MEDHER;BOTSAF;HERCOM;HTCH;PPP;EP8;PPHPP;GRINHV;TNF27";s:21:"field_mono_citation_f";s:130:"HERMED2;HBNPD;EXPCEM;ENHCI;BPH8;BHCOM;UPHCDI8;FLORE;PHAPHY;THEPHA;CHMHV;ESCOP;ECMM;AMODHER;MEDHER;BOTSAF;HTCH;PPP;EP8;PPHPP;GRINHV";s:26:"field_reference_reviewed_e";s:75:"BHP2;BPC;BPC2;HERCDI;KAD;THEHER;EBHM;DMH;NAE;MART35;PHC;PNCBDP;PCBDP;HAMVIR";s:26:"field_reference_reviewed_f";s:81:"BHP2;BPC;BPC2;HERCDI;KAD;THEHER;EBHM;DMH;NAE;MART35;TNF27;PHC;PNCBDP;PCBDP;HAMVIR";}i:216660;a:36:{s:5:"title";s:31:"HWA_T_Hamamelis Water - Topical";s:3:"nid";s:6:"216660";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"HWA_T";s:18:"field_group_name_e";s:11:"Witch Hazel";s:18:"field_group_name_f";s:10:"Hamamélis";s:22:"field_monograph_name_e";s:25:"Hamamelis Water - Topical";s:22:"field_monograph_name_f";s:26:"Eau d'hamamélis - Topique";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:46:"atReq.do?atid=hamamelis.water.topical&lang=eng";s:21:"field_monograph_url_f";s:46:"atReq.do?atid=hamamelis.water.topical&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:616:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.   Notes: Text in parentheses is additional optional information which can be included on PLA and on product label at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:786:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient (ou des ingrédients) médicinal (médicinaux). La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.   Nota : La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués. Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:244:"The medicinal ingredient may comply with the specifications outlined in the Hamamelis Leaf Monograph published in the British Pharmacopoeia or the European Pharmacopoeia or the Witch hazel monograph published in the United States Pharmacopoeia.";s:21:"field_specification_f";s:253:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies Hamamelis Leaf publiées dans les pharmacopées britannique (BP) ou européenne (Ph. Eur.) et Witch Hazel publiée par la pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2010-05-17";s:16:"field_legacy_nid";s:6:"100970";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:4:"ADU2";s:15:"field_dose_note";s:13:"APP1;SSPR;HWA";s:15:"field_mono_risk";s:17:"PERS;WORS;WHZT_AR";s:21:"field_mono_citation_e";s:130:"HERMED2;HBNPD;EXPCEM;ENHCI;BPH8;BHCOM;UPHCDI8;THEPHA;CHMHV;ESCOP;ECMM;AMODHER;MEDHER;BOTSAF;HERCOM;HTCH;PPP;EP8;PPHPP;GRINHV;TNF27";s:21:"field_mono_citation_f";s:130:"HERMED2;HBNPD;EXPCEM;ENHCI;BPH8;BHCOM;UPHCDI8;FLORE;PHAPHY;THEPHA;CHMHV;ESCOP;ECMM;AMODHER;MEDHER;BOTSAF;HTCH;PPP;EP8;PPHPP;GRINHV";s:26:"field_reference_reviewed_e";s:75:"BHP2;BPC;BPC2;HERCDI;KAD;THEHER;EBHM;DMH;NAE;MART35;PHC;PNCBDP;PCBDP;HAMVIR";s:26:"field_reference_reviewed_f";s:81:"BHP2;BPC;BPC2;HERCDI;KAD;THEHER;EBHM;DMH;NAE;MART35;TNF27;PHC;PNCBDP;PCBDP;HAMVIR";}i:216661;a:35:{s:5:"title";s:30:"HWA_B_Hamamelis Water - Buccal";s:3:"nid";s:6:"216661";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"HWA_B";s:18:"field_group_name_e";s:11:"Witch Hazel";s:18:"field_group_name_f";s:10:"Hamamélis";s:22:"field_monograph_name_e";s:24:"Hamamelis Water - Buccal";s:22:"field_monograph_name_f";s:26:"Eau d'hamamélis - Buccale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:616:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.   Notes: Text in parentheses is additional optional information which can be included on PLA and on product label at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:786:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient (ou des ingrédients) médicinal (médicinaux). La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.   Nota : La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués. Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:244:"The medicinal ingredient may comply with the specifications outlined in the Hamamelis Leaf Monograph published in the British Pharmacopoeia or the European Pharmacopoeia or the Witch hazel monograph published in the United States Pharmacopoeia.";s:21:"field_specification_f";s:253:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies Hamamelis Leaf publiées dans les pharmacopées britannique (BP) ou européenne (Ph. Eur.) et Witch Hazel publiée par la pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2010-05-17";s:16:"field_legacy_nid";s:6:"100971";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:8:"APP1;HWA";s:15:"field_mono_risk";s:9:"PERS;WORS";s:21:"field_mono_citation_e";s:130:"HERMED2;HBNPD;EXPCEM;ENHCI;BPH8;BHCOM;UPHCDI8;THEPHA;CHMHV;ESCOP;ECMM;AMODHER;MEDHER;BOTSAF;HERCOM;HTCH;PPP;EP8;PPHPP;GRINHV;TNF27";s:21:"field_mono_citation_f";s:130:"HERMED2;HBNPD;EXPCEM;ENHCI;BPH8;BHCOM;UPHCDI8;FLORE;PHAPHY;THEPHA;CHMHV;ESCOP;ECMM;AMODHER;MEDHER;BOTSAF;HTCH;PPP;EP8;PPHPP;GRINHV";s:26:"field_reference_reviewed_e";s:75:"BHP2;BPC;BPC2;HERCDI;KAD;THEHER;EBHM;DMH;NAE;MART35;PHC;PNCBDP;PCBDP;HAMVIR";s:26:"field_reference_reviewed_f";s:81:"BHP2;BPC;BPC2;HERCDI;KAD;THEHER;EBHM;DMH;NAE;MART35;TNF27;PHC;PNCBDP;PCBDP;HAMVIR";}i:216662;a:36:{s:5:"title";s:35:"HWA_OP_Hamamelis Water - Ophthalmic";s:3:"nid";s:6:"216662";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"HWA_OP";s:18:"field_group_name_e";s:11:"Witch Hazel";s:18:"field_group_name_f";s:10:"Hamamélis";s:22:"field_monograph_name_e";s:28:"Hamamelis Water - Ophthalmic";s:22:"field_monograph_name_f";s:30:"Eau d'hamamélis - Ophtalmique";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:616:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.   Notes: Text in parentheses is additional optional information which can be included on PLA and on product label at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:786:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient (ou des ingrédients) médicinal (médicinaux). La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.   Nota : La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués. Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:443:"The medicinal ingredient may comply with the specifications outlined in the Hamamelis Leaf Monograph published in the British Pharmacopoeia or the European Pharmacopoeia or the Witch hazel monograph published in the United States Pharmacopoeia.; Products for ophthalmic uses must meet the specifications outlined in the current NHPD "Evidence for Quality of Finished Natural Health Products or Good Manufacturing Practices" Guidance Documents.";s:21:"field_specification_f";s:508:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies Hamamelis Leaf publiées dans les pharmacopées britannique (BP) ou européenne (Ph. Eur.) et Witch Hazel publiée par la pharmacopée américaine (USP).;  Les produits pour usage ophtalmique doivent être conformes aux spécifications énoncées dans les versions actuelles des documents "Preuves attestant de la qualité des produits de santé naturels finis ou Bonnes pratiques de fabrication" de la DPSN.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2010-05-17";s:16:"field_legacy_nid";s:6:"100972";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:5:"ADU14";s:15:"field_dose_note";s:8:"APP1;HWA";s:19:"field_mono_duration";s:8:"WHZOPDUR";s:15:"field_mono_risk";s:18:"PERS;WORS;WHZOP_CW";s:21:"field_mono_citation_e";s:130:"HERMED2;HBNPD;EXPCEM;ENHCI;BPH8;BHCOM;UPHCDI8;THEPHA;CHMHV;ESCOP;ECMM;AMODHER;MEDHER;BOTSAF;HERCOM;HTCH;PPP;EP8;PPHPP;GRINHV;TNF27";s:21:"field_mono_citation_f";s:130:"HERMED2;HBNPD;EXPCEM;ENHCI;BPH8;BHCOM;UPHCDI8;FLORE;PHAPHY;THEPHA;CHMHV;ESCOP;ECMM;AMODHER;MEDHER;BOTSAF;HTCH;PPP;EP8;PPHPP;GRINHV";s:26:"field_reference_reviewed_e";s:75:"BHP2;BPC;BPC2;HERCDI;KAD;THEHER;EBHM;DMH;NAE;MART35;PHC;PNCBDP;PCBDP;HAMVIR";s:26:"field_reference_reviewed_f";s:81:"BHP2;BPC;BPC2;HERCDI;KAD;THEHER;EBHM;DMH;NAE;MART35;TNF27;PHC;PNCBDP;PCBDP;HAMVIR";}i:216663;a:36:{s:5:"title";s:41:"ZIN_NP_Zinc (from non-picolinate sources)";s:3:"nid";s:6:"216663";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"ZIN_NP";s:18:"field_group_name_e";s:4:"Zinc";s:18:"field_group_name_f";s:4:"Zinc";s:22:"field_monograph_name_e";s:34:"Zinc (from non-picolinate sources)";s:22:"field_monograph_name_f";s:29:"Zinc (sources non picolinate)";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:32:"atReq.do?atid=zinc.mono&lang=eng";s:21:"field_monograph_url_f";s:32:"atReq.do?atid=zinc.mono&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:732:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.      Note: Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant. (ii) For Zinc sourced from Zinc picolinate, please refer to the monograph entitled `Zinc (from Zinc picolinate)'";s:12:"field_note_f";s:892:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.      Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués. (ii) Pour du zinc provenant du Picolinate de zinc, veuillez faire référence à la monographie intitulée `Zinc (du Picolinate de zinc)`.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:554:"The medicinal ingredient may comply with the specifications outlined in the following pharmacopoeias:  Zinc Acetate , Zinc Chloride, Zinc Oxide, Zinc Sulphate Monohydrate and Zinc Sulphate Heptahydrate from the British Pharmacopoeia (BP);  Zinc Acetate Dihydrate, Zinc Chloride, Zinc Oxide, Zinc Sulphate Monohydrate and Zinc Sulphate Heptahydrate from the European Pharmacopoeia (Ph. Eur.);  and Zinc Acetate, Zinc Chloride, Zinc Gluconate, Zinc Oxide, Zinc Sulfate, Zinc Sulfate Oral Solution and Zinc Sulfate Tablets from the U.S. Pharmacopoeia (USP).";s:21:"field_specification_f";s:561:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies suivantes:  Zinc Acetate , Zinc Chloride, Zinc Oxide, Zinc Sulphate Monohydrate et Zinc Sulphate Heptahydrate de la pharmacopée britannique (BP);  Zinc Acetate Dihydrate, Zinc Chloride, Zinc Oxide, Zinc Sulphate Monohydrate et Zinc Sulphate Heptahydrate de la pharmacopée européenne (Ph. Eur.);  et Zinc Acetate, Zinc Chloride, Zinc Gluconate, Zinc Oxide, Zinc Sulfate, Zinc Sulfate Oral Solution et Zinc Sulfate Tablets de la pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-07-18";s:16:"field_legacy_nid";s:6:"100973";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:33:"ADU;AD1418;AD913;CH48;CH13;INF012";s:15:"field_dose_note";s:45:"ZNCSPEC;MIN;MAXZNC;ADUL;ZNCCOP;ZINC_3;ZIN_DEF";s:15:"field_mono_risk";s:6:"ZINADR";s:21:"field_mono_citation_e";s:164:"MCBA;HALF;MFTM;AHFS;BPH8;CHDIET;EFSAA;EFSAB;EVM3;ZINCSUP;ANHM;DPD;NHPDEAC5;IOMDRI;FCC;DRIVAVK;COPFNCT;ENCNS;MERCK15;EP8;SAKAVP;SCF3Z;ZSKINH;MNHD;MART35;IRCOZI;TNF27";s:21:"field_mono_citation_f";s:164:"MCBA;HALF;MFTM;AHFS;BPH8;CHDIET;EFSAA;EFSAB;EVM3;ZINCSUP;ANHM;DPD;NHPDEAC5;IOMDRI;FCC;DRIVAVK;COPFNCT;ENCNS;MERCK15;EP8;SAKAVP;SCF3Z;ZSKINH;MNHD;MART35;IRCOZI;TNF27";s:26:"field_reference_reviewed_e";s:236:"BAILVP2;BAILVP;BAWPZN;BERNVP;BESKVP;BOSCVP;COM4;FERNVP;GODAVP;GOODVP;GUIDVP;DDLS;HCMM;LNHPD;KMSSZN;MANYVP;MEHLVP;MELIVP;READVP;RHODVP;ROTHVP;SANVPA;SANVPB;SCFEFSA;SPEETVP;SPEETVP2;STEARVP2;STEARVWP;SNCWKCH;SUGDVP;TGACMEC;WSCSDCH;WHOTEHN";s:26:"field_reference_reviewed_f";s:236:"BAILVP2;BAILVP;BAWPZN;BERNVP;BESKVP;BOSCVP;COM4;FERNVP;GODAVP;GOODVP;GUIDVP;DDLS;HCMM;LNHPD;KMSSZN;MANYVP;MEHLVP;MELIVP;READVP;RHODVP;ROTHVP;SANVPA;SANVPB;SCFEFSA;SPEETVP;SPEETVP2;STEARVP2;STEARVWP;SNCWKCH;SUGDVP;TGACMEC;WSCSDCH;WHOTEHN";}i:216664;a:36:{s:5:"title";s:35:"ZIN_PIC_Zinc (from Zinc picolinate)";s:3:"nid";s:6:"216664";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:7:"ZIN_PIC";s:18:"field_group_name_e";s:4:"Zinc";s:18:"field_group_name_f";s:4:"Zinc";s:22:"field_monograph_name_e";s:27:"Zinc (from Zinc picolinate)";s:22:"field_monograph_name_f";s:28:"Zinc (du Picolinate de Zinc)";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:746:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.      Note: Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant. (ii) For Zinc sourced from non-picolinate sources, please refer to the monograph entitled `Zinc (from non-picolinate sources)'";s:12:"field_note_f";s:900:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.      Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit. La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués. (ii) Pour du zinc ne provenant pas du Picolinate de zinc, veuillez faire référence à la monographie intitulée `Zinc (sources non picolinate)`.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-12-11";s:16:"field_legacy_nid";s:6:"100974";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:24:"ADUL_ZINC;ZINC_1;ZIN_DEF";s:19:"field_mono_duration";s:4:"ZINC";s:15:"field_mono_risk";s:7:"ZINC_CI";s:21:"field_mono_citation_e";s:164:"MCBA;HALF;MFTM;AHFS;BPH8;CHDIET;EFSAA;EFSAB;EVM3;ZINCSUP;ANHM;DPD;NHPDEAC5;IOMDRI;FCC;DRIVAVK;COPFNCT;ENCNS;MERCK15;EP8;SAKAVP;SCF3Z;ZSKINH;MNHD;MART35;IRCOZI;TNF27";s:21:"field_mono_citation_f";s:164:"MCBA;HALF;MFTM;AHFS;BPH8;CHDIET;EFSAA;EFSAB;EVM3;ZINCSUP;ANHM;DPD;NHPDEAC5;IOMDRI;FCC;DRIVAVK;COPFNCT;ENCNS;MERCK15;EP8;SAKAVP;SCF3Z;ZSKINH;MNHD;MART35;IRCOZI;TNF27";s:26:"field_reference_reviewed_e";s:236:"BAILVP2;BAILVP;BAWPZN;BERNVP;BESKVP;BOSCVP;COM4;FERNVP;GODAVP;GOODVP;GUIDVP;DDLS;HCMM;LNHPD;KMSSZN;MANYVP;MEHLVP;MELIVP;READVP;RHODVP;ROTHVP;SANVPA;SANVPB;SCFEFSA;SPEETVP;SPEETVP2;STEARVP2;STEARVWP;SNCWKCH;SUGDVP;TGACMEC;WSCSDCH;WHOTEHN";s:26:"field_reference_reviewed_f";s:236:"BAILVP2;BAILVP;BAWPZN;BERNVP;BESKVP;BOSCVP;COM4;FERNVP;GODAVP;GOODVP;GUIDVP;DDLS;HCMM;LNHPD;KMSSZN;MANYVP;MEHLVP;MELIVP;READVP;RHODVP;ROTHVP;SANVPA;SANVPB;SCFEFSA;SPEETVP;SPEETVP2;STEARVP2;STEARVWP;SNCWKCH;SUGDVP;TGACMEC;WSCSDCH;WHOTEHN";}i:216665;a:29:{s:5:"title";s:39:"MULTI_Multi-Vitamin/Mineral Supplements";s:3:"nid";s:6:"216665";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"MULTI";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:33:"Multi-Vitamin/Mineral Supplements";s:22:"field_monograph_name_f";s:41:"Multivitamines/minéraux, Suppléments de";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"C;P";s:21:"field_monograph_url_e";s:41:"atReq.do?atid=multi_vitmin_suppl&lang=eng";s:21:"field_monograph_url_f";s:41:"atReq.do?atid=multi_vitmin_suppl&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2007-10-22";s:16:"field_legacy_nid";s:6:"100975";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216666;a:36:{s:5:"title";s:46:"PSEUCH_Pseudoephedrine for children 6-12 years";s:3:"nid";s:6:"216666";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"PSEUCH";s:18:"field_group_name_e";s:15:"Pseudoephedrine";s:18:"field_group_name_f";s:17:"Pseudoéphédrine";s:22:"field_monograph_name_e";s:39:"Pseudoephedrine for children 6-12 years";s:22:"field_monograph_name_f";s:45:"Pseudoéphédrine pour enfants de 6 à 12 ans";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:994:"COMPLIANCE WITH PRECURSOR CONTROL REGULATIONS:    The Precursor Control Regulations (PCR) (JC 2010a) allows Canada to fulfill its international obligations with respect to the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988, and provides a framework for the regulation of activities involving precursor chemicals which can be used in the production of illicit drugs and substances. Under the PCR, regulated chemicals are grouped into two classes: Class A and Class B. For class A precursors such as pseudoephedrine and/or products   containing them, persons wishing to be involved in activities such as importation, exportation, production, packaging, selling, and/or providing must 
first obtain a licence.      Further information regarding compliance with the PCR, including application forms and guidance documents pertaining to the application for a Class A precursor licence, is available at: http://www.healthcanada.gc.ca/precursors.";s:12:"field_note_f";s:1156:"CONFORMITE AVEC LE REGLEMENT SUR LES PRECURSEURS:     Le Règlement sur les précurseurs (le Règlement) (JC 2010a) fournit un cadre règlementaire qui permet au Canada de s’acquitter de ses obligations contractées à l’échelle internationale dans le cadre de la Convention des Nations Unies contre le trafic illicite de stupéfiants et de substances psychotropes, 1988, et les clauses spécifiques pour la surveillance et le contrôle des précurseurs utilisés dans la production des drogues illégales. Selon le Règlement, les substances sont classées en deux catégories : catégorie A et catégorie B. Les personnes désirant importer, exporter, produire, emballer, vendre ou fournir des produits contenant des précurseurs de la catégorie A, tel que la pseudoéphédrine et/ou des produits qui en contiennent, doivent tout d’abord obtenir une licence.     Des renseignements supplémentaires concernant la conformité au Règlement, incluant les formulaires de demandes et les documents d’orientation pour l’obtention d’une licence d’un précurseur de la catégorie A sont disponibles à : http://www.santecanada.gc.ca/precurseurs.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:313:"The medicinal ingredient may comply with the specifications outlined in the following monographs:  (i) Pseudoephedrine Hydrochloride published in the European Pharmacopoeia (Ph. Eur. 2007) and   (ii) Pseudoephedrine Hydrochloride and Pseudoephedrine Sulfate monographs published in the U.S. Pharmacopeia (USP 32).";s:21:"field_specification_f";s:341:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes:  (i) 'Pseudoephedrine Hydrochloride' publiée dans la pharmacopée européenne (Ph. Eur. 2007), et  (ii) 'Pseudoephedrine Hydrochloride' et 'Pseudoephedrine Sulfate' publiées dans la pharmacopée américaine (USP 32).";s:25:"field_storage_condition_e";s:73:"Store protected from light and moisture (BP 2009, USP 32, Ph. Eur. 2007).";s:25:"field_storage_condition_f";s:91:"Entreposer à l’abri de la lumière et de l’humidité (BP 2009, USP 32, Ph. Eur. 2007).";s:10:"field_date";s:10:"2010-06-09";s:16:"field_legacy_nid";s:6:"100978";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:7:"CH_6_12";s:15:"field_dose_note";s:5:"PSEUC";s:19:"field_mono_duration";s:7:"PSEUDUR";s:15:"field_mono_risk";s:187:"PERS;WORS;PSEUC_CW1;PSEUC_CW2;PSEUC_CW3;PSEUC_CW4;PSEUC_CW5;PSEUC_CW6;PSEUC_CW7;PSEUC_CW8;PSEUC_CW9;PSEUC_CW10;PSEUC_CW11;PSEUC_CW12;PSEUC_CW13;PSEUC_CW14;PSEUC_CW15;PSEUC_ADR1;PSEUC_ADR2";s:21:"field_mono_citation_e";s:206:"PSEUCR1;PSEUCR2;PSEUCR3;PSEUCR4;PSEUCR5;PSEUCR6;PSEUCR7;PSEUCR8;PSEUCR9;PSEUCR10;PSEUCR11;PSEUCR12;PSEUCR13;PSEUCR14;PSEUCR15;PSEUCR16;PSEUCR17;PSEUCR18;PSEUCR19;PSEUCR20;PSEUCR21;PSEUCR22;PSEUCR23;PSEUCR24";s:21:"field_mono_citation_f";s:206:"PSEUCR1;PSEUCR2;PSEUCR3;PSEUCR4;PSEUCR5;PSEUCR6;PSEUCR7;PSEUCR8;PSEUCR9;PSEUCR10;PSEUCR11;PSEUCR12;PSEUCR13;PSEUCR14;PSEUCR15;PSEUCR16;PSEUCR17;PSEUCR18;PSEUCR19;PSEUCR20;PSEUCR21;PSEUCR22;PSEUCR23;PSEUCR24";s:26:"field_reference_reviewed_e";s:340:"PSEUCRR1;PSEUCRR2;PSEUCRR3;PSEUCRR4;PSEUCRR5;PSEUCRR6;PSEUCRR7;PSEUCRR8;PSEUCRR9;PSEUCRR10;PSEUCRR11;PSEUCRR12;PSEUCRR13;PSEUCRR14;PSEUCRR15;PSEUCRR16;PSEUCRR17;PSEUCRR18;PSEUCRR19;PSEUCRR20;PSEUCRR21;PSEUCRR22;PSEUCRR23;PSEUCRR24;PSEUCRR25;PSEUCRR26;PSEUCRR27;PSEUCRR28;PSEUCRR29;PSEUCRR30;PSEUCRR31;PSEUCRR32;PSEUCRR33;PSEUCRR34;PSEUCRR35";s:26:"field_reference_reviewed_f";s:340:"PSEUCRR1;PSEUCRR2;PSEUCRR3;PSEUCRR4;PSEUCRR5;PSEUCRR6;PSEUCRR7;PSEUCRR8;PSEUCRR9;PSEUCRR10;PSEUCRR11;PSEUCRR12;PSEUCRR13;PSEUCRR14;PSEUCRR15;PSEUCRR16;PSEUCRR17;PSEUCRR18;PSEUCRR19;PSEUCRR20;PSEUCRR21;PSEUCRR22;PSEUCRR23;PSEUCRR24;PSEUCRR25;PSEUCRR26;PSEUCRR27;PSEUCRR28;PSEUCRR29;PSEUCRR30;PSEUCRR31;PSEUCRR32;PSEUCRR33;PSEUCRR34;PSEUCRR35";}i:216667;a:36:{s:5:"title";s:61:"PSEUAD_Pseudoephedrine for Adolescents 13-18 years and Adults";s:3:"nid";s:6:"216667";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"PSEUAD";s:18:"field_group_name_e";s:15:"Pseudoephedrine";s:18:"field_group_name_f";s:17:"Pseudoéphédrine";s:22:"field_monograph_name_e";s:54:"Pseudoephedrine for Adolescents 13-18 years and Adults";s:22:"field_monograph_name_f";s:61:"Pseudoéphédrine pour adolescents de 13 à 18 ans et adultes";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:992:"COMPLIANCE WITH PRECURSOR CONTROL REGULATIONS:    The Precursor Control Regulations (PCR) (JC 2010) allows Canada to fulfill its international obligations with respect to the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988, and provides a framework for the regulation of activities involving precursor chemicals which can be used in the production of illicit drugs and substances. Under the PCR, regulated chemicals are grouped into two classes: Class A and Class B. For class A precursors such as pseudoephedrine and/or products  containing them, persons wishing to be involved in activities such as importation, exportation, production, packaging, selling, and/or providing must 
first obtain a licence.      Further information regarding compliance with the PCR, including application forms and guidance documents pertaining to the application for a Class A precursor licence, is available at: http://www.healthcanada.gc.ca/precursors.";s:12:"field_note_f";s:1155:"CONFORMITE AVEC LE REGLEMENT SUR LES PRECURSEURS:     Le Règlement sur les précurseurs (le Règlement) (JC 2010) fournit un cadre règlementaire qui permet au Canada de s’acquitter de ses obligations contractées à l’échelle internationale dans le cadre de la Convention des Nations Unies contre le trafic illicite de stupéfiants et de substances psychotropes, 1988, et les clauses spécifiques pour la surveillance et le contrôle des précurseurs utilisés dans la production des drogues illégales. Selon le Règlement, les substances sont classées en deux catégories : catégorie A et catégorie B. Les personnes désirant importer, exporter, produire, emballer, vendre ou fournir des produits contenant des précurseurs de la catégorie A, tel que la pseudoéphédrine et/ou des produits qui en contiennent, doivent tout d’abord obtenir une licence.     Des renseignements supplémentaires concernant la conformité au Règlement, incluant les formulaires de demandes et les documents d’orientation pour l’obtention d’une licence d’un précurseur de la catégorie A sont disponibles à : http://www.santecanada.gc.ca/precurseurs.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:313:"The medicinal ingredient may comply with the specifications outlined in the following monographs:  (i) Pseudoephedrine Hydrochloride published in the European Pharmacopoeia (Ph. Eur. 2007) and   (ii) Pseudoephedrine Hydrochloride and Pseudoephedrine Sulfate monographs published in the U.S. Pharmacopeia (USP 32).";s:21:"field_specification_f";s:341:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes:  (i) 'Pseudoephedrine Hydrochloride' publiée dans la pharmacopée européenne (Ph. Eur. 2007), et  (ii) 'Pseudoephedrine Hydrochloride' et 'Pseudoephedrine Sulfate' publiées dans la pharmacopée américaine (USP 32).";s:25:"field_storage_condition_e";s:73:"Store protected from light and moisture (BP 2009, USP 32, Ph. Eur. 2007).";s:25:"field_storage_condition_f";s:91:"Entreposer à l’abri de la lumière et de l’humidité (BP 2009, USP 32, Ph. Eur. 2007).";s:10:"field_date";s:10:"2010-06-09";s:16:"field_legacy_nid";s:6:"100979";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:5:"ADU13";s:15:"field_dose_note";s:5:"PSEUA";s:19:"field_mono_duration";s:8:"PSEUADUR";s:15:"field_mono_risk";s:207:"PERS;WORS;PSEUA_CW1;PSEUA_CW2;PSEUA_CW3;PSEUA_CW4;PSEUA_CW5;PSEUA_CW6;PSEUA_CW7;PSEUA_CW8;PSEUA_CW9;PSEUA_CW10;PSEUA_CW11;PSEUA_CW12;PSEUA_CW13;PSEUA_CW14;PSEUA_CW15;PSEUA_CW16;PSEUA_CI;PSEUA_ADR1;PSEUA_ADR2";s:21:"field_mono_citation_e";s:233:"PSEUAR1;PSEUAR2;PSEUAR3;PSEUAR4;PSEUAR5;PSEUAR6;PSEUAR7;PSEUAR8;PSEUAR9;PSEUAR10;PSEUAR11;PSEUAR12;PSEUAR13;PSEUAR14;PSEUAR15;PSEUAR16;PSEUAR17;PSEUAR18;PSEUAR19;PSEUAR20;PSEUAR21;PSEUAR22;PSEUAR23;PSEUAR24;PSEUAR25;PSEUAR26;PSEUAR27";s:21:"field_mono_citation_f";s:233:"PSEUAR1;PSEUAR2;PSEUAR3;PSEUAR4;PSEUAR5;PSEUAR6;PSEUAR7;PSEUAR8;PSEUAR9;PSEUAR10;PSEUAR11;PSEUAR12;PSEUAR13;PSEUAR14;PSEUAR15;PSEUAR16;PSEUAR17;PSEUAR18;PSEUAR19;PSEUAR20;PSEUAR21;PSEUAR22;PSEUAR23;PSEUAR24;PSEUAR25;PSEUAR26;PSEUAR27";s:26:"field_reference_reviewed_e";s:310:"PSEUARR1;PSEUARR2;PSEUARR3;PSEUARR4;PSEUARR5;PSEUARR6;PSEUARR7;PSEUARR8;PSEUARR9;PSEUARR10;PSEUARR11;PSEUARR12;PSEUARR13;PSEUARR14;PSEUARR15;PSEUARR16;PSEUARR17;PSEUARR18;PSEUARR19;PSEUARR20;PSEUARR21;PSEUARR22;PSEUARR23;PSEUARR24;PSEUARR25;PSEUARR26;PSEUARR27;PSEUARR28;PSEUARR29;PSEUARR30;PSEUARR31;PSEUARR32";s:26:"field_reference_reviewed_f";s:310:"PSEUARR1;PSEUARR2;PSEUARR3;PSEUARR4;PSEUARR5;PSEUARR6;PSEUARR7;PSEUARR8;PSEUARR9;PSEUARR10;PSEUARR11;PSEUARR12;PSEUARR13;PSEUARR14;PSEUARR15;PSEUARR16;PSEUARR17;PSEUARR18;PSEUARR19;PSEUARR20;PSEUARR21;PSEUARR22;PSEUARR23;PSEUARR24;PSEUARR25;PSEUARR26;PSEUARR27;PSEUARR28;PSEUARR29;PSEUARR30;PSEUARR31;PSEUARR32";}i:216668;a:36:{s:5:"title";s:20:"LEPHED_Ephedrine, L-";s:3:"nid";s:6:"216668";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"LEPHED";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:13:"Ephedrine, L-";s:22:"field_monograph_name_f";s:15:"Éphédrine, L-";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:986:"COMPLIANCE WITH PRECURSOR CONTROL REGULATIONS:    The Precursor Control Regulations (PCR) (JC 2010) allows Canada to fulfill its international obligations with respect to the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988, and provides a framework for the regulation of activities involving precursor chemicals which can be used in the production of illicit drugs and substances. Under the PCR, regulated chemicals are grouped into two classes: Class A and Class B. For class A precursors such as ephedrine and/or products  containing them, persons wishing to be involved in activities such as importation, exportation, production, packaging, selling, and/or providing must 
first obtain a licence.      Further information regarding compliance with the PCR, including application forms and guidance documents pertaining to the application for a Class A precursor licence, is available at: http://www.healthcanada.gc.ca/precursors.";s:12:"field_note_f";s:1151:"CONFORMITE AVEC LE REGLEMENT SUR LES PRECURSEURS:     Le Règlement sur les précurseurs (le Règlement) (JC 2010) fournit un cadre règlementaire qui permet au Canada de s’acquitter de ses obligations contractées à l’échelle internationale dans le cadre de la Convention des Nations Unies contre le trafic illicite de stupéfiants et de substances psychotropes, 1988, et les clauses spécifiques pour la surveillance et le contrôle des précurseurs utilisés dans la production des drogues illégales. Selon le Règlement, les substances sont classées en deux catégories : catégorie A et catégorie B. Les personnes désirant importer, exporter, produire, emballer, vendre ou fournir des produits contenant des précurseurs de la catégorie A, tel que l’ éphédrine et/ou des produits qui en contiennent, doivent tout d’abord obtenir une licence.     Des renseignements supplémentaires concernant la conformité au Règlement, incluant les formulaires de demandes et les documents d’orientation pour l’obtention d’une licence d’un précurseur de la catégorie A sont disponibles à : http://www.santecanada.gc.ca/precurseurs.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:354:"The medicinal ingredient may comply with the specifications outlined in the following monographs:  (i) Ephedrine Anhydrous, Ephedrine Hydrochloride and Ephedrine Hydrochloride, Racemic published in the European Pharmacopoeia (Ph. Eur. 2007) and   (ii) Ephedrine, Ephedrine Hydrochloride and Ephedrine Sulfate  published in the U.S. Pharmacopeia (USP 32).";s:21:"field_specification_f";s:370:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes: 'Ephedrine, Anyhdrous,' 'Ephedrine Hydrochloride,' et 'Ephedrine Hydrochloride, Racemic,' de la Pharmacopée européenne (Ph. Eur. 2007) ainsi que 'Ephedrine,' 'Ephedrine Hydrochloride' et 'Ephedrine Sulfate' de la Pharmacopée américaine (USP 32).";s:25:"field_storage_condition_e";s:73:"Store protected from light and moisture (BP 2009, USP 32, Ph. Eur. 2007).";s:25:"field_storage_condition_f";s:91:"Entreposer à l’abri de la lumière et de l’humidité (BP 2009, USP 32, Ph. Eur. 2007).";s:10:"field_date";s:10:"2010-07-06";s:16:"field_legacy_nid";s:6:"100980";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:5:"ADU12";s:15:"field_dose_note";s:6:"LEPHED";s:19:"field_mono_duration";s:8:"LEPHADUR";s:15:"field_mono_risk";s:248:"PERS;WORS;LEPH_CW1;LEPH_CW2;LEPH_CW3;LEPH_CW4;LEPH_CW5;LEPH_CW6;LEPH_CW7;LEPH_CW8;LEPH_CW9;LEPH_CW10;LEPH_CW11;LEPH_CW12;LEPH_CW13;LEPH_CW14;LEPH_CW15;LEPH_CW16;LEPH_CW17;LEPH_CI;LEPH_ADR1;LEPH_ADR2;LEPH_ADR3;LEPH_ADR4;LEPH_ADR5;LEPH_ADR6;LEPH_ADR7";s:21:"field_mono_citation_e";s:350:"EPHEDNR1;EPHEDNR2;EPHEDNR3;EPHEDNR4;EPHEDNR5;EPHEDNR6;EPHEDNR7;EPHEDNR8;EPHEDNR9;EPHEDNR10;EPHEDNR11;EPHEDNR12;EPHEDNR13;EPHEDNR14;EPHEDNR15;EPHEDNR16;EPHEDNR17;EPHEDNR18;EPHEDNR19;EPHEDNR20;EPHEDNR21;EPHEDNR22;EPHEDNR23;EPHEDNR24;EPHEDNR25;EPHEDNR26;EPHEDNR27;EPHEDNR28;EPHEDNR29;EPHEDNR30;EPHEDNR31;EPHEDNR32;EPHEDNR33;EPHEDNR34;EPHEDNR35;EPHEDNR36";s:21:"field_mono_citation_f";s:350:"EPHEDNR1;EPHEDNR2;EPHEDNR3;EPHEDNR4;EPHEDNR5;EPHEDNR6;EPHEDNR7;EPHEDNR8;EPHEDNR9;EPHEDNR10;EPHEDNR11;EPHEDNR12;EPHEDNR13;EPHEDNR14;EPHEDNR15;EPHEDNR16;EPHEDNR17;EPHEDNR18;EPHEDNR19;EPHEDNR20;EPHEDNR21;EPHEDNR22;EPHEDNR23;EPHEDNR24;EPHEDNR25;EPHEDNR26;EPHEDNR27;EPHEDNR28;EPHEDNR29;EPHEDNR30;EPHEDNR31;EPHEDNR32;EPHEDNR33;EPHEDNR34;EPHEDNR35;EPHEDNR36";s:26:"field_reference_reviewed_e";s:606:"EPHEDNRR1;EPHEDNRR2;EPHEDNRR3;EPHEDNRR4;EPHEDNRR5;EPHEDNRR6;EPHEDNRR7;EPHEDNRR8;EPHEDNRR9;EPHEDNRR10;EPHEDNRR11;EPHEDNRR12;EPHEDNRR13;EPHEDNRR14;EPHEDNRR15;EPHEDNRR16;EPHEDNRR17;EPHEDNRR18;EPHEDNRR19;EPHEDNRR20;EPHEDNRR21;EPHEDNRR22;EPHEDNRR23;EPHEDNRR24;EPHEDNRR25;EPHEDNRR26;EPHEDNRR27;EPHEDNRR28;EPHEDNRR29;EPHEDNRR30;EPHEDNRR31;EPHEDNRR32;EPHEDNRR33;EPHEDNRR34;EPHEDNRR35;EPHEDNRR36;EPHEDNRR37;EPHEDNRR38;EPHEDNRR39;EPHEDNRR40;EPHEDNRR41;EPHEDNRR42;EPHEDNRR43;EPHEDNRR44;EPHEDNRR45;EPHEDNRR46;EPHEDNRR47;EPHEDNRR48;EPHEDNRR49;EPHEDNRR50;EPHEDNRR51;EPHEDNRR52;EPHEDNRR53;EPHEDNRR54;EPHEDNRR55;EPHEDNRR56";s:26:"field_reference_reviewed_f";s:606:"EPHEDNRR1;EPHEDNRR2;EPHEDNRR3;EPHEDNRR4;EPHEDNRR5;EPHEDNRR6;EPHEDNRR7;EPHEDNRR8;EPHEDNRR9;EPHEDNRR10;EPHEDNRR11;EPHEDNRR12;EPHEDNRR13;EPHEDNRR14;EPHEDNRR15;EPHEDNRR16;EPHEDNRR17;EPHEDNRR18;EPHEDNRR19;EPHEDNRR20;EPHEDNRR21;EPHEDNRR22;EPHEDNRR23;EPHEDNRR24;EPHEDNRR25;EPHEDNRR26;EPHEDNRR27;EPHEDNRR28;EPHEDNRR29;EPHEDNRR30;EPHEDNRR31;EPHEDNRR32;EPHEDNRR33;EPHEDNRR34;EPHEDNRR35;EPHEDNRR36;EPHEDNRR37;EPHEDNRR38;EPHEDNRR39;EPHEDNRR40;EPHEDNRR41;EPHEDNRR42;EPHEDNRR43;EPHEDNRR44;EPHEDNRR45;EPHEDNRR46;EPHEDNRR47;EPHEDNRR48;EPHEDNRR49;EPHEDNRR50;EPHEDNRR51;EPHEDNRR52;EPHEDNRR53;EPHEDNRR54;EPHEDNRR55;EPHEDNRR56";}i:216669;a:36:{s:5:"title";s:18:"CHASET_Chaste tree";s:3:"nid";s:6:"216669";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"CHASET";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:11:"Chaste tree";s:22:"field_monograph_name_f";s:5:"Vitex";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:616:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.   Notes: Text in parentheses is additional optional information which can be included on PLA and on product label at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:786:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient (ou des ingrédients) médicinal (médicinaux). La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.   Nota : La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués. Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:312:"The medicinal ingredient may comply with the specifications outlined in the following monographs:  (i) Agnus Castus Fruit published in the European Pharmacopoeia (Ph. Eur. 2007) and British Pharmacopoeia (BP)  (ii) Chaste Tree, Powdered Chaste Tree, Powdered Chaste Tree Extract in the U.S. Pharmacopeia (USP 32)";s:21:"field_specification_f";s:311:"ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales suivantes:Agnus Castus Fruit dans les pharmacopées britanniques (BP), européenne (Ph. Eur.). (ii) Chaste Tree, Powdered Chaste Tree, Powdered Chaste Tree Extract dans les pharmacopée américaine (USP)";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2010-06-09";s:16:"field_legacy_nid";s:6:"100981";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:6:"CHASED";s:19:"field_mono_duration";s:8:"CHASEDUR";s:15:"field_mono_risk";s:19:"PERS;WORS;CHASE_CW1";s:21:"field_mono_citation_e";s:170:"CHASER1;CHASER2;CHASER3;CHASER4;CHASER5;CHASER6;CHASER7;CHASER8;CHASER9;CHASER10;CHASER11;CHASER12;CHASER13;CHASER14;CHASER15;CHASER16;CHASER17;CHASER18;CHASER19;CHASER20";s:21:"field_mono_citation_f";s:170:"CHASER1;CHASER2;CHASER3;CHASER4;CHASER5;CHASER6;CHASER7;CHASER8;CHASER9;CHASER10;CHASER11;CHASER12;CHASER13;CHASER14;CHASER15;CHASER16;CHASER17;CHASER18;CHASER19;CHASER20";s:26:"field_reference_reviewed_e";s:44:"CHASERR1;CHASERR2;CHASERR3;CHASERR4;CHASERR5";s:26:"field_reference_reviewed_f";s:44:"CHASERR1;CHASERR2;CHASERR3;CHASERR4;CHASERR5";}i:216670;a:35:{s:5:"title";s:40:"DGL_O_Deglycyrrhizinated licorice - Oral";s:3:"nid";s:6:"216670";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"DGL_O";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:34:"Deglycyrrhizinated licorice - Oral";s:22:"field_monograph_name_f";s:36:"Réglisse déglycyrrhizinée - Orale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:616:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.   Notes: Text in parentheses is additional optional information which can be included on PLA and on product label at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:786:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient (ou des ingrédients) médicinal (médicinaux). La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.   Nota : La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués. Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:294:"The finished product must not contain more than 3% of the original quantity of glycyrrhizic acid found in the source material (Bradley 1992);
The medicinal ingredient may comply with the specifications outlined in the Deglycyrrhizinised Liquorice Extract of the British Pharmacopoeia (BP 1988).";s:21:"field_specification_f";s:331:"Le produit fini ne doit pas contenir plus de 3% de la quantité originale d’acide glycyrrhizique présente dans la matière d’origine (Bradley 1992);
 L’ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie Deglycyrrhizinised Liquorice Extract de la pharmacopée britannique (BP 1988).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2010-10-15";s:16:"field_legacy_nid";s:6:"100982";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:25:"CH24;ADU15;CH_5_9;CH10_14";s:15:"field_dose_note";s:13:"DGLO_1;DGLO_2";s:15:"field_mono_risk";s:9:"PERS;WORS";s:21:"field_mono_citation_e";s:116:"DGLR1;DGLR2;DGLR3;DGLR4;DGLR5;DGLR6;DGLR7;DGLR8;DGLR9;DGLR10;DGLR11;DGLR12;DGLR13;DGLR14;DGLR15;DGLR16;DGLR17;DGLR18";s:21:"field_mono_citation_f";s:116:"DGLR1;DGLR2;DGLR3;DGLR4;DGLR5;DGLR6;DGLR7;DGLR8;DGLR9;DGLR10;DGLR11;DGLR12;DGLR13;DGLR14;DGLR15;DGLR16;DGLR17;DGLR18";s:26:"field_reference_reviewed_e";s:157:"DGLRR1;DGLRR2;DGLRR3;DGLRR4;DGLRR5;DGLRR6;DGLRR7;DGLRR8;DGLRR9;DGLRR10;DGLRR11;DGLRR12;DGLRR13;DGLRR14;DGLRR15;DGLRR16;DGLRR17;DGLRR18;DGLRR19;DGLRR20;EXPDGL";s:26:"field_reference_reviewed_f";s:157:"DGLRR1;DGLRR2;DGLRR3;DGLRR4;DGLRR5;DGLRR6;DGLRR7;DGLRR8;DGLRR9;DGLRR10;DGLRR11;DGLRR12;DGLRR13;DGLRR14;DGLRR15;DGLRR16;DGLRR17;DGLRR18;DGLRR19;DGLRR20;EXPDGL";}i:216671;a:35:{s:5:"title";s:42:"DGL_B_Deglycyrrhizinated licorice - Buccal";s:3:"nid";s:6:"216671";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"DGL_B";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:36:"Deglycyrrhizinated licorice - Buccal";s:22:"field_monograph_name_f";s:38:"Réglisse déglycyrrhizinée - Buccale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:616:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.   Notes: Text in parentheses is additional optional information which can be included on PLA and on product label at the applicant’s discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:786:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient (ou des ingrédients) médicinal (médicinaux). La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.   Nota : La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués. Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:294:"The finished product must not contain more than 3% of the original quantity of glycyrrhizic acid found in the source material (Bradley 1992);
The medicinal ingredient may comply with the specifications outlined in the Deglycyrrhizinised Liquorice Extract of the British Pharmacopoeia (BP 1988).";s:21:"field_specification_f";s:331:"Le produit fini ne doit pas contenir plus de 3% de la quantité originale d’acide glycyrrhizique présente dans la matière d’origine (Bradley 1992);
 L’ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie Deglycyrrhizinised Liquorice Extract de la pharmacopée britannique (BP 1988).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2010-10-15";s:16:"field_legacy_nid";s:6:"100983";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:25:"CH24;ADU15;CH_5_9;CH10_14";s:15:"field_dose_note";s:13:"DGLB_1;DGLB_2";s:15:"field_mono_risk";s:9:"PERS;WORS";s:21:"field_mono_citation_e";s:116:"DGLR1;DGLR2;DGLR3;DGLR4;DGLR5;DGLR6;DGLR7;DGLR8;DGLR9;DGLR10;DGLR11;DGLR12;DGLR13;DGLR14;DGLR15;DGLR16;DGLR17;DGLR18";s:21:"field_mono_citation_f";s:116:"DGLR1;DGLR2;DGLR3;DGLR4;DGLR5;DGLR6;DGLR7;DGLR8;DGLR9;DGLR10;DGLR11;DGLR12;DGLR13;DGLR14;DGLR15;DGLR16;DGLR17;DGLR18";s:26:"field_reference_reviewed_e";s:157:"DGLRR1;DGLRR2;DGLRR3;DGLRR4;DGLRR5;DGLRR6;DGLRR7;DGLRR8;DGLRR9;DGLRR10;DGLRR11;DGLRR12;DGLRR13;DGLRR14;DGLRR15;DGLRR16;DGLRR17;DGLRR18;DGLRR19;DGLRR20;EXPDGL";s:26:"field_reference_reviewed_f";s:157:"DGLRR1;DGLRR2;DGLRR3;DGLRR4;DGLRR5;DGLRR6;DGLRR7;DGLRR8;DGLRR9;DGLRR10;DGLRR11;DGLRR12;DGLRR13;DGLRR14;DGLRR15;DGLRR16;DGLRR17;DGLRR18;DGLRR19;DGLRR20;EXPDGL";}i:216672;a:29:{s:5:"title";s:21:"COUI_Counterirritants";s:3:"nid";s:6:"216672";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"COUI";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:16:"Counterirritants";s:22:"field_monograph_name_f";s:16:"Contre-irritants";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"C;P";s:21:"field_monograph_url_e";s:30:"atReq.do?atid=counter&lang=eng";s:21:"field_monograph_url_f";s:30:"atReq.do?atid=counter&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-12-03";s:16:"field_legacy_nid";s:6:"100984";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216673;a:29:{s:5:"title";s:37:"ARNSS_Arnica - semisolid dosage forms";s:3:"nid";s:6:"216673";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"ARNSS";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:31:"Arnica - semisolid dosage forms";s:22:"field_monograph_name_f";s:41:"Arnica - formes posologiques semi-solides";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:34:"atReq.do?atid=arnica.semi&lang=eng";s:21:"field_monograph_url_f";s:34:"atReq.do?atid=arnica.semi&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:0:"";s:16:"field_legacy_nid";s:6:"100985";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216674;a:29:{s:5:"title";s:59:"MAREI_Marigold Extract and Isolates (Lutein and Zeaxanthin)";s:3:"nid";s:6:"216674";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"MAREI";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:53:"Marigold Extract and Isolates (Lutein and Zeaxanthin)";s:22:"field_monograph_name_f";s:69:"Tagète rose d'Inde et isolats (lutéine et zéaxanthine), Extrait du";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"C;P";s:21:"field_monograph_url_e";s:28:"atReq.do?atid=marei&lang=eng";s:21:"field_monograph_url_f";s:28:"atReq.do?atid=marei&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:0:"";s:16:"field_legacy_nid";s:6:"100986";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216675;a:34:{s:5:"title";s:58:"AHCC_Active hexose correlated compound - Granule (AHCC-FG)";s:3:"nid";s:6:"216675";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"AHCC";s:18:"field_group_name_e";s:4:"AHCC";s:18:"field_group_name_f";s:4:"AHCC";s:22:"field_monograph_name_e";s:53:"Active hexose correlated compound - Granule (AHCC-FG)";s:22:"field_monograph_name_f";s:53:"Composé corrélé d'hexose actif - Granule (AHCC-FG)";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:669:"For products in powder form, please refer to the “Active Hexose Correlated Compound – Powder (AHCC-FD)” monograph.; This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:782:"A noter:  Pour les produits sous formes de poudre, se référer à la monographie « Composé Corrélé d’Hexose Actif - Poudre (AHCC-FD) ».; La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:128:"The medicinal ingredient must comply with the requirements outlined in the Natural Health Products Ingredients Database (NHPID).";s:21:"field_specification_f";s:156:"L’ingrédient médicinal doit être conforme aux exigences mentionnées dans la Base de données d’ingrédients de produits de santé naturels (BDIPSN).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2012-11-15";s:16:"field_legacy_nid";s:6:"100988";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_mono_risk";s:8:"AHCC_ADR";s:21:"field_mono_citation_e";s:56:"AHCC1;AHCC2;AHCC5;AHCC7;AHCC8;AHCC9;AHCC27;AHCC30;AHCC31";s:21:"field_mono_citation_f";s:56:"AHCC1;AHCC2;AHCC5;AHCC7;AHCC8;AHCC9;AHCC27;AHCC30;AHCC31";s:26:"field_reference_reviewed_e";s:171:"AHCC34;AHCC11;AHCC12;AHCC13;AHCC33;AHCC14;AHCC15;AHCC16;AHCC17;AHCC18;AHCC19;AHCC3;AHCC4;AHCC20;AHCC21;AHCC6;AHCC22;AHCC23;AHCC24;AHCC25;AHCC26;AHCC10;AHCC28;AHCC29;AHCC32";s:26:"field_reference_reviewed_f";s:171:"AHCC34;AHCC11;AHCC12;AHCC13;AHCC33;AHCC14;AHCC15;AHCC16;AHCC17;AHCC18;AHCC19;AHCC3;AHCC4;AHCC20;AHCC21;AHCC6;AHCC22;AHCC23;AHCC24;AHCC25;AHCC26;AHCC10;AHCC28;AHCC29;AHCC32";}i:216676;a:34:{s:5:"title";s:58:"AHCC2_Active hexose correlated compound - Powder (AHCC-FD)";s:3:"nid";s:6:"216676";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"AHCC2";s:18:"field_group_name_e";s:4:"AHCC";s:18:"field_group_name_f";s:4:"AHCC";s:22:"field_monograph_name_e";s:52:"Active hexose correlated compound - Powder (AHCC-FD)";s:22:"field_monograph_name_f";s:52:"Composé corrélé d'hexose actif - Poudre (AHCC-FD)";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:671:"For products in granule form, please refer to the “Active Hexose Correlated Compound – Granule (AHCC-FG)” monograph.; This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:783:"A noter:  Pour les produits sous forme de granule, se référer à la monographie « Composé Corrélé d’Hexose Actif - Granule (AHCC-FG) ».; La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:128:"The medicinal ingredient must comply with the requirements outlined in the Natural Health Products Ingredients Database (NHPID).";s:21:"field_specification_f";s:156:"L’ingrédient médicinal doit être conforme aux exigences mentionnées dans la Base de données d’ingrédients de produits de santé naturels (BDIPSN).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2012-11-15";s:16:"field_legacy_nid";s:6:"100989";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_mono_risk";s:8:"AHCC_ADR";s:21:"field_mono_citation_e";s:63:"AHCC1;AHCC2;AHCC5;AHCC7;AHCC8;AHCC9;AHCC10;AHCC27;AHCC30;AHCC31";s:21:"field_mono_citation_f";s:63:"AHCC1;AHCC2;AHCC5;AHCC7;AHCC8;AHCC9;AHCC10;AHCC27;AHCC30;AHCC31";s:26:"field_reference_reviewed_e";s:164:"AHCC34;AHCC11;AHCC12;AHCC13;AHCC33;AHCC14;AHCC15;AHCC16;AHCC17;AHCC18;AHCC19;AHCC3;AHCC4;AHCC20;AHCC21;AHCC6;AHCC22;AHCC23;AHCC24;AHCC25;AHCC26;AHCC28;AHCC29;AHCC32";s:26:"field_reference_reviewed_f";s:164:"AHCC34;AHCC11;AHCC12;AHCC13;AHCC33;AHCC14;AHCC15;AHCC16;AHCC17;AHCC18;AHCC19;AHCC3;AHCC4;AHCC20;AHCC21;AHCC6;AHCC22;AHCC23;AHCC24;AHCC25;AHCC26;AHCC28;AHCC29;AHCC32";}i:216677;a:35:{s:5:"title";s:14:"QUER_Quercetin";s:3:"nid";s:6:"216677";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"QUER";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:9:"Quercetin";s:22:"field_monograph_name_f";s:11:"Quercétine";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:626:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant. (iii) A claim for traditional use must include the term “Herbal Medicine”.";s:12:"field_note_f";s:744:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués. (iii) Une allégation pour un usage traditionnel doit inclure le terme « phytothérapie/herboristerie ».";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:298:"The medicinal ingredient must comply with the requirements outlined in the Natural Health Products Ingredients Database (NHPID). In addition, the medicinal ingredient may comply with the quality specifications outlined in the Quercetin dihydrate monograph in the British and European Pharmcopoeias.";s:21:"field_specification_f";s:365:"L’ingrédient médicinal doit être conforme aux exigences mentionnées dans la Base de données d’ingrédients de produits de santé naturels (BDIPSN). De plus, l’ingrédient médicinal peut être conforme aux spécifications de qualité énoncées dans la monographie Quercétine dihydratée/Quercetin dihydrate des pharmacopées britannique et européenne.";s:25:"field_storage_condition_e";s:52:"Store in a light-resistant container (Ph.Eur. 2013).";s:25:"field_storage_condition_f";s:75:"Entreposer dans un contenant à l’épreuve de la lumière (Ph.Eur. 2013).";s:10:"field_date";s:10:"2012-11-27";s:16:"field_legacy_nid";s:6:"100992";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:19:"field_mono_duration";s:7:"QUERDUR";s:15:"field_mono_risk";s:7:"QUER_CW";s:21:"field_mono_citation_e";s:158:"QUER1;QUER2;QUER3;QUER4;QUER5;QUER6;QUER7;QUER8;QUER9;QUER10;QUER11;QUER12;QUER13;QUER48;QUER15;QUER31;QUER45;QUER16;QUER27;QUER49;QUER50;QUER51;QUER52;QUER53";s:21:"field_mono_citation_f";s:165:"QUER1;QUER2;QUER3;QUER4;QUER5;QUER6;QUER7;QUER8;QUER9;QUER10;QUER11;QUER12;QUER13;QUER48;QUER47;QUER15;QUER31;QUER45;QUER16;QUER27;QUER49;QUER50;QUER51;QUER52;QUER53";s:26:"field_reference_reviewed_e";s:202:"QUER14;QUER16;QUER17;QUER18;QUER19;QUER20;QUER21;QUER22;QUER23;QUER24;QUER25;QUER26;QUER28;QUER29;QUER30;QUER32;QUER33;QUER34;QUER35;QUER36;QUER37;QUER38;QUER39;QUER40;QUER41;QUER42;QUER43;QUER44;QUER46";s:26:"field_reference_reviewed_f";s:202:"QUER14;QUER16;QUER17;QUER18;QUER19;QUER20;QUER21;QUER22;QUER23;QUER24;QUER25;QUER26;QUER28;QUER29;QUER30;QUER32;QUER33;QUER34;QUER35;QUER36;QUER37;QUER38;QUER39;QUER40;QUER41;QUER42;QUER43;QUER44;QUER46";}i:216678;a:35:{s:5:"title";s:9:"RUT_Rutin";s:3:"nid";s:6:"216678";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"RUT";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:5:"Rutin";s:22:"field_monograph_name_f";s:6:"Rutine";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:547:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:637:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:309:"The medicinal ingredient must comply with the requirements outlined in the Natural Health Products Ingredients Database (NHPID). In addition, the medicinal ingredient may comply with the quality specifications outlined in the Rutin or Rutoside Trihydrate monographs of the British and European Pharmacopoeias.";s:21:"field_specification_f";s:354:"L’ingrédient médicinal doit être conforme aux exigences mentionnées dans la Base de données d’ingrédients de produits de santé naturels (BDIPSN). De plus, l’ingrédient médicinal peut être conforme aux spécifications de qualité énoncées dans les monographies Rutine ou Rutoside Trihydraté des pharmacopées britannique et européenne.";s:25:"field_storage_condition_e";s:52:"Store in a light-resistant container (Ph.Eur. 2013).";s:25:"field_storage_condition_f";s:75:"Entreposer dans un contenant à l’épreuve de la lumière (Ph.Eur. 2013).";s:10:"field_date";s:10:"2012-11-27";s:16:"field_legacy_nid";s:6:"100993";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:19:"field_mono_duration";s:6:"RUTDUR";s:15:"field_mono_risk";s:6:"RUT_CW";s:21:"field_mono_citation_e";s:95:"QUER1;RUT1;QUER3;QUER4;QUER22;QUER7;RUT2;QUER8;RUT3;QUER12;QUER9;QUER11;RUT4;RUT9;QUER49;QUER52";s:21:"field_mono_citation_f";s:100:"QUER1;RUT1;QUER3;QUER4;QUER22;QUER7;RUT2;QUER8;RUT3;QUER12;QUER9;QUER11;RUT4;RUT8;RUT9;QUER49;QUER52";s:26:"field_reference_reviewed_e";s:14:"RUT5;RUT6;RUT7";s:26:"field_reference_reviewed_f";s:14:"RUT5;RUT6;RUT7";}i:216679;a:35:{s:5:"title";s:31:"AMLA_Amla - Phyllanthus emblica";s:3:"nid";s:6:"216679";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"AMLA";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:26:"Amla - Phyllanthus emblica";s:22:"field_monograph_name_f";s:26:"Amla - Phyllanthus emblica";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:547:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:637:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:128:"The medicinal ingredient must comply with the requirements outlined in the Natural Health Products Ingredients Database (NHPID).";s:21:"field_specification_f";s:156:"L’ingrédient médicinal doit être conforme aux exigences mentionnées dans la Base de données d’ingrédients de produits de santé naturels (BDIPSN).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2012-11-27";s:16:"field_legacy_nid";s:6:"100994";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";s:19:"field_subpopulation";s:3:"ADU";s:19:"field_mono_duration";s:16:"AMLADUR;AMLADUR2";s:15:"field_mono_risk";s:25:"AMLA_CW;AMLA_CW2;AMLA_ADR";s:21:"field_mono_citation_e";s:124:"TURM1;AMLA1;AMLA2;AMLA3;AMLA4;AMLA24;TURM8;MMIT;AMLA5;AMLA6;BOTSAF;AMLA25;TURM14;AMLA7;NPPT;AMLA8;AMLA9;AMLA10;TURM22;AMLA26";s:21:"field_mono_citation_f";s:131:"TURM1;AMLA1;AMLA2;AMLA3;AMLA4;AMLA24;TURM8;MMIT;AMLA5;AMLA6;BOTSAF;AMLA25;TURM14;AMLA7;NPPT;AMLA8;AMLA9;AMLA10;TURM22;AMLA23;AMLA26";s:26:"field_reference_reviewed_e";s:139:"AMLA11;HERCDI;AMLA12;AMLA13;AMLA14;AMLA15;AMLA16;AMLA17;AMLA18;HERSAF;AMLA19;AMLA20;AMLA21;AMLA22;AMLA27;AMLA28;AMLA29;AMLA30;AMLA31;AMLA32";s:26:"field_reference_reviewed_f";s:139:"AMLA11;HERCDI;AMLA12;AMLA13;AMLA14;AMLA15;AMLA16;AMLA17;AMLA18;HERSAF;AMLA19;AMLA20;AMLA21;AMLA22;AMLA27;AMLA28;AMLA29;AMLA30;AMLA31;AMLA32";}i:216681;a:36:{s:5:"title";s:37:"TRIB_Tribulus – Tribulus terrestris";s:3:"nid";s:6:"216681";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"TRIB";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:32:"Tribulus – Tribulus terrestris";s:22:"field_monograph_name_f";s:32:"Tribulus – Tribulus terrestris";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:686:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.   Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant. (iii) A claim for traditional use must include the term “Traditional Chinese Medicine”, “Ayurveda”, or “Ayurvedic medicine”.";s:12:"field_note_f";s:801:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués. (iii) Une allégation pour un usage traditionnel doit inclure les termes « Médecine Traditionnelle Chinoise » ou « Médecine Ayurvédique » ou « Ayurveda ».";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:128:"The medicinal ingredient must comply with the requirements outlined in the Natural Health Products Ingredients Database (NHPID).";s:21:"field_specification_f";s:156:"L’ingrédient médicinal doit être conforme aux exigences mentionnées dans la Base de données d’ingrédients de produits de santé naturels (BDIPSN).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-01-22";s:16:"field_legacy_nid";s:6:"101011";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:7:"TRIB_OR";s:14:"field_mono_use";s:60:"TRIB1;TRIB2;TRIB3;TRIB4;TRIB5;TRIB6;TRIB7;TRIB8;TRIB9;TRIB10";s:19:"field_subpopulation";s:3:"ADU";s:19:"field_mono_duration";s:4:"TRIB";s:15:"field_mono_risk";s:64:"TRIB_CW2;TRIB_CW3;TRIB_CW4;TRIB_CI1;TRIB_CI2;TRIB_ADR1;TRIB_ADR2";s:21:"field_mono_citation_e";s:81:"TRIB1;TRIB2;TRIB3;TRIB4;TRIB5;TRIB6;TRIB7;TRIB8;TRIB9;TRIB10;TRIB11;TRIB12;TRIB13";s:21:"field_mono_citation_f";s:88:"TRIB1;TRIB2;TRIB3;TRIB4;TRIB5;TRIB6;TRIB7;TRIB8;TRIB9;TRIB10;TRIB11;TRIB12;TRIB13;TRIB14";s:26:"field_reference_reviewed_e";s:216:"TRIB15;TRIB16;TRIB17;TRIB18;TRIB19;TRIB20;TRIB21;TRIB22;TRIB23;TRIB24;TRIB25;TRIB26;TRIB27;TRIB28;TRIB29;TRIB30;TRIB31;TRIB32;TRIB33;TRIB34;TRIB35;TRIB36;TRIB37;TRIB38;TRIB39;TRIB40;TRIB41;TRIB42;TRIB43;TRIB44;TRIB45";s:26:"field_reference_reviewed_f";s:216:"TRIB15;TRIB16;TRIB17;TRIB18;TRIB19;TRIB20;TRIB21;TRIB22;TRIB23;TRIB24;TRIB25;TRIB26;TRIB27;TRIB28;TRIB29;TRIB30;TRIB31;TRIB32;TRIB33;TRIB34;TRIB35;TRIB36;TRIB37;TRIB38;TRIB39;TRIB40;TRIB41;TRIB42;TRIB43;TRIB44;TRIB45";}i:216682;a:29:{s:5:"title";s:11:"NOS_Nosodes";s:3:"nid";s:6:"216682";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"NOS";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:7:"Nosodes";s:22:"field_monograph_name_f";s:7:"Nosodes";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"P";s:21:"field_monograph_url_e";s:30:"atReq.do?atid=nosodes&lang=eng";s:21:"field_monograph_url_f";s:30:"atReq.do?atid=nosodes&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-06-24";s:16:"field_legacy_nid";s:6:"101038";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216683;a:35:{s:5:"title";s:28:"ACAI_Acai - Euterpe oleracea";s:3:"nid";s:6:"216683";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"ACAI";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:23:"Acai - Euterpe oleracea";s:22:"field_monograph_name_f";s:25:"Açaï - Euterpe oleracea";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:549:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.   Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:637:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:128:"The medicinal ingredient must comply with the requirements outlined in the Natural Health Products Ingredients Database (NHPID).";s:21:"field_specification_f";s:156:"L’ingrédient médicinal doit être conforme aux exigences mentionnées dans la Base de données d’ingrédients de produits de santé naturels (BDIPSN).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-01-15";s:16:"field_legacy_nid";s:6:"101013";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:7:"ACAI_OR";s:14:"field_mono_use";s:5:"ACAI1";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_mono_risk";s:16:"ACAI_CW;ACAI_ADR";s:21:"field_mono_citation_e";s:67:"ACAI1;ACAI2;ACAI3;ACAI4;ACAI5;ACAI6;ACAI7;ACAI8;ACAI9;ACAI10;ACAI17";s:21:"field_mono_citation_f";s:74:"ACAI1;ACAI2;ACAI3;ACAI4;ACAI5;ACAI6;ACAI7;ACAI8;ACAI9;ACAI10;ACAI11;ACAI17";s:26:"field_reference_reviewed_e";s:48:"ACAI12;ACAI13;ACAI14;ACAI15;ACAI16;ACAI20;ACAI21";s:26:"field_reference_reviewed_f";s:48:"ACAI12;ACAI13;ACAI14;ACAI15;ACAI16;ACAI20;ACAI21";}i:216684;a:36:{s:5:"title";s:28:"MACA_Maca - Lepidium meyenii";s:3:"nid";s:6:"216684";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"MACA";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:23:"Maca - Lepidium meyenii";s:22:"field_monograph_name_f";s:23:"Maca - Lepidium meyenii";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:549:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.   Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:637:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:128:"The medicinal ingredient must comply with the requirements outlined in the Natural Health Products Ingredients Database (NHPID).";s:21:"field_specification_f";s:156:"L’ingrédient médicinal doit être conforme aux exigences mentionnées dans la Base de données d’ingrédients de produits de santé naturels (BDIPSN).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-03-06";s:16:"field_legacy_nid";s:6:"101014";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:7:"MACA_OR";s:14:"field_mono_use";s:17:"MACA1;MACA2;MACA3";s:19:"field_subpopulation";s:3:"ADU";s:19:"field_mono_duration";s:17:"MACADUR1;MACADUR2";s:15:"field_mono_risk";s:44:"MACA_CW1;MACA_CW2;MACA_CW3;MACA_CW4;MACA_CW5";s:21:"field_mono_citation_e";s:88:"MACA1;MACA2;MACA3;MACA4;MACA5;MACA6;MACA7;MACA8;MACA9;MACA10;MACA11;MACA12;MACA13;MACA33";s:21:"field_mono_citation_f";s:95:"MACA1;MACA2;MACA3;MACA4;MACA5;MACA6;MACA7;MACA8;MACA9;MACA10;MACA11;MACA12;MACA13;MACA14;MACA33";s:26:"field_reference_reviewed_e";s:125:"MACA15;MACA16;MACA17;MACA18;MACA19;MACA20;MACA21;MACA22;MACA23;MACA25;MACA26;MACA27;MACA28;MACA29;MACA30;MACA31;MACA32;MACA24";s:26:"field_reference_reviewed_f";s:125:"MACA15;MACA16;MACA17;MACA18;MACA19;MACA20;MACA21;MACA22;MACA23;MACA25;MACA26;MACA27;MACA28;MACA29;MACA30;MACA31;MACA32;MACA24";}i:216685;a:36:{s:5:"title";s:31:"CIN_Cinnamon - Cinnamomum verum";s:3:"nid";s:6:"216685";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"CIN";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:27:"Cinnamon - Cinnamomum verum";s:22:"field_monograph_name_f";s:27:"Cannelle - Cinnamomum verum";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:655:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.   Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant. (iii) A claim for a traditional use must include either the term “Herbal Medicine” or “Ayurveda”.";s:12:"field_note_f";s:765:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués. (iii) Une allégation pour un usage traditionnel doit inclure les termes « Phytothérapie/Herboristerie » ou « Ayurvéda ».";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:357:"The medicinal ingredient must comply with the requirements outlined in the Natural Health Products Ingredients Database (NHPID). In addition, the medicinal ingredient may comply with the quality specifications outlined in the current Cinnamon - Cinnamomi cortex or the Cinnamon tincture - Cinnamomi corticis tinctura monographs in the European Pharmcopoeia.";s:21:"field_specification_f";s:400:"L’ingrédient médicinal doit être conforme aux exigences mentionnées dans la Base de données d’ingrédients de produits de santé naturels (BDIPSN). De plus, l’ingrédient médicinal peut être conforme aux spécifications de qualité énoncées dans les monographies officinales Cinnamon - Cinnamomi cortex ou Cinnamon tincture - Cinnamomi corticis tinctura de la pharmacopée Européenne.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-02-08";s:16:"field_legacy_nid";s:6:"101015";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:6:"CIN_OR";s:14:"field_mono_use";s:19:"CIN1;CIN2;CIN3;CIN4";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:3:"CIN";s:15:"field_mono_risk";s:30:"CIN_CW1;CIN_CW2;CIN_CW3;CIN_CI";s:21:"field_mono_citation_e";s:140:"CIN1;CIN2;CIN3;CIN4;CIN5;CIN6;CIN7;CIN8;CIN9;CIN10;CIN11;CIN12;CIN13;CIN14;CIN15;CIN16;CIN17;CIN18;CIN19;CIN20;REDOXAC;CINAPI;HOBAL6;HOBAS32";s:21:"field_mono_citation_f";s:153:"CIN1;CIN2;CIN3;CIN4;CIN5;CIN6;CIN7;CIN8;CIN9;CIN10;CIN11;CIN12;CIN13;CIN14;CIN15;CIN16;CIN17;CIN18;CIN19;CIN20;CIN52;REDOXAC;CINAPI;HOBAL6;HOBAS32;PHAPHY";s:26:"field_reference_reviewed_e";s:179:"CIN21;CIN22;CIN23;CIN24;CIN25;CIN26;CIN27;CIN28;CIN29;CIN30;CIN31;CIN32;CIN33;CIN34;CIN35;CIN36;CIN37;CIN38;CIN39;CIN41;CIN42;CIN43;CIN44;CIN45;CIN46;CIN47;CIN48;CIN49;CIN50;CIN51";s:26:"field_reference_reviewed_f";s:179:"CIN21;CIN22;CIN23;CIN24;CIN25;CIN26;CIN27;CIN28;CIN29;CIN30;CIN31;CIN32;CIN33;CIN34;CIN35;CIN36;CIN37;CIN38;CIN39;CIN41;CIN42;CIN43;CIN44;CIN45;CIN46;CIN47;CIN48;CIN49;CIN50;CIN51";}i:216686;a:35:{s:5:"title";s:32:"DESEN_Male Genital Desensitizers";s:3:"nid";s:6:"216686";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"DESEN";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:26:"Male Genital Desensitizers";s:22:"field_monograph_name_f";s:39:"Désensibilisateur Génital Pour Hommes";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:549:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.   Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:637:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:513:"The medicinal ingredient must comply with the requirements outlined in the Natural Health Products Ingredients Database (NHPID). In addition, the medicinal ingredient may comply with the specifications outlined in the pharmacopoeial monographs: "Benzocaine" in the British Pharmacopoeia(BP), "Benzocaine" in the European Pharmacopoeia(Ph. Eur.) as well as "Benzocaine", "Benzocaine cream", "Benzocaine gel", "Benzocaine topical solution" and "Benzocaine topical aerosol" in the United States (USP) Pharmacopoeias.";s:21:"field_specification_f";s:576:"L’ingrédient médicinal doit être conforme aux exigences mentionnées dans la Base de données d’ingrédients de produits de santé naturels (BDIPSN). De plus, l’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies publiées dans les pharmacopées suivantes: "Benzocaine" de la Pharmacopée britannique (BP), "Benzocaine" de la Pharmacopée européenne (Ph. Eur.) ainsi que "Benzocaine", "Benzocaine cream", "Benzocaine gel", "Benzocaine topical solution" et "Benzocaine topical aerosol" de la Pharmacopée américaine (USP).";s:25:"field_storage_condition_e";s:271:"Aerosols/aerosol sprays and pump sprays: Store below 40C. (USP DI 2006)  All products: Store in airtight container.  Protect from light. (Martindale 2010)  Semi-solid preparations (e.g. gels): Store between 15-30C. (USP DI 2006)  Solutions: Store below 30C. (USP DI 2006)";s:25:"field_storage_condition_f";s:356:"Aérosols et atomiseurs : Conserver à une température inférieure à 40C. (USP DI 2006)  Préparations semi-solides (p.ex. gels) : Conserver entre 15 à 30C. (USP DI 2006)  Solutions : Conserver à une température inférieure à 30C. (USP DI 2006)  Tous les produits : Entreposer dans un contenant hermétique à l'abri de la lumière. (Martindale 2010)";s:10:"field_date";s:10:"2013-01-22";s:16:"field_legacy_nid";s:6:"101016";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:8:"DESEN_TP";s:14:"field_mono_use";s:27:"DESEN1;DESEN2;DESEN3;DESEN4";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_mono_risk";s:27:"DESEN_CW;DESEN_CI;DESEN_ADR";s:21:"field_mono_citation_e";s:78:"DESEN1;DESEN2;DESEN3;DESEN4;DESEN5;DESEN6;DESEN7;DESEN8;DESEN9;DESEN10;DESEN50";s:21:"field_mono_citation_f";s:78:"DESEN1;DESEN2;DESEN3;DESEN4;DESEN5;DESEN6;DESEN7;DESEN8;DESEN9;DESEN10;DESEN50";s:26:"field_reference_reviewed_e";s:311:"DESEN12;DESEN13;DESEN14;DESEN15;DESEN16;DESEN17;DESEN18;DESEN19;DESEN20;DESEN21;DESEN22;DESEN23;DESEN24;DESEN25;DESEN26;DESEN27;DESEN28;DESEN29;DESEN30;DESEN31;DESEN32;DESEN33;DESEN34;DESEN35;DESEN36;DESEN37;DESEN38;DESEN39;DESEN40;DESEN41;DESEN42;DESEN43;DESEN44;DESEN45;DESEN46;DESEN47;DESEN48;DESEN49;DESEN11";s:26:"field_reference_reviewed_f";s:311:"DESEN12;DESEN13;DESEN14;DESEN15;DESEN16;DESEN17;DESEN18;DESEN19;DESEN20;DESEN21;DESEN22;DESEN23;DESEN24;DESEN25;DESEN26;DESEN27;DESEN29;DESEN30;DESEN31;DESEN32;DESEN33;DESEN34;DESEN35;DESEN36;DESEN37;DESEN38;DESEN39;DESEN40;DESEN41;DESEN42;DESEN43;DESEN44;DESEN45;DESEN46;DESEN47;DESEN48;DESEN49;DESEN11;DESEN28";}i:216687;a:29:{s:5:"title";s:18:"ORALHCP_Benzocaine";s:3:"nid";s:6:"216687";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:7:"ORALHCP";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:10:"Benzocaine";s:22:"field_monograph_name_f";s:10:"Benzocaine";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"C;P";s:21:"field_monograph_url_e";s:31:"atReq.do?atid=oral.hcp&lang=eng";s:21:"field_monograph_url_f";s:31:"atReq.do?atid=oral.hcp&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2012-07-30";s:16:"field_legacy_nid";s:6:"101017";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216688;a:29:{s:5:"title";s:51:"SAGEBT_Sage - Salvia officinalis - Buccal & Topical";s:3:"nid";s:6:"216688";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"SAGEBT";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:44:"Sage - Salvia officinalis - Buccal & Topical";s:22:"field_monograph_name_f";s:46:"Sauge - Salvia officinalis - Buccale & Topique";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:30:"atReq.do?atid=sage.bt&lang=eng";s:21:"field_monograph_url_f";s:30:"atReq.do?atid=sage.bt&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2012-08-02";s:16:"field_legacy_nid";s:6:"101018";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216689;a:29:{s:5:"title";s:39:"SAGEOR_Sage - Salvia officinalis - Oral";s:3:"nid";s:6:"216689";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"SAGEOR";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:32:"Sage - Salvia officinalis - Oral";s:22:"field_monograph_name_f";s:34:"Sauge - Salvia officinalis - Orale";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:30:"atReq.do?atid=sage.or&lang=eng";s:21:"field_monograph_url_f";s:30:"atReq.do?atid=sage.or&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2012-08-02";s:16:"field_legacy_nid";s:6:"101019";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216690;a:29:{s:5:"title";s:44:"TCM_Traditional Chinese Medicine Ingredients";s:3:"nid";s:6:"216690";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"TCM";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:40:"Traditional Chinese Medicine Ingredients";s:22:"field_monograph_name_f";s:54:"Médecine traditionnelle chinoise - Ingrédients de la";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"C;P";s:21:"field_monograph_url_e";s:26:"atReq.do?atid=tcm&lang=eng";s:21:"field_monograph_url_f";s:26:"atReq.do?atid=tcm&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-06-10";s:16:"field_legacy_nid";s:6:"101020";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216692;a:36:{s:5:"title";s:23:"BOVCOL_Bovine Colostrum";s:3:"nid";s:6:"216692";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"BOVCOL";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:16:"Bovine Colostrum";s:22:"field_monograph_name_f";s:15:"Colostrum bovin";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:549:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.   Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:637:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:136:"Note: The list of priority allergens is maintained at: http://hc-sc.gc.ca/fn-an/label-etiquet/allergen/guide_ligne_direct_indust-eng.php";s:17:"field_risk_note_f";s:160:"Nota: La liste des allergènes prioritaires se trouve à l'adresse suivante : http://hc- sc.gc.ca/fn-an/label-etiquet/allergen/guide_ligne_direct_indust-fra.php";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-03-25";s:16:"field_legacy_nid";s:6:"101022";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:9:"BOVCOL_OR";s:14:"field_mono_use";s:15:"BOVCOL1;BOVCOL2";s:19:"field_subpopulation";s:3:"ADU";s:19:"field_mono_duration";s:7:"BOVCOL1";s:15:"field_mono_risk";s:65:"BOVCOL_CI1;BOVCOL_CW2;BOVCOL_CW3;BOVCOL_CW4;BOVCOL_CW5;BOVCOL_CW1";s:21:"field_mono_citation_e";s:179:"BOVCOL1;BOVCOL10;BOVCOL11;BOVCOL12;BOVCOL13;BOVCOL14;BOVCOL15;BOVCOL16;BOVCOL17;BOVCOL18;BOVCOL19;BOVCOL2;BOVCOL20;BOVCOL21;BOVCOL3;BOVCOL4;BOVCOL5;BOVCOL6;BOVCOL7;BOVCOL8;BOVCOL9";s:21:"field_mono_citation_f";s:179:"BOVCOL1;BOVCOL10;BOVCOL11;BOVCOL12;BOVCOL13;BOVCOL14;BOVCOL15;BOVCOL16;BOVCOL17;BOVCOL18;BOVCOL19;BOVCOL2;BOVCOL20;BOVCOL21;BOVCOL3;BOVCOL4;BOVCOL5;BOVCOL6;BOVCOL7;BOVCOL8;BOVCOL9";s:26:"field_reference_reviewed_e";s:332:"BOVCOL22;BOVCOL24;BOVCOL25;BOVCOL26;BOVCOL27;BOVCOL28;BOVCOL29;BOVCOL30;BOVCOL31;BOVCOL32;BOVCOL33;BOVCOL34;BOVCOL35;BOVCOL36;BOVCOL37;BOVCOL38;BOVCOL39;BOVCOL40;BOVCOL41;BOVCOL42;BOVCOL43;BOVCOL44;BOVCOL45;BOVCOL46;BOVCOL47;BOVCOL48;BOVCOL49;BOVCOL50;BOVCOL51;BOVCOL52;BOVCOL53;BOVCOL54;BOVCOL55;BOVCOL56;BOVCOL57;BOVCOL58;BOVCOL59";s:26:"field_reference_reviewed_f";s:332:"BOVCOL22;BOVCOL24;BOVCOL25;BOVCOL26;BOVCOL27;BOVCOL28;BOVCOL29;BOVCOL30;BOVCOL31;BOVCOL32;BOVCOL33;BOVCOL34;BOVCOL35;BOVCOL36;BOVCOL37;BOVCOL38;BOVCOL39;BOVCOL40;BOVCOL41;BOVCOL42;BOVCOL43;BOVCOL44;BOVCOL45;BOVCOL46;BOVCOL47;BOVCOL48;BOVCOL49;BOVCOL50;BOVCOL51;BOVCOL52;BOVCOL53;BOVCOL54;BOVCOL55;BOVCOL56;BOVCOL57;BOVCOL58;BOVCOL59";}i:216693;a:35:{s:5:"title";s:45:"HOBAS_Holy Basil - Ocimum Tenuliflorun - Seed";s:3:"nid";s:6:"216693";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"HOBAS";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:39:"Holy Basil - Ocimum Tenuliflorun - Seed";s:22:"field_monograph_name_f";s:45:"Basilic sacré - Ocimum Tenuliflorun - Graine";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:640:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.   Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant. (iii) A claim for traditional use must include the term “Ayurvedic Medicine/Ayurveda”.";s:12:"field_note_f";s:749:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués. (iii) Une allégation pour un usage traditionnel doit inclure les termes « Médecine Ayurvédique/Ayurvéda».";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:128:"The medicinal ingredient must comply with the requirements outlined in the Natural Health Products Ingredients Database (NHPID).";s:21:"field_specification_f";s:156:"L’ingrédient médicinal doit être conforme aux exigences mentionnées dans la Base de données d’ingrédients de produits de santé naturels (BDIPSN).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-03-22";s:16:"field_legacy_nid";s:6:"101023";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:8:"HOBAS_OR";s:14:"field_mono_use";s:20:"HOBAS1;HOBAS2;HOBAS3";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_mono_risk";s:29:"HOBAS_CW1;HOBAS_CW2;HOBAS_CW3";s:21:"field_mono_citation_e";s:55:"HOBAS1;HOBAS2;HOBAS3;HOBAS4;HOBAS5;HOBAS6;HOBAS7;HOBAS8";s:21:"field_mono_citation_f";s:63:"HOBAS1;HOBAS2;HOBAS3;HOBAS4;HOBAS5;HOBAS6;HOBAS7;HOBAS8;HOBAS48";s:26:"field_reference_reviewed_e";s:311:"HOBAS10;HOBAS11;HOBAS12;HOBAS13;HOBAS14;HOBAS15;HOBAS16;HOBAS17;HOBAS18;HOBAS19;HOBAS20;HOBAS21;HOBAS22;HOBAS23;HOBAS24;HOBAS25;HOBAS26;HOBAS27;HOBAS28;HOBAS29;HOBAS30;HOBAS31;HOBAS32;HOBAS33;HOBAS34;HOBAS35;HOBAS36;HOBAS37;HOBAS38;HOBAS39;HOBAS40;HOBAS41;HOBAS42;HOBAS43;HOBAS44;HOBAS45;HOBAS46;HOBAS47;HOBAS49";s:26:"field_reference_reviewed_f";s:311:"HOBAS10;HOBAS11;HOBAS12;HOBAS13;HOBAS14;HOBAS15;HOBAS16;HOBAS17;HOBAS18;HOBAS19;HOBAS20;HOBAS21;HOBAS22;HOBAS23;HOBAS24;HOBAS25;HOBAS26;HOBAS27;HOBAS28;HOBAS29;HOBAS30;HOBAS31;HOBAS32;HOBAS33;HOBAS34;HOBAS35;HOBAS36;HOBAS37;HOBAS38;HOBAS39;HOBAS40;HOBAS41;HOBAS42;HOBAS43;HOBAS44;HOBAS45;HOBAS46;HOBAS47;HOBAS49";}i:216695;a:35:{s:5:"title";s:45:"HOBAL_Holy Basil - Ocimum Tenuliflorun - Leaf";s:3:"nid";s:6:"216695";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"HOBAL";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:39:"Holy Basil - Ocimum Tenuliflorun - Leaf";s:22:"field_monograph_name_f";s:46:"Basilic sacré - Ocimum Tenuliflorun - Feuille";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:665:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.   Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant. (iii) A claim for traditional use must include the term “Herbal Medicine” or “Ayurvedic medicine/Ayurveda”.";s:12:"field_note_f";s:788:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués. (iii) Une allégation pour un usage traditionnel doit inclure les termes « Phytothérapie/Herboristerie » ou « Médecine Ayurvédique/Ayurvéda ».";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:128:"The medicinal ingredient must comply with the requirements outlined in the Natural Health Products Ingredients Database (NHPID).";s:21:"field_specification_f";s:156:"L’ingrédient médicinal doit être conforme aux exigences mentionnées dans la Base de données d’ingrédients de produits de santé naturels (BDIPSN).";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-03-22";s:16:"field_legacy_nid";s:6:"101025";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:8:"HOBAL_OR";s:14:"field_mono_use";s:41:"HOBAL1;HOBAL2;HOBAL3;HOBAL4;HOBAL5;HOBAL6";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_mono_risk";s:48:"HOBAL_CI;HOBAL_CW1;HOBAL_CW2;HOBAL_CW3;HOBAL_CW4";s:21:"field_mono_citation_e";s:190:"HOBAL1;HOBAL10;HOBAL11;HOBAL12;HOBAL13;HOBAL14;HOBAL15;HOBAL16;HOBAL17;HOBAL18;HOBAL19;HOBAL2;HOBAL20;HOBAL3;HOBAL4;HOBAL5;HOBAL6;HOBAL7;HOBAL8;HOBAL9;HOBAL48;HOBAL50;HOBAL49;HOBAL45;HOBAL51";s:21:"field_mono_citation_f";s:190:"HOBAL1;HOBAL10;HOBAL11;HOBAL12;HOBAL13;HOBAL14;HOBAL15;HOBAL16;HOBAL17;HOBAL18;HOBAL19;HOBAL2;HOBAL20;HOBAL3;HOBAL4;HOBAL5;HOBAL6;HOBAL7;HOBAL8;HOBAL9;HOBAL48;HOBAL50;HOBAL49;HOBAL45;HOBAL51";s:26:"field_reference_reviewed_e";s:215:"HOBAL21;HOBAL22;HOBAL23;HOBAL24;HOBAL25;HOBAL27;HOBAL28;HOBAL29;HOBAL30;HOBAL31;HOBAL32;HOBAL33;HOBAL34;HOBAL35;HOBAL36;HOBAL37;HOBAL38;HOBAL39;HOBAL40;HOBAL41;HOBAL42;HOBAL43;HOBAL44;HOBAL46;HOBAL47;HOBAL52;HOBAL53";s:26:"field_reference_reviewed_f";s:215:"HOBAL21;HOBAL22;HOBAL23;HOBAL24;HOBAL25;HOBAL27;HOBAL28;HOBAL29;HOBAL30;HOBAL31;HOBAL32;HOBAL33;HOBAL34;HOBAL35;HOBAL36;HOBAL37;HOBAL38;HOBAL39;HOBAL40;HOBAL41;HOBAL42;HOBAL43;HOBAL44;HOBAL46;HOBAL47;HOBAL52;HOBAL53";}i:216696;a:29:{s:5:"title";s:24:"HCOL_Hydrolyzed collagen";s:3:"nid";s:6:"216696";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"HCOL";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:19:"Hydrolyzed collagen";s:22:"field_monograph_name_f";s:21:"Collagène hydrolysé";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:42:"atReq.do?atid=hydrolized.collagen&lang=eng";s:21:"field_monograph_url_f";s:42:"atReq.do?atid=hydrolized.collagen&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:0:"";s:16:"field_legacy_nid";s:6:"101037";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216697;a:35:{s:5:"title";s:47:"MRSHRT_Marshmallow - Althaea officinalis - Root";s:3:"nid";s:6:"216697";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"MRSHRT";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:40:"Marshmallow - Althaea officinalis - Root";s:22:"field_monograph_name_f";s:50:"Guimauve officinale - Althaea officinalis - Racine";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:547:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.
Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:635:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal.
Nota: (i) Les parenthèses contiennent des éléments d’information facultatifs - il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:180:"The medicinal ingredient may comply with the specifications outlined in the Marshmallow monographs published in the British Pharmacopoeia (BP) and European Pharmacopoeia (Ph. Eur.)";s:21:"field_specification_f";s:203:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies Guimauve Officinale publiées dans la Pharmacopée britannique (BP) et Pharmacopée européenne (Ph.Eur.)";s:25:"field_storage_condition_e";s:22:"No statement required.";s:25:"field_storage_condition_f";s:20:"Énoncé non requis.";s:10:"field_date";s:10:"2013-05-23";s:16:"field_legacy_nid";s:6:"101027";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:11:"MRSHRT_Oral";s:14:"field_mono_use";s:15:"MRSHRT1;MRSHRT2";s:19:"field_subpopulation";s:24:"AD1318;CH_6_12;ADU;CH3_6";s:15:"field_mono_risk";s:21:"MRSHRT_CW1;MRSHRT_CW2";s:21:"field_mono_citation_e";s:136:"MRSHRT1;MRSHRT10;MRSHRT11;MRSHRT12;MRSHRT13;MRSHRT14;MRSHRT15;MRSHRT17;MRSHRT18;MRSHRT19;MRSHRT5;MRSHRT6;MRSHRT8;MRSHRT9;MRSHRT2;MRSHRT3";s:21:"field_mono_citation_f";s:161:"MRSHRT1;MRSHRT10;MRSHRT11;MRSHRT12;MRSHRT13;MRSHRT14;MRSHRT15;MRSHRT16;MRSHRT17;MRSHRT18;MRSHRT19;MRSHRT2;MRSHRT3;MRSHRT4;MRSHRT5;MRSHRT6;MRSHRT7;MRSHRT8;MRSHRT9";s:26:"field_reference_reviewed_e";s:215:"MRSHRT20;MRSHRT21;MRSHRT22;MRSHRT24;MRSHRT25;MRSHRT26;MRSHRT28;MRSHRT29;MRSHRT30;MRSHRT31;MRSHRT33;MRSHRT34;MRSHRT35;MRSHRT36;MRSHRT37;MRSHRT38;MRSHRT39;MRSHRT41;MRSHRT42;MRSHRT43;MRSHRT44;MRSHRT45;MRSHRT32;MRSHRT23";s:26:"field_reference_reviewed_f";s:233:"MRSHRT20;MRSHRT21;MRSHRT22;MRSHRT24;MRSHRT25;MRSHRT26;MRSHRT27;MRSHRT28;MRSHRT29;MRSHRT30;MRSHRT31;MRSHRT33;MRSHRT34;MRSHRT35;MRSHRT36;MRSHRT37;MRSHRT38;MRSHRT39;MRSHRT40;MRSHRT41;MRSHRT42;MRSHRT43;MRSHRT44;MRSHRT45;MRSHRT32;MRSHRT23";}i:216698;a:29:{s:5:"title";s:23:"FLWRESS_Flower Essences";s:3:"nid";s:6:"216698";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:7:"FLWRESS";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:15:"Flower Essences";s:22:"field_monograph_name_f";s:18:"Essences de fleurs";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"P";s:21:"field_monograph_url_e";s:38:"atReq.do?atid=flower.essences&lang=eng";s:21:"field_monograph_url_f";s:38:"atReq.do?atid=flower.essences&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-06-24";s:16:"field_legacy_nid";s:6:"101036";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216699;a:29:{s:5:"title";s:20:"ORGANO_Organotherapy";s:3:"nid";s:6:"216699";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"ORGANO";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:13:"Organotherapy";s:22:"field_monograph_name_f";s:15:"Organothérapie";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"P";s:21:"field_monograph_url_e";s:36:"atReq.do?atid=organotherapy&lang=eng";s:21:"field_monograph_url_f";s:36:"atReq.do?atid=organotherapy&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-06-24";s:16:"field_legacy_nid";s:6:"101029";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216700;a:29:{s:5:"title";s:18:"OLIGO_Oligotherapy";s:3:"nid";s:6:"216700";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"OLIGO";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:12:"Oligotherapy";s:22:"field_monograph_name_f";s:14:"Oligothérapie";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"P";s:21:"field_monograph_url_e";s:35:"atReq.do?atid=oligotherapy&lang=eng";s:21:"field_monograph_url_f";s:35:"atReq.do?atid=oligotherapy&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-06-24";s:16:"field_legacy_nid";s:6:"101030";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216701;a:29:{s:5:"title";s:16:"HOMEO_Homeopathy";s:3:"nid";s:6:"216701";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"HOMEO";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:10:"Homeopathy";s:22:"field_monograph_name_f";s:12:"Homéopathie";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"P";s:21:"field_monograph_url_e";s:33:"atReq.do?atid=homeopathy&lang=eng";s:21:"field_monograph_url_f";s:33:"atReq.do?atid=homeopathy&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-06-24";s:16:"field_legacy_nid";s:6:"101031";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216703;a:29:{s:5:"title";s:18:"LITHO_Lithotherapy";s:3:"nid";s:6:"216703";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"LITHO";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:12:"Lithotherapy";s:22:"field_monograph_name_f";s:14:"Lithothérapie";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"P";s:21:"field_monograph_url_e";s:35:"atReq.do?atid=lithotherapy&lang=eng";s:21:"field_monograph_url_f";s:35:"atReq.do?atid=lithotherapy&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-06-24";s:16:"field_legacy_nid";s:6:"101033";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216705;a:29:{s:5:"title";s:18:"GEMMO_Gemmotherapy";s:3:"nid";s:6:"216705";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"GEMMO";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:12:"Gemmotherapy";s:22:"field_monograph_name_f";s:14:"Gemmothérapie";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"P";s:21:"field_monograph_url_e";s:35:"atReq.do?atid=gemmotherapy&lang=eng";s:21:"field_monograph_url_f";s:35:"atReq.do?atid=gemmotherapy&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-06-24";s:16:"field_legacy_nid";s:6:"101035";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216706;a:29:{s:5:"title";s:25:"MULTENZ_Digestive Enzymes";s:3:"nid";s:6:"216706";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:7:"MULTENZ";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:17:"Digestive Enzymes";s:22:"field_monograph_name_f";s:18:"Enzymes digestives";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"C;P";s:21:"field_monograph_url_e";s:35:"atReq.do?atid=enzyme.multi&lang=eng";s:21:"field_monograph_url_f";s:35:"atReq.do?atid=enzyme.multi&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2012-03-30";s:16:"field_legacy_nid";s:6:"101010";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216707;a:29:{s:5:"title";s:19:"WHEYP_Whey products";s:3:"nid";s:6:"216707";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"WHEYP";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:13:"Whey products";s:22:"field_monograph_name_f";s:31:"Produits à base de lactosérum";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"C;P";s:21:"field_monograph_url_e";s:43:"atReq.do?atid=whey.prod.lactoserum&lang=eng";s:21:"field_monograph_url_f";s:43:"atReq.do?atid=whey.prod.lactoserum&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-04-23";s:16:"field_legacy_nid";s:6:"101045";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216708;a:29:{s:5:"title";s:32:"RHOROS_Rhodiola - Rhodiola rosea";s:3:"nid";s:6:"216708";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"RHOROS";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:25:"Rhodiola - Rhodiola rosea";s:22:"field_monograph_name_f";s:25:"Rhodiole - Rhodiola rosea";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:30:"atReq.do?atid=rhodiol&lang=eng";s:21:"field_monograph_url_f";s:30:"atReq.do?atid=rhodiol&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-04-23";s:16:"field_legacy_nid";s:6:"101044";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216709;a:29:{s:5:"title";s:47:"GARGUMG_Malabar tamarind - Garcinia gummi-gutta";s:3:"nid";s:6:"216709";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:7:"GARGUMG";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:39:"Malabar tamarind - Garcinia gummi-gutta";s:22:"field_monograph_name_f";s:44:"Tamarinier de Malabar - Garcinia gummi-gutta";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:36:"atReq.do?atid=tamar.malabar&lang=eng";s:21:"field_monograph_url_f";s:36:"atReq.do?atid=tamar.malabar&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-04-23";s:16:"field_legacy_nid";s:6:"101043";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216710;a:29:{s:5:"title";s:51:"CALPOT_Calcium-Potassium Salt of Hydroxycitric Acid";s:3:"nid";s:6:"216710";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"CALPOT";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:44:"Calcium-Potassium Salt of Hydroxycitric Acid";s:22:"field_monograph_name_f";s:50:"Sel de calcium-potassium d’acide hydroxycitrique";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:40:"atReq.do?atid=calcium.potassium&lang=eng";s:21:"field_monograph_url_f";s:40:"atReq.do?atid=calcium.potassium&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-04-23";s:16:"field_legacy_nid";s:6:"101041";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216711;a:37:{s:5:"title";s:34:"DONG_Dong quai - Angelica sinensis";s:3:"nid";s:6:"216711";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"DONG";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:29:"Dong quai - Angelica sinensis";s:22:"field_monograph_name_f";s:39:"Angélique chinoise - Angelica sinensis";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:673:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant. (iii) A claim for a traditional use must include either the term “Herbal Medicine” or “Traditional Chinese Medicine”.";s:12:"field_note_f";s:789:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués. (iii) Une allégation pour un usage traditionnel doit inclure les termes « Phytothérapie/Herboristerie » ou « Médecine Traditionnelle Chinoise ».";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:446:"The medicinal ingredient must comply with the requirements outlined in the Natural Health Products Ingredients Database (NHPID). In addition, the medicinal ingredient may comply with the specifications outlined in the 'Angelica Sinensis Root for use in THM' and 'Processed Angelica Sinensis Root for use in THMP' monographs of the British Pharmacopoeia (BP) and in the 'Angelica sinensis radix' monograph of the European Pharmacopoeia (Ph. Eur.).";s:21:"field_specification_f";s:483:"L’ingrédient médicinal doit être conforme aux exigences mentionnées dans la Base de données d’ingrédients de produits de santé naturels (BDIPSN). De plus, l’ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies officinales 'Angelica Sinensis Root for use in THM' et 'Processed Angelica Sinensis Root for use in THMP' de la pharmacopée britannique (BP) et dans 'Angelica sinensis radix' de la pharmacopée européenne (Ph.Eur.).";s:25:"field_storage_condition_e";s:101:"Store in an airtight container in a cool, dry place protected from moisture (Ph.Eur. 2013; WHO 2004).";s:25:"field_storage_condition_f";s:125:"Entreposer dans un contenant hermétique dans un endroit frais et sec, à l’abri de l’humidité (Ph.Eur. 2013; WHO 2004).";s:10:"field_date";s:10:"2012-11-27";s:16:"field_legacy_nid";s:6:"100995";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:7:"DONG_OR";s:14:"field_mono_use";s:4:"DONG";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"DONG";s:19:"field_mono_duration";s:7:"DONGDUR";s:15:"field_mono_risk";s:98:"DONG_CW1;DONG_CW2;DONG_CW3;DONG_CW4;DONG_CW5;DONG_CW6;DONG_CI1;DONG_CI2;DONG_CI3;DONG_CI4;DONG_ADR";s:21:"field_mono_citation_e";s:101:"EPEDR2;MAROIL1;DONG1;POR3;DONG18;DONG2;DONG3;DONG4;QUER12;HERCOM;DONG16;DONG5;DONG6;DONG7;DONG9;DONG8";s:21:"field_mono_citation_f";s:108:"EPEDR2;MAROIL1;DONG1;POR3;DONG18;DONG2;DONG3;DONG4;QUER12;HERCOM;DONG16;DONG5;DONG6;DONG7;DONG9;DONG8;DONG21";s:26:"field_reference_reviewed_e";s:61:"HERBS;DONG11;DONG12;DONG13;DONG14;DONG15;DONG17;DONG19;DONG20";s:26:"field_reference_reviewed_f";s:61:"HERBS;DONG11;DONG12;DONG13;DONG14;DONG15;DONG17;DONG19;DONG20";}i:216712;a:35:{s:5:"title";s:14:"KOIL_Krill Oil";s:3:"nid";s:6:"216712";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"KOIL";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:9:"Krill Oil";s:22:"field_monograph_name_f";s:15:"Krill, Huile de";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:547:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:637:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:2216:"Peroxide, anisidine, and totox values of krill oil or omega-3 fatty acids derived from krill oil must be in accordance with the methods set out by the Association of Analytical Community (AOAC) and/or Pharmacopoeial analytical methods. These specifications are necessary to ensure the oxidative stability of the krill oil and the omega-3 fatty acids from krill oil (HC 2007).  The maximum peroxide value (PV) must be 5 mEq/kg, the maximum anisidine value (AV) must be 20 while the maximum Totox value must be 26 (calculated as 2 X PV + AV).;  The dioxins, polychlorinated dibenzo-para-dioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs), the dioxin-like polychlorinated biphenyls (DL PCBs), and the polychlorinated biphenyls (PCBs) are contaminants in oils from marine sources. Testing for these contaminants are required, and must be performed using either the analytical method of the European Commission Regulation EU 252/2012 (EU 2012) or the U.S. Environmental Protection Agency’s method 1613B for PCDDs and PCDFs and method 1668A for PCBs (USP 35, US EPA 2010, 2008, 1994). Applicants are advised to consult the Council of the European Union document on these contaminants for further information (EU 2011).  The maximum limits from EU1259/2011 are: for dioxins (sum of PCDDs and PCDFs) -- a maximum of 1.75 pg/g, for the sum of dioxins and DL PCBs -- a maximum of 6 pg/g, and for PCBs -- a maximum of 200 ng/g. The maximum limits from USP 35 are  for dioxins (sum of PCDDs and PCDFs) -- a maximum of 1.0 pg/g, and for PCBs -- a maximum of 0.5 ppm [(i)Maximums levels are expressed in World Health Organization (WHO) toxic equivalents using WHO-toxic equivalent factors (TEFs). Analytical results relating to 17 individual dioxin congeners of toxicological concern are expressed in a single quantifiable unit: 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) toxic equivalent concentration (TEQ) (USP 35, EU 2011)  (ii)Reference for sum of dioxins is: WHO-PCDD/F-TEQ (USP 35, EU 2011)  (iii) Reference for sum of dioxins and dioxin-like PCBs is: WHO-PCDD/F-PCB-TEQ (EU 2011)  (iv) Reference for sum of PCB congeners 28, 52, 101, 118, 138, 153 and 180 is (USP 35, EU 2011)  (v) Equivalence: 0.5 ppm = 500ng/g]";s:21:"field_specification_f";s:2639:"Les niveaux de peroxyde et d'anisidine, et les niveaux totaux d'oxydation de l'huile de krill ou des dérivés d'acides gras oméga-3 provenant de l'huile de krill doivent respecter les normes établies par l' « Association of Analytical Community (AOAC)» et/ou par les méthodes analytiques de pharmacopées. Ces spécifications assureront la résistance à l'oxydation de l'huile de krill et des acides gras oméga-3 provenant de l'huile de krill (SC 2007). Le niveau maximal de l'indice de peroxyde (IP) doit être 5 mEq/kg, le niveau maximal de l'indice d'anisidine (IA) doit être 20 tandis que le niveau maximal du total d'oxydation doit être 26 (calculé selon la formule : 2 X IP + IA).;  Les dioxines polychorodibenzo-para-dioxines (PCDD) et les polycholorodibenzofuranes (PCDF), les polychlorobiphényles de type dioxine (PCBTD), et les polychlorobiphényles (PCB) sont des contaminants présents dans les huiles marines. Des analyses pour détecter ces contaminants sont obligatoires et doivent être effectuées soit au moyen de la méthode analytique du Règlement EU 252/2012 de la Commission européenne (UE 2012), soit au moyen de la méthode 1613B de la U.S. Environmental Protection Agency pour les PCDD et les PCDF et la méthode 1668A pour les PCB (USP 35, US EPA 2010, 2008, 1994). Les demandeurs sont avisés de consulter le document du Conseil de l’Union européenne sur ces contaminants pour de plus amples informations (UE 2011). Les teneurs maximales de UE 1259/2011:  pour les dioxines (somme des PCDD et des PCDF) --  un maximum de 1,75 pg/g, pour la somme des dioxines et des PCBTD -- un maximum de 6 pg/g, et pour le total PCB-6 -- 200 ng/g. Les teneurs maximales de USP 35:  pour les dioxines (somme des PCDD et des PCDF) --  un maximum de 1,0 pg/g, et pour PCBs -- 0,5ppm [(i)Les teneurs maximales sont: exprimées en équivalents toxiques tels que définis par l’Organisation mondiale de la santé (OMS), en appliquant les facteurs d’équivalence toxique de l’OMS (TEF-OMS). Les résultats de l’analyse de 17 congénères de dioxines représentant un risque toxicologique sont exprimés sous la forme d’une seule unité quantifiable : la concentration en équivalents toxiques (TEQ) de 2,3,7,8-tétrachlorodibenzo-p-dioxine (TCDD) (USP 35, UE 2011)  (ii) Les références pour la somme des dioxines sont : OMS-PCDD/F-TEQ (USP 35, UE 2011) (iii) Les références pour la somme des dioxines et des PCBTD sont: OMS-PCDD/F-PCB-TEQ (UE 2011) (iv) Les références pour la Somme des congénères 28, 52, 101, 118, 138, 153 et 180 de PCB sont (USP 35, UE 2011) (v) Equivalence : 0,5 ppm = 500 ng/g]";s:25:"field_storage_condition_e";s:190:"For all products:  Store in airtight container, protected from light. (Ph.Eur. 2012 - USP 35); For all products, except those encapsulated:  Refrigerate after opening. (Wille and Gonus 1989)";s:25:"field_storage_condition_f";s:217:"Pour tous les produits: Entreposer dans un contenant hermétique à l’abri de la lumière. (Ph.Eur. 2012 - USP 35); Pour tous les produits, sauf ceux encapsulés: Réfrigérer après ouverture. (Wille et Gonus 1989)";s:10:"field_date";s:10:"2012-07-04";s:16:"field_legacy_nid";s:6:"100996";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:7:"KOIL_OR";s:14:"field_mono_use";s:11:"KOIL1;KOIL2";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_mono_risk";s:15:"PREGC2;KOIL_ADR";s:21:"field_mono_citation_e";s:94:"ENDOCAN;NEPKO;KO3;FALLERG;KO4;DRIECF;KOPMS;FAAST;KO5;KO6;KO7;KO8;MAROIL14;PFODA;PHEUR;MAROIL42";s:21:"field_mono_citation_f";s:94:"ENDOCAN;NEPKO;KO3;FALLERG;KO4;DRIECF;KOPMS;FAAST;KO5;KO6;KO7;KO8;MAROIL14;PFODA;PHEUR;MAROIL42";s:26:"field_reference_reviewed_e";s:63:"ASTKID;DMIL;REGPOTN3;FAIRA;ASTAX;AAARC;O3HDGD;MAROIL44;MAROIL45";s:26:"field_reference_reviewed_f";s:63:"ASTKID;DMIL;REGPOTN3;FAIRA;ASTAX;AAARC;O3HDGD;MAROIL44;MAROIL45";}i:216713;a:37:{s:5:"title";s:21:"ALPHA_Amylase, alpha-";s:3:"nid";s:6:"216713";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"ALPHA";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:15:"Amylase, alpha-";s:22:"field_monograph_name_f";s:15:"Amylase, alpha-";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:547:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:637:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:602:"The specifications must include testing for enzymatic activity of the medicinal ingredient at appropriate stages of formulation and manufacturing using the assay outlined in the current Food Chemicals Codex (FCC): α-AMYLASE ACTIVITY (NONBACTERIAL).;  Details of the manufacturing of the enzyme at the raw material stage should include fermentation medium, and the isolation process of the medicinal ingredient.;  Where published methods are not suitable for use, manufacturers will use due diligence to ensure that the enzymes remain active to the end of the shelf life indicated on the product label.";s:21:"field_specification_f";s:746:"Les spécifications doivent présenter l’analyse de l’activité enzymatique de l’ingrédient médicinal aux stades appropriés de la formulation et du procédé de fabrication conformément à l’épreuve décrite dans la version actuelle du Food Chemicals Codex (FCC) :α-AMYLASE ACTIVITY (NONBACTERIAL).;  Les détails de fabrication de l’enzyme à l'étape de la matière première doivent comprendre le milieu de fermentation, et le procédé d'isolement des ingrédients médicinaux.;  Lorsque les méthodes publiées ne sont pas appropriées, le fabriquant fera preuve de diligence raisonnable afin de s'assurer que les enzymes demeurent actives jusqu'à la fin de la période de conservation indiquée sur l'étiquette du produit.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2012-07-05";s:16:"field_legacy_nid";s:6:"100997";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:8:"ALPHA_OR";s:14:"field_mono_use";s:6:"DIGENZ";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:12:"ENZYME;ALPHA";s:19:"field_mono_duration";s:9:"PROLONGED";s:15:"field_mono_risk";s:29:"ALPHA_CW1;ALPHA_CW2;ALPHA_ADR";s:21:"field_mono_citation_e";s:57:"ALPHA1;ALPHA2;ALPHA3;ALPHA15;ALPHA5;ALPHA6;ALPHA14;ALPHA9";s:21:"field_mono_citation_f";s:57:"ALPHA1;ALPHA2;ALPHA3;ALPHA15;ALPHA5;ALPHA6;ALPHA14;ALPHA9";s:26:"field_reference_reviewed_e";s:31:"ALPHA10;ALPHA11;ALPHA12;ALPHA13";s:26:"field_reference_reviewed_f";s:31:"ALPHA10;ALPHA11;ALPHA12;ALPHA13";}i:216714;a:37:{s:5:"title";s:23:"FRBROM_Bromelain, Fruit";s:3:"nid";s:6:"216714";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"FRBROM";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:16:"Bromelain, Fruit";s:22:"field_monograph_name_f";s:21:"Bromélaïne de fruit";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:547:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:637:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:594:"The specifications must include testing for enzymatic activity of the medicinal ingredient at appropriate stages of formulation and manufacturing using the assay outlined in the current Food Chemicals Codex (FCC): PLANT PROTEOLYTIC ACTIVITY.;  Details of the manufacturing of the enzyme at the raw material stage should include fermentation medium, and the isolation process of the medicinal ingredient.;  Where published methods are not suitable for use, manufacturers will use due diligence to ensure that the enzymes remain active to the end of the shelf life indicated on the product label.";s:21:"field_specification_f";s:766:"Les spécifications doivent présenter l’analyse de l’activité enzymatique de l’ingrédient médicinal aux stades appropriés de la formulation et du procédé de fabrication conformément à l’épreuve décrite dans la version actuelle du Food Chemicals Codex (FCC) : : PLANT PROTEOLYTIC ACTIVITY.;  Les détails de fabrication de l’enzyme à l'étape de la matière première doivent être fournis et doivent comprendre le milieu de fermentation, et le procédé d'isolement des ingrédients médicinaux.;  Lorsque les méthodes publiées ne sont pas appropriées, le fabriquant fera preuve de diligence raisonnable afin de s'assurer que les enzymes demeurent actives jusqu'à la fin de la période de conservation indiquée sur l'étiquette du produit.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2012-07-05";s:16:"field_legacy_nid";s:6:"100998";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:7:"FRBR_OR";s:14:"field_mono_use";s:6:"DIGENZ";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:18:"ENZYME;FRBR1;FRBR2";s:19:"field_mono_duration";s:9:"PROLONGED";s:15:"field_mono_risk";s:34:"PREGC2;FRBR_CW;FRBR_ADR1;FRBR_ADR2";s:21:"field_mono_citation_e";s:109:"BROFR1;BROFR2;BROFR3;BROFR4;ALPHA15;ALPHA5;BROFR5;BROFR6;BROFR7;BROFR8;BROFR9;BROFR10;BROFR17;BROFR12;BROFR13";s:21:"field_mono_citation_f";s:109:"BROFR1;BROFR2;BROFR3;BROFR4;ALPHA15;ALPHA5;BROFR5;BROFR6;BROFR7;BROFR8;BROFR9;BROFR10;BROFR17;BROFR12;BROFR13";s:26:"field_reference_reviewed_e";s:23:"BROFR14;BROFR15;BROFR16";s:26:"field_reference_reviewed_f";s:23:"BROFR14;BROFR15;BROFR16";}i:216715;a:37:{s:5:"title";s:22:"STBROM_Bromelain, Stem";s:3:"nid";s:6:"216715";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"STBROM";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:15:"Bromelain, Stem";s:22:"field_monograph_name_f";s:20:"Bromélaïne de tige";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:547:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:637:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:596:"The specifications must include testing for enzymatic activity of the medicinal ingredient at appropriate stages of formulation and manufacturing using the assay outlined in the current Food Chemicals Codex (FCC) :  PLANT PROTEOLYTIC ACTIVITY.;  Details of the manufacturing of the enzyme at the raw material stage should include fermentation medium, and the isolation process of the medicinal ingredient.;  Where published methods are not suitable for use, manufacturers will use due diligence to ensure that the enzymes remain active to the end of the shelf life indicated on the product label.";s:21:"field_specification_f";s:764:"Les spécifications doivent présenter l’analyse de l’activité enzymatique de l’ingrédient médicinal aux stades appropriés de la formulation et du procédé de fabrication conformément à l’épreuve décrite dans la version actuelle du Food Chemicals Codex (FCC) : PLANT PROTEOLYTIC ACTIVITY.;  Les détails de fabrication de l’enzyme à l'étape de la matière première doivent être fournis et doivent comprendre le milieu de fermentation, et le procédé d'isolement des ingrédients médicinaux.;  Lorsque les méthodes publiées ne sont pas appropriées, le fabriquant fera preuve de diligence raisonnable afin de s'assurer que les enzymes demeurent actives jusqu'à la fin de la période de conservation indiquée sur l'étiquette du produit.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2012-07-05";s:16:"field_legacy_nid";s:6:"100999";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:7:"STBR_OR";s:14:"field_mono_use";s:6:"DIGENZ";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:18:"ENZYME;FRBR1;FRBR2";s:19:"field_mono_duration";s:9:"PROLONGED";s:15:"field_mono_risk";s:34:"PREGC2;FRBR_CW;FRBR_ADR1;FRBR_ADR2";s:21:"field_mono_citation_e";s:109:"BROFR1;BROFR2;BROFR3;BROFR4;ALPHA15;ALPHA5;BROFR5;BROFR6;BROFR7;BROFR8;BROFR9;BROFR10;BROFR17;BROFR12;BROFR13";s:21:"field_mono_citation_f";s:109:"BROFR1;BROFR2;BROFR3;BROFR4;ALPHA15;ALPHA5;BROFR5;BROFR6;BROFR7;BROFR8;BROFR9;BROFR10;BROFR17;BROFR12;BROFR13";s:26:"field_reference_reviewed_e";s:23:"BROFR14;BROFR15;BROFR16";s:26:"field_reference_reviewed_f";s:23:"BROFR14;BROFR15;BROFR16";}i:216716;a:29:{s:5:"title";s:25:"PANENZ_Pancreatic Enzymes";s:3:"nid";s:6:"216716";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"PANENZ";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:18:"Pancreatic Enzymes";s:22:"field_monograph_name_f";s:22:"Enzymes pancréatiques";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:29:"atReq.do?atid=panenz&lang=eng";s:21:"field_monograph_url_f";s:29:"atReq.do?atid=panenz&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2012-07-13";s:16:"field_legacy_nid";s:6:"101000";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216717;a:37:{s:5:"title";s:17:"CHYM_Chymotrypsin";s:3:"nid";s:6:"216717";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"CHYM";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:12:"Chymotrypsin";s:22:"field_monograph_name_f";s:13:"Chymotrypsine";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:549:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.   Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:637:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:719:"The medicinal ingredient may comply with the specifications outlined in the current United States Pharmacopeia (USP): Chymotrypsin.; The specifications must include testing for enzymatic activity of the medicinal ingredient at appropriate stages of formulation and manufacturing using the assay outlined in the current Food Chemicals Codex (FCC): CHYMOTRYPSIN ACTIVITY;  Details of the manufacturing of the enzyme at the raw material stage should include fermentation medium and the isolation process of the medicinal ingredient.; Where published methods are not suitable for use, manufacturers will use due diligence to ensure that the enzymes remain active to the end of the shelf life indicated on the product label.";s:21:"field_specification_f";s:918:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans la version actuelle de la pharmacopée des États-Unis (USP) : Chymotrypsin.;  Les spécifications doivent présenter l’analyse de l’activité enzymatique de l’ingrédient médicinal aux stades appropriés de la formulation et du procédé de fabrication conformément à l’épreuve décrite dans la version actuelle du Food Chemicals Codex (FCC):  CHYMOTRYPSIN ACTIVITY; Les détails de fabrication de l’enzyme à l'étape de la matière première doivent être fournis et doivent comprendre le milieu de fermentation et le procédé d'isolement des ingrédients médicinaux.;  Lorsque les méthodes publiées ne sont pas appropriées, le fabriquant fera preuve de diligence raisonnable afin de s'assurer que les enzymes demeurent actives jusqu'à la fin de la période de conservation indiquée sur l'étiquette du produit.";s:25:"field_storage_condition_e";s:98:"Store in a tightly closed, light-resistant container in a cool, dry place (Ph.Eur. 2012 - USP 35).";s:25:"field_storage_condition_f";s:125:"Entreposer dans un contenant fermé hermétiquement et photorésistant, dans un endroit frais et sec (Ph.Eur. 2012 - USP 35).";s:10:"field_date";s:10:"2012-07-12";s:16:"field_legacy_nid";s:6:"101001";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:7:"CHYM_OR";s:14:"field_mono_use";s:6:"DIGENZ";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:11:"ENZYME;CHYM";s:19:"field_mono_duration";s:9:"PROLONGED";s:15:"field_mono_risk";s:23:"PREGC2;CHYM_CW;CHYM_ADR";s:21:"field_mono_citation_e";s:62:"CHYM1;ALPHA3;CHYM2;CHYM3;ALPHA15;CHYM4;CHYM5;CHYM6;CHYM7;USP35";s:21:"field_mono_citation_f";s:62:"CHYM1;ALPHA3;CHYM2;CHYM3;ALPHA15;CHYM4;CHYM5;CHYM6;CHYM7;USP35";s:26:"field_reference_reviewed_e";s:7:"ALPHA10";s:26:"field_reference_reviewed_f";s:7:"ALPHA10";}i:216718;a:37:{s:5:"title";s:12:"TRYP_Trypsin";s:3:"nid";s:6:"216718";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"TRYP";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:7:"Trypsin";s:22:"field_monograph_name_f";s:8:"Trypsine";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:549:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.   Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:637:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:863:"The medicinal ingredient may comply with the specifications outlined in the current European (Ph.Eur.) or current United States (USP) pharmacopoeias:  Ph.Eur: Trypsin or USP: Crystallized Trypsin.; The specifications must include testing for enzymatic activity of the medicinal ingredient at appropriate stages of formulation and manufacturing using the assay outlined in the current Food Chemicals Codex (FCC) or the current United States Pharmacopeia (USP):  FCC: TRYPSIN ACTIVITY or USP: Crystallized Trypsin.; Details of the manufacturing of the enzyme at the raw material stage should include fermentation medium and the isolation process of the medicinal ingredient.;  Where published methods are not suitable for use, manufacturers will use due diligence to ensure that the enzymes remain active to the end of the shelf life indicated on the product label.";s:21:"field_specification_f";s:1064:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans la version actuelle des pharmacopées Etats-Unis (USP) ou européenne (Ph.Eur.) : USP: Crystallized Trypsin ou Ph.Eur: Trypsin.; Les spécifications doivent présenter l’analyse de l’activité enzymatique de l’ingrédient médicinal aux stades appropriés de la formulation et du procédé de fabrication conformément à l’épreuve décrite dans la version actuelle du Food Chemicals Codex (FCC) ou la version actuelle de la pharmacopée des Etats-Unis (USP) :  FCC: TRYPSIN ACTIVITY  ou  USP: Crystallized Trypsin.; Les détails de fabrication de l’enzyme à l'étape de la matière première doivent être fournis et doivent comprendre le milieu de fermentation et le procédé d'isolement des ingrédients médicinaux.;  Lorsque les méthodes publiées ne sont pas appropriées, le fabriquant fera preuve de diligence raisonnable afin de s'assurer que les enzymes demeurent actives jusqu'à la fin de la période de conservation indiquée sur l'étiquette du produit.";s:25:"field_storage_condition_e";s:98:"Store in a tightly closed, light-resistant container in a cool, dry place (Ph.Eur. 2012 - USP 35).";s:25:"field_storage_condition_f";s:125:"Entreposer dans un contenant fermé hermétiquement et photorésistant, dans un endroit frais et sec (Ph.Eur. 2012 - USP 35).";s:10:"field_date";s:10:"2012-07-12";s:16:"field_legacy_nid";s:6:"101002";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:7:"TRYP_OR";s:14:"field_mono_use";s:6:"DIGENZ";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:11:"ENZYME;TRYP";s:19:"field_mono_duration";s:9:"PROLONGED";s:15:"field_mono_risk";s:25:"PREGC2;FUNPRO_CW;TRYP_ADR";s:21:"field_mono_citation_e";s:62:"CHYM1;ALPHA3;CHYM2;CHYM3;ALPHA15;TRYP1;CHYM5;CHYM6;TRYP2;USP35";s:21:"field_mono_citation_f";s:62:"CHYM1;ALPHA3;CHYM2;CHYM3;ALPHA15;TRYP1;CHYM5;CHYM6;TRYP2;USP35";s:26:"field_reference_reviewed_e";s:7:"ALPHA10";s:26:"field_reference_reviewed_f";s:7:"ALPHA10";}i:216719;a:37:{s:5:"title";s:11:"LIPA_Lipase";s:3:"nid";s:6:"216719";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"LIPA";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:6:"Lipase";s:22:"field_monograph_name_f";s:6:"Lipase";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:549:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.   Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:637:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:586:"The specifications must include testing for enzymatic activity of the medicinal ingredient at the appropriate stages of formulation and manufacturing using the assay outlined in the current Food Chemicals Codex (FCC) : LIPASE ACTIVITY.; Details of the manufacturing of the enzyme at the raw material stage should include fermentation medium and the isolation process of the medicinal ingredient.;  Where published methods are not suitable for use, manufacturers will use due diligence to ensure that the enzymes remain active to the end of the shelf life indicated on the product label.";s:21:"field_specification_f";s:738:"Les spécifications doivent inclure l’analyse de l’activité enzymatique de l’ingrédient médicinal aux stades appropriés de la formulation et de la fabrication conformément aux méthodes décrites dans la version actuelle du Food Chemicals Codex (FCC) : LIPASE ACTIVITY,;  Les détails de fabrication de l’enzyme à l'étape de la matière première doivent être fournis et doivent comprendre le milieu de fermentation et le procédé d'isolement des ingrédients médicinaux.;  Lorsque les méthodes publiées ne sont pas appropriées, le fabriquant fera preuve de diligence raisonnable afin de s'assurer que les enzymes demeurent actives jusqu'à la fin de la période de conservation indiquée sur l'étiquette du produit.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2012-07-12";s:16:"field_legacy_nid";s:6:"101003";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:7:"LIPA_OR";s:14:"field_mono_use";s:6:"DIGENZ";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:11:"ENZYME;LIPA";s:19:"field_mono_duration";s:9:"PROLONGED";s:15:"field_mono_risk";s:15:"PREGC2;LIPA_ADR";s:21:"field_mono_citation_e";s:49:"ALPHA1;ALPHA2;ALPHA3;ALPHA15;ALPHA5;LIPA1;FUNPRO4";s:21:"field_mono_citation_f";s:49:"ALPHA1;ALPHA2;ALPHA3;ALPHA15;ALPHA5;LIPA1;FUNPRO4";s:26:"field_reference_reviewed_e";s:21:"ALPHA10;ALPHA11;LIPA2";s:26:"field_reference_reviewed_f";s:21:"ALPHA10;ALPHA11;LIPA2";}i:216720;a:37:{s:5:"title";s:28:"ALPGAL_Galactosidase, alpha-";s:3:"nid";s:6:"216720";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"ALPGAL";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:21:"Galactosidase, alpha-";s:22:"field_monograph_name_f";s:21:"Galactosidase, alpha-";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:549:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.   Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:637:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:598:"The specifications must include testing for enzymatic activity of the medicinal ingredient at the appropriate stages of formulation and manufacturing  using the assay outlined in the current Food Chemicals Codex (FCC) : α-GALACTOSIDASE ACTIVITY.; Details of the manufacturing of the enzyme at the raw material stage should include fermentation medium and the  isolation process of the medicinal ingredient.;  Where published methods are not suitable for use, manufacturers will use due diligence to ensure that the enzymes remain active to the end of the shelf life indicated on the product label.";s:21:"field_specification_f";s:726:"Les spécifications doivent présenter l’analyse de l’activité enzymatique de l’ingrédient médicinal aux stades appropriés de la formulation et de la fabrication conformément à l’épreuve décrite dans la version actuelle du Food Chemicals Codex (FCC) : α-GALACTOSIDASE ACTIVITY.; Les détails de fabrication de l’enzyme à l'étape de la matière première doivent comprendre le milieu de fermentation et le procédé d'isolement des ingrédients médicinaux.;  Lorsque les méthodes publiées ne sont pas appropriées, le fabriquant fera preuve de diligence raisonnable afin de s'assurer que les enzymes demeurent actives jusqu'à la fin de la période de conservation indiquée sur l'étiquette du produit.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2012-07-11";s:16:"field_legacy_nid";s:6:"101004";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:9:"ALPGAL_OR";s:14:"field_mono_use";s:22:"ALPGAL1;ALPGAL2;DIGENZ";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:12:"ENZYME;GALAC";s:19:"field_mono_duration";s:9:"PROLONGED";s:15:"field_mono_risk";s:34:"PREGC2;GALAC_PW;GALAC_CW;GALAC_ADR";s:21:"field_mono_citation_e";s:70:"ALPHA1;ALPHA2;GALAC1;GALAC2;ALPHA15;GALAC3;GALAC4;GALAC5;GALAC6;GALAC7";s:21:"field_mono_citation_f";s:70:"ALPHA1;ALPHA2;GALAC1;GALAC2;ALPHA15;GALAC3;GALAC4;GALAC5;GALAC6;GALAC7";s:26:"field_reference_reviewed_e";s:21:"ALPHA11;GALAC8;GALAC9";s:26:"field_reference_reviewed_f";s:21:"ALPHA11;GALAC8;GALAC9";}i:216721;a:37:{s:5:"title";s:14:"CELL_Cellulase";s:3:"nid";s:6:"216721";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"CELL";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:9:"Cellulase";s:22:"field_monograph_name_f";s:9:"Cellulase";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:549:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.   Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:637:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:586:"The specifications must include testing for enzymatic activity of the medicinal ingredient at appropriate stages of formulation and manufacturing using the assay outlined in the current Food Chemicals Codex (FCC): CELLULASE ACTIVITY.; Details of the manufacturing of the enzyme at the raw material stage should include fermentation medium and the isolation process of the medicinal ingredient.;  Where published methods are not suitable for use, manufacturers will use due diligence to ensure that the enzymes remain active to the end of their shelf life indicated on the product label.";s:21:"field_specification_f";s:766:"Les spécifications doivent présenter l’analyse de l’activité enzymatique de l’ingrédient médicinal aux stades appropriés de la formulation et du procédé de fabrication conformément à l’épreuve décrite dans la version actuelle du Food Chemicals Codex (FCC): CELLULASE ACTIVITY.; Les détails de fabrication de l’enzyme à l'étape de la matière première doivent comprendre le milieu de fermentation et le procédé d'isolement des ingrédients médicinaux.;  Lorsque les méthodes publiées ne sont pas appropriées, le fabriquant fera preuve de diligence raisonnable afin de s'assurer que les enzymes demeurent actives jusqu'à la fin de la période de conservation indiquée sur l'étiquette du produit indiquée sur l'étiquette du produit.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2012-07-11";s:16:"field_legacy_nid";s:6:"101005";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:7:"CELL_OR";s:14:"field_mono_use";s:5:"CELL1";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:11:"ENZYME;CELL";s:19:"field_mono_duration";s:9:"PROLONGED";s:15:"field_mono_risk";s:25:"PREGC2;ALPHA_CW2;CELL_ADR";s:21:"field_mono_citation_e";s:47:"ALPHA1;ALPHA2;ALPHA3;ALPHA15;ALPHA5;CELL1;CELL3";s:21:"field_mono_citation_f";s:47:"ALPHA1;ALPHA2;ALPHA3;ALPHA15;ALPHA5;CELL1;CELL3";s:26:"field_reference_reviewed_e";s:19:"CELL2;ALPHA11;CELL4";s:26:"field_reference_reviewed_f";s:19:"CELL2;ALPHA11;CELL4";}i:216722;a:37:{s:5:"title";s:11:"PAPA_Papain";s:3:"nid";s:6:"216722";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"PAPA";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:6:"Papain";s:22:"field_monograph_name_f";s:8:"Papaïne";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:549:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.   Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:637:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:721:"The medicinal ingredient may comply with the specifications outlined in the current United States Pharmacopeia (USP): Papain.; The specifications must include testing for enzymatic activity of the medicinal ingredient at appropriate stages of formulation and manufacturing using the assay outlined in the current Food Chemicals Codex (FCC): PLANT PROTEOLYTIC ACTIVITY.; Details of the manufacturing of the enzyme at the raw material stage should include fermentation medium and the isolation process of the medicinal ingredient.;  Where published methods are not suitable for use, manufacturers will use due diligence to ensure that the enzymes remain active to the end of their shelf life indicated on the product label.";s:21:"field_specification_f";s:919:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans la version actuelle de la pharmacopée des États-Unis (USP) : Papain.; Les spécifications doivent présenter l’analyse de l’activité enzymatique de l’ingrédient médicinal aux stades appropriés de la formulation et du procédé de fabrication conformément à l’épreuve décrite dans la version actuelle du Food Chemicals Codex (FCC) : PLANT PROTEOLYTIC ACTIVITY.; Les détails de fabrication de l’enzyme à l'étape de la matière première doivent être fournis et doivent comprendre le milieu de fermentation et le procédé d'isolement des ingrédients médicinaux.;  Lorsque les méthodes publiées ne sont pas appropriées, le fabriquant fera preuve de diligence raisonnable afin de s'assurer que les enzymes demeurent actives jusqu'à la fin de leur période de conservation indiquée sur l'étiquette du produit.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2012-07-10";s:16:"field_legacy_nid";s:6:"101006";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:7:"PAPA_OR";s:14:"field_mono_use";s:5:"PAPA1";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:24:"ENZYME;PAPA1;PAPA2;PAPA3";s:19:"field_mono_duration";s:9:"PROLONGED";s:15:"field_mono_risk";s:32:"PREGC2;PAPA_CW2;PAPA_ADR;PAPA_CW";s:21:"field_mono_citation_e";s:90:"PAPA1;CHYM2;CHYM3;ALPHA15;PAPA2;PAPA3;CHYM5;PAPA4;PAPA5;PAPA6;PAPA7;USP35;PAPAAPHA;PAMERCK";s:21:"field_mono_citation_f";s:90:"PAPA1;CHYM2;CHYM3;ALPHA15;PAPA2;PAPA3;CHYM5;PAPA4;PAPA5;PAPA6;PAPA7;USP35;PAPAAPHA;PAMERCK";s:26:"field_reference_reviewed_e";s:15:"ALPHA11;BROFR16";s:26:"field_reference_reviewed_f";s:15:"ALPHA11;BROFR16";}i:216723;a:35:{s:5:"title";s:12:"LACT_Lactase";s:3:"nid";s:6:"216723";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"LACT";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:7:"Lactase";s:22:"field_monograph_name_f";s:7:"Lactase";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:549:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.   Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:637:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:785:"The specifications must include testing for enzymatic activity of the medicinal ingredient at appropriate stages of formulation and manufacturing using the assay outlined in the current Food Chemicals Codex (FCC): Lactase (Acid) (Beta-Galactosidase) activity (ALU).; The medicinal ingredient may comply with the specifications (quality specifications only) outlined in the current United States (USP) pharmacopoeial monograph: Lactase.; Details of the manufacturing of the enzyme at the raw material stage should include fermentation medium and the isolation process of the medicinal ingredient.; Where published methods are not suitable for use, manufacturers will use due diligence to ensure that the enzymes remain active to the end of the shelf life indicated on the product label.";s:21:"field_specification_f";s:966:"Les détails de fabrication de l’enzyme à l'étape de la matière première doivent comprendre le milieu de fermentation et le procédé d'isolement de l’ingrédient médicinal.; Les spécifications doivent inclure l’analyse de l’activité enzymatique de l'ingrédient médicinal aux stades appropriés de la formulation et de la fabrication conformément aux méthode décrites dans la version actuelle du Food Chemicals Codex (FCC) : Lactase (Acid) (Beta-Galactosidase) activity (ALU).; L’ingrédient médicinal peut être conforme aux spécifications (spécifications pour la qualité uniquement) énoncées dans la monographie de la version actuelle de la pharmacopée américaine (USP) : Lactase.; Lorsque les méthodes d’analyse publiées ne sont pas appropriées, le fabricant fera preuve de diligence raisonnable afin de s’assurer que les enzymes demeurent actives jusqu’à la fin de la durée de vie indiquée sur l’étiquette du produit.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2012-07-10";s:16:"field_legacy_nid";s:6:"101007";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:6:"LAC_OR";s:14:"field_mono_use";s:16:"DIGENZ;LAC1;LAC2";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:11:"ENZYME;LAC1";s:19:"field_mono_duration";s:4:"LAC1";s:15:"field_mono_risk";s:14:"LAC1;LAC2;LAC3";s:21:"field_mono_citation_e";s:71:"ELTM;ALPHA1;INGFUNG2;CVOD2;ALPHA15;ANHM;ENZNOM;EXOLAC;OERT;ALLLAC;USP35";s:21:"field_mono_citation_f";s:71:"ELTM;ALPHA1;INGFUNG2;CVOD2;ALPHA15;ANHM;ENZNOM;EXOLAC;OERT;ALLLAC;USP35";}i:216724;a:29:{s:5:"title";s:32:"WHTWIL_White willow - Salix alba";s:3:"nid";s:6:"216724";s:7:"changed";s:10:"2013-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"WHTWIL";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:25:"White willow - Salix alba";s:22:"field_monograph_name_f";s:24:"Saule blanc - Salix alba";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:42:"atReq.do?atid=white.wil.saule.bla&lang=eng";s:21:"field_monograph_url_f";s:42:"atReq.do?atid=white.wil.saule.bla&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-04-23";s:16:"field_legacy_nid";s:6:"101040";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216725;a:29:{s:5:"title";s:15:"OBG_Beta-Glucan";s:3:"nid";s:6:"216725";s:7:"changed";s:10:"2014-01-13";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"OBG";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:11:"Beta-Glucan";s:22:"field_monograph_name_f";s:13:"Bêta-glucane";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:35:"atReq.do?atid=beta.glucane&lang=eng";s:21:"field_monograph_url_f";s:35:"atReq.do?atid=beta.glucane&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-05-13";s:16:"field_legacy_nid";s:6:"101050";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216726;a:29:{s:5:"title";s:10:"INU_Inulin";s:3:"nid";s:6:"216726";s:7:"changed";s:10:"2014-01-13";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"INU";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:6:"Inulin";s:22:"field_monograph_name_f";s:7:"Inuline";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:30:"atReq.do?atid=inuline&lang=eng";s:21:"field_monograph_url_f";s:30:"atReq.do?atid=inuline&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-05-13";s:16:"field_legacy_nid";s:6:"101049";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216727;a:29:{s:5:"title";s:18:"LCAR_Carnitine, L-";s:3:"nid";s:6:"216727";s:7:"changed";s:10:"2014-01-13";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"LCAR";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:13:"Carnitine, L-";s:22:"field_monograph_name_f";s:13:"Carnitine, L-";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:34:"atReq.do?atid=l.carnitine&lang=eng";s:21:"field_monograph_url_f";s:34:"atReq.do?atid=l.carnitine&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-05-13";s:16:"field_legacy_nid";s:6:"101048";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216728;a:29:{s:5:"title";s:30:"KIDB_White Kidney bean extract";s:3:"nid";s:6:"216728";s:7:"changed";s:10:"2014-01-13";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"KIDB";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:25:"White Kidney bean extract";s:22:"field_monograph_name_f";s:23:"Haricot blanc - extrait";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:41:"atReq.do?atid=phaseolus.vulgaris&lang=eng";s:21:"field_monograph_url_f";s:41:"atReq.do?atid=phaseolus.vulgaris&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-05-13";s:16:"field_legacy_nid";s:6:"101047";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216729;a:29:{s:5:"title";s:13:"CHIT_Chitosan";s:3:"nid";s:6:"216729";s:7:"changed";s:10:"2014-01-13";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"CHIT";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:8:"Chitosan";s:22:"field_monograph_name_f";s:9:"Chitosane";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:31:"atReq.do?atid=chitosan&lang=eng";s:21:"field_monograph_url_f";s:31:"atReq.do?atid=chitosan&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-05-13";s:16:"field_legacy_nid";s:6:"101046";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216730;a:38:{s:5:"title";s:32:"CAY_Cayenne - Capsicum annuum L.";s:3:"nid";s:6:"216730";s:7:"changed";s:10:"2014-01-13";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"CAY";s:18:"field_group_name_e";s:7:"Cayenne";s:18:"field_group_name_f";s:7:"Cayenne";s:22:"field_monograph_name_e";s:28:"Cayenne - Capsicum annuum L.";s:22:"field_monograph_name_f";s:28:"Cayenne - Capsicum annuum L.";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:30:"atReq.do?atid=cayenne&lang=eng";s:21:"field_monograph_url_f";s:30:"atReq.do?atid=cayenne&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:154:"The medicinal ingredient may comply with the specifications outlined in the Capsicum Monographs published in the U.S., European or British Pharmacopoeias.";s:21:"field_specification_f";s:126:"Doivent respecter les spécifications minimales énoncées dans la version actuelle du Compendium des monographies de la DPSN.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-05-13";s:16:"field_legacy_nid";s:6:"100833";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:6:"CAY_TP";s:14:"field_mono_use";s:17:"CAYT1;CAYT2;CAYT3";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"APP1";s:19:"field_mono_duration";s:6:"CAYDUR";s:15:"field_mono_risk";s:26:"PERS;WORS;CAYT_CW1;CAYT_AR";s:21:"field_mono_citation_e";s:152:"HBNPD;CPHN;BHP;ABC;EXPCEM;50COM;BPC;BHCOM2;HERCDI;ARTTC;THEPHA;ECMM;KAD;AMODHER;PCDND;MEDHER;HERBBK;TOPCAP;HERCOM;CAP075;PAINDIA;TPDIAN;RANVC;PCBDP;GRIN";s:21:"field_mono_citation_f";s:149:"HBNPD;CPHN;BHP;ABC;EXPCEM;50COM;BPC;BHCOM2;HERCDI;ARTTC;THEPHA;ECMM;KAD;AMODHER;PCDND;MEDHER;HERBBK;TOPCAP;PPS;CAP075;PAINDIA;TPDIAN;RANVC;PCBDP;GRIN";s:26:"field_reference_reviewed_e";s:212:"4WKCHILI;HERMED2;TRTCPHN;DYSRP;REFCTRL;CGRPH;RCPDNA;GENDDIF;PHARCH;POTIN;NEURFLAR;IPAC;SAFCAP;RHEUART;DUODEN;FACSENS;RASYNOV;CIMH;RGED;GASTULC;TCCREAM;WRELBL;ELEFF;BIPHAS;REPRO;HIGHFIB;VANIL;SATIETY;HUMHAND;APPEI";s:26:"field_reference_reviewed_f";s:212:"4WKCHILI;HERMED2;TRTCPHN;DYSRP;REFCTRL;CGRPH;RCPDNA;GENDDIF;PHARCH;POTIN;NEURFLAR;IPAC;SAFCAP;RHEUART;DUODEN;FACSENS;RASYNOV;CIMH;RGED;GASTULC;TCCREAM;WRELBL;ELEFF;BIPHAS;REPRO;HIGHFIB;VANIL;SATIETY;HUMHAND;APPEI";}i:216732;a:29:{s:5:"title";s:44:"CARROT_Carrot - Daucus carota L. ssp sativus";s:3:"nid";s:6:"216732";s:7:"changed";s:10:"2014-01-30";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"CARROT";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:37:"Carrot - Daucus carota L. ssp sativus";s:22:"field_monograph_name_f";s:38:"Carotte - Daucus carota L. ssp sativus";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:29:"atReq.do?atid=carrot&lang=eng";s:21:"field_monograph_url_f";s:29:"atReq.do?atid=carrot&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2012-08-15";s:16:"field_legacy_nid";s:6:"101026";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216733;a:29:{s:5:"title";s:14:"BLBR_Blueberry";s:3:"nid";s:6:"216733";s:7:"changed";s:10:"2014-03-05";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"BLBR";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:9:"Blueberry";s:22:"field_monograph_name_f";s:6:"Bleuet";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:39:"atReq.do?atid=blueberry.bleuet&lang=eng";s:21:"field_monograph_url_f";s:39:"atReq.do?atid=blueberry.bleuet&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-02-07";s:16:"field_legacy_nid";s:6:"101052";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216734;a:29:{s:5:"title";s:15:"POM_Pomegranate";s:3:"nid";s:6:"216734";s:7:"changed";s:10:"2014-03-05";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"POM";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:11:"Pomegranate";s:22:"field_monograph_name_f";s:7:"Grenade";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:42:"atReq.do?atid=pomegranate.grenade&lang=eng";s:21:"field_monograph_url_f";s:42:"atReq.do?atid=pomegranate.grenade&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-02-07";s:16:"field_legacy_nid";s:6:"101053";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216735;a:29:{s:5:"title";s:27:"CBFLAV_Citrus Bioflavonoids";s:3:"nid";s:6:"216735";s:7:"changed";s:10:"2014-03-05";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"CBFLAV";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:20:"Citrus Bioflavonoids";s:22:"field_monograph_name_f";s:25:"Bioflavonoïdes d'agrumes";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:45:"atReq.do?atid=citrus.bioflav.agrumes&lang=eng";s:21:"field_monograph_url_f";s:45:"atReq.do?atid=citrus.bioflav.agrumes&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-02-07";s:16:"field_legacy_nid";s:6:"101055";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216736;a:29:{s:5:"title";s:39:"SRPSE_Serrapeptase (Under consultation)";s:3:"nid";s:6:"216736";s:7:"changed";s:10:"2014-03-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"SRPSE";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:33:"Serrapeptase (Under consultation)";s:22:"field_monograph_name_f";s:32:"Serrapeptase (Sous consultation)";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:35:"atReq.do?atid=serrapeptase&lang=eng";s:21:"field_monograph_url_f";s:35:"atReq.do?atid=serrapeptase&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-02-07";s:16:"field_legacy_nid";s:6:"106395";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216737;a:37:{s:5:"title";s:23:"FUNPRO_Protease, Fungal";s:3:"nid";s:6:"216737";s:7:"changed";s:10:"2014-03-20";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"FUNPRO";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:16:"Protease, Fungal";s:22:"field_monograph_name_f";s:18:"Protéase fongique";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:549:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.   Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:637:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:1019:"The finished product specifications must be established in accordance with the requirements described in the NHPD Quality of Natural Health Products Guide.; The medicinal ingredient must comply with the requirements outlined in the Natural Health Products Ingredients Database (NHPID); Details of the manufacturing of the enzyme at the raw material stage should include fermentation medium and the isolation process of the medicinal ingredient.; No traces of any antibiotics or their residues should be detectable in the finished product.; The specifications must include testing for enzymatic activity of the medicinal ingredient at appropriate stages of formulation and manufacturing using the assay outlined in the current Food Chemicals Codex (FCC): PROTEOLYTIC ACTIVITY, FUNGAL (HUT) and PROTEOLYTIC ACTIVITY, FUNGAL (SAP).;  Where published methods are not suitable for use, manufacturers will use due diligence to ensure that the enzymes remain active to the end of the shelf life indicated on the product label.";s:21:"field_specification_f";s:1249:"Les spécifications du produit fini doivent être établies conformément aux exigences décrites dans le Guide de référence sur la qualité des produits de santé naturels de la DPSN.; L’ingrédient médicinal doit être conforme aux exigences mentionnées dans la Base de données d’ingrédients de produits de santé naturels (BDIPSN).; Aucune trace d’antibiotiques ou de leurs résidus ne devrait être détectable dans le produit fini.; Les spécifications doivent présenter l’analyse de l’activité enzymatique de l’ingrédient médicinal aux stades appropriés de la formulation et de la fabrication conformément aux méthodes décrites dans la version actuelle du Food Chemicals Codex (FCC) : PROTEOLYTIC ACTIVITY, FUNGAL (HUT)  et  PROTEOLYTIC ACTIVITY, FUNGAL (SAP).; Les détails de fabrication de l’enzyme à l'étape de la matière première doivent être fournis et doivent comprendre le milieu de fermentation et le procédé d'isolement des ingrédients médicinaux.;  Lorsque les méthodes publiées ne sont pas appropriées, le fabriquant fera preuve de diligence raisonnable afin de s'assurer que les enzymes demeurent actives jusqu'à la fin de la période de conservation indiquée sur l'étiquette du produit.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-03-11";s:16:"field_legacy_nid";s:6:"101008";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:9:"FUNPRO_OR";s:14:"field_mono_use";s:23:"FUNPRO1;FUNPRO2;FUNPRO3";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:38:"ENZYME;FUNPRO1;FUNPRO2;FUNPRO3;FUNPRO4";s:19:"field_mono_duration";s:9:"PROLONGED";s:15:"field_mono_risk";s:25:"CELL_ADR;FUNPRO_CW;PREGC2";s:21:"field_mono_citation_e";s:60:"ALPHA1;ALPHA2;ALPHA3;ALPHA15;FUNPRO1;FUNPRO2;FUNPRO3;FUNPRO5";s:21:"field_mono_citation_f";s:60:"ALPHA1;ALPHA2;ALPHA3;ALPHA15;FUNPRO1;FUNPRO2;FUNPRO3;FUNPRO5";s:26:"field_reference_reviewed_e";s:23:"ALPHA10;ALPHA11;FUNPRO4";s:26:"field_reference_reviewed_f";s:23:"ALPHA10;ALPHA11;FUNPRO4";}i:216738;a:35:{s:5:"title";s:51:"MRSHLF_Marshmallow – Althaea Officinalis – Leaf";s:3:"nid";s:6:"216738";s:7:"changed";s:10:"2014-03-31";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"MRSHLF";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:44:"Marshmallow – Althaea Officinalis – Leaf";s:22:"field_monograph_name_f";s:53:"Guimauve Officinale – Althaea Officinalis - Feuille";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:547:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:635:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota: (i) Les parenthèses contiennent des éléments d’information facultatifs - il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:180:"The medicinal ingredient may comply with the specifications outlined in the Marshmallow monographs published in the British Pharmacopoeia (BP) and European Pharmacopoeia (Ph. Eur.)";s:21:"field_specification_f";s:203:"L'ingrédient médicinal peut être conforme aux spécifications énoncées dans les monographies Guimauve Officinale publiées dans la Pharmacopée britannique (BP) et Pharmacopée européenne (Ph.Eur.)";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-05-21";s:16:"field_legacy_nid";s:6:"101028";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:11:"MRSHLF_Oral";s:14:"field_mono_use";s:15:"MRSHLF1;MRSHLF2";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_mono_risk";s:21:"MRSHLF_CW1;MRSHLF_CW2";s:21:"field_mono_citation_e";s:109:"MRSHLF1;MRSHLF2;MRSHLF3;MRSHLF4;MRSHLF5;MRSHLF6;MRSHLF7;MRSHRT12;MRSHRT13;MRSHRT14;MRSHRT18;MRSHRT19;MRSHRT43";s:21:"field_mono_citation_f";s:109:"MRSHLF1;MRSHLF2;MRSHLF3;MRSHLF4;MRSHLF5;MRSHLF6;MRSHLF7;MRSHRT12;MRSHRT13;MRSHRT14;MRSHRT16;MRSHRT18;MRSHRT19";s:26:"field_reference_reviewed_e";s:303:"MRSHLF8;MRSHLF9;MRSHLF10;MRSHLF11;MRSHLF12;MRSHLF14;MRSHLF15;MRSHLF16;MRSHLF17;MRSHLF18;MRSHLF19;MRSHRT14;MRSHRT15;MRSHRT20;MRSHRT21;MRSHRT22;MRSHRT23;MRSHRT24;MRSHRT25;MRSHRT26;MRSHRT28;MRSHRT29;MRSHRT30;MRSHRT31;MRSHRT32;MRSHRT33;MRSHRT34;MRSHRT35;MRSHRT38;MRSHRT39;MRSHRT41;MRSHRT42;MRSHRT43;MRSHRT45";s:26:"field_reference_reviewed_f";s:312:"MRSHLF8;MRSHLF9;MRSHLF10;MRSHLF11;MRSHLF12;MRSHLF13;MRSHLF14;MRSHLF15;MRSHLF16;MRSHLF17;MRSHLF18;MRSHLF19;MRSHRT20;MRSHRT21;MRSHRT22;MRSHRT23;MRSHRT24;MRSHRT25;MRSHRT26;MRSHRT28;MRSHRT29;MRSHRT30;MRSHRT31;MRSHRT32;MRSHRT33;MRSHRT34;MRSHRT35;MRSHRT36;MRSHRT38;MRSHRT39;MRSHRT41;MRSHRT42;MRSHRT43;MRSHRT44;MRSHRT45";}i:216739;a:29:{s:5:"title";s:20:"RWE_Red Wine Extract";s:3:"nid";s:6:"216739";s:7:"changed";s:10:"2014-04-02";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"RWE";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:16:"Red Wine Extract";s:22:"field_monograph_name_f";s:20:"Extrait de vin rouge";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:45:"atReq.do?atid=red.wine.ext.vin.rouge&lang=eng";s:21:"field_monograph_url_f";s:45:"atReq.do?atid=red.wine.ext.vin.rouge&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-03-07";s:16:"field_legacy_nid";s:6:"101056";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216740;a:29:{s:5:"title";s:16:"RESV_Resveratrol";s:3:"nid";s:6:"216740";s:7:"changed";s:10:"2014-04-02";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"RESV";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:11:"Resveratrol";s:22:"field_monograph_name_f";s:12:"Resvératrol";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:34:"atReq.do?atid=resveratrol&lang=eng";s:21:"field_monograph_url_f";s:34:"atReq.do?atid=resveratrol&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-08-13";s:16:"field_legacy_nid";s:6:"101051";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216741;a:29:{s:5:"title";s:24:"NALC_N-Acetyl-L-Cysteine";s:3:"nid";s:6:"216741";s:7:"changed";s:10:"2014-04-02";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"NALC";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:19:"N-Acetyl-L-Cysteine";s:22:"field_monograph_name_f";s:21:"N-Acétyl-L-Cystéine";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:42:"atReq.do?atid=n-acetyl-l-cysteine&lang=eng";s:21:"field_monograph_url_f";s:42:"atReq.do?atid=n-acetyl-l-cysteine&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-08-16";s:16:"field_legacy_nid";s:6:"101054";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216742;a:29:{s:5:"title";s:54:"COGHP_Cognitive function products (Under consultation)";s:3:"nid";s:6:"216742";s:7:"changed";s:10:"2014-06-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"COGHP";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:48:"Cognitive function products (Under consultation)";s:22:"field_monograph_name_f";s:40:"Fonctions cognitives (Sous consultation)";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"P;C";s:21:"field_monograph_url_e";s:42:"atReq.do?atid=fonc.cognitive.func&lang=eng";s:21:"field_monograph_url_f";s:42:"atReq.do?atid=fonc.cognitive.func&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-05-21";s:16:"field_legacy_nid";s:6:"106964";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216743;a:29:{s:5:"title";s:26:"WRKSUP_Workout Supplements";s:3:"nid";s:6:"216743";s:7:"changed";s:10:"2014-06-16";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"WRKSUP";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:19:"Workout Supplements";s:22:"field_monograph_name_f";s:31:"Suppléments à l'entraînement";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"P;C";s:21:"field_monograph_url_e";s:55:"atReq.do?atid=workout.supplements.entrainement&lang=eng";s:21:"field_monograph_url_f";s:55:"atReq.do?atid=workout.supplements.entrainement&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-12-20";s:16:"field_legacy_nid";s:6:"105533";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216744;a:29:{s:5:"title";s:15:"PROB_Probiotics";s:3:"nid";s:6:"216744";s:7:"changed";s:10:"2014-07-10";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"PROB";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:10:"Probiotics";s:22:"field_monograph_name_f";s:12:"Probiotiques";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"P;C";s:21:"field_monograph_url_e";s:29:"atReq.do?atid=probio&lang=eng";s:21:"field_monograph_url_f";s:29:"atReq.do?atid=probio&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:0:"";s:16:"field_legacy_nid";s:6:"100987";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216745;a:29:{s:5:"title";s:48:"MULJH_Joint Health Products, Multiple Ingredient";s:3:"nid";s:6:"216745";s:7:"changed";s:10:"2014-07-10";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"MULJH";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:42:"Joint Health Products, Multiple Ingredient";s:22:"field_monograph_name_f";s:66:"Articulations, Produits à ingrédients multiples pour le soin des";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"P;C";s:21:"field_monograph_url_e";s:44:"atReq.do?atid=multiple.joint.health&lang=eng";s:21:"field_monograph_url_f";s:44:"atReq.do?atid=multiple.joint.health&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-11-26";s:16:"field_legacy_nid";s:6:"100976";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216746;a:36:{s:5:"title";s:12:"SEA_Seal Oil";s:3:"nid";s:6:"216746";s:7:"changed";s:10:"2014-07-10";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"SEA";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:8:"Seal Oil";s:22:"field_monograph_name_f";s:16:"Phoque, Huile de";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:31:"atReq.do?atid=seal.oil&lang=eng";s:21:"field_monograph_url_f";s:31:"atReq.do?atid=seal.oil&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:853:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.   There are many N-3 polyunsaturated fatty acids, popularly known as omega-3 acids/ω-3 fatty acids (Ph.Eur. 2012). This monograph is specific to eicosapentaenoic acid (C20:5 n-3, EPA) and docosahexaenoic acid (C22:6 n-3, DHA) and docosapentaenoic acid (C22:5 n-3; DPA).    Notes: (i) Text in parentheses is additional optional information which can be included on the Product Licence Application and product labels at the applicants’ discretion. (ii) The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:972:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal.   Il existe plusieurs acides gras polyinsaturés N-3, mieux connus sous les noms d’acides gras omega-3/acides gras ω-3 (Ph.Eur. 2012). Cette monographie est spécifique à l’acide eicosapentaénoïque (C20:5 n-3, AEP) et à l’acide docosahexaénoïque (C22:6 n-3, ADH) et d’acide docosapentanoïque (C22:5 n-3; ADP).    Nota :   (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit.  (ii) La barre oblique (/) indique que les termes sont synonymes. Le demandeur peut utiliser n’importe lequel des termes indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:2086:"Peroxide, anisidine, and totox values of seal oil or omega-3 fatty acids derived from seal oil must be in accordance with the methods set out by the Association of Analytical Community (AOAC) and/or Pharmacopoeial analytical methods. These specifications are necessary to ensure the oxidative stability of the seal oil and the omega-3 fatty acids from seal oil (HC 2007).  The maximum peroxide value (PV) must be 5 mEq/kg, the maximum anisidine value (AV) must be 20 while the maximum Totox value must be 26 (calculated as 2 X PV + AV).;  The dioxins, polychlorinated dibenzo-para-dioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs), the dioxin-like polychlorinated biphenyls (DL PCBs), and the polychlorinated biphenyls (PCBs) are contaminants in oils from marine sources. Testing for these contaminants are required, and must be performed using appropriate analytical methods, such as the Commission of the European Communities’ Regulation 1883/2006 (EC 2006a) or the U.S. Environmental Protection Agency’s method 1613B for PCDDs and PCDFs and method 1668A for PCBs (US EPA 2010, 2008, 1994). Applicants are advised to consult the Council of the European Union document on these contaminants for further information (EU 2011, EC 2006b).  The maximum limits are: for dioxins (sum of PCDDs and PCDFs) -- a maximum of 1.75 pg/g of fat, for the sum of dioxins and DL PCBs -- a maximum of 6 pg/g fat, and for total PCB-6 -- a maximum of 200 ng/g fat [(i)Maximums levels are expressed in World Health Organization (WHO) toxic equivalents using WHO-toxic equivalent factors (TEFs). Analytical results relating to 17 individual dioxin congeners of toxicological concern are expressed in a single quantifiable unit: 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) toxic equivalent concentration (TEQ) (EU 2011, EC 2006b)  (ii)Reference for sum of dioxins is: WHO-PCDD/F-TEQ (EU 2011, EC 2006b)  (iii) Reference for sum of dioxins and dioxin-like PCBs is: WHO-PCDD/F-PCB-TEQ (EU 2011, EC 2006b)  (iv) Reference for sum of PCB congeners 28, 52, 101, 138, 153 and 180 is (EU 2011, EC 2006b)]";s:21:"field_specification_f";s:2539:"Les niveaux de peroxyde, d’anisidine et les niveaux totaux d’oxydation de l’huile de phoque et des dérivés d’acides gras oméga-3 provenant de l’huile de phoque doivent respecter les normes établies par l’Association of Analytical Community (AOAC) et/ou les méthodes analytiques des pharmacopées. Ces spécifications assureront la résistance à l'oxydation de l'huile de phoque et des acides gras oméga-3 provenant de l'huile de phoque (SC 2007). Le niveau maximal de l'indice de peroxyde (IP) doit être 5 mEq/kg, le niveau maximal de l'indice d'anisidine (IA) doit être 20 tandis que le niveau maximal du total d'oxydation doit être 26 (calculé selon la formule : 2 X IP + IA).;  Les dioxines polychorodibenzo-para-dioxines (PCDD) et les polycholorodibenzofuranes (PCDF), les polychlorobiphényles de type dioxine (PCBTD), et les polychlorobiphényles (PCB) sont des contaminants présents dans les huiles marines. Des analyses pour détecter ces contaminants sont obligatoires et doivent être effectuées au moyen d'une méthode analytique appropriée, telle que la méthode du Règlement 1883/2006 de la Commission des communautés européennes (CE 2006a) ou la méthode 1613B de la U.S. Environmental Protection Agency pour les PCDD et les PCDF ainsi que la méthode 1668A pour les BPC (US EPA 2010, 2008, 1994). Les demandeurs sont avisés de consulter le document du Conseil de l’Union européenne sur ces contaminants pour de plus amples informations (UE 2011, CE 2006b). Les teneurs maximales sont:  pour les dioxines (somme des PCDD et des PCDF) --  un maximum de 1,75 pg/g graisse, pour la somme des dioxines et des PCBTD -- un maximum de 6 pg/g graisse, et pour le total PCB-6 -- 200 ng/g graisse [(i)Les teneurs maximales sont: exprimées en équivalents toxiques tels que définis par l’Organisation mondiale de la santé (OMS), en appliquant les facteurs d’équivalence toxique de l’OMS (TEF-OMS). Les résultats de l’analyse de 17 congénères de dioxines représentant un risque toxicologique sont exprimés sous la forme d’une seule unité quantifiable : la concentration en équivalents toxiques (TEQ) de 2,3,7,8-tétrachlorodibenzo-p-dioxine (TCDD) (UE 2011, CE 2006b)  (ii) Les références pour la somme des dioxines sont : OMS-PCDD/F-TEQ (EU 2011,  CE 2006b) (iii) Les références pour la somme des dioxines et des PCBTD sont: OMS-PCDD/F-PCB-TEQ (UE 2011, CE 2006b) (iv) Les références pour la Somme des congénères 28, 52, 101, 138, 153 et 180 de PCB sont (UE 2011, CE 2006b)]";s:25:"field_storage_condition_e";s:187:"For all products: Store in airtight container, protected from light (Ph.Eur. 2012, USP 35).; For all products, except those encapsulated: Refrigerate after opening (Wille and Gonus 1989).";s:25:"field_storage_condition_f";s:191:"Pour tous les produits : Entreposer dans un contenant hermétique à l’abri de la lumière (Ph.Eur. 2012, USP 35).;  Tous les produits, sauf ceux encapsulés : Réfrigérer après ouverture";s:10:"field_date";s:10:"2012-03-23";s:16:"field_legacy_nid";s:6:"100938";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:6:"SEA_OR";s:14:"field_mono_use";s:17:"SOIL1;SOIL2;SOIL3";s:19:"field_subpopulation";s:21:"AD913;AD1418;ADU;CH18";s:15:"field_dose_note";s:22:"ADUL;FOIL1;RESMIN;SOIL";s:21:"field_mono_citation_e";s:210:"COAGU;DHACOG;DOCOSA;EFABRAIN;EFAHCD;EYECHLD;FCC7;MAROIL2;MAROIL3;MAROIL4;MAROIL6;MAROIL8;MAROIL10;MAROIL11;MAROIL12;MAROIL13;MAROIL14;MAROIL34;MAROIL35;MAROIL36;MAROIL37;MAROIL38;MRISTD;O3ATHL;PREPFO;PRIMC;SCLO";s:21:"field_mono_citation_f";s:210:"COAGU;DHACOG;DOCOSA;EFABRAIN;EFAHCD;EYECHLD;FCC7;MAROIL2;MAROIL3;MAROIL4;MAROIL6;MAROIL8;MAROIL10;MAROIL11;MAROIL12;MAROIL13;MAROIL14;MAROIL34;MAROIL35;MAROIL36;MAROIL37;MAROIL38;MRISTD;O3ATHL;PREPFO;PRIMC;SCLO";s:26:"field_reference_reviewed_e";s:55:"GUINEA;HPCRATS;MAROIL39;MAROIL40;MENHADEN;MODARF;SUPDSO";s:26:"field_reference_reviewed_f";s:64:"GUINEA;HPCRATS;MAROIL39;MAROIL40;MAROIL41;MENHADEN;MODARF;SUPDSO";}i:216747;a:29:{s:5:"title";s:14:"TRPLA_Triphala";s:3:"nid";s:6:"216747";s:7:"changed";s:10:"2014-07-10";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"TRPLA";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:8:"Triphala";s:22:"field_monograph_name_f";s:8:"Triphala";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"P;C";s:21:"field_monograph_url_e";s:31:"atReq.do?atid=triphala&lang=eng";s:21:"field_monograph_url_f";s:31:"atReq.do?atid=triphala&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-06-11";s:16:"field_legacy_nid";s:6:"106394";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216748;a:29:{s:5:"title";s:15:"UBNOL_Ubiquinol";s:3:"nid";s:6:"216748";s:7:"changed";s:10:"2014-07-10";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"UBNOL";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:9:"Ubiquinol";s:22:"field_monograph_name_f";s:9:"Ubiquinol";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:32:"atReq.do?atid=ubiquinol&lang=eng";s:21:"field_monograph_url_f";s:32:"atReq.do?atid=ubiquinol&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-06-11";s:16:"field_legacy_nid";s:6:"106396";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216749;a:29:{s:5:"title";s:30:"GCBE_Green Coffee Bean Extract";s:3:"nid";s:6:"216749";s:7:"changed";s:10:"2014-07-10";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"GCBE";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:25:"Green Coffee Bean Extract";s:22:"field_monograph_name_f";s:31:"Extrait de Fèves de Café Vert";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:56:"atReq.do?atid=greencoffeebean.ext.fevescafevert&lang=eng";s:21:"field_monograph_url_f";s:56:"atReq.do?atid=greencoffeebean.ext.fevescafevert&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-06-11";s:16:"field_legacy_nid";s:6:"105531";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216750;a:29:{s:5:"title";s:33:"BLPEP_Black Pepper - Piper nigrum";s:3:"nid";s:6:"216750";s:7:"changed";s:10:"2014-07-10";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"BLPEP";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:27:"Black Pepper - Piper nigrum";s:22:"field_monograph_name_f";s:26:"Poivre noir - Piper nigrum";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:45:"atReq.do?atid=blackpepper.poivrenoir&lang=eng";s:21:"field_monograph_url_f";s:45:"atReq.do?atid=blackpepper.poivrenoir&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-06-11";s:16:"field_legacy_nid";s:6:"105532";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216751;a:29:{s:5:"title";s:51:"ANSC_Antiseptic Skin Cleansers (Under consultation)";s:3:"nid";s:6:"216751";s:7:"changed";s:10:"2014-08-21";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"ANSC";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:46:"Antiseptic Skin Cleansers (Under consultation)";s:22:"field_monograph_name_f";s:58:"Peau, Nettoyants antiseptiques pour la (Sous consultation)";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"P;C";s:21:"field_monograph_url_e";s:46:"atReq.do?atid=antiseptic_antiseptique&lang=eng";s:21:"field_monograph_url_f";s:46:"atReq.do?atid=antiseptic_antiseptique&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:0:"";s:16:"field_legacy_nid";s:6:"100802";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216752;a:29:{s:5:"title";s:62:"BRBRY_Bearberry - Arctostaphylos uva-ursi (Under consultation)";s:3:"nid";s:6:"216752";s:7:"changed";s:10:"2014-09-30";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"BRBRY";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:56:"Bearberry - Arctostaphylos uva-ursi (Under consultation)";s:22:"field_monograph_name_f";s:59:"Raisin d'ours - Arctostaphylos uva-ursi (sous consultation)";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:46:"atReq.do?atid=arctostaphylos.uva.ursi&lang=eng";s:21:"field_monograph_url_f";s:46:"atReq.do?atid=arctostaphylos.uva.ursi&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-09-05";s:16:"field_legacy_nid";s:6:"107447";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216753;a:29:{s:5:"title";s:58:"AROMTPY_Aromatherapy - Essential oils (Under consultation)";s:3:"nid";s:6:"216753";s:7:"changed";s:10:"2014-09-30";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:7:"AROMTPY";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:50:"Aromatherapy - Essential oils (Under consultation)";s:22:"field_monograph_name_f";s:56:"Aromathérapie - huiles essentielles (Sous consultation)";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"P;C";s:21:"field_monograph_url_e";s:34:"atReq.do?atid=aromatherap&lang=eng";s:21:"field_monograph_url_f";s:34:"atReq.do?atid=aromatherap&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-08-25";s:16:"field_legacy_nid";s:6:"107448";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216754;a:29:{s:5:"title";s:59:"CHLORLA_Chlorella - Cholrella vulgaris (Under consultation)";s:3:"nid";s:6:"216754";s:7:"changed";s:10:"2014-11-14";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:7:"CHLORLA";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:51:"Chlorella - Cholrella vulgaris (Under consultation)";s:22:"field_monograph_name_f";s:50:"Chlorelle - Chlorella vulgaris (sous consultation)";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:41:"atReq.do?atid=chlorella.vulgaris&lang=eng";s:21:"field_monograph_url_f";s:41:"atReq.do?atid=chlorella.vulgaris&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-11-18";s:16:"field_legacy_nid";s:6:"108242";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216755;a:29:{s:5:"title";s:60:"BETAINE_Betaine / Betaine hydrochloride (Under consultation)";s:3:"nid";s:6:"216755";s:7:"changed";s:10:"2014-11-14";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:7:"BETAINE";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:52:"Betaine / Betaine hydrochloride (Under consultation)";s:22:"field_monograph_name_f";s:56:"Bétaïne/ chlorhydrate de bétaïne (sous consultation)";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:30:"atReq.do?atid=betaine&lang=eng";s:21:"field_monograph_url_f";s:30:"atReq.do?atid=betaine&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-11-04";s:16:"field_legacy_nid";s:6:"107966";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216756;a:29:{s:5:"title";s:56:"OLIVE_LF_Olive leaf - Olea europaea (Under consultation)";s:3:"nid";s:6:"216756";s:7:"changed";s:10:"2014-11-14";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:8:"OLIVE_LF";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:47:"Olive leaf - Olea europaea (Under consultation)";s:22:"field_monograph_name_f";s:58:"olivier, feuillle d' – Olea europaea (sous consultation)";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:49:"atReq.do?atid=feuille.olea.europaea.leaf&lang=eng";s:21:"field_monograph_url_f";s:49:"atReq.do?atid=feuille.olea.europaea.leaf&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-11-04";s:16:"field_legacy_nid";s:6:"107965";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216757;a:36:{s:5:"title";s:44:"CASS_Cassia cinnamon - Cinnamomum aromaticum";s:3:"nid";s:6:"216757";s:7:"changed";s:10:"2014-11-27";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"CASS";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:39:"Cassia cinnamon - Cinnamomum aromaticum";s:22:"field_monograph_name_f";s:41:"Cannelle de Chine - Cinnamomum aromaticum";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:0:"";s:21:"field_monograph_url_f";s:0:"";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:673:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant. (iii) A claim for a traditional use must include either the term “Herbal Medicine” or “Traditional Chinese Medicine”.";s:12:"field_note_f";s:789:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués. (iii) Une allégation pour un usage traditionnel doit inclure les termes « Phytothérapie/Herboristerie » ou « Médecine Traditionnelle Chinoise ».";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-11-04";s:16:"field_legacy_nid";s:6:"100991";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:9:"CASSIA_OR";s:14:"field_mono_use";s:47:"CASS1;CASS2;CASS3;CASS4;CASS5;CASS6;CASS7;CASS8";s:19:"field_subpopulation";s:3:"ADU";s:19:"field_mono_duration";s:9:"CASSIADUR";s:15:"field_mono_risk";s:65:"CASSIA_ADR;CASSIA_CI1;CASSIA_CI2;CASSIA_CW1;CASSIA_CW2;CASSIA_CW3";s:21:"field_mono_citation_e";s:185:"CASSIA1;CASSIA3;CASSIA4;CASSIA5;CASSIA7;CASSIA8;CASSIA9;CASSIA10;CASSIA11;CASSIA12;CASSIA30;CASSIA32;CASSIA42;CASSIA44;CASSIA46;CASSIA48;CASSIA49;CINHLTH;DAVYOK;POR1;POR3;REDOXAC;WHOMON";s:21:"field_mono_citation_f";s:208:"CASSIA1;CASSIA3;CASSIA4;CASSIA5;CASSIA7;CASSIA8;CASSIA9;CASSIA10;CASSIA11;CASSIA12;CASSIA30;CASSIA32;CASSIA42;CASSIA44;CASSIA46;CASSIA47;CASSIA48;CASSIA49;CINHLTH;DAVYOK;PHAPHY;PLATHE;POR1;POR3;REDOXAC;WHOMON";s:26:"field_reference_reviewed_e";s:276:"AHFS;CASSIA14;CASSIA15;CASSIA16;CASSIA17;CASSIA18;CASSIA19;CASSIA20;CASSIA21;CASSIA24;CASSIA25;CASSIA26;CASSIA27;CASSIA28;CASSIA29;CASSIA31;CASSIA33;CASSIA34;CASSIA35;CASSIA36;CASSIA37;CASSIA38;CASSIA39;CASSIA40;CASSIA41;CASSIA42;CASSIA45;CASSIA50;CASSIA51;GLUC18;HERCDI;TOXBM";s:26:"field_reference_reviewed_f";s:276:"AHFS;CASSIA14;CASSIA15;CASSIA16;CASSIA17;CASSIA18;CASSIA19;CASSIA20;CASSIA21;CASSIA24;CASSIA25;CASSIA26;CASSIA27;CASSIA28;CASSIA29;CASSIA31;CASSIA33;CASSIA34;CASSIA35;CASSIA36;CASSIA37;CASSIA38;CASSIA39;CASSIA40;CASSIA41;CASSIA42;CASSIA45;CASSIA50;CASSIA51;GLUC18;HERCDI;TOXBM";}i:216758;a:29:{s:5:"title";s:43:"ELDER_Elder - Sambucus (Under consultation)";s:3:"nid";s:6:"216758";s:7:"changed";s:10:"2014-11-27";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"ELDER";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:37:"Elder - Sambucus (Under consultation)";s:22:"field_monograph_name_f";s:37:"Sureau - Sambucus (sous consultation)";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:35:"atReq.do?atid=elder.sureau&lang=eng";s:21:"field_monograph_url_f";s:35:"atReq.do?atid=elder.sureau&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-12-02";s:16:"field_legacy_nid";s:6:"108350";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216759;a:29:{s:5:"title";s:25:"FCAP_Oral Health Products";s:3:"nid";s:6:"216759";s:7:"changed";s:10:"2014-11-27";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"FCAP";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:20:"Oral Health Products";s:22:"field_monograph_name_f";s:39:"Bucco-dentaire, Produits pour la santé";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"P;C";s:21:"field_monograph_url_e";s:55:"atReq.do?atid=oral.health.sante.bucco.dentaire&lang=eng";s:21:"field_monograph_url_f";s:55:"atReq.do?atid=oral.health.sante.bucco.dentaire&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-12-02";s:16:"field_legacy_nid";s:6:"100864";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216760;a:29:{s:5:"title";s:49:"PYG_Pygeum - Prunus africana (Under consultation)";s:3:"nid";s:6:"216760";s:7:"changed";s:10:"2014-11-27";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:3:"PYG";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:45:"Pygeum - Prunus africana (Under consultation)";s:22:"field_monograph_name_f";s:44:"Pygeum - Prunus africana (sous consultation)";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:29:"atReq.do?atid=pygeum&lang=eng";s:21:"field_monograph_url_f";s:29:"atReq.do?atid=pygeum&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-12-01";s:16:"field_legacy_nid";s:6:"108349";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216761;a:29:{s:5:"title";s:55:"DIMM_3,3’-diindolylmethane (DIM) (Under consultation)";s:3:"nid";s:6:"216761";s:7:"changed";s:10:"2014-12-11";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"DIMM";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:50:"3,3’-diindolylmethane (DIM) (Under consultation)";s:22:"field_monograph_name_f";s:48:"3,3'-diindolylméthane (DIM) (sous consultation)";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:39:"atReq.do?atid=diindolylmethane&lang=eng";s:21:"field_monograph_url_f";s:39:"atReq.do?atid=diindolylmethane&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-12-16";s:16:"field_legacy_nid";s:6:"108404";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216762;a:29:{s:5:"title";s:43:"I3CM_Indole-3-carbinol (Under consultation)";s:3:"nid";s:6:"216762";s:7:"changed";s:10:"2014-12-12";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"I3CM";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:38:"Indole-3-carbinol (Under consultation)";s:22:"field_monograph_name_f";s:37:"Indole-3-carbinol (sous consultation)";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:38:"atReq.do?atid=indole3carbinol&lang=eng";s:21:"field_monograph_url_f";s:38:"atReq.do?atid=indole3carbinol&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-12-16";s:16:"field_legacy_nid";s:6:"108407";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216763;a:29:{s:5:"title";s:35:"SOYF_Soy Flour (Under consultation)";s:3:"nid";s:6:"216763";s:7:"changed";s:10:"2015-01-05";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"SOYF";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:30:"Soy Flour (Under consultation)";s:22:"field_monograph_name_f";s:34:"Farine de soja (sous consultation)";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:42:"atReq.do?atid=soyflour.farinesoja&lang=eng";s:21:"field_monograph_url_f";s:42:"atReq.do?atid=soyflour.farinesoja&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2015-01-07";s:16:"field_legacy_nid";s:6:"108461";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216764;a:29:{s:5:"title";s:67:"MULOIL_Oil Products, Multiple Ingredient Fixed (Under consultation)";s:3:"nid";s:6:"216764";s:7:"changed";s:10:"2015-01-05";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"MULOIL";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:60:"Oil Products, Multiple Ingredient Fixed (Under consultation)";s:22:"field_monograph_name_f";s:79:"Huiles fixes, Produits à ingrédients multiples à base d' (sous consultation)";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"P;C";s:21:"field_monograph_url_e";s:35:"atReq.do?atid=multiple.oil&lang=eng";s:21:"field_monograph_url_f";s:35:"atReq.do?atid=multiple.oil&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2009-11-16";s:16:"field_legacy_nid";s:6:"100977";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216765;a:29:{s:5:"title";s:15:"SPLNA_Spirulina";s:3:"nid";s:6:"216765";s:7:"changed";s:10:"2015-01-15";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"SPLNA";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:9:"Spirulina";s:22:"field_monograph_name_f";s:9:"Spiruline";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:31:"atReq.do?atid=spirulin&lang=eng";s:21:"field_monograph_url_f";s:31:"atReq.do?atid=spirulin&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2015-01-20";s:16:"field_legacy_nid";s:6:"106573";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216766;a:29:{s:5:"title";s:18:"ROYJEL_Royal Jelly";s:3:"nid";s:6:"216766";s:7:"changed";s:10:"2015-01-15";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"ROYJEL";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:11:"Royal Jelly";s:22:"field_monograph_name_f";s:14:"Gélée royale";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:40:"atReq.do?atid=gelee.royal.jelly&lang=eng";s:21:"field_monograph_url_f";s:40:"atReq.do?atid=gelee.royal.jelly&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2015-05-20";s:16:"field_legacy_nid";s:6:"106965";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216767;a:29:{s:5:"title";s:34:"RCIE_Red Clover Isoflavone Extract";s:3:"nid";s:6:"216767";s:7:"changed";s:10:"2015-01-15";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"RCIE";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:29:"Red Clover Isoflavone Extract";s:22:"field_monograph_name_f";s:38:"Extrait D'Isoflavones De Trèfle Rouge";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:27:"atReq.do?atid=rcie&lang=eng";s:21:"field_monograph_url_f";s:27:"atReq.do?atid=rcie&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-05-07";s:16:"field_legacy_nid";s:6:"106757";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216768;a:29:{s:5:"title";s:34:"BLKWN_Black Walnut - Juglans nigra";s:3:"nid";s:6:"216768";s:7:"changed";s:10:"2015-01-15";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"BLKWN";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:28:"Black Walnut - Juglans nigra";s:22:"field_monograph_name_f";s:26:"Noyer noir - Juglans nigra";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:36:"atReq.do?atid=juglans.nigra&lang=eng";s:21:"field_monograph_url_f";s:36:"atReq.do?atid=juglans.nigra&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2015-01-20";s:16:"field_legacy_nid";s:6:"106671";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216769;a:29:{s:5:"title";s:47:"AFWMAN_African Wild Mango - Irvingia gabonensis";s:3:"nid";s:6:"216769";s:7:"changed";s:10:"2015-01-15";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"AFWMAN";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:40:"African Wild Mango - Irvingia gabonensis";s:22:"field_monograph_name_f";s:38:"Manguier sauvage - Irvingia gabonensis";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:42:"atReq.do?atid=irvingia.gabonensis&lang=eng";s:21:"field_monograph_url_f";s:42:"atReq.do?atid=irvingia.gabonensis&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2015-01-20";s:16:"field_legacy_nid";s:6:"107341";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216770;a:29:{s:5:"title";s:31:"KUTKI_Kutki - Picrorhiza kuuooa";s:3:"nid";s:6:"216770";s:7:"changed";s:10:"2015-01-15";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"KUTKI";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:25:"Kutki - Picrorhiza kuuooa";s:22:"field_monograph_name_f";s:25:"Kutki - Picrorhiza kuuooa";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:28:"atReq.do?atid=kutki&lang=eng";s:21:"field_monograph_url_f";s:28:"atReq.do?atid=kutki&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-07-22";s:16:"field_legacy_nid";s:6:"107340";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216771;a:29:{s:5:"title";s:32:"ALO_LG_Aloe vera Leaf Gel - Oral";s:3:"nid";s:6:"216771";s:7:"changed";s:10:"2015-01-15";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"ALO_LG";s:18:"field_group_name_e";s:4:"Aloe";s:18:"field_group_name_f";s:6:"Aloès";s:22:"field_monograph_name_e";s:25:"Aloe vera Leaf Gel - Oral";s:22:"field_monograph_name_f";s:43:"Aloe vera, gel de feuilles d'aloès - orale";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:31:"atReq.do?atid=aloe.gel&lang=eng";s:21:"field_monograph_url_f";s:31:"atReq.do?atid=aloe.gel&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2015-01-20";s:16:"field_legacy_nid";s:6:"107342";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216772;a:38:{s:5:"title";s:32:"REIS_Reishi - Ganoderma lucidium";s:3:"nid";s:6:"216772";s:7:"changed";s:10:"2015-01-15";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:4:"REIS";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:27:"Reishi - Ganoderma lucidium";s:22:"field_monograph_name_f";s:27:"Reishi - Ganoderma lucidium";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:29:"atReq.do?atid=reishi&lang=eng";s:21:"field_monograph_url_f";s:29:"atReq.do?atid=reishi&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:662:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.   Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant. (iii) A claim for traditional use must include the term " Herbal Medicine" or “Traditional Chinese Medicine”";s:12:"field_note_f";s:788:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués. (iii) Une allégation pour un usage traditionnel doit inclure les termes « Phytothérapie/Herboristerie » ou « Médecine Traditionnelle Chinoise »";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:128:"The medicinal ingredient must comply with the requirements outlined in the Natural Health Products Ingredients Database (NHPID).";s:21:"field_specification_f";s:156:"L’ingrédient médicinal doit être conforme aux exigences mentionnées dans la Base de données d’ingrédients de produits de santé naturels (BDIPSN).";s:25:"field_storage_condition_e";s:53:"Store in a dry place at room temperature (PPRC 2010).";s:25:"field_storage_condition_f";s:71:"Entreposer dans un endroit sec à la température ambiante (PPRC 2010).";s:10:"field_date";s:10:"2015-01-20";s:16:"field_legacy_nid";s:6:"101012";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:7:"REIS_OR";s:14:"field_mono_use";s:41:"REIS1;REIS2;REIS3;REIS4;REIS5;REIS6;REIS7";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:4:"REIS";s:19:"field_mono_duration";s:4:"REIS";s:15:"field_mono_risk";s:26:"REIS_ADR;REIS_CW1;REIS_CW2";s:21:"field_mono_citation_e";s:192:"POR10;REIS1;REIS2;REIS3;REIS4;REIS5;REIS6;REIS7;REIS8;REIS9;REIS10;REIS11;REIS12;REIS13;REIS14;REIS15;REIS16;REIS17;REIS18;REIS19;REIS20;REIS21;REIS22;REIS23;REIS24;REIS25;REIS27;REIS28;REIS30";s:21:"field_mono_citation_f";s:199:"POR10;REIS1;REIS2;REIS3;REIS4;REIS5;REIS6;REIS7;REIS8;REIS9;REIS10;REIS11;REIS12;REIS13;REIS14;REIS15;REIS16;REIS17;REIS18;REIS19;REIS20;REIS21;REIS22;REIS23;REIS24;REIS25;REIS26;REIS27;REIS28;REIS30";s:26:"field_reference_reviewed_e";s:659:"REIS31;REIS32;REIS33;REIS34;REIS35;REIS36;REIS37;REIS38;REIS39;REIS40;REIS41;REIS42;REIS43;REIS44;REIS45;REIS46;REIS47;REIS48;REIS49;REIS50;REIS51;REIS52;REIS53;REIS54;REIS55;REIS56;REIS57;REIS58;REIS59;REIS60;REIS61;REIS62;REIS63;REIS64;REIS65;REIS66;REIS67;REIS68;REIS69;REIS70;REIS71;REIS72;REIS73;REIS74;REIS75;REIS76;REIS78;REIS79;REIS80;REIS81;REIS82;REIS83;REIS84;REIS85;REIS86;REIS87;REIS88;REIS89;REIS90;REIS91;REIS92;REIS93;REIS94;REIS95;REIS96;REIS97;REIS98;REIS99;REIS100;REIS101;REIS102;REIS103;REIS104;REIS105;REIS106;REIS107;REIS108;REIS109;REIS110;REIS111;REIS112;REIS113;REIS114;REIS115;REIS116;REIS117;REIS118;REIS120;REIS121;REIS122;REIS123";s:26:"field_reference_reviewed_f";s:645:"REIS31;REIS32;REIS33;REIS34;REIS35;REIS36;REIS37;REIS38;REIS39;REIS40;REIS41;REIS42;REIS43;REIS44;REIS45;REIS46;REIS47;REIS48;REIS49;REIS50;REIS51;REIS52;REIS53;REIS54;REIS55;REIS56;REIS57;REIS58;REIS59;REIS60;REIS61;REIS62;REIS63;REIS64;REIS65;REIS66;REIS67;REIS68;REIS69;REIS70;REIS71;REIS72;REIS74;REIS76;REIS77;REIS78;REIS80;REIS81;REIS82;REIS83;REIS84;REIS85;REIS86;REIS87;REIS88;REIS89;REIS90;REIS91;REIS92;REIS93;REIS94;REIS95;REIS96;REIS97;REIS98;REIS99;REIS100;REIS101;REIS102;REIS103;REIS104;REIS105;REIS106;REIS107;REIS108;REIS109;REIS110;REIS112;REIS113;REIS114;REIS115;REIS116;REIS117;REIS118;REIS119;REIS120;REIS121;REIS122;REIS123";}i:216773;a:29:{s:5:"title";s:54:"GRIFRO_Maitake - Grifola frondosa (Under consultation)";s:3:"nid";s:6:"216773";s:7:"changed";s:10:"2015-01-15";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:6:"GRIFRO";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:47:"Maitake - Grifola frondosa (Under consultation)";s:22:"field_monograph_name_f";s:46:"Maitake - Grifola frondosa (sous consultation)";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:30:"atReq.do?atid=maitake&lang=eng";s:21:"field_monograph_url_f";s:30:"atReq.do?atid=maitake&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2013-04-23";s:16:"field_legacy_nid";s:6:"101042";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216774;a:37:{s:5:"title";s:53:"PORIA_Poria - Wolfiporia extensa (Under consultation)";s:3:"nid";s:6:"216774";s:7:"changed";s:10:"2015-01-15";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"PORIA";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:47:"Poria - Wolfiporia extensa (Under consultation)";s:22:"field_monograph_name_f";s:48:"Pachyme - Wolfiporia extensa (sous consultation)";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:1:"C";s:21:"field_monograph_url_e";s:28:"atReq.do?atid=poria&lang=eng";s:21:"field_monograph_url_f";s:28:"atReq.do?atid=poria&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:547:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. Notes: (i) Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant’s discretion. (ii) The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant.";s:12:"field_note_f";s:637:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence (DLMM) et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. Nota : (i) Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la DLMM ou sur l’étiquette du produit. (ii) La barre oblique (/) indique que les termes ou les énoncés sont synonymes. Le demandeur peut utiliser n’importe lequel des termes ou énoncés indiqués.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:86:"Store in a tightly closed, light-resistant container in a cool, dry place (PPRC 2010).";s:25:"field_storage_condition_f";s:111:"Garder dans un contenant bien fermé et à l'épreuve de la lumière, dans un endroit frais et sec (PPRC 2010).";s:10:"field_date";s:10:"2015-01-20";s:16:"field_legacy_nid";s:6:"100990";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:8:"PORIA_OR";s:14:"field_mono_use";s:34:"POR1;POR2;POR3;POR4;POR5;POR6;POR7";s:19:"field_subpopulation";s:3:"ADU";s:15:"field_dose_note";s:5:"PORIA";s:15:"field_mono_risk";s:28:"PORIA_ADR;PORIA_CW;PORIA_CW2";s:21:"field_mono_citation_e";s:41:"POR1;POR2;POR3;POR4;POR7;POR9;POR10;POR11";s:21:"field_mono_citation_f";s:46:"POR1;POR2;POR3;POR4;POR7;POR8;POR9;POR10;POR11";s:26:"field_reference_reviewed_e";s:20:"AHCC14;PCH;POR5;POR6";s:26:"field_reference_reviewed_f";s:20:"AHCC14;PCH;POR5;POR6";}i:216775;a:29:{s:5:"title";s:36:"MSHRM_Mushrooms (Under consultation)";s:3:"nid";s:6:"216775";s:7:"changed";s:10:"2015-01-15";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"MSHRM";s:18:"field_group_name_e";s:0:"";s:18:"field_group_name_f";s:0:"";s:22:"field_monograph_name_e";s:30:"Mushrooms (Under consultation)";s:22:"field_monograph_name_f";s:11:"Champignons";s:22:"field_monograph_status";s:1:"E";s:20:"field_monograph_type";s:3:"P;C";s:21:"field_monograph_url_e";s:44:"atReq.do?atid=mushrooms.champignons&lang=eng";s:21:"field_monograph_url_f";s:44:"atReq.do?atid=mushrooms.champignons&lang=fra";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:0:"";s:12:"field_note_f";s:0:"";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:0:"";s:21:"field_specification_f";s:0:"";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2015-01-20";s:16:"field_legacy_nid";s:6:"108546";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:79:" (Referred field is not set. Please set the referred fields for field_mono_roa)";}i:216776;a:36:{s:5:"title";s:21:"PRO_O_Propolis - Oral";s:3:"nid";s:6:"216776";s:7:"changed";s:10:"2015-01-16";s:14:"workflow_state";s:9:"Published";s:4:"body";s:0:"";s:10:"field_code";s:5:"PRO_O";s:18:"field_group_name_e";s:8:"Propolis";s:18:"field_group_name_f";s:8:"Propolis";s:22:"field_monograph_name_e";s:15:"Propolis - Oral";s:22:"field_monograph_name_f";s:16:"Propolis - Orale";s:22:"field_monograph_status";s:1:"G";s:21:"field_monograph_url_e";s:96:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_propolis-eng.php";s:21:"field_monograph_url_f";s:96:"http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_propolis-fra.php";s:16:"field_nmi_note_e";s:0:"";s:16:"field_nmi_note_f";s:0:"";s:12:"field_note_e";s:468:"This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.     Notes: Text in parentheses is additional optional information which can be included on the PLA and product labels at the applicant’s discretion.";s:12:"field_note_f";s:624:"La présente monographie vise à servir de guide à l'industrie pour la préparation de demandes de licence et d'étiquettes dans le but d'obtenir une autorisation de mise en marché d'un produit de santé naturel. Elle ne vise pas à être une étude approfondie de l'ingrédient médicinal. La présente monographie est un document, avec références à l'appui, à utiliser en tant que norme d'étiquetage.     Nota : Les parenthèses contiennent des éléments d’information facultatifs -- il n’est pas nécessaire de les inclure dans la demande de licence de mise en marché (DLMM) ou sur l’étiquette du produit.";s:17:"field_risk_note_e";s:0:"";s:17:"field_risk_note_f";s:0:"";s:21:"field_specification_e";s:162:"The medicinal ingredient may comply with the specifications outlined in the Propolis monograph published in the Pharmacopoeia of the People’s Republic of China.";s:21:"field_specification_f";s:174:"L’ingrédient médicinal peut être conforme aux spécifications énoncées dans la monographie Propolis publiée dans la Pharmacopée de la République Populaire de Chine.";s:25:"field_storage_condition_e";s:0:"";s:25:"field_storage_condition_f";s:0:"";s:10:"field_date";s:10:"2014-01-08";s:16:"field_legacy_nid";s:6:"100925";s:18:"field_parent_space";s:85:"85 (Referred field is not set. Please set the referred fields for field_parent_space)";s:14:"field_workflow";s:9:"Published";s:14:"field_mono_roa";s:6:"PRO_OR";s:14:"field_mono_use";s:11:"PROO1;PROO2";s:19:"field_subpopulation";s:3:"ADU";s:19:"field_mono_duration";s:6:"PRODUR";s:15:"field_mono_risk";s:30:"PRO_AR;PRO_CW1;PRO_CW2;PRO_CW3";s:21:"field_mono_citation_e";s:151:"11DIME;605CON;APHTH;BABPHD;BACKGR;BRAZPRO;CCBPTA;CCMM2;DERMPRO;DERPRO;EDEMA;GRANUL;HEART;HERCDI;KAINITE;OCCDER;OLDREM;PGNM;PPP;PROORAMOS;PROPSUP;SCAVEN";s:21:"field_mono_citation_f";s:151:"11DIME;605CON;APHTH;BABPHD;BACKGR;BRAZPRO;CCBPTA;CCMM2;DERMPRO;DERPRO;EDEMA;GRANUL;HEART;HERCDI;KAINITE;OCCDER;OLDREM;PGNM;PPP;PROORAMOS;PROPSUP;SCAVEN";s:26:"field_reference_reviewed_e";s:201:"1255CH;ADJUV;ADRPRO;AQUPRO;BEEPROD;CANDID;CHRYSIN;EICOPR;FPHPRJ;FREEAA;GRNPRO;HSV;IMMUNE;INRATS;ITIS;NIVCRI;NMCD;NMQS;NOVOPL;PPS;PROFOOD;PRORES;PROREV;PYLORI;RBPTBP;RINSE;SILICAT;SULCO;SULFAD;VAGIN;VAP";s:26:"field_reference_reviewed_f";s:201:"1255CH;ADJUV;ADRPRO;AQUPRO;BEEPROD;CANDID;CHRYSIN;EICOPR;FPHPRJ;FREEAA;GRNPRO;HSV;IMMUNE;INRATS;ITIS;NIVCRI;NMCD;NMQS;NOVOPL;PPS;PROFOOD;PRORES;PROREV;PYLORI;RBPTBP;RINSE;SILICAT;SULCO;SULFAD;VAGIN;VAP";}}